{"d84dc192b414d743582554dc14edd75f2866b172": [["IntroductionAn outbreak of novel coronavirus disease occurred in Wuhan, a city in central China, in December 2019.", [["coronavirus disease", "DISEASE", 33, 52], ["coronavirus", "ORGANISM", 33, 44], ["novel coronavirus disease", "PROBLEM", 27, 52], ["novel coronavirus disease", "OBSERVATION", 27, 52], ["central China", "ANATOMY", 82, 95]]], ["This disease, characterized by rapid human transmission, has been related to the severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["adult respiratory syndrome coronavirus", "DISEASE", 88, 126], ["human", "ORGANISM", 37, 42], ["adult respiratory syndrome coronavirus 2", "ORGANISM", 88, 128], ["SARS-CoV-2", "ORGANISM", 130, 140], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["severe adult respiratory syndrome coronavirus", "SPECIES", 81, 126], ["SARS-CoV-2", "SPECIES", 130, 140], ["This disease", "PROBLEM", 0, 12], ["rapid human transmission", "PROBLEM", 31, 55], ["the severe adult respiratory syndrome coronavirus", "PROBLEM", 77, 126], ["CoV", "TEST", 135, 138], ["disease", "OBSERVATION", 5, 12], ["rapid", "OBSERVATION_MODIFIER", 31, 36], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["respiratory syndrome", "OBSERVATION", 94, 114]]], ["Since the first Italian SARS-CoV-2 infection case was reported on 21 February 2020 in Codogno (Lodi), the outspread of the disease particularly affected Italy, which became the main outbreak site in Europe [1] [2] [3] [4] [5] [6] .", [["SARS-CoV-2 infection", "DISEASE", 24, 44], ["SARS-CoV-2", "ORGANISM", 24, 34], ["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 206, 229], ["the disease", "PROBLEM", 119, 130], ["disease", "OBSERVATION", 123, 130], ["main", "OBSERVATION_MODIFIER", 177, 181]]], ["The first case of COVID-19 in the United States was reported in January 2020 in Snohomish, Washington, in a patient who had traveled to Wuhan [7] .", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115]]], ["Ever since, the infection has been spreading and increasing worldwide.", [["infection", "DISEASE", 16, 25], ["the infection", "PROBLEM", 12, 25], ["infection", "OBSERVATION", 16, 25], ["spreading", "OBSERVATION_MODIFIER", 35, 44], ["increasing", "OBSERVATION_MODIFIER", 49, 59], ["worldwide", "OBSERVATION_MODIFIER", 60, 69]]], ["The World Health Organization (WHO) first declared COVID-19 a \"Public Health Emergency of International Concern\", and on 11 March a \"pandemic\" [8] .IntroductionIn Italy, the data reported by the Ministry of Health on 12 April showed 156,363 infection cases, 27,847 symptomatic hospitalized patients, of which there were 3343 admitted to intensive care units (ICU), 19,899 deaths, and 34,211 recoveries.", [["infection", "DISEASE", 241, 250], ["deaths", "DISEASE", 372, 378], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 290, 298], ["infection cases", "PROBLEM", 241, 256]]], ["The Emilia Romagna Region is the second Italian area by number of infections with 20,098 total cases; within this region, the Province of Reggio Emilia had 3849 cases reported [9] .IntroductionIn the COVID-19 pandemic, cancer patients could be a high-risk group due to their immunosuppressed status and vulnerability to infection resulting from their disease and/or the oncological treatments [10] .", [["cancer", "ANATOMY", 219, 225], ["infections", "DISEASE", 66, 76], ["cancer", "DISEASE", 219, 225], ["infection", "DISEASE", 320, 329], ["cancer", "CANCER", 219, 225], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 226, 234], ["infections", "PROBLEM", 66, 76], ["their immunosuppressed status", "PROBLEM", 269, 298], ["vulnerability to infection", "PROBLEM", 303, 329], ["their disease", "PROBLEM", 345, 358], ["the oncological treatments", "TREATMENT", 366, 392], ["Emilia", "OBSERVATION_MODIFIER", 4, 10], ["second", "OBSERVATION_MODIFIER", 33, 39], ["number", "OBSERVATION_MODIFIER", 56, 62], ["infections", "OBSERVATION", 66, 76], ["infection", "OBSERVATION", 320, 329]]], ["The susceptibility of cancer patients to the influenza virus has already been reported.", [["cancer", "ANATOMY", 22, 28], ["cancer", "DISEASE", 22, 28], ["influenza virus", "DISEASE", 45, 60], ["cancer", "CANCER", 22, 28], ["patients", "ORGANISM", 29, 37], ["influenza virus", "ORGANISM", 45, 60], ["patients", "SPECIES", 29, 37], ["influenza virus", "SPECIES", 45, 60], ["influenza virus", "SPECIES", 45, 60], ["The susceptibility of cancer", "PROBLEM", 0, 28], ["the influenza virus", "PROBLEM", 41, 60], ["cancer", "OBSERVATION", 22, 28]]], ["Oncological patients infected with the influenza virus have shown four times higher risk of hospitalization for respiratory distress, and the risk of death is ten times higher than in patients without cancer [11] .", [["respiratory", "ANATOMY", 112, 123], ["cancer", "ANATOMY", 201, 207], ["influenza virus", "DISEASE", 39, 54], ["respiratory distress", "DISEASE", 112, 132], ["death", "DISEASE", 150, 155], ["cancer", "DISEASE", 201, 207], ["patients", "ORGANISM", 12, 20], ["influenza virus", "ORGANISM", 39, 54], ["patients", "ORGANISM", 184, 192], ["cancer", "CANCER", 201, 207], ["patients", "SPECIES", 12, 20], ["influenza virus", "SPECIES", 39, 54], ["patients", "SPECIES", 184, 192], ["influenza virus", "SPECIES", 39, 54], ["the influenza virus", "PROBLEM", 35, 54], ["respiratory distress", "PROBLEM", 112, 132], ["death", "PROBLEM", 150, 155], ["cancer", "PROBLEM", 201, 207], ["respiratory distress", "OBSERVATION", 112, 132]]], ["Therefore, cancer patients may have higher risks of SARS-CoV-2 infection, and during the infection, a more severe prognosis.", [["cancer", "ANATOMY", 11, 17], ["cancer", "DISEASE", 11, 17], ["SARS-CoV-2 infection", "DISEASE", 52, 72], ["infection", "DISEASE", 89, 98], ["cancer", "CANCER", 11, 17], ["patients", "ORGANISM", 18, 26], ["SARS-CoV-2", "ORGANISM", 52, 62], ["patients", "SPECIES", 18, 26], ["SARS-CoV", "SPECIES", 52, 60], ["SARS", "PROBLEM", 52, 56], ["CoV", "PROBLEM", 57, 60], ["2 infection", "PROBLEM", 61, 72], ["the infection", "PROBLEM", 85, 98], ["cancer", "OBSERVATION", 11, 17], ["SARS", "OBSERVATION", 52, 56], ["infection", "OBSERVATION", 63, 72], ["infection", "OBSERVATION", 89, 98]]], ["In this context, we have no definitive evidence yet.", [["no definitive evidence", "UNCERTAINTY", 25, 47]]], ["As of today, we have available data for the United States population, after the early reports published in the first weeks of the epidemic on the Chinese population, which differs from the western population in epidemiological, genetic, and clinical characteristics [12] [13] [14] [15] [16] [17] [18] [19] .IntroductionConsidering all of the above, there is a high demand for more homogenous data in order to choose the timing and type of antineoplastic treatments, reducing the risk of care disruptions related to social distancing requirements, and manage the appropriate allocation of health care.", [["antineoplastic", "ANATOMY", 439, 453], ["[12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 266, 305], ["a high demand", "PROBLEM", 358, 371], ["antineoplastic treatments", "TREATMENT", 439, 464], ["care disruptions", "PROBLEM", 487, 503]]], ["This information will also be necessary to select which clinical trials to prioritize among the others, and which ones to suspend [17] [18] [19] [20] [21] [22] [23] .IntroductionThis paper reports the results of a cohort study comparing the outcomes of patients admitted to the Provincial Hospital of Reggio Emilia for COVID-19 according to the oncological history.", [["[17] [18] [19] [20] [21] [22] [23]", "CHEMICAL", 130, 164], ["[17] [18] [19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 130, 164], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["a cohort study", "TEST", 212, 226], ["COVID", "TREATMENT", 319, 324]]], ["We also compare the standardized COVID-19 hospitalization ratio of cancer patients with the general population and describe characteristics of cancer patients in the cohort.Study DesignThis is an Observational cohort Study performed in the Hospitals in the province of Reggio Emilia (530,000 inhabitants), which has designated COVID-19 Units in four sites (Reggio Emilia City, Castelnovo Monti, Guastalla and Scandiano).", [["cancer", "ANATOMY", 67, 73], ["cancer", "ANATOMY", 143, 149], ["cancer", "DISEASE", 67, 73], ["cancer", "DISEASE", 143, 149], ["cancer", "CANCER", 67, 73], ["patients", "ORGANISM", 74, 82], ["cancer", "CANCER", 143, 149], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 150, 158], ["cancer", "PROBLEM", 67, 73], ["cancer", "PROBLEM", 143, 149], ["an Observational cohort Study", "TEST", 193, 222], ["Castelnovo Monti", "TREATMENT", 377, 393], ["Guastalla", "TREATMENT", 395, 404], ["cancer", "OBSERVATION", 67, 73], ["cancer", "OBSERVATION", 143, 149]]], ["All hospitalizations of patients with COVID-19 disease were identified between 1 February and 3 April 2020 through the hospital electronic system.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["COVID-19 disease", "PROBLEM", 38, 54]]], ["Cases were followed up for ICU admission and death until 30 June 2020.", [["death", "DISEASE", 45, 50]]], ["Epidemiological, clinical, laboratory, and radiological data were collected and evaluated from the electronic medical records and the Reggio Emilia Tumor Registry archive.", [["Tumor", "DISEASE", 148, 153], ["radiological data", "TEST", 43, 60], ["Tumor", "OBSERVATION", 148, 153]]], ["This study was approved by the local Ethics Committee of the Area Vasta Emilia Nord (AVEN) (Study No. 281/2020/OSS/IRCCSRE approved on 24 March 2020).DefinitionsA COVID-19 patient was diagnosed based on real-time reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal specimens according to WHO indications [24] .", [["nasopharyngeal specimens", "ANATOMY", 273, 297], ["patient", "ORGANISM", 172, 179], ["nasopharyngeal specimens", "CANCER", 273, 297], ["patient", "SPECIES", 172, 179], ["This study", "TEST", 0, 10], ["chain reaction", "TEST", 246, 260], ["RT-PCR", "TEST", 262, 268], ["nasopharyngeal specimens", "PROBLEM", 273, 297], ["nasopharyngeal", "ANATOMY", 273, 287]]], ["The presence of SARS-CoV2 related pneumonia was assessed through computer tomography (CT) according to the typical findings of mostly peripherally distributed ground glass opacities (GGO) and consolidations.DefinitionsA cancer patient, excluding non-melanoma skin cancers, was defined if the patient was in the Reggio Emilia Tumor Registry archive; for diagnoses that occurred in the last two years, for which the cancer registry is not complete, the Oncology Unit electronic clinical records were checked.Imaging EvaluationLung CT scans were performed using one of three scanners (128-slice Somatom Definition Edge, Siemens Healthcare; 64-slice Ingenuity, Philips Healthcare; 16-slice GE Brightspeed, GE Medical System) without contrast media injection, with the patient in supine position, during end-inspiration.", [["cancer", "ANATOMY", 220, 226], ["non-melanoma skin cancers", "ANATOMY", 246, 271], ["cancer", "ANATOMY", 414, 420], ["SARS", "DISEASE", 16, 20], ["pneumonia", "DISEASE", 34, 43], ["GGO", "DISEASE", 183, 186], ["cancer", "DISEASE", 220, 226], ["non-melanoma skin cancers", "DISEASE", 246, 271], ["Tumor", "DISEASE", 325, 330], ["cancer", "DISEASE", 414, 420], ["cancer", "CANCER", 220, 226], ["patient", "ORGANISM", 227, 234], ["non-melanoma skin cancers", "CANCER", 246, 271], ["patient", "ORGANISM", 292, 299], ["Tumor", "CANCER", 325, 330], ["cancer", "CANCER", 414, 420], ["patient", "ORGANISM", 764, 771], ["patient", "SPECIES", 227, 234], ["patient", "SPECIES", 292, 299], ["patient", "SPECIES", 764, 771], ["SARS", "PROBLEM", 16, 20], ["CoV2 related pneumonia", "PROBLEM", 21, 43], ["computer tomography", "TEST", 65, 84], ["CT", "TEST", 86, 88], ["mostly peripherally distributed ground glass opacities", "PROBLEM", 127, 181], ["consolidations", "PROBLEM", 192, 206], ["DefinitionsA cancer", "PROBLEM", 207, 226], ["non-melanoma skin cancers", "PROBLEM", 246, 271], ["Imaging", "TEST", 506, 513], ["CT scans", "TEST", 529, 537], ["16-slice GE Brightspeed, GE Medical System", "TREATMENT", 677, 719], ["contrast media injection", "TREATMENT", 729, 753], ["SARS", "OBSERVATION", 16, 20], ["pneumonia", "OBSERVATION", 34, 43], ["mostly", "OBSERVATION_MODIFIER", 127, 133], ["peripherally", "OBSERVATION_MODIFIER", 134, 146], ["distributed", "OBSERVATION_MODIFIER", 147, 158], ["ground glass opacities", "OBSERVATION", 159, 181], ["GGO", "OBSERVATION_MODIFIER", 183, 186], ["consolidations", "OBSERVATION", 192, 206], ["cancer", "OBSERVATION", 220, 226], ["skin", "ANATOMY", 259, 263], ["cancers", "OBSERVATION", 264, 271], ["Tumor", "OBSERVATION", 325, 330], ["cancer", "OBSERVATION", 414, 420]]], ["Scanning parameters were: tube voltage 120 KV, automatic tube current modulation, collimation width 0.625 or 1.25 mm, acquisition slice thickness 2.5 mm, and interval 1.25 mm.", [["tube", "ANATOMY", 57, 61], ["slice", "ANATOMY", 130, 135], ["tube", "TISSUE", 26, 30], ["tube", "TISSUE", 57, 61], ["Scanning parameters", "TEST", 0, 19], ["tube voltage", "TEST", 26, 38], ["automatic tube current modulation", "TREATMENT", 47, 80], ["collimation width", "TEST", 82, 99], ["acquisition slice thickness", "TEST", 118, 145], ["1.25 mm", "OBSERVATION_MODIFIER", 167, 174]]], ["Images were reconstructed with a high-resolution algorithm at slice thickness 1.0/1.25 mm.", [["Images", "TEST", 0, 6], ["slice thickness", "TEST", 62, 77]]], ["During CT reporting, each radiologist completed both the usual radiology report as well as a structured report, including the presence/absence of GGO and consolidations, and the extension of pulmonary lesions using a visual scoring system (0%, 1-19%, 20-39%, 40-59%, and \u226560% of parenchymal involvement) [25] .Statistical AnalysisFor descriptive analysis continuous variables were presented in median and range, while categorical variables were presented as frequencies and proportions.", [["pulmonary lesions", "ANATOMY", 191, 208], ["parenchymal", "ANATOMY", 279, 290], ["GGO", "DISEASE", 146, 149], ["pulmonary lesions", "DISEASE", 191, 208], ["pulmonary lesions", "CANCER", 191, 208], ["parenchymal", "TISSUE", 279, 290], ["GGO", "PROBLEM", 146, 149], ["consolidations", "PROBLEM", 154, 168], ["pulmonary lesions", "PROBLEM", 191, 208], ["a visual scoring system", "TEST", 215, 238], ["\u2265", "TEST", 271, 272], ["Statistical Analysis", "TEST", 310, 330], ["descriptive analysis", "TEST", 334, 354], ["categorical variables", "TEST", 418, 439], ["GGO", "OBSERVATION", 146, 149], ["consolidations", "OBSERVATION", 154, 168], ["pulmonary", "ANATOMY", 191, 200], ["lesions", "OBSERVATION", 201, 208], ["parenchymal", "ANATOMY_MODIFIER", 279, 290]]], ["Pearson chi-squared test were implemented to test sex ratio differences between groups.", [["Pearson chi-squared test", "TEST", 0, 24]]], ["Age and sex standardized hospitalization ratio (SHR) was also calculated with indirect standardization method to compare the risk of hospitalization for COVID-19 in people 0 to 84 years old with a previous diagnosis of cancer and the general population, and denominators were estimated according to data on cancer prevalence by age from 0 to 84, as reported by the Reggio Emilia cancer registry [26] .", [["cancer", "ANATOMY", 219, 225], ["cancer", "ANATOMY", 307, 313], ["cancer", "ANATOMY", 379, 385], ["cancer", "DISEASE", 219, 225], ["cancer", "DISEASE", 307, 313], ["cancer", "DISEASE", 379, 385], ["people", "ORGANISM", 165, 171], ["cancer", "CANCER", 219, 225], ["cancer", "CANCER", 307, 313], ["cancer", "CANCER", 379, 385], ["people", "SPECIES", 165, 171], ["indirect standardization method", "TREATMENT", 78, 109], ["cancer", "PROBLEM", 219, 225], ["the general population", "PROBLEM", 230, 252], ["cancer", "OBSERVATION", 219, 225], ["cancer", "OBSERVATION", 379, 385]]], ["To compare intensive care unit (ICU) admission and mortality between SARS-CoV-2 infected cancer and non-cancer patients, sex and age adjusted odds ratios (OR) and the corresponding 95% confidence interval (95% CI) were calculated using multivariate logistic regression models.", [["cancer", "ANATOMY", 89, 95], ["non-cancer", "ANATOMY", 100, 110], ["SARS-CoV-2 infected cancer", "DISEASE", 69, 95], ["non-cancer", "DISEASE", 100, 110], ["SARS-CoV-2", "ORGANISM", 69, 79], ["cancer", "CANCER", 89, 95], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["SARS-CoV", "SPECIES", 69, 77], ["SARS", "PROBLEM", 69, 73], ["infected cancer", "PROBLEM", 80, 95], ["multivariate logistic regression models", "TREATMENT", 236, 275], ["infected", "OBSERVATION_MODIFIER", 80, 88], ["cancer", "OBSERVATION", 89, 95]]], ["Odds ratio of death and ICU admission at 40 days since hospital admission in oncologic patients were also calculated by means of multivariate logistic regression analysis, adjusting for age, gender, metastatic disease, and time since cancer diagnosis.", [["cancer", "ANATOMY", 234, 240], ["death", "DISEASE", 14, 19], ["cancer", "DISEASE", 234, 240], ["patients", "ORGANISM", 87, 95], ["cancer", "CANCER", 234, 240], ["patients", "SPECIES", 87, 95], ["death", "PROBLEM", 14, 19], ["metastatic disease", "PROBLEM", 199, 217], ["cancer diagnosis", "PROBLEM", 234, 250], ["metastatic", "OBSERVATION", 199, 209]]], ["Computed tomography (CT) findings were compared between cancer and non-cancer patients by means of chi-squared test, and odds ratios (OR) for each CT finding (ground-glass opacities (GGO), consolidations, and visual extension of pulmonary lesions \u226540% and \u226560%) were calculated by means of multivariate logistic regression analysis, adjusting for age and sex.", [["cancer", "ANATOMY", 56, 62], ["non-cancer", "ANATOMY", 67, 77], ["pulmonary lesions", "ANATOMY", 229, 246], ["cancer", "DISEASE", 56, 62], ["non-cancer", "DISEASE", 67, 77], ["cancer", "CANCER", 56, 62], ["patients", "ORGANISM", 78, 86], ["pulmonary lesions", "CANCER", 229, 246], ["patients", "SPECIES", 78, 86], ["Computed tomography (CT) findings", "TEST", 0, 33], ["chi-squared test", "TEST", 99, 115], ["each CT finding", "TEST", 142, 157], ["ground-glass opacities (GGO)", "PROBLEM", 159, 187], ["consolidations", "PROBLEM", 189, 203], ["visual extension of pulmonary lesions", "PROBLEM", 209, 246], ["glass opacities", "OBSERVATION", 166, 181], ["consolidations", "OBSERVATION", 189, 203], ["pulmonary", "ANATOMY", 229, 238], ["lesions", "OBSERVATION", 239, 246]]], ["All statistical analysis was performed using SPSS Statistics version 26.0.ResultsBetween 1 February and 3 April 2020, a total of 1226 COVID-19 infected patients were admitted at the Provincial Hospital of Reggio Emilia (Table 1) , representing the 0.23% of the resident population.", [["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["All statistical analysis", "TEST", 0, 24], ["SPSS Statistics version", "TEST", 45, 68]]], ["The gender distribution was 493 (40.2%) females and 733 (59.8%) males.", [["The gender distribution", "TEST", 0, 23]]], ["The median age of all patients was 73 years (range 23-100), ICU admission was needed for 92 (7.5%) patients, and 330 patients (26.9%) died.", [["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 99, 107], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 117, 125]]], ["The number of cancer patients hospitalized with SARS-CoV-2 infection was 138 (11.3%) for a standardized hospitalization ratio compared with the general population-98 (95% CI 73-131).", [["cancer", "ANATOMY", 14, 20], ["cancer", "DISEASE", 14, 20], ["SARS-CoV-2 infection", "DISEASE", 48, 68], ["cancer", "CANCER", 14, 20], ["patients", "ORGANISM", 21, 29], ["SARS-CoV-2", "ORGANISM", 48, 58], ["patients", "SPECIES", 21, 29], ["SARS-CoV-2", "SPECIES", 48, 58], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["2 infection", "PROBLEM", 57, 68], ["a standardized hospitalization ratio", "TEST", 89, 125], ["CI", "TEST", 171, 173], ["cancer", "OBSERVATION", 14, 20]]], ["There were no small differences or no differences between the hospitalized patients with and without cancer by median age (76 vs. 73 years), risk of ICU admission (10.1% vs. 6.7%; OR 1.23, 95% CI 0.63-2.41), and fatality rate (34.1% vs. 26.0%; OR 1.07, 95% CI 0.71-1.61).", [["cancer", "ANATOMY", 101, 107], ["cancer", "DISEASE", 101, 107], ["patients", "ORGANISM", 75, 83], ["cancer", "CANCER", 101, 107], ["patients", "SPECIES", 75, 83], ["small differences", "PROBLEM", 14, 31], ["cancer", "PROBLEM", 101, 107], ["CI", "TEST", 193, 195], ["fatality rate", "TEST", 212, 225], ["CI", "TEST", 257, 259], ["no", "UNCERTAINTY", 11, 13], ["small", "OBSERVATION_MODIFIER", 14, 19], ["differences", "OBSERVATION", 20, 31]]], ["The percentage of patients with a cancer diagnosis occurred more than 5 years before the COVID-19 hospitalization was 64.5% (89/138), 23.9% (33/138) had a diagnosis from 5 to \u22651 years, and 11.6% (16/138) had the cancer diagnosis in the last year.", [["cancer", "ANATOMY", 34, 40], ["cancer", "ANATOMY", 212, 218], ["cancer", "DISEASE", 34, 40], ["cancer", "DISEASE", 212, 218], ["patients", "ORGANISM", 18, 26], ["cancer", "CANCER", 34, 40], ["cancer", "CANCER", 212, 218], ["patients", "SPECIES", 18, 26], ["a cancer", "PROBLEM", 32, 40], ["the COVID", "TEST", 85, 94], ["the cancer", "PROBLEM", 208, 218], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["cancer", "OBSERVATION", 34, 40], ["cancer", "OBSERVATION", 212, 218]]], ["The five most frequent tumor sites were: prostate cancer (30 patients), breast cancer (27 patients), colorectal cancer (25 patients), bladder cancer (12 patients), and lung cancer (9 patients).", [["tumor sites", "ANATOMY", 23, 34], ["prostate cancer", "ANATOMY", 41, 56], ["breast cancer", "ANATOMY", 72, 85], ["colorectal cancer", "ANATOMY", 101, 118], ["bladder cancer", "ANATOMY", 134, 148], ["lung cancer", "ANATOMY", 168, 179], ["tumor", "DISEASE", 23, 28], ["prostate cancer", "DISEASE", 41, 56], ["breast cancer", "DISEASE", 72, 85], ["colorectal cancer", "DISEASE", 101, 118], ["bladder cancer", "DISEASE", 134, 148], ["lung cancer", "DISEASE", 168, 179], ["tumor", "CANCER", 23, 28], ["prostate cancer", "CANCER", 41, 56], ["patients", "ORGANISM", 61, 69], ["breast cancer", "CANCER", 72, 85], ["patients", "ORGANISM", 90, 98], ["colorectal cancer", "CANCER", 101, 118], ["patients", "ORGANISM", 123, 131], ["bladder cancer", "CANCER", 134, 148], ["patients", "ORGANISM", 153, 161], ["lung cancer", "CANCER", 168, 179], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 183, 191], ["The five most frequent tumor sites", "PROBLEM", 0, 34], ["prostate cancer", "PROBLEM", 41, 56], ["breast cancer", "PROBLEM", 72, 85], ["colorectal cancer", "PROBLEM", 101, 118], ["bladder cancer", "PROBLEM", 134, 148], ["lung cancer", "PROBLEM", 168, 179], ["five", "OBSERVATION_MODIFIER", 4, 8], ["most", "OBSERVATION_MODIFIER", 9, 13], ["frequent", "OBSERVATION_MODIFIER", 14, 22], ["tumor", "OBSERVATION", 23, 28], ["prostate", "ANATOMY", 41, 49], ["cancer", "OBSERVATION", 50, 56], ["breast", "ANATOMY", 72, 78], ["cancer", "OBSERVATION", 79, 85], ["colorectal", "ANATOMY", 101, 111], ["cancer", "OBSERVATION", 112, 118], ["bladder", "ANATOMY", 134, 141], ["cancer", "OBSERVATION", 142, 148], ["lung", "ANATOMY", 168, 172], ["cancer", "OBSERVATION", 173, 179]]], ["Patients with a period of time >5 years between cancer diagnosis and COVID-19 hospitalization had a higher median age (79 years; range 57-98) and more frequently had one or more comorbidities (chronic obstructive pulmonary disease in 13.5%, hypertension in 79.8%, cardiovascular disease in 62.9%, and diabetes mellitus in 31.5%) compared with patients with a more recent cancer diagnosis (Table 2, Figure 1 ).", [["cancer", "ANATOMY", 48, 54], ["pulmonary", "ANATOMY", 213, 222], ["cardiovascular", "ANATOMY", 264, 278], ["cancer", "ANATOMY", 371, 377], ["cancer", "DISEASE", 48, 54], ["chronic obstructive pulmonary disease", "DISEASE", 193, 230], ["hypertension", "DISEASE", 241, 253], ["cardiovascular disease", "DISEASE", 264, 286], ["diabetes mellitus", "DISEASE", 301, 318], ["cancer", "DISEASE", 371, 377], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 48, 54], ["pulmonary", "ORGAN", 213, 222], ["patients", "ORGANISM", 343, 351], ["cancer", "CANCER", 371, 377], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 343, 351], ["chronic obstructive pulmonary disease", "PROBLEM", 193, 230], ["hypertension", "PROBLEM", 241, 253], ["cardiovascular disease", "PROBLEM", 264, 286], ["diabetes mellitus", "PROBLEM", 301, 318], ["a more recent cancer diagnosis", "PROBLEM", 357, 387], ["chronic", "OBSERVATION_MODIFIER", 193, 200], ["obstructive", "OBSERVATION_MODIFIER", 201, 212], ["pulmonary", "ANATOMY", 213, 222], ["disease", "OBSERVATION", 223, 230], ["cancer", "OBSERVATION", 371, 377]]], ["The number of cancer patients hospitalized with SARS-CoV-2 infection was 138 (11.3%) for a standardized hospitalization ratio compared with the general population-98 (95% CI 73-131).", [["cancer", "ANATOMY", 14, 20], ["cancer", "DISEASE", 14, 20], ["SARS-CoV-2 infection", "DISEASE", 48, 68], ["cancer", "CANCER", 14, 20], ["patients", "ORGANISM", 21, 29], ["SARS-CoV-2", "ORGANISM", 48, 58], ["patients", "SPECIES", 21, 29], ["SARS-CoV-2", "SPECIES", 48, 58], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["2 infection", "PROBLEM", 57, 68], ["a standardized hospitalization ratio", "TEST", 89, 125], ["CI", "TEST", 171, 173], ["cancer", "OBSERVATION", 14, 20]]], ["There were no small differences or no differences between the hospitalized patients with and without cancer by median age (76 vs. 73 years), risk of ICU admission (10.1% vs. 6.7%; OR 1.23, 95% CI 0.63-2.41), and fatality rate (34.1% vs. 26.0%; OR 1.07, 95% CI 0.71-1.61).", [["cancer", "ANATOMY", 101, 107], ["cancer", "DISEASE", 101, 107], ["patients", "ORGANISM", 75, 83], ["cancer", "CANCER", 101, 107], ["patients", "SPECIES", 75, 83], ["small differences", "PROBLEM", 14, 31], ["cancer", "PROBLEM", 101, 107], ["CI", "TEST", 193, 195], ["fatality rate", "TEST", 212, 225], ["CI", "TEST", 257, 259], ["no", "UNCERTAINTY", 11, 13], ["small", "OBSERVATION_MODIFIER", 14, 19], ["differences", "OBSERVATION", 20, 31]]], ["The percentage of patients with a cancer diagnosis occurred more than 5 years before the COVID-19 hospitalization was 64.5% (89/138), 23.9% (33/138) had a diagnosis from 5 to \u22651 years, and 11.6% (16/138) had the cancer diagnosis in the last year.", [["cancer", "ANATOMY", 34, 40], ["cancer", "ANATOMY", 212, 218], ["cancer", "DISEASE", 34, 40], ["cancer", "DISEASE", 212, 218], ["patients", "ORGANISM", 18, 26], ["cancer", "CANCER", 34, 40], ["cancer", "CANCER", 212, 218], ["patients", "SPECIES", 18, 26], ["a cancer", "PROBLEM", 32, 40], ["the COVID", "TEST", 85, 94], ["the cancer", "PROBLEM", 208, 218], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["cancer", "OBSERVATION", 34, 40], ["cancer", "OBSERVATION", 212, 218]]], ["The five most frequent tumor sites were: prostate cancer (30 patients), breast cancer (27 patients), colorectal cancer (25 patients), bladder cancer (12 patients), and lung cancer (9 patients).", [["tumor sites", "ANATOMY", 23, 34], ["prostate cancer", "ANATOMY", 41, 56], ["breast cancer", "ANATOMY", 72, 85], ["colorectal cancer", "ANATOMY", 101, 118], ["bladder cancer", "ANATOMY", 134, 148], ["lung cancer", "ANATOMY", 168, 179], ["tumor", "DISEASE", 23, 28], ["prostate cancer", "DISEASE", 41, 56], ["breast cancer", "DISEASE", 72, 85], ["colorectal cancer", "DISEASE", 101, 118], ["bladder cancer", "DISEASE", 134, 148], ["lung cancer", "DISEASE", 168, 179], ["tumor", "CANCER", 23, 28], ["prostate cancer", "CANCER", 41, 56], ["patients", "ORGANISM", 61, 69], ["breast cancer", "CANCER", 72, 85], ["patients", "ORGANISM", 90, 98], ["colorectal cancer", "CANCER", 101, 118], ["patients", "ORGANISM", 123, 131], ["bladder cancer", "CANCER", 134, 148], ["patients", "ORGANISM", 153, 161], ["lung cancer", "CANCER", 168, 179], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 183, 191], ["The five most frequent tumor sites", "PROBLEM", 0, 34], ["prostate cancer", "PROBLEM", 41, 56], ["breast cancer", "PROBLEM", 72, 85], ["colorectal cancer", "PROBLEM", 101, 118], ["bladder cancer", "PROBLEM", 134, 148], ["lung cancer", "PROBLEM", 168, 179], ["five", "OBSERVATION_MODIFIER", 4, 8], ["most", "OBSERVATION_MODIFIER", 9, 13], ["frequent", "OBSERVATION_MODIFIER", 14, 22], ["tumor", "OBSERVATION", 23, 28], ["prostate", "ANATOMY", 41, 49], ["cancer", "OBSERVATION", 50, 56], ["breast", "ANATOMY", 72, 78], ["cancer", "OBSERVATION", 79, 85], ["colorectal", "ANATOMY", 101, 111], ["cancer", "OBSERVATION", 112, 118], ["bladder", "ANATOMY", 134, 141], ["cancer", "OBSERVATION", 142, 148], ["lung", "ANATOMY", 168, 172], ["cancer", "OBSERVATION", 173, 179]]], ["Patients with a period of time >5 years between cancer diagnosis and COVID-19 hospitalization had a higher median age (79 years; range 57-98) and more frequently had one or more comorbidities (chronic obstructive pulmonary disease in 13.5%, hypertension in 79.8%, cardiovascular disease in 62.9%, and diabetes mellitus in 31.5%) compared with patients with a more recent cancer diagnosis (Table 2, Figure 1 ).", [["cancer", "ANATOMY", 48, 54], ["pulmonary", "ANATOMY", 213, 222], ["cardiovascular", "ANATOMY", 264, 278], ["cancer", "ANATOMY", 371, 377], ["cancer", "DISEASE", 48, 54], ["chronic obstructive pulmonary disease", "DISEASE", 193, 230], ["hypertension", "DISEASE", 241, 253], ["cardiovascular disease", "DISEASE", 264, 286], ["diabetes mellitus", "DISEASE", 301, 318], ["cancer", "DISEASE", 371, 377], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 48, 54], ["pulmonary", "ORGAN", 213, 222], ["patients", "ORGANISM", 343, 351], ["cancer", "CANCER", 371, 377], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 343, 351], ["chronic obstructive pulmonary disease", "PROBLEM", 193, 230], ["hypertension", "PROBLEM", 241, 253], ["cardiovascular disease", "PROBLEM", 264, 286], ["diabetes mellitus", "PROBLEM", 301, 318], ["a more recent cancer diagnosis", "PROBLEM", 357, 387], ["chronic", "OBSERVATION_MODIFIER", 193, 200], ["obstructive", "OBSERVATION_MODIFIER", 201, 212], ["pulmonary", "ANATOMY", 213, 222], ["disease", "OBSERVATION", 223, 230], ["cancer", "OBSERVATION", 371, 377]]], ["Having a recent cancer diagnosis, COPD, and diabetes were associated with lower mortality, while former smokers had higher mortality than smokers and never smokers in this subpopulation.", [["cancer", "ANATOMY", 16, 22], ["cancer", "DISEASE", 16, 22], ["COPD", "DISEASE", 34, 38], ["diabetes", "DISEASE", 44, 52], ["cancer", "CANCER", 16, 22], ["a recent cancer diagnosis", "PROBLEM", 7, 32], ["COPD", "PROBLEM", 34, 38], ["diabetes", "PROBLEM", 44, 52], ["cancer", "OBSERVATION", 16, 22], ["COPD", "OBSERVATION", 34, 38], ["diabetes", "OBSERVATION", 44, 52]]], ["Male gender (OR 1.66, 95% CI 0.77-3.55), metastatic disease (OR 2.14, 0.50-9.16), and bladder cancer (OR 1.52, 95% CI 0.42-5.47) were associated with an overall OR of death or ICU admission.", [["metastatic disease", "ANATOMY", 41, 59], ["bladder cancer", "ANATOMY", 86, 100], ["bladder cancer", "DISEASE", 86, 100], ["death", "DISEASE", 167, 172], ["bladder cancer", "CANCER", 86, 100], ["CI", "TEST", 26, 28], ["metastatic disease", "PROBLEM", 41, 59], ["bladder cancer", "PROBLEM", 86, 100], ["CI", "TEST", 115, 117], ["metastatic", "OBSERVATION", 41, 51], ["bladder", "ANATOMY", 86, 93], ["cancer", "OBSERVATION", 94, 100]]], ["A total of 14 (1.1%) cancer patients had ongoing oncological treatment within 60 days before the COVID-19 infection hospitalization (Table 5) .", [["cancer", "ANATOMY", 21, 27], ["cancer", "DISEASE", 21, 27], ["infection", "DISEASE", 106, 115], ["cancer", "CANCER", 21, 27], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["ongoing oncological treatment", "TREATMENT", 41, 70], ["the COVID-19 infection hospitalization", "TREATMENT", 93, 131], ["total", "OBSERVATION_MODIFIER", 2, 7], ["infection", "OBSERVATION", 106, 115]]], ["A lung involvement was detected in 9 (64.3%) of these patients (3 primary tumors and 6 lung metastases).", [["lung", "ANATOMY", 2, 6], ["primary tumors", "ANATOMY", 66, 80], ["lung metastases", "ANATOMY", 87, 102], ["primary tumors", "DISEASE", 66, 80], ["lung metastases", "DISEASE", 87, 102], ["lung", "ORGAN", 2, 6], ["patients", "ORGANISM", 54, 62], ["tumors", "CANCER", 74, 80], ["lung", "ORGAN", 87, 91], ["patients", "SPECIES", 54, 62], ["A lung involvement", "PROBLEM", 0, 18], ["3 primary tumors", "PROBLEM", 64, 80], ["6 lung metastases", "PROBLEM", 85, 102], ["lung", "ANATOMY", 2, 6], ["involvement", "OBSERVATION", 7, 18], ["primary", "OBSERVATION_MODIFIER", 66, 73], ["tumors", "OBSERVATION", 74, 80], ["lung", "ANATOMY", 87, 91], ["metastases", "OBSERVATION", 92, 102]]], ["Bladder cancer (3 patients) and ovarian cancer (3 patients) were the other most two frequent tumor types.", [["Bladder cancer", "ANATOMY", 0, 14], ["ovarian cancer", "ANATOMY", 32, 46], ["tumor", "ANATOMY", 93, 98], ["Bladder cancer", "DISEASE", 0, 14], ["ovarian cancer", "DISEASE", 32, 46], ["tumor", "DISEASE", 93, 98], ["Bladder cancer", "CANCER", 0, 14], ["patients", "ORGANISM", 18, 26], ["ovarian cancer", "CANCER", 32, 46], ["patients", "ORGANISM", 50, 58], ["tumor", "CANCER", 93, 98], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 50, 58], ["Bladder cancer", "PROBLEM", 0, 14], ["ovarian cancer", "PROBLEM", 32, 46], ["two frequent tumor types", "PROBLEM", 80, 104], ["cancer", "OBSERVATION", 8, 14], ["ovarian", "ANATOMY", 32, 39], ["cancer", "OBSERVATION", 40, 46], ["most two", "OBSERVATION_MODIFIER", 75, 83], ["frequent", "OBSERVATION_MODIFIER", 84, 92], ["tumor", "OBSERVATION", 93, 98]]], ["Most of the patients had metastatic disease (78.6%).", [["metastatic disease", "ANATOMY", 25, 43], ["patients", "ORGANISM", 12, 20], ["metastatic disease", "CANCER", 25, 43], ["patients", "SPECIES", 12, 20], ["metastatic disease", "PROBLEM", 25, 43], ["metastatic", "OBSERVATION", 25, 35]]], ["Chemotherapy was administered in 12 (85.7%) cases (alone in 8 patients, in combination with antiangiogenic drugs in 4 patients and with immunotherapy in 1 patient).", [["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 118, 126], ["patient", "ORGANISM", 155, 162], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 118, 126], ["patient", "SPECIES", 155, 162], ["Chemotherapy", "TREATMENT", 0, 12], ["antiangiogenic drugs", "TREATMENT", 92, 112], ["immunotherapy", "TREATMENT", 136, 149]]], ["Two patients underwent hormone therapy (tamoxifen in 1 breast cancer patient and leuprolide plus enzalutamide in 1 prostate cancer patient).", [["breast cancer", "ANATOMY", 55, 68], ["prostate cancer", "ANATOMY", 115, 130], ["tamoxifen", "CHEMICAL", 40, 49], ["breast cancer", "DISEASE", 55, 68], ["leuprolide", "CHEMICAL", 81, 91], ["enzalutamide", "CHEMICAL", 97, 109], ["prostate cancer", "DISEASE", 115, 130], ["tamoxifen", "CHEMICAL", 40, 49], ["leuprolide", "CHEMICAL", 81, 91], ["enzalutamide", "CHEMICAL", 97, 109], ["patients", "ORGANISM", 4, 12], ["tamoxifen", "SIMPLE_CHEMICAL", 40, 49], ["breast cancer", "CANCER", 55, 68], ["patient", "ORGANISM", 69, 76], ["leuprolide", "SIMPLE_CHEMICAL", 81, 91], ["enzalutamide", "SIMPLE_CHEMICAL", 97, 109], ["prostate cancer", "CANCER", 115, 130], ["patient", "ORGANISM", 131, 138], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 69, 76], ["patient", "SPECIES", 131, 138], ["hormone therapy", "TREATMENT", 23, 38], ["tamoxifen in 1 breast cancer", "TREATMENT", 40, 68], ["leuprolide", "TREATMENT", 81, 91], ["enzalutamide", "TREATMENT", 97, 109], ["hormone therapy", "OBSERVATION", 23, 38], ["breast", "ANATOMY", 55, 61], ["cancer", "OBSERVATION", 62, 68], ["prostate", "ANATOMY", 115, 123], ["cancer", "OBSERVATION", 124, 130]]], ["The treatment of COVID-19 infection for those patients was: hydroxychloroquine and/or azithromycin in the 92.8%, antiviral drugs in the 50%, and glucocorticoids and heparin in the 85.7%.", [["COVID-19", "CHEMICAL", 17, 25], ["infection", "DISEASE", 26, 35], ["hydroxychloroquine", "CHEMICAL", 60, 78], ["azithromycin", "CHEMICAL", 86, 98], ["glucocorticoids", "CHEMICAL", 145, 160], ["heparin", "CHEMICAL", 165, 172], ["hydroxychloroquine", "CHEMICAL", 60, 78], ["azithromycin", "CHEMICAL", 86, 98], ["COVID-19", "ORGANISM", 17, 25], ["patients", "ORGANISM", 46, 54], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 60, 78], ["azithromycin", "SIMPLE_CHEMICAL", 86, 98], ["glucocorticoids", "SIMPLE_CHEMICAL", 145, 160], ["heparin", "SIMPLE_CHEMICAL", 165, 172], ["patients", "SPECIES", 46, 54], ["COVID-19", "SPECIES", 17, 25], ["COVID-19 infection", "PROBLEM", 17, 35], ["hydroxychloroquine", "TREATMENT", 60, 78], ["azithromycin", "TREATMENT", 86, 98], ["antiviral drugs", "TREATMENT", 113, 128], ["glucocorticoids", "TREATMENT", 145, 160], ["heparin", "TREATMENT", 165, 172]]], ["Fatal events occurred in 5/14 (35.6%) in all-male patients (2 colorectal cancer, 2 bladder cancer, and 1 non-small cell lung cancer).", [["colorectal cancer", "ANATOMY", 62, 79], ["bladder cancer", "ANATOMY", 83, 97], ["non-small cell lung cancer", "ANATOMY", 105, 131], ["colorectal cancer", "DISEASE", 62, 79], ["bladder cancer", "DISEASE", 83, 97], ["small cell lung cancer", "DISEASE", 109, 131], ["patients", "ORGANISM", 50, 58], ["colorectal cancer", "CANCER", 62, 79], ["bladder cancer", "CANCER", 83, 97], ["non-small cell lung cancer", "CANCER", 105, 131], ["patients", "SPECIES", 50, 58], ["Fatal events", "PROBLEM", 0, 12], ["2 colorectal cancer", "PROBLEM", 60, 79], ["2 bladder cancer", "PROBLEM", 81, 97], ["1 non-small cell lung cancer", "PROBLEM", 103, 131], ["colorectal", "ANATOMY", 62, 72], ["cancer", "OBSERVATION", 73, 79], ["bladder", "ANATOMY", 83, 90], ["cancer", "OBSERVATION", 91, 97], ["non-small", "OBSERVATION_MODIFIER", 105, 114], ["cell", "OBSERVATION", 115, 119], ["lung", "ANATOMY", 120, 124], ["cancer", "OBSERVATION", 125, 131]]], ["The median age of patients was 79 years (range 65-81).", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26]]], ["Of the 5 deceased patients, 4 were current/former smokers, 3 were taking medical therapy for hypertension, and only one had been vaccinated for influenza virus.", [["hypertension", "DISEASE", 93, 105], ["influenza virus", "DISEASE", 144, 159], ["patients", "ORGANISM", 18, 26], ["influenza virus", "ORGANISM", 144, 159], ["patients", "SPECIES", 18, 26], ["medical therapy", "TREATMENT", 73, 88], ["hypertension", "PROBLEM", 93, 105], ["influenza virus", "PROBLEM", 144, 159]]], ["Lastly, 4/5 (80%) patients had a metastatic disease and underwent to chemotherapy; specifically, 2 patients with chemotherapy alone and 2 patients with chemotherapy plus antiangiogenic therapy.DiscussionConsidering the estimated prevalence of resident people who had a diagnosis of cancer in their life, we found a similar hospitalization rate for COVID-19 compared with the general population (SHR 98, 95% CI 73-131), suggesting small, if any, differences in susceptibility to infection.", [["cancer", "ANATOMY", 282, 288], ["cancer", "DISEASE", 282, 288], ["infection", "DISEASE", 478, 487], ["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 99, 107], ["patients", "ORGANISM", 138, 146], ["people", "ORGANISM", 252, 258], ["cancer", "CANCER", 282, 288], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 138, 146], ["people", "SPECIES", 252, 258], ["a metastatic disease", "PROBLEM", 31, 51], ["chemotherapy", "TREATMENT", 69, 81], ["chemotherapy", "TREATMENT", 113, 125], ["chemotherapy", "TREATMENT", 152, 164], ["antiangiogenic therapy", "TREATMENT", 170, 192], ["cancer", "PROBLEM", 282, 288], ["COVID", "TEST", 348, 353], ["SHR", "TEST", 395, 398], ["CI", "TEST", 407, 409], ["infection", "PROBLEM", 478, 487], ["metastatic", "OBSERVATION", 33, 43], ["cancer", "OBSERVATION", 282, 288], ["small", "OBSERVATION_MODIFIER", 430, 435], ["infection", "OBSERVATION", 478, 487]]], ["Surprisingly, within hospitalized COVID-19 patients, we found no excess of ICU admission and deaths in patients with cancer compared with patients without cancer.", [["cancer", "ANATOMY", 117, 123], ["cancer", "ANATOMY", 155, 161], ["deaths", "DISEASE", 93, 99], ["cancer", "DISEASE", 117, 123], ["cancer", "DISEASE", 155, 161], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 103, 111], ["cancer", "CANCER", 117, 123], ["patients", "ORGANISM", 138, 146], ["cancer", "CANCER", 155, 161], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 138, 146], ["cancer", "PROBLEM", 117, 123], ["cancer", "PROBLEM", 155, 161], ["cancer", "OBSERVATION", 117, 123], ["cancer", "OBSERVATION", 155, 161]]], ["This finding is consistent with the results obtained in a cohort of patients with COVID-19 in the same area, that showed a small excess of death (HR 1.4), but also a small excess of being hospitalized (HR 1.4), suggesting that, once hospitalized, there should not be any excess of death [27] .", [["death", "DISEASE", 139, 144], ["death", "DISEASE", 281, 286], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["COVID", "TEST", 82, 87], ["a small excess of death", "PROBLEM", 121, 144], ["HR", "TEST", 146, 148], ["HR", "TEST", 202, 204], ["consistent with", "UNCERTAINTY", 16, 31], ["small", "OBSERVATION_MODIFIER", 123, 128], ["excess", "OBSERVATION_MODIFIER", 129, 135], ["small", "OBSERVATION_MODIFIER", 166, 171]]], ["Among cancer patients only having a metastatic disease, there was a strong determinant of mortality, together with age and male gender; a small increase was also observed for cardiovascular disease.", [["cancer", "ANATOMY", 6, 12], ["cardiovascular", "ANATOMY", 175, 189], ["cancer", "DISEASE", 6, 12], ["cardiovascular disease", "DISEASE", 175, 197], ["cancer", "CANCER", 6, 12], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["a metastatic disease", "PROBLEM", 34, 54], ["a small increase", "PROBLEM", 136, 152], ["cardiovascular disease", "PROBLEM", 175, 197], ["cancer", "OBSERVATION", 6, 12], ["metastatic", "OBSERVATION", 36, 46], ["small", "OBSERVATION_MODIFIER", 138, 143], ["increase", "OBSERVATION", 144, 152]]], ["On the contrary, having a recent diagnosis, diabetes, and COPD were associated with lower mortality in this cohort of hospitalized COVID-19 patients with cancer, suggesting that probably these conditions favor hospitalization of patients even when COVID-disease is less severe or life-threatening.DiscussionAmong the limits of this study, the small number of cancer patients affects the precision of our estimates, particularly for the comparisons within cancer patients.", [["cancer", "ANATOMY", 154, 160], ["cancer", "ANATOMY", 359, 365], ["cancer", "ANATOMY", 455, 461], ["diabetes", "DISEASE", 44, 52], ["COPD", "DISEASE", 58, 62], ["cancer", "DISEASE", 154, 160], ["cancer", "DISEASE", 359, 365], ["cancer", "DISEASE", 455, 461], ["patients", "ORGANISM", 140, 148], ["cancer", "CANCER", 154, 160], ["patients", "ORGANISM", 229, 237], ["cancer", "CANCER", 359, 365], ["patients", "ORGANISM", 366, 374], ["cancer", "CANCER", 455, 461], ["patients", "ORGANISM", 462, 470], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 366, 374], ["patients", "SPECIES", 462, 470], ["diabetes", "PROBLEM", 44, 52], ["COPD", "PROBLEM", 58, 62], ["cancer", "PROBLEM", 154, 160], ["these conditions", "PROBLEM", 187, 203], ["disease", "PROBLEM", 254, 261], ["this study", "TEST", 327, 337], ["diabetes", "OBSERVATION", 44, 52], ["COPD", "OBSERVATION", 58, 62], ["cancer", "OBSERVATION", 154, 160], ["less severe", "OBSERVATION_MODIFIER", 265, 276], ["small", "OBSERVATION_MODIFIER", 343, 348], ["cancer", "OBSERVATION", 359, 365]]], ["Another limit is that we only included hospitalized patients, thus we could not study the effect of having had a cancer on the probability of infection and mortality.", [["cancer", "ANATOMY", 113, 119], ["cancer", "DISEASE", 113, 119], ["infection", "DISEASE", 142, 151], ["patients", "ORGANISM", 52, 60], ["cancer", "CANCER", 113, 119], ["patients", "SPECIES", 52, 60], ["a cancer", "PROBLEM", 111, 119], ["infection", "PROBLEM", 142, 151], ["cancer", "OBSERVATION", 113, 119], ["infection", "OBSERVATION", 142, 151]]], ["Furthermore, limiting the cohort to hospitalized patients may introduce a collider bias, in fact some conditions, in particular comorbidities, may increase the probability of being hospitalized in COVID-19 patients.", [["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 206, 214], ["a collider bias", "TREATMENT", 72, 87]]], ["Therefore, their effect on mortality can be masked or even reverted, when comparing the mortality of people with the comorbidity and those without the comorbidity, conditional that both have been hospitalized.DiscussionSome early reports on the Chinese population suggest that cancer patients are at higher risk of SARS-CoV-2 infection and could have higher morbidity and mortality than the general population.", [["cancer", "ANATOMY", 277, 283], ["cancer", "DISEASE", 277, 283], ["SARS-CoV-2 infection", "DISEASE", 315, 335], ["people", "ORGANISM", 101, 107], ["cancer", "CANCER", 277, 283], ["patients", "ORGANISM", 284, 292], ["SARS-CoV-2", "ORGANISM", 315, 325], ["people", "SPECIES", 101, 107], ["patients", "SPECIES", 284, 292], ["SARS-CoV", "SPECIES", 315, 323], ["the comorbidity", "PROBLEM", 113, 128], ["the comorbidity", "PROBLEM", 147, 162], ["cancer", "PROBLEM", 277, 283], ["SARS", "PROBLEM", 315, 319], ["CoV-2 infection", "PROBLEM", 320, 335], ["higher morbidity", "PROBLEM", 351, 367], ["the general population", "PROBLEM", 387, 409], ["cancer", "OBSERVATION", 277, 283], ["SARS", "OBSERVATION", 315, 319], ["higher", "OBSERVATION_MODIFIER", 351, 357], ["morbidity", "OBSERVATION", 358, 367]]], ["In a nationwide analysis that collected 1590 COVID-19 cases from 575 Chinese hospitals, 18 (1%) patients had a history of cancer, which seems to be higher than the cancer incidence in China of 285.83 per 100,000 people (0.29%).", [["cancer", "ANATOMY", 122, 128], ["cancer", "ANATOMY", 164, 170], ["cancer", "DISEASE", 122, 128], ["cancer", "DISEASE", 164, 170], ["patients", "ORGANISM", 96, 104], ["cancer", "CANCER", 122, 128], ["cancer", "CANCER", 164, 170], ["patients", "SPECIES", 96, 104], ["people", "SPECIES", 212, 218], ["a nationwide analysis", "TEST", 3, 24], ["cancer", "PROBLEM", 122, 128], ["cancer", "OBSERVATION", 122, 128], ["higher", "OBSERVATION_MODIFIER", 148, 154], ["cancer", "OBSERVATION", 164, 170]]], ["Cancer diseases were associated to a higher risk of severe events, defined as admission to the ICU or death, seen in 7/18 (39%) patients with cancer compared with 124/1572 (8%) patients without cancer (p = 0.0003) [12] .", [["Cancer", "ANATOMY", 0, 6], ["cancer", "ANATOMY", 142, 148], ["cancer", "ANATOMY", 194, 200], ["Cancer diseases", "DISEASE", 0, 15], ["death", "DISEASE", 102, 107], ["cancer", "DISEASE", 142, 148], ["cancer", "DISEASE", 194, 200], ["Cancer", "CANCER", 0, 6], ["patients", "ORGANISM", 128, 136], ["cancer", "CANCER", 142, 148], ["patients", "ORGANISM", 177, 185], ["cancer", "CANCER", 194, 200], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 177, 185], ["Cancer diseases", "PROBLEM", 0, 15], ["severe events", "PROBLEM", 52, 65], ["death", "PROBLEM", 102, 107], ["cancer", "PROBLEM", 142, 148], ["cancer", "PROBLEM", 194, 200], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["cancer", "OBSERVATION", 142, 148], ["without", "UNCERTAINTY", 186, 193], ["cancer", "OBSERVATION", 194, 200]]], ["In another series from a single institution (Zhongnan Hospital of Wuhan University), the infection rate of SARS-Cov-2 in patients with cancer was 0.79%, which was higher than the cumulative incidence of all diagnosed COVID-19 cases in the city of Wuhan over the same time period (41,152 cases on 11,081,000 residents, 0.37%) [13] .", [["cancer", "ANATOMY", 135, 141], ["infection", "DISEASE", 89, 98], ["SARS", "DISEASE", 107, 111], ["cancer", "DISEASE", 135, 141], ["COVID", "DISEASE", 217, 222], ["patients", "ORGANISM", 121, 129], ["cancer", "CANCER", 135, 141], ["patients", "SPECIES", 121, 129], ["the infection rate of SARS", "PROBLEM", 85, 111], ["Cov", "TEST", 112, 115], ["cancer", "PROBLEM", 135, 141], ["infection", "OBSERVATION", 89, 98], ["cancer", "OBSERVATION", 135, 141]]], ["In the retrospective cohort study, which included 28 COVID-19 infected cancer patients from three hospitals in Wuhan, 15 (53.6%) patients had severe events and mortality was 28.6% [14] .", [["cancer", "ANATOMY", 71, 77], ["infected cancer", "DISEASE", 62, 77], ["cancer", "CANCER", 71, 77], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 129, 137], ["the retrospective cohort study", "TEST", 3, 33], ["COVID", "TEST", 53, 58], ["infected cancer", "PROBLEM", 62, 77], ["severe events", "PROBLEM", 142, 155], ["mortality", "TEST", 160, 169], ["infected", "OBSERVATION_MODIFIER", 62, 70], ["cancer", "OBSERVATION", 71, 77]]], ["The Chinese Center for Disease Control and Prevention reported the characteristics of 72,314 COVID-19 cases.", [["Disease Control", "TREATMENT", 23, 38], ["COVID", "TEST", 93, 98]]], ["In the 107 (0.5%) cancer patients, the mortality was 5.6%, higher than the overall reported deaths from COVID-19 (2.3%) [15] .", [["cancer", "ANATOMY", 18, 24], ["cancer", "DISEASE", 18, 24], ["deaths", "DISEASE", 92, 98], ["cancer", "CANCER", 18, 24], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["the mortality", "TEST", 35, 48], ["COVID", "TEST", 104, 109]]], ["The WHO-China Joint Mission on COVID-19 also reported higher mortality among patients with pre-existing cancers (7.6%) than patients without comorbidity (1.4%) [16] .", [["cancers", "ANATOMY", 104, 111], ["cancers", "DISEASE", 104, 111], ["patients", "ORGANISM", 77, 85], ["cancers", "CANCER", 104, 111], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 124, 132], ["pre-existing cancers", "PROBLEM", 91, 111], ["comorbidity", "PROBLEM", 141, 152], ["Joint", "ANATOMY", 14, 19], ["cancers", "OBSERVATION", 104, 111]]], ["A multi-center study performed in 14 hospitals of Hubei Province evaluated 105 patients with cancer and 536 without cancer.", [["cancer", "ANATOMY", 93, 99], ["cancer", "ANATOMY", 116, 122], ["cancer", "DISEASE", 93, 99], ["cancer", "DISEASE", 116, 122], ["patients", "ORGANISM", 79, 87], ["cancer", "CANCER", 93, 99], ["cancer", "CANCER", 116, 122], ["patients", "SPECIES", 79, 87], ["A multi-center study", "TEST", 0, 20], ["cancer", "PROBLEM", 93, 99], ["cancer", "PROBLEM", 116, 122], ["cancer", "OBSERVATION", 93, 99], ["without", "UNCERTAINTY", 108, 115], ["cancer", "OBSERVATION", 116, 122]]], ["Compared with COVID-19 patients without cancer, cancer patients had higher rates of ICU admissions (OR 2.84; p < 0.01) and deaths (OR 2.34; p = 0.03) [17] .DiscussionA total of 167 cases of COVID-19 were found in the United States in a long-term care facility in King Country, Washington (101 residents, 50 health care personnel, and 16 visitors).", [["cancer", "ANATOMY", 40, 46], ["cancer", "ANATOMY", 48, 54], ["cancer", "DISEASE", 40, 46], ["cancer", "DISEASE", 48, 54], ["deaths", "DISEASE", 123, 129], ["patients", "ORGANISM", 23, 31], ["cancer", "CANCER", 40, 46], ["cancer", "CANCER", 48, 54], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 55, 63], ["cancer", "PROBLEM", 40, 46], ["cancer", "PROBLEM", 48, 54], ["COVID", "TEST", 190, 195], ["without", "UNCERTAINTY", 32, 39], ["cancer", "OBSERVATION", 40, 46], ["cancer", "OBSERVATION", 48, 54]]], ["Most facility residents (94.1% of 101) had a chronic underlying health condition, which was cancer in 15 (14.9%) [28] .", [["cancer", "ANATOMY", 92, 98], ["cancer", "DISEASE", 92, 98], ["cancer", "CANCER", 92, 98], ["a chronic underlying health condition", "PROBLEM", 43, 80], ["chronic", "OBSERVATION_MODIFIER", 45, 52]]], ["Among the 393 patients with confirmed COVID-19 admitted between 5 March (date of the first positive case) and 27 March 2020 at a referral center and community hospital of Manhattan, New York City, 23 (5.9%) were cancer patients.", [["cancer", "ANATOMY", 212, 218], ["cancer", "DISEASE", 212, 218], ["patients", "ORGANISM", 14, 22], ["cancer", "CANCER", 212, 218], ["patients", "ORGANISM", 219, 227], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 219, 227]]], ["The cancer patients underwent mechanical and non-mechanical ventilation in 7.7% and 4.9% of cases, respectively [29] .", [["cancer", "ANATOMY", 4, 10], ["cancer", "DISEASE", 4, 10], ["cancer", "CANCER", 4, 10], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["The cancer", "PROBLEM", 0, 10], ["mechanical and non-mechanical ventilation", "TREATMENT", 30, 71], ["cancer", "OBSERVATION", 4, 10]]], ["A total of 164 patients with COVID-19 infection and solid tumors were treated in Montefiore Health Hospital System in New York, from 18 March to 8 April 2020.", [["solid tumors", "ANATOMY", 52, 64], ["COVID-19 infection", "DISEASE", 29, 47], ["tumors", "DISEASE", 58, 64], ["patients", "ORGANISM", 15, 23], ["solid tumors", "CANCER", 52, 64], ["patients", "SPECIES", 15, 23], ["COVID", "TEST", 29, 34], ["infection", "PROBLEM", 38, 47], ["solid tumors", "PROBLEM", 52, 64], ["infection", "OBSERVATION", 38, 47], ["solid", "OBSERVATION_MODIFIER", 52, 57], ["tumors", "OBSERVATION", 58, 64]]], ["The mortality was 25% for all patients suffering of solid tumors.", [["solid tumors", "ANATOMY", 52, 64], ["tumors", "DISEASE", 58, 64], ["patients", "ORGANISM", 30, 38], ["solid tumors", "CANCER", 52, 64], ["patients", "SPECIES", 30, 38], ["solid tumors", "PROBLEM", 52, 64], ["solid tumors", "OBSERVATION", 52, 64]]], ["Active chemotherapy and radiation therapy treatment were not associated with increase case fatality [18] .", [["Active chemotherapy", "TREATMENT", 0, 19], ["radiation therapy treatment", "TREATMENT", 24, 51], ["chemotherapy", "OBSERVATION", 7, 19], ["radiation therapy", "OBSERVATION", 24, 41]]], ["In a subsample of 355 patients with COVID-19 who died in Italy, 87 (24.5%) patients had active cancer [30] .DiscussionIn the Reggio Emilia Study, 138 (11.3%) of 1226 hospitalized COVID-19 patients had a history of cancer.", [["cancer", "ANATOMY", 95, 101], ["cancer", "ANATOMY", 214, 220], ["cancer", "DISEASE", 95, 101], ["cancer", "DISEASE", 214, 220], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 75, 83], ["cancer", "CANCER", 95, 101], ["patients", "ORGANISM", 188, 196], ["cancer", "CANCER", 214, 220], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 188, 196], ["active cancer", "PROBLEM", 88, 101], ["cancer", "PROBLEM", 214, 220], ["active", "OBSERVATION_MODIFIER", 88, 94], ["cancer", "OBSERVATION", 95, 101], ["cancer", "OBSERVATION", 214, 220]]], ["Comparing all hospitalized COVID-19 cancer patients with patients without cancer, there were small or no differences in median age (76 vs. 73 years), admission to the ICU (10.1% vs. 6.7%), fatal events (34.1% vs. 26.0%), and in the severity of lung scan CT findings.", [["cancer", "ANATOMY", 36, 42], ["cancer", "ANATOMY", 74, 80], ["lung", "ANATOMY", 244, 248], ["cancer", "DISEASE", 36, 42], ["cancer", "DISEASE", 74, 80], ["COVID-19 cancer", "CANCER", 27, 42], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 57, 65], ["cancer", "CANCER", 74, 80], ["lung", "ORGAN", 244, 248], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 57, 65], ["cancer", "PROBLEM", 74, 80], ["fatal events", "PROBLEM", 189, 201], ["lung scan CT findings", "TEST", 244, 265], ["without", "UNCERTAINTY", 66, 73], ["cancer", "OBSERVATION", 74, 80], ["small", "OBSERVATION_MODIFIER", 93, 98], ["no", "UNCERTAINTY", 102, 104], ["lung", "ANATOMY", 244, 248]]], ["These data are different from those described in the reports in China, and there could be several reasons for these discrepancies.", [["these discrepancies", "PROBLEM", 110, 129], ["different", "OBSERVATION_MODIFIER", 15, 24]]], ["Generally, the composition by age and the overall/site incidence of tumors are different between the Chinese and Italian populations.", [["tumors", "ANATOMY", 68, 74], ["tumors", "DISEASE", 68, 74], ["tumors", "CANCER", 68, 74], ["tumors", "PROBLEM", 68, 74], ["tumors", "OBSERVATION", 68, 74], ["different", "OBSERVATION_MODIFIER", 79, 88]]], ["The cancer incidence in Italy and in China is 562.54 and 285.83 per 100,000 people, respectively [31, 32] .", [["cancer", "ANATOMY", 4, 10], ["cancer", "DISEASE", 4, 10], ["cancer", "CANCER", 4, 10], ["people", "SPECIES", 76, 82], ["cancer", "OBSERVATION", 4, 10], ["China", "ANATOMY", 37, 42]]], ["The distribution of COVID-19 infected cases is very different in the two countries: people aged \u226570 years represent 37.6% of cases in Italy and only 11.9% in China [30] .", [["people", "ORGANISM", 84, 90], ["people", "SPECIES", 84, 90], ["COVID", "TEST", 20, 25], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["Furthermore, the different potentialities of access to antineoplastic therapies and the availability of regional data from cancer registries must be considered.", [["antineoplastic", "ANATOMY", 55, 69], ["cancer", "ANATOMY", 123, 129], ["cancer", "DISEASE", 123, 129], ["cancer", "CANCER", 123, 129], ["antineoplastic therapies", "TREATMENT", 55, 79], ["cancer registries", "TREATMENT", 123, 140], ["cancer", "OBSERVATION", 123, 129]]], ["The Italian data are similar in general characteristics of population, median age, ICU admission, and mortality to those reported in the United States [28, 29, [33] [34] [35] .DiscussionThe correlations between cancer immunotherapy and COVID-19 developments have been the subject of several hypotheses, none of which have been conclusive [36, 37] .", [["cancer", "ANATOMY", 211, 217], ["cancer", "DISEASE", 211, 217], ["cancer", "CANCER", 211, 217], ["cancer immunotherapy", "TREATMENT", 211, 231], ["COVID", "TEST", 236, 241]]], ["In the multi-center study of Hubei Province 6/105 (5.71%) cancer patients had undergone immunotherapy for lung cancer within 40 days before the onset of COVID-19 symptoms and 2/6 patients (33.3%) had died [17] .", [["cancer", "ANATOMY", 58, 64], ["lung cancer", "ANATOMY", 106, 117], ["cancer", "DISEASE", 58, 64], ["lung cancer", "DISEASE", 106, 117], ["cancer", "CANCER", 58, 64], ["patients", "ORGANISM", 65, 73], ["lung cancer", "CANCER", 106, 117], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 179, 187], ["immunotherapy", "TREATMENT", 88, 101], ["lung cancer", "PROBLEM", 106, 117], ["COVID-19 symptoms", "PROBLEM", 153, 170], ["lung", "ANATOMY", 106, 110], ["cancer", "OBSERVATION", 111, 117]]], ["Another study that included 69 outpatients with diagnosis of advanced lung cancer and COVID-19 infection, treated at Memorial Sloan Kettering Cancer Center in New York, found no significant association between receipt of prior PD-1 blockade and COVID-19 severity [19] .", [["lung cancer", "ANATOMY", 70, 81], ["lung cancer", "DISEASE", 70, 81], ["COVID-19 infection", "DISEASE", 86, 104], ["Cancer", "DISEASE", 142, 148], ["outpatients", "ORGANISM", 31, 42], ["lung cancer", "CANCER", 70, 81], ["PD-1", "GENE_OR_GENE_PRODUCT", 227, 231], ["outpatients", "SPECIES", 31, 42], ["COVID-19", "SPECIES", 86, 94], ["Another study", "TEST", 0, 13], ["advanced lung cancer", "PROBLEM", 61, 81], ["COVID-19 infection", "PROBLEM", 86, 104], ["prior PD-1 blockade", "TREATMENT", 221, 240], ["COVID", "TEST", 245, 250], ["advanced", "OBSERVATION_MODIFIER", 61, 69], ["lung", "ANATOMY", 70, 74], ["cancer", "OBSERVATION", 75, 81], ["infection", "OBSERVATION", 95, 104], ["no", "UNCERTAINTY", 175, 177], ["significant", "OBSERVATION_MODIFIER", 178, 189]]], ["The Cohort Study of Reggio Emilia in hospitalized COVID-19 infected patients found that only 1/14 (7.1%) cancer patient was undergoing immunotherapy (plus chemotherapy) for advanced malignant pleural mesothelioma.", [["cancer", "ANATOMY", 105, 111], ["malignant pleural mesothelioma", "ANATOMY", 182, 212], ["COVID-19 infected", "DISEASE", 50, 67], ["cancer", "DISEASE", 105, 111], ["malignant pleural mesothelioma", "DISEASE", 182, 212], ["patients", "ORGANISM", 68, 76], ["cancer", "CANCER", 105, 111], ["patient", "ORGANISM", 112, 119], ["malignant pleural mesothelioma", "CANCER", 182, 212], ["patients", "SPECIES", 68, 76], ["patient", "SPECIES", 112, 119], ["immunotherapy", "TREATMENT", 135, 148], ["chemotherapy", "TREATMENT", 155, 167], ["advanced malignant pleural mesothelioma", "PROBLEM", 173, 212], ["cancer", "OBSERVATION", 105, 111], ["advanced", "OBSERVATION_MODIFIER", 173, 181], ["malignant", "OBSERVATION_MODIFIER", 182, 191], ["pleural", "ANATOMY", 192, 199], ["mesothelioma", "OBSERVATION", 200, 212]]], ["In the clinical records of the Medical Oncology Unit of Reggio Emilia and University of Modena and Reggio Emilia, 337 patients were registered and treated with checkpoint inhibitors between 1 January and 30 April 2020.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["checkpoint inhibitors", "TREATMENT", 160, 181]]], ["Among this group of cancer patients, only 3 (0.89%) were hospitalized for COVID-19 (1 metastatic colorectal cancer patient treated with FOLFOXIRI/bevacizumab/atezolizumab, 1 advanced malignant pleural mesothelioma patient treated with cisplatin/pemetrexed/pembrolizumab, 1 metastatic clear cell renal cancer patient treated with ipilimumab/nivolumab), and among them, only 1 (0.30%) died [38] .", [["cancer", "ANATOMY", 20, 26], ["metastatic colorectal cancer", "ANATOMY", 86, 114], ["malignant pleural mesothelioma", "ANATOMY", 183, 213], ["metastatic clear cell renal cancer", "ANATOMY", 273, 307], ["cancer", "DISEASE", 20, 26], ["colorectal cancer", "DISEASE", 97, 114], ["FOLFOXIRI", "CHEMICAL", 136, 145], ["bevacizumab", "CHEMICAL", 146, 157], ["atezolizumab", "CHEMICAL", 158, 170], ["malignant pleural mesothelioma", "DISEASE", 183, 213], ["cisplatin", "CHEMICAL", 235, 244], ["pemetrexed", "CHEMICAL", 245, 255], ["pembrolizumab", "CHEMICAL", 256, 269], ["clear cell renal cancer", "DISEASE", 284, 307], ["ipilimumab", "CHEMICAL", 329, 339], ["nivolumab", "CHEMICAL", 340, 349], ["bevacizumab", "CHEMICAL", 146, 157], ["cisplatin", "CHEMICAL", 235, 244], ["pemetrexed", "CHEMICAL", 245, 255], ["pembrolizumab", "CHEMICAL", 256, 269], ["ipilimumab", "CHEMICAL", 329, 339], ["cancer", "CANCER", 20, 26], ["patients", "ORGANISM", 27, 35], ["colorectal cancer", "CANCER", 97, 114], ["patient", "ORGANISM", 115, 122], ["bevacizumab", "SIMPLE_CHEMICAL", 146, 157], ["malignant pleural mesothelioma", "CANCER", 183, 213], ["patient", "ORGANISM", 214, 221], ["cisplatin", "SIMPLE_CHEMICAL", 235, 244], ["pemetrexed", "SIMPLE_CHEMICAL", 245, 255], ["clear cell renal cancer", "CANCER", 284, 307], ["patient", "ORGANISM", 308, 315], ["ipilimumab", "SIMPLE_CHEMICAL", 329, 339], ["patients", "SPECIES", 27, 35], ["patient", "SPECIES", 115, 122], ["patient", "SPECIES", 214, 221], ["patient", "SPECIES", 308, 315], ["COVID", "TEST", 74, 79], ["1 metastatic colorectal cancer", "PROBLEM", 84, 114], ["FOLFOXIRI/bevacizumab", "TREATMENT", 136, 157], ["atezolizumab", "TREATMENT", 158, 170], ["1 advanced malignant pleural mesothelioma", "PROBLEM", 172, 213], ["cisplatin", "TREATMENT", 235, 244], ["pemetrexed", "TREATMENT", 245, 255], ["pembrolizumab", "TREATMENT", 256, 269], ["1 metastatic clear cell renal cancer", "TREATMENT", 271, 307], ["ipilimumab/nivolumab", "TREATMENT", 329, 349], ["cancer", "OBSERVATION", 20, 26], ["metastatic", "OBSERVATION_MODIFIER", 86, 96], ["colorectal cancer", "OBSERVATION", 97, 114], ["malignant", "OBSERVATION_MODIFIER", 183, 192], ["pleural", "ANATOMY", 193, 200], ["mesothelioma", "OBSERVATION", 201, 213], ["renal", "ANATOMY", 295, 300], ["cancer", "OBSERVATION", 301, 307]]], ["These early data are promising for the safety of the continued use of checkpoint inhibitors during the COVID-19 epidemic and the next phase II.", [["checkpoint inhibitors", "TREATMENT", 70, 91], ["the COVID", "TEST", 99, 108]]], ["Furthermore, the observation of lower mortality in cases with recent diagnosis, even if the probably is biased by a higher hospitalization of COVID-19 patients with concomitant diseases as cancer, is supportive for the real impact of cancer and cancer treatments on COVID-19 prognosis.DiscussionAnother topic of debate concerns the risks and correlations between SARS-CoV-2 pneumonia and lung cancer [39] .", [["cancer", "ANATOMY", 189, 195], ["cancer", "ANATOMY", 234, 240], ["cancer", "ANATOMY", 245, 251], ["lung cancer", "ANATOMY", 388, 399], ["cancer", "DISEASE", 189, 195], ["cancer", "DISEASE", 234, 240], ["cancer", "DISEASE", 245, 251], ["SARS-CoV-2 pneumonia", "DISEASE", 363, 383], ["lung cancer", "DISEASE", 388, 399], ["patients", "ORGANISM", 151, 159], ["cancer", "CANCER", 189, 195], ["cancer", "CANCER", 234, 240], ["cancer", "CANCER", 245, 251], ["SARS-CoV-2", "ORGANISM", 363, 373], ["lung cancer", "CANCER", 388, 399], ["patients", "SPECIES", 151, 159], ["SARS-CoV", "SPECIES", 363, 371], ["concomitant diseases", "PROBLEM", 165, 185], ["cancer", "PROBLEM", 189, 195], ["cancer", "PROBLEM", 234, 240], ["cancer treatments", "TREATMENT", 245, 262], ["COVID", "TREATMENT", 266, 271], ["SARS", "TEST", 363, 367], ["CoV", "TEST", 368, 371], ["pneumonia", "PROBLEM", 374, 383], ["lung cancer", "PROBLEM", 388, 399], ["diseases", "OBSERVATION", 177, 185], ["cancer", "OBSERVATION", 189, 195], ["cancer", "OBSERVATION", 234, 240], ["cancer", "OBSERVATION", 245, 251], ["pneumonia", "OBSERVATION", 374, 383], ["lung", "ANATOMY", 388, 392], ["cancer", "OBSERVATION", 393, 399]]], ["Lung cancer patients usually have altered lung function, and therefore they could have of severe forms of COVID-19 infection.", [["Lung cancer", "ANATOMY", 0, 11], ["lung", "ANATOMY", 42, 46], ["Lung cancer", "DISEASE", 0, 11], ["infection", "DISEASE", 115, 124], ["Lung cancer", "CANCER", 0, 11], ["patients", "ORGANISM", 12, 20], ["lung", "ORGAN", 42, 46], ["COVID-19", "GENE_OR_GENE_PRODUCT", 106, 114], ["patients", "SPECIES", 12, 20], ["Lung cancer", "PROBLEM", 0, 11], ["altered lung function", "PROBLEM", 34, 55], ["COVID-19 infection", "PROBLEM", 106, 124], ["cancer", "OBSERVATION", 5, 11], ["altered", "OBSERVATION_MODIFIER", 34, 41], ["lung", "ANATOMY", 42, 46], ["function", "OBSERVATION", 47, 55], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["infection", "OBSERVATION", 115, 124]]], ["Furthermore, the habit of tobacco smoking usually present in lung cancer patients is the main cause of chronic obstructive pulmonary disease, which has been reported as an independent risk factor in severe COVID-19 cases [19, 40] , but not in Reggio Emilia Province [27] .", [["lung cancer", "ANATOMY", 61, 72], ["pulmonary", "ANATOMY", 123, 132], ["smoking", "CHEMICAL", 34, 41], ["lung cancer", "DISEASE", 61, 72], ["chronic obstructive pulmonary disease", "DISEASE", 103, 140], ["COVID", "DISEASE", 206, 211], ["tobacco", "ORGANISM", 26, 33], ["lung cancer", "CANCER", 61, 72], ["patients", "ORGANISM", 73, 81], ["pulmonary", "ORGAN", 123, 132], ["patients", "SPECIES", 73, 81], ["tobacco", "SPECIES", 26, 33], ["lung cancer", "PROBLEM", 61, 72], ["chronic obstructive pulmonary disease", "PROBLEM", 103, 140], ["severe COVID", "PROBLEM", 199, 211], ["lung", "ANATOMY", 61, 65], ["cancer", "OBSERVATION", 66, 72], ["chronic", "OBSERVATION_MODIFIER", 103, 110], ["obstructive", "OBSERVATION_MODIFIER", 111, 122], ["pulmonary", "ANATOMY", 123, 132], ["disease", "OBSERVATION", 133, 140]]], ["Reports in the Chinese population regarding a small group of COVID-19 infected patients with cancer have shown that lung cancer was the most frequent type of malignancy: 5 (27.8%) of 18 patients in a nationwide analysis [12] , 7 (58.3%) of 12 patients in the Zhongan Hospital series [13] , 7 (25.0%) of 28 patients in three hospitals in Wuhan [14] , and 22 (20.9%) of 105 in Hubei Hospital series [17] .", [["cancer", "ANATOMY", 93, 99], ["lung cancer", "ANATOMY", 116, 127], ["COVID-19 infected", "DISEASE", 61, 78], ["cancer", "DISEASE", 93, 99], ["lung cancer", "DISEASE", 116, 127], ["malignancy", "DISEASE", 158, 168], ["COVID-19", "ORGANISM", 61, 69], ["patients", "ORGANISM", 79, 87], ["cancer", "CANCER", 93, 99], ["lung cancer", "CANCER", 116, 127], ["malignancy", "CANCER", 158, 168], ["patients", "ORGANISM", 186, 194], ["patients", "ORGANISM", 243, 251], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 186, 194], ["patients", "SPECIES", 243, 251], ["patients", "SPECIES", 306, 314], ["cancer", "PROBLEM", 93, 99], ["lung cancer", "PROBLEM", 116, 127], ["malignancy", "PROBLEM", 158, 168], ["a nationwide analysis", "TEST", 198, 219], ["small", "OBSERVATION_MODIFIER", 46, 51], ["cancer", "OBSERVATION", 93, 99], ["lung", "ANATOMY", 116, 120], ["cancer", "OBSERVATION", 121, 127], ["most frequent type", "OBSERVATION_MODIFIER", 136, 154], ["malignancy", "OBSERVATION", 158, 168]]], ["Among the 157 patients with solid tumors in Montefiore Health System, 11 (7.0%) had a lung cancer and 6/11 (55%) of these died from COVID-19 infection [18] .", [["solid tumors", "ANATOMY", 28, 40], ["lung cancer", "ANATOMY", 86, 97], ["tumors", "DISEASE", 34, 40], ["lung cancer", "DISEASE", 86, 97], ["COVID-19", "CHEMICAL", 132, 140], ["infection", "DISEASE", 141, 150], ["patients", "ORGANISM", 14, 22], ["solid tumors", "CANCER", 28, 40], ["lung cancer", "CANCER", 86, 97], ["patients", "SPECIES", 14, 22], ["solid tumors", "PROBLEM", 28, 40], ["a lung cancer", "PROBLEM", 84, 97], ["COVID-19 infection", "PROBLEM", 132, 150], ["tumors", "OBSERVATION", 34, 40], ["lung", "ANATOMY", 86, 90], ["cancer", "OBSERVATION", 91, 97]]], ["Univariable analyses in the 200 patients included in the Thoracic Cancers International COVID-19 Collaboration Registry (TERAVOLT Cohort Study), age > 65 years, status of current/former smoker, treatment with chemotherapy, and presence of any comorbidity were associated with increased risk of death.", [["death", "DISEASE", 294, 299], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["Univariable analyses", "TEST", 0, 20], ["chemotherapy", "TREATMENT", 209, 221], ["any comorbidity", "PROBLEM", 239, 254], ["death", "PROBLEM", 294, 299], ["Thoracic", "ANATOMY", 57, 65], ["Cancers", "OBSERVATION", 66, 73]]], ["However, in a multivariable analysis, only smoking history (OR 3.18, 95% CI 1.11-9.06) was associated with increased risk of death [41] .", [["smoking", "CHEMICAL", 43, 50], ["death", "DISEASE", 125, 130], ["a multivariable analysis", "TEST", 12, 36], ["CI", "TEST", 73, 75], ["death", "PROBLEM", 125, 130]]], ["In our study regarding the Reggio Emilia Province, 9/138 (6.5%) lung cancer patients were reported and 3 (21.4%) out of 14 cancer patients had undergone an active antineoplastic treatment within 60 days before COVID-19 infection hospitalization.", [["lung cancer", "ANATOMY", 64, 75], ["cancer", "ANATOMY", 123, 129], ["antineoplastic", "ANATOMY", 163, 177], ["lung cancer", "DISEASE", 64, 75], ["cancer", "DISEASE", 123, 129], ["infection", "DISEASE", 219, 228], ["lung cancer", "CANCER", 64, 75], ["patients", "ORGANISM", 76, 84], ["cancer", "CANCER", 123, 129], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 130, 138], ["our study", "TEST", 3, 12], ["lung cancer", "PROBLEM", 64, 75], ["an active antineoplastic treatment", "TREATMENT", 153, 187], ["COVID-19 infection hospitalization", "TREATMENT", 210, 244], ["lung", "ANATOMY", 64, 68], ["cancer", "OBSERVATION", 69, 75], ["cancer", "OBSERVATION", 123, 129], ["active", "OBSERVATION_MODIFIER", 156, 162], ["antineoplastic", "OBSERVATION_MODIFIER", 163, 177], ["infection", "OBSERVATION", 219, 228]]], ["Among the 5 deaths of this group, only one patient was undergoing treatment for lung cancer.ConclusionsIn the Reggio Emilia Cohort Study, the incidence COVID-19 hospitalization in people who had a previous diagnosis of cancer was similar to that in the general population.", [["lung cancer", "ANATOMY", 80, 91], ["cancer", "ANATOMY", 219, 225], ["deaths", "DISEASE", 12, 18], ["lung cancer", "DISEASE", 80, 91], ["cancer", "DISEASE", 219, 225], ["patient", "ORGANISM", 43, 50], ["lung cancer", "CANCER", 80, 91], ["people", "ORGANISM", 180, 186], ["cancer", "CANCER", 219, 225], ["patient", "SPECIES", 43, 50], ["people", "SPECIES", 180, 186], ["treatment", "TREATMENT", 66, 75], ["lung cancer", "PROBLEM", 80, 91], ["cancer", "PROBLEM", 219, 225], ["lung", "ANATOMY", 80, 84], ["cancer", "OBSERVATION", 85, 91], ["cancer", "OBSERVATION", 219, 225]]], ["In our study, we observed that after hospitalization, cancer patients have a similar risk of ICU and no excess of risk of death compared with patients without cancer.", [["cancer", "ANATOMY", 54, 60], ["cancer", "ANATOMY", 159, 165], ["cancer", "DISEASE", 54, 60], ["death", "DISEASE", 122, 127], ["cancer", "DISEASE", 159, 165], ["cancer", "CANCER", 54, 60], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 142, 150], ["cancer", "CANCER", 159, 165], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 142, 150], ["our study", "TEST", 3, 12], ["cancer", "PROBLEM", 54, 60], ["death", "PROBLEM", 122, 127], ["cancer", "PROBLEM", 159, 165], ["cancer", "OBSERVATION", 159, 165]]], ["Male gender, age > 70 years, metastatic disease bladder cancer, and cardiovascular disease were associated with mortality risk in these cancer patients.", [["metastatic disease bladder cancer", "ANATOMY", 29, 62], ["cardiovascular", "ANATOMY", 68, 82], ["cancer", "ANATOMY", 136, 142], ["bladder cancer", "DISEASE", 48, 62], ["cardiovascular disease", "DISEASE", 68, 90], ["cancer", "DISEASE", 136, 142], ["bladder cancer", "CANCER", 48, 62], ["cardiovascular", "ANATOMICAL_SYSTEM", 68, 82], ["cancer", "CANCER", 136, 142], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["metastatic disease bladder cancer", "PROBLEM", 29, 62], ["cardiovascular disease", "PROBLEM", 68, 90], ["mortality risk in these cancer patients", "PROBLEM", 112, 151], ["metastatic", "OBSERVATION_MODIFIER", 29, 39], ["bladder", "ANATOMY", 48, 55], ["cancer", "OBSERVATION", 56, 62], ["cardiovascular", "ANATOMY", 68, 82], ["disease", "OBSERVATION", 83, 90], ["cancer", "OBSERVATION", 136, 142]]], ["The analysis of clinical data shows no strong associations with previous cancer immunotherapy and antineoplastic treatments for lung cancer.", [["cancer", "ANATOMY", 73, 79], ["antineoplastic", "ANATOMY", 98, 112], ["lung cancer", "ANATOMY", 128, 139], ["cancer", "DISEASE", 73, 79], ["lung cancer", "DISEASE", 128, 139], ["cancer", "CANCER", 73, 79], ["lung cancer", "CANCER", 128, 139], ["The analysis", "TEST", 0, 12], ["clinical data", "TEST", 16, 29], ["previous cancer immunotherapy", "TREATMENT", 64, 93], ["antineoplastic treatments", "TREATMENT", 98, 123], ["lung cancer", "PROBLEM", 128, 139], ["cancer", "OBSERVATION", 73, 79], ["lung", "ANATOMY", 128, 132], ["cancer", "OBSERVATION", 133, 139]]], ["However, our study has limitations related to the retrospective nature, source of information, and size of the sample that could limit the power.ConclusionsThe clinical decisions regarding the beginning, timing, and type of therapy should consider only the biological tumor characteristics and the clinical aspects of the patient.", [["tumor", "ANATOMY", 268, 273], ["tumor", "DISEASE", 268, 273], ["tumor", "CANCER", 268, 273], ["patient", "ORGANISM", 322, 329], ["patient", "SPECIES", 322, 329], ["our study", "TEST", 9, 18], ["therapy", "TREATMENT", 224, 231], ["size", "OBSERVATION_MODIFIER", 99, 103], ["tumor", "OBSERVATION", 268, 273]]], ["The increasing population of cancer survivors and the increased percentage of cancer survivors over the age of 65 years, with different coexisting medical conditions, needs special attention as public health issue [33] , but our data suggest that mainly metastatic cancer patients have really different prognosis for COVID-19.", [["cancer", "ANATOMY", 29, 35], ["cancer", "ANATOMY", 78, 84], ["metastatic cancer", "ANATOMY", 254, 271], ["cancer", "DISEASE", 29, 35], ["cancer", "DISEASE", 78, 84], ["cancer", "DISEASE", 265, 271], ["cancer", "CANCER", 29, 35], ["cancer", "CANCER", 78, 84], ["metastatic cancer", "CANCER", 254, 271], ["patients", "ORGANISM", 272, 280], ["patients", "SPECIES", 272, 280], ["cancer survivors", "PROBLEM", 29, 45], ["the increased percentage of cancer", "PROBLEM", 50, 84], ["different coexisting medical conditions", "PROBLEM", 126, 165], ["mainly metastatic cancer", "PROBLEM", 247, 271], ["COVID", "TEST", 317, 322], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["population", "OBSERVATION_MODIFIER", 15, 25], ["cancer", "OBSERVATION", 29, 35], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["percentage", "OBSERVATION_MODIFIER", 64, 74], ["cancer", "OBSERVATION", 78, 84], ["metastatic", "OBSERVATION_MODIFIER", 254, 264], ["cancer", "OBSERVATION", 265, 271]]], ["Moreover, the outbreaks of COVID-19 in long-term care facilities, hospices, and home care assistance can have a considerable impact on vulnerable advanced cancer patients and older patients.", [["cancer", "ANATOMY", 155, 161], ["COVID-19", "CHEMICAL", 27, 35], ["cancer", "DISEASE", 155, 161], ["cancer", "CANCER", 155, 161], ["patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 181, 189], ["home care assistance", "TREATMENT", 80, 100], ["cancer", "OBSERVATION", 155, 161]]], ["A public health strategy is needed that considers globally, in all situations, the preventive and care aspects for cancer patients in the COVID-19 emergency and phase II challenges.Conflicts of Interest:Authors declare that they do not have: (1) any financial interest or (2) any other financial connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the", [["cancer", "ANATOMY", 115, 121], ["cancer", "DISEASE", 115, 121], ["cancer", "CANCER", 115, 121], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["cancer", "PROBLEM", 115, 121]]]], "89e4efea500c7f98cd67b0ff34d416b9d49b6459": [["Abstract:COVID-19, caused by the SARS-CoV-2 virus, is a major source of morbidity and mortality due to its inflammatory effects in the lungs and heart.", [["lungs", "ANATOMY", 135, 140], ["heart", "ANATOMY", 145, 150], ["SARS-CoV-2 virus", "ORGANISM", 33, 49], ["lungs", "ORGAN", 135, 140], ["heart", "ORGAN", 145, 150], ["CoV-2 virus", "SPECIES", 38, 49], ["SARS-CoV-2 virus", "SPECIES", 33, 49], ["COVID", "TEST", 9, 14], ["the SARS-CoV-2 virus", "PROBLEM", 29, 49], ["morbidity", "PROBLEM", 72, 81], ["its inflammatory effects in the lungs and heart", "PROBLEM", 103, 150], ["morbidity", "OBSERVATION", 72, 81], ["inflammatory", "OBSERVATION", 107, 119], ["lungs", "ANATOMY", 135, 140], ["heart", "ANATOMY", 145, 150]]], ["The p38 MAPK pathway plays a crucial role in the release of pro-inflammatory cytokines such as IL-6 and has been implicated in acute lung injury and myocardial dysfunction.", [["lung", "ANATOMY", 133, 137], ["myocardial", "ANATOMY", 149, 159], ["acute lung injury", "DISEASE", 127, 144], ["myocardial dysfunction", "DISEASE", 149, 171], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 4, 12], ["IL-6", "GENE_OR_GENE_PRODUCT", 95, 99], ["lung", "ORGAN", 133, 137], ["myocardial", "MULTI-TISSUE_STRUCTURE", 149, 159], ["p38 MAPK", "PROTEIN", 4, 12], ["pro-inflammatory cytokines", "PROTEIN", 60, 86], ["IL-6", "PROTEIN", 95, 99], ["The p38 MAPK pathway", "TEST", 0, 20], ["pro-inflammatory cytokines", "PROBLEM", 60, 86], ["acute lung injury", "PROBLEM", 127, 144], ["myocardial dysfunction", "PROBLEM", 149, 171], ["pro-inflammatory cytokines", "OBSERVATION", 60, 86], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["lung", "ANATOMY", 133, 137], ["injury", "OBSERVATION", 138, 144], ["myocardial", "ANATOMY", 149, 159], ["dysfunction", "OBSERVATION", 160, 171]]], ["The overwhelming inflammatory response in COVID-19 infection may be due to caused by disproportionately upregulated p38 activity, explained by two mechanisms.", [["COVID-19", "CHEMICAL", 42, 50], ["infection", "DISEASE", 51, 60], ["COVID-19", "CELL", 42, 50], ["p38", "GENE_OR_GENE_PRODUCT", 116, 119], ["p38", "PROTEIN", 116, 119], ["COVID-19", "SPECIES", 42, 50], ["The overwhelming inflammatory response", "PROBLEM", 0, 38], ["COVID-19 infection", "PROBLEM", 42, 60], ["disproportionately upregulated p38 activity", "PROBLEM", 85, 128], ["overwhelming", "OBSERVATION_MODIFIER", 4, 16], ["inflammatory", "OBSERVATION_MODIFIER", 17, 29], ["infection", "OBSERVATION", 51, 60], ["may be due to", "UNCERTAINTY", 61, 74], ["p38 activity", "OBSERVATION", 116, 128]]], ["First, angiotensin-converting enzyme 2 (ACE2) activity is lost during SARS-CoV-2 viral entry.", [["angiotensin", "CHEMICAL", 7, 18], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 7, 38], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 70, 80], ["angiotensin-converting enzyme 2", "PROTEIN", 7, 38], ["ACE2", "PROTEIN", 40, 44], ["angiotensin", "TEST", 7, 18], ["converting enzyme", "TEST", 19, 36], ["ACE2", "TEST", 40, 44], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78]]], ["ACE2 is highly expressed in the lungs and heart and converts Angiotensin II into Angiotensin 1-7.", [["lungs", "ANATOMY", 32, 37], ["heart", "ANATOMY", 42, 47], ["Angiotensin II", "CHEMICAL", 61, 75], ["Angiotensin 1-7", "CHEMICAL", 81, 96], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["lungs", "ORGAN", 32, 37], ["heart", "ORGAN", 42, 47], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 61, 75], ["Angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 81, 96], ["ACE2", "PROTEIN", 0, 4], ["Angiotensin II", "PROTEIN", 61, 75], ["ACE2", "TEST", 0, 4], ["Angiotensin II into Angiotensin", "TREATMENT", 61, 92], ["lungs", "ANATOMY", 32, 37], ["heart", "ANATOMY", 42, 47]]], ["Angiotensin II signals proinflammatory, pro-vasoconstrictive, pro-thrombotic activity through p38 MAPK activation, which is countered by Angiotensin 1-7 downregulation of p38 activity.", [["Angiotensin II", "CHEMICAL", 0, 14], ["Angiotensin", "CHEMICAL", 137, 148], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 0, 14], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 94, 102], ["Angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 137, 152], ["p38", "GENE_OR_GENE_PRODUCT", 171, 174], ["Angiotensin II", "PROTEIN", 0, 14], ["p38 MAPK", "PROTEIN", 94, 102], ["p38", "PROTEIN", 171, 174], ["Angiotensin II signals proinflammatory", "PROBLEM", 0, 38], ["pro-thrombotic activity", "PROBLEM", 62, 85], ["p38 MAPK activation", "TREATMENT", 94, 113], ["Angiotensin", "TEST", 137, 148], ["proinflammatory", "OBSERVATION_MODIFIER", 23, 38]]], ["Loss of ACE2 during upon viral entry may tip the balance towards destructive p38 signaling through Angiotensin II.", [["Angiotensin II", "CHEMICAL", 99, 113], ["ACE2", "GENE_OR_GENE_PRODUCT", 8, 12], ["p38", "GENE_OR_GENE_PRODUCT", 77, 80], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 99, 113], ["ACE2", "PROTEIN", 8, 12], ["p38", "PROTEIN", 77, 80], ["Angiotensin II", "PROTEIN", 99, 113], ["Loss of ACE2", "PROBLEM", 0, 12]]], ["Second, SARS-CoV was previously shown to directly upregulate p38 activity via a viral protein, similar to other RNA respiratory viruses that may hijack p38 activity to promote replication.", [["SARS", "DISEASE", 8, 12], ["SARS-CoV", "ORGANISM", 8, 16], ["p38", "GENE_OR_GENE_PRODUCT", 61, 64], ["p38", "GENE_OR_GENE_PRODUCT", 152, 155], ["p38", "PROTEIN", 61, 64], ["viral protein", "PROTEIN", 80, 93], ["p38", "PROTEIN", 152, 155], ["SARS-CoV", "SPECIES", 8, 16], ["a viral protein", "TEST", 78, 93], ["other RNA respiratory viruses", "PROBLEM", 106, 135], ["respiratory viruses", "OBSERVATION", 116, 135]]], ["Given the homology between SARS-CoV and SARS-CoV-2, the latter may employ a similar mechanism.", [["SARS-CoV", "ORGANISM", 27, 35], ["SARS-CoV-2", "ORGANISM", 40, 50], ["SARS-CoV", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 40, 48], ["SARS", "TEST", 27, 31], ["SARS", "PROBLEM", 40, 44]]], ["Thus, SARS-CoV-2 may induce overwhelming inflammation by directly activating p38 and downregulating a key inhibitory pathway, while simultaneously taking advantage of p38 activity to replicate.", [["inflammation", "DISEASE", 41, 53], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 6, 16], ["p38", "GENE_OR_GENE_PRODUCT", 77, 80], ["p38", "GENE_OR_GENE_PRODUCT", 167, 170], ["p38", "PROTEIN", 77, 80], ["p38", "PROTEIN", 167, 170], ["SARS-CoV", "SPECIES", 6, 14], ["SARS", "PROBLEM", 6, 10], ["overwhelming inflammation", "PROBLEM", 28, 53], ["downregulating a key inhibitory pathway", "TREATMENT", 85, 124], ["inflammation", "OBSERVATION", 41, 53]]], ["Therapeutic inhibition of p38 could therefore attenuate COVID-19 infection.", [["infection", "DISEASE", 65, 74], ["p38", "GENE_OR_GENE_PRODUCT", 26, 29], ["COVID-19", "GENE_OR_GENE_PRODUCT", 56, 64], ["p38", "PROTEIN", 26, 29], ["Therapeutic inhibition of p38", "TREATMENT", 0, 29], ["COVID", "TEST", 56, 61], ["infection", "PROBLEM", 65, 74], ["infection", "OBSERVATION", 65, 74]]], ["Interestingly, a prior preclinical study showed protective effects of p38 inhibition in a SARS-CoV mouse model.", [["p38", "GENE_OR_GENE_PRODUCT", 70, 73], ["SARS-CoV mouse", "ORGANISM", 90, 104], ["p38", "PROTEIN", 70, 73], ["mouse", "SPECIES", 99, 104], ["SARS-CoV mouse", "SPECIES", 90, 104], ["a prior preclinical study", "TEST", 15, 40], ["p38 inhibition", "TREATMENT", 70, 84], ["a SARS-CoV mouse model", "TREATMENT", 88, 110]]], ["A number of p38 inhibitors are in the clinical stage and should be considered for clinical trials in seriousIntroduction:The COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus, has caused resulted in substantial ICU admissions and excess mortality worldwide.", [["p38", "GENE_OR_GENE_PRODUCT", 12, 15], ["COVID-19", "ORGANISM", 125, 133], ["SARS-CoV-2 coronavirus", "ORGANISM", 158, 180], ["CoV-2 coronavirus", "SPECIES", 163, 180], ["SARS-CoV-2 coronavirus", "SPECIES", 158, 180], ["p38 inhibitors", "TREATMENT", 12, 26], ["The COVID", "TEST", 121, 130], ["pandemic", "PROBLEM", 134, 142], ["the SARS", "PROBLEM", 154, 162], ["coronavirus", "PROBLEM", 169, 180]]], ["Similar to the SARS-CoV virus implicated in the 2003 SARS outbreak, SARS-CoV-2 facilitates cell entry by attaching to angiotensin converting enzyme 2 (ACE2) located on the cell surface [1] .", [["cell", "ANATOMY", 91, 95], ["cell surface", "ANATOMY", 172, 184], ["SARS-CoV virus", "DISEASE", 15, 29], ["SARS", "DISEASE", 53, 57], ["SARS", "DISEASE", 68, 72], ["angiotensin", "CHEMICAL", 118, 129], ["SARS-CoV virus", "ORGANISM", 15, 29], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 78], ["cell", "CELL", 91, 95], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 118, 149], ["ACE2", "GENE_OR_GENE_PRODUCT", 151, 155], ["cell surface", "CELLULAR_COMPONENT", 172, 184], ["angiotensin converting enzyme 2", "PROTEIN", 118, 149], ["ACE2", "PROTEIN", 151, 155], ["CoV virus", "SPECIES", 20, 29], ["SARS-CoV virus", "SPECIES", 15, 29], ["SARS-CoV", "SPECIES", 68, 76], ["the SARS-CoV virus", "PROBLEM", 11, 29], ["SARS", "PROBLEM", 68, 72], ["angiotensin converting enzyme", "TEST", 118, 147]]], ["ACE2 is present in multiple tissues and is highly expressed in the lungs and heart [2] .", [["tissues", "ANATOMY", 28, 35], ["lungs", "ANATOMY", 67, 72], ["heart", "ANATOMY", 77, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissues", "TISSUE", 28, 35], ["lungs", "ORGAN", 67, 72], ["heart", "ORGAN", 77, 82], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["multiple tissues", "OBSERVATION_MODIFIER", 19, 35], ["lungs", "ANATOMY", 67, 72], ["heart", "ANATOMY", 77, 82]]], ["Given this distribution, it is unsurprising that Acute Respiratory Distress Syndrome (ARDS) and myocarditis are the primary causes of death in COVID-19 patients [3] .", [["Respiratory Distress Syndrome", "DISEASE", 55, 84], ["ARDS", "DISEASE", 86, 90], ["myocarditis", "DISEASE", 96, 107], ["death", "DISEASE", 134, 139], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["Acute Respiratory Distress Syndrome", "PROBLEM", 49, 84], ["ARDS)", "PROBLEM", 86, 91], ["myocarditis", "PROBLEM", 96, 107], ["death", "PROBLEM", 134, 139], ["Acute", "OBSERVATION_MODIFIER", 49, 54], ["Respiratory Distress", "OBSERVATION", 55, 75], ["myocarditis", "OBSERVATION", 96, 107]]], ["The cause of overwhelming inflammation induced by SARS-CoV-2 is unclear, however.", [["inflammation", "DISEASE", 26, 38], ["SARS", "DISEASE", 50, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 50, 60], ["SARS-CoV", "SPECIES", 50, 58], ["overwhelming inflammation", "PROBLEM", 13, 38], ["SARS", "PROBLEM", 50, 54], ["cause of", "UNCERTAINTY", 4, 12], ["overwhelming", "OBSERVATION_MODIFIER", 13, 25], ["inflammation", "OBSERVATION", 26, 38]]], ["One particular pathway that has been previously implicated in animal models of acute lung injury and myocardial injury is the p38 MAPK system [4, 5] .Introduction:Upregulation of the p38 MAPK pathway activates pro-inflammatory cytokines such as IL-6, TNF-\u03b1 and IL-1\u03b2 [6] .", [["lung", "ANATOMY", 85, 89], ["myocardial", "ANATOMY", 101, 111], ["lung injury", "DISEASE", 85, 96], ["myocardial injury", "DISEASE", 101, 118], ["lung", "ORGAN", 85, 89], ["myocardial", "MULTI-TISSUE_STRUCTURE", 101, 111], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 126, 134], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 183, 191], ["IL-6", "GENE_OR_GENE_PRODUCT", 245, 249], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 251, 256], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 261, 266], ["p38 MAPK", "PROTEIN", 126, 134], ["p38 MAPK", "PROTEIN", 183, 191], ["pro-inflammatory cytokines", "PROTEIN", 210, 236], ["IL-6", "PROTEIN", 245, 249], ["TNF", "PROTEIN", 251, 254], ["acute lung injury", "PROBLEM", 79, 96], ["myocardial injury", "PROBLEM", 101, 118], ["the p38 MAPK pathway", "TEST", 179, 199], ["pro-inflammatory cytokines", "TEST", 210, 236], ["IL", "TEST", 245, 247], ["TNF", "TEST", 251, 254], ["IL", "TEST", 261, 263], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["lung", "ANATOMY", 85, 89], ["injury", "OBSERVATION", 90, 96], ["myocardial", "ANATOMY", 101, 111], ["injury", "OBSERVATION", 112, 118]]], ["Herein, we argue that the inflammatory injury provoked by SARS-CoV-2 may be due to a disproportionate upregulation of p38 MAPK activity.", [["inflammatory injury", "DISEASE", 26, 45], ["SARS", "DISEASE", 58, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 58, 68], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 118, 126], ["p38 MAPK", "PROTEIN", 118, 126], ["the inflammatory injury", "PROBLEM", 22, 45], ["SARS", "PROBLEM", 58, 62], ["p38 MAPK activity", "TREATMENT", 118, 135], ["inflammatory", "OBSERVATION_MODIFIER", 26, 38], ["p38 MAPK activity", "OBSERVATION", 118, 135]]], ["This inflammation may be attenuated by p38 small molecule inhibitors, many of which have been safely studied in clinical trials for other indications.p38 activation in SARS-CoV-2: the perfect stormLike SARS-CoV, SARS-CoV-2 binds and downregulates ACE2 upon cell entry [7] .p38 activation in SARS-CoV-2: the perfect stormACE2 converts Angiotensin II (Ang II) into Angiotensin 1-7 (Ang 1-7), which then binds to the Mas receptor to counterbalance the vasoconstrictive and pro-inflammatory effects of Ang II [8, 9] .", [["cell", "ANATOMY", 257, 261], ["inflammation", "DISEASE", 5, 17], ["Angiotensin II", "CHEMICAL", 334, 348], ["Ang II", "CHEMICAL", 350, 356], ["Angiotensin 1-7", "CHEMICAL", 363, 378], ["Ang 1-7", "CHEMICAL", 380, 387], ["Ang II", "CHEMICAL", 498, 504], ["p38", "GENE_OR_GENE_PRODUCT", 39, 42], ["p38", "GENE_OR_GENE_PRODUCT", 150, 153], ["SARS-CoV-2", "ORGANISM", 168, 178], ["stormLike SARS-CoV", "ORGANISM", 192, 210], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 212, 222], ["ACE2", "GENE_OR_GENE_PRODUCT", 247, 251], ["cell", "CELL", 257, 261], ["stormACE2", "GENE_OR_GENE_PRODUCT", 315, 324], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 334, 348], ["Ang II", "GENE_OR_GENE_PRODUCT", 350, 356], ["Angiotensin 1-7", "GENE_OR_GENE_PRODUCT", 363, 378], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 380, 387], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 414, 426], ["Ang II", "GENE_OR_GENE_PRODUCT", 498, 504], ["p38", "PROTEIN", 150, 153], ["ACE2", "PROTEIN", 247, 251], ["stormACE2", "DNA", 315, 324], ["Angiotensin II", "PROTEIN", 334, 348], ["Ang II", "PROTEIN", 350, 356], ["Mas receptor", "PROTEIN", 414, 426], ["Ang II", "PROTEIN", 498, 504], ["SARS-CoV", "SPECIES", 202, 210], ["SARS-CoV", "SPECIES", 212, 220], ["This inflammation", "PROBLEM", 0, 17], ["p38 small molecule inhibitors", "TREATMENT", 39, 68], ["p38 activation", "TEST", 150, 164], ["SARS", "TEST", 168, 172], ["CoV", "TEST", 173, 176], ["the perfect stormLike SARS", "PROBLEM", 180, 206], ["SARS", "PROBLEM", 212, 216], ["CoV", "TEST", 217, 220], ["cell entry", "TEST", 257, 267], ["the perfect stormACE2", "TREATMENT", 303, 324], ["Angiotensin II (Ang II) into Angiotensin", "TREATMENT", 334, 374], ["the vasoconstrictive and pro-inflammatory effects of Ang II", "TREATMENT", 445, 504], ["inflammation", "OBSERVATION", 5, 17], ["may be", "UNCERTAINTY", 18, 24], ["small molecule inhibitors", "OBSERVATION", 43, 68], ["vasoconstrictive", "OBSERVATION", 449, 465]]], ["Ang II mediates its effects through p38 MAPK activation [10] .", [["Ang II", "CHEMICAL", 0, 6], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 36, 44], ["Ang II", "PROTEIN", 0, 6], ["p38 MAPK", "PROTEIN", 36, 44], ["Ang II mediates", "TREATMENT", 0, 15], ["p38 MAPK activation", "TEST", 36, 55]]], ["Ang 1-7 stimulation of the Mas receptor decreases p38 MAPK activation to attenuate inflammation [11] .", [["Ang", "CHEMICAL", 0, 3], ["inflammation", "DISEASE", 83, 95], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 0, 7], ["Mas receptor", "GENE_OR_GENE_PRODUCT", 27, 39], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 50, 58], ["Mas receptor", "PROTEIN", 27, 39], ["p38 MAPK", "PROTEIN", 50, 58], ["Ang", "TEST", 0, 3], ["the Mas receptor", "TEST", 23, 39], ["MAPK activation", "TEST", 54, 69], ["attenuate inflammation", "PROBLEM", 73, 95]]], ["The loss of ACE2 activity upon viral entry may therefore allow Ang II mediated activation of p38 to predominate in the lungs and heart as Ang 1-7 is downregulated.", [["lungs", "ANATOMY", 119, 124], ["heart", "ANATOMY", 129, 134], ["Ang II", "CHEMICAL", 63, 69], ["Ang", "CHEMICAL", 138, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["Ang II", "GENE_OR_GENE_PRODUCT", 63, 69], ["p38", "GENE_OR_GENE_PRODUCT", 93, 96], ["lungs", "ORGAN", 119, 124], ["heart", "ORGAN", 129, 134], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 138, 145], ["ACE2", "PROTEIN", 12, 16], ["Ang II", "PROTEIN", 63, 69], ["p38", "PROTEIN", 93, 96], ["Ang 1-7", "PROTEIN", 138, 145], ["The loss of ACE2 activity", "PROBLEM", 0, 25], ["viral entry", "PROBLEM", 31, 42], ["Ang II mediated activation of p38", "PROBLEM", 63, 96], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["lungs", "ANATOMY", 119, 124], ["heart", "ANATOMY", 129, 134]]], ["This allows unchecked inflammation and J o u r n a l P r e -p r o o f Journal Pre-proof produces a positive feedback loop as p38 activation also upregulates ADAM17, a protease known to cleave the ACE2 ectodomain to further reduce local ACE2 protective activity [12] .", [["inflammation", "DISEASE", 22, 34], ["p38", "GENE_OR_GENE_PRODUCT", 125, 128], ["ADAM17", "GENE_OR_GENE_PRODUCT", 157, 163], ["ACE2", "GENE_OR_GENE_PRODUCT", 196, 200], ["ACE2", "GENE_OR_GENE_PRODUCT", 236, 240], ["p38", "PROTEIN", 125, 128], ["ADAM17", "PROTEIN", 157, 163], ["protease", "PROTEIN", 167, 175], ["ACE2 ectodomain", "PROTEIN", 196, 211], ["ACE2", "PROTEIN", 236, 240], ["unchecked inflammation", "PROBLEM", 12, 34], ["a positive feedback loop", "PROBLEM", 97, 121], ["a protease", "TREATMENT", 165, 175], ["the ACE2 ectodomain", "TREATMENT", 192, 211], ["local ACE2 protective activity", "TREATMENT", 230, 260], ["inflammation", "OBSERVATION", 22, 34]]], ["It is worth noting that while the role of the renin-angiotensin system (RAS) is still being fully elucidated in the pathogenesis of SARS-CoV-2, a recent study found that inhibition of RAS via angiotensin-converting enzyme inhibitors or angiotensin receptor blockers may reduce all-cause mortality in COVID-19 patients [13] .", [["angiotensin", "CHEMICAL", 52, 63], ["SARS", "DISEASE", 132, 136], ["angiotensin", "CHEMICAL", 192, 203], ["angiotensin", "CHEMICAL", 236, 247], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 46, 70], ["RAS", "GENE_OR_GENE_PRODUCT", 72, 75], ["RAS", "GENE_OR_GENE_PRODUCT", 184, 187], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 192, 221], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 236, 265], ["patients", "ORGANISM", 309, 317], ["renin", "PROTEIN", 46, 51], ["RAS", "PROTEIN", 184, 187], ["patients", "SPECIES", 309, 317], ["SARS-CoV", "SPECIES", 132, 140], ["the renin-angiotensin system", "TREATMENT", 42, 70], ["SARS", "PROBLEM", 132, 136], ["a recent study", "TEST", 144, 158], ["RAS via angiotensin", "TREATMENT", 184, 203], ["converting enzyme inhibitors", "TREATMENT", 204, 232], ["angiotensin receptor blockers", "TREATMENT", 236, 265], ["COVID", "TEST", 300, 305]]], ["In another study of COVID-19 patients, Ang II levels were linearly associated with degree of lung injury and viral load, further implicating RAS imbalance in the COVID-19 pathogenesis [14] .p38 activation in SARS-CoV-2: the perfect stormFurthermore, the previous SARS-CoV virus was shown to express a protein that directly upregulates p38 MAPK in vitro, a pathogenic step thought to be utilized in the lifecycle of many RNA respiratory viruses, including influenza strains associated with severe inflammatory responses such as H5N1 [15, 16] .", [["lung", "ANATOMY", 93, 97], ["Ang II", "CHEMICAL", 39, 45], ["lung injury", "DISEASE", 93, 104], ["SARS", "DISEASE", 208, 212], ["respiratory viruses", "DISEASE", 424, 443], ["influenza", "DISEASE", 455, 464], ["H5N1", "DISEASE", 527, 531], ["patients", "ORGANISM", 29, 37], ["Ang II", "GENE_OR_GENE_PRODUCT", 39, 45], ["lung", "ORGAN", 93, 97], ["RAS", "GENE_OR_GENE_PRODUCT", 141, 144], ["SARS-CoV-2", "ORGANISM", 208, 218], ["SARS-CoV virus", "ORGANISM", 263, 277], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 335, 343], ["influenza strains", "ORGANISM", 455, 472], ["Ang II", "PROTEIN", 39, 45], ["p38 MAPK", "PROTEIN", 335, 343], ["patients", "SPECIES", 29, 37], ["CoV virus", "SPECIES", 268, 277], ["SARS-CoV", "SPECIES", 208, 216], ["SARS-CoV virus", "SPECIES", 263, 277], ["COVID", "TEST", 20, 25], ["Ang II levels", "TEST", 39, 52], ["lung injury", "PROBLEM", 93, 104], ["viral load", "PROBLEM", 109, 119], ["RAS imbalance", "PROBLEM", 141, 154], ["the COVID", "TEST", 158, 167], ["the previous SARS", "PROBLEM", 250, 267], ["CoV virus", "PROBLEM", 268, 277], ["a pathogenic step", "PROBLEM", 354, 371], ["many RNA respiratory viruses", "PROBLEM", 415, 443], ["influenza strains", "PROBLEM", 455, 472], ["severe inflammatory responses", "PROBLEM", 489, 518], ["H5N1", "PROBLEM", 527, 531], ["lung", "ANATOMY", 93, 97], ["injury", "OBSERVATION", 98, 104], ["viral load", "OBSERVATION", 109, 119], ["respiratory viruses", "OBSERVATION", 424, 443], ["severe", "OBSERVATION_MODIFIER", 489, 495], ["inflammatory", "OBSERVATION", 496, 508]]], ["It has been suggested that, among other functions, viral p38 MAPK activation induces endocytosis of viral receptors to facilitate cell entry [17] .p38 activation in SARS-CoV-2: the perfect stormInterestingly, p38 MAPK activation has been implicated in the endocytosis of ACE2 [18] .", [["cell", "ANATOMY", 130, 134], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 57, 65], ["cell", "CELL", 130, 134], [".p38", "GENE_OR_GENE_PRODUCT", 146, 150], ["SARS-CoV-2", "ORGANISM", 165, 175], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 209, 217], ["ACE2", "GENE_OR_GENE_PRODUCT", 271, 275], ["p38 MAPK", "PROTEIN", 57, 65], ["viral receptors", "PROTEIN", 100, 115], [".p38", "PROTEIN", 146, 150], ["p38 MAPK", "PROTEIN", 209, 217], ["ACE2", "PROTEIN", 271, 275], ["viral p38 MAPK activation", "TEST", 51, 76], ["viral receptors", "TREATMENT", 100, 115], ["cell entry", "TEST", 130, 140]]], ["Given its homology to SARS-CoV, SARS-CoV-2 could use a similar mechanism to directly upregulate p38 MAPK.", [["SARS", "DISEASE", 22, 26], ["SARS-CoV", "ORGANISM", 22, 30], ["SARS-CoV-2", "ORGANISM", 32, 42], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 96, 104], ["p38 MAPK", "PROTEIN", 96, 104], ["SARS-CoV", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 32, 40], ["SARS", "PROBLEM", 22, 26], ["CoV", "PROBLEM", 27, 30], ["SARS", "PROBLEM", 32, 36]]], ["If this is the case, then SARS-CoV-2 could be propagating severe inflammation and organ damage both by both directly upregulating p38 MAPK activity and by downregulating a key p38 MAPK shut off mechanism by reducing ACE2 activity.", [["organ", "ANATOMY", 82, 87], ["SARS", "DISEASE", 26, 30], ["inflammation", "DISEASE", 65, 77], ["organ damage", "DISEASE", 82, 94], ["organ", "ORGAN", 82, 87], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 130, 138], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 176, 184], ["ACE2", "GENE_OR_GENE_PRODUCT", 216, 220], ["p38 MAPK", "PROTEIN", 130, 138], ["p38 MAPK", "PROTEIN", 176, 184], ["ACE2", "PROTEIN", 216, 220], ["severe inflammation", "PROBLEM", 58, 77], ["organ damage", "PROBLEM", 82, 94], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["inflammation", "OBSERVATION", 65, 77]]], ["Furthermore, p38 MAPK activation could simultaneously be propagating the SARS-CoV-2 viral lifecycle.", [["p38 MAPK", "GENE_OR_GENE_PRODUCT", 13, 21], ["CoV-2", "ORGANISM", 78, 83], ["p38 MAPK", "PROTEIN", 13, 21], ["p38 MAPK activation", "TEST", 13, 32], ["the SARS", "TEST", 69, 77], ["CoV", "TEST", 78, 81]]], ["Interestingly, a small preclinical study with a p38 inhibitor in SARS-CoV infected mice showed 80% survival in the treatment group (N=5) and 0% in the control (N=5) [19] .p38 activation in SARS-CoV-2: the perfect stormImportantly, overactivation of p38 MAPK activity can also explain additional clinical findings in patients of with SARS-CoV-2 infection.", [["SARS-CoV infected", "DISEASE", 65, 82], ["SARS-CoV-2 infection", "DISEASE", 333, 353], ["p38", "GENE_OR_GENE_PRODUCT", 48, 51], ["SARS-CoV", "ORGANISM", 65, 73], ["mice", "ORGANISM", 83, 87], ["SARS-CoV-2", "ORGANISM", 189, 199], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 249, 257], ["patients", "ORGANISM", 316, 324], ["SARS-CoV-2", "ORGANISM", 333, 343], ["p38", "PROTEIN", 48, 51], ["p38 MAPK", "PROTEIN", 249, 257], ["mice", "SPECIES", 83, 87], ["patients", "SPECIES", 316, 324], ["SARS-CoV", "SPECIES", 65, 73], ["mice", "SPECIES", 83, 87], ["SARS-CoV", "SPECIES", 189, 197], ["SARS-CoV-2", "SPECIES", 333, 343], ["a small preclinical study", "TEST", 15, 40], ["a p38 inhibitor", "TREATMENT", 46, 61], ["SARS", "TEST", 65, 69], ["CoV infected mice", "TEST", 70, 87], ["SARS", "TEST", 189, 193], ["CoV", "TEST", 194, 197], ["overactivation of p38 MAPK activity", "PROBLEM", 231, 266], ["SARS", "PROBLEM", 333, 337], ["CoV", "PROBLEM", 338, 341], ["2 infection", "PROBLEM", 342, 353], ["small", "OBSERVATION_MODIFIER", 17, 22], ["infection", "OBSERVATION", 344, 353]]], ["There are reports of significant thrombotic J o u r n a l P r e -p r o o f events in severely ill COVID-19 patients, and a recent study in COVID-19 patients notes that the vascular endothelium is directly infected in target organs of SARS-CoV-2 [20] [21] [22] .", [["vascular endothelium", "ANATOMY", 172, 192], ["organs", "ANATOMY", 224, 230], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 148, 156], ["vascular endothelium", "TISSUE", 172, 192], ["organs", "ORGAN", 224, 230], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 148, 156], ["significant thrombotic J", "PROBLEM", 21, 45], ["events", "PROBLEM", 75, 81], ["a recent study", "TEST", 121, 135], ["COVID", "TEST", 139, 144], ["the vascular endothelium", "PROBLEM", 168, 192], ["SARS", "TEST", 234, 238], ["CoV", "TEST", 239, 242], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["thrombotic", "OBSERVATION", 33, 43], ["vascular endothelium", "ANATOMY", 172, 192], ["infected", "OBSERVATION", 205, 213]]], ["Elevated p38 MAPK activity in the endothelium has been implicated in platelet aggregation, and arterial thrombosis, and apoptosis of endothelial cells, a clinical finding also shown in the histology of the aforementioned study [23] .", [["endothelium", "ANATOMY", 34, 45], ["platelet", "ANATOMY", 69, 77], ["arterial", "ANATOMY", 95, 103], ["endothelial cells", "ANATOMY", 133, 150], ["platelet aggregation", "DISEASE", 69, 89], ["arterial thrombosis", "DISEASE", 95, 114], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 9, 17], ["endothelium", "TISSUE", 34, 45], ["platelet", "CELL", 69, 77], ["arterial", "MULTI-TISSUE_STRUCTURE", 95, 103], ["endothelial cells", "CELL", 133, 150], ["p38 MAPK", "PROTEIN", 9, 17], ["endothelial cells", "CELL_TYPE", 133, 150], ["Elevated p38 MAPK activity", "PROBLEM", 0, 26], ["platelet aggregation", "PROBLEM", 69, 89], ["arterial thrombosis", "PROBLEM", 95, 114], ["apoptosis of endothelial cells", "PROBLEM", 120, 150], ["the aforementioned study", "TEST", 202, 226], ["p38 MAPK activity", "OBSERVATION", 9, 26], ["endothelium", "ANATOMY", 34, 45], ["platelet aggregation", "OBSERVATION", 69, 89], ["arterial", "ANATOMY", 95, 103], ["thrombosis", "OBSERVATION", 104, 114], ["endothelial cells", "OBSERVATION", 133, 150]]], ["Cardiac dysfunction in COVID-19 patients could partly be due to this endothelial dysfunction, or due to overactivation of p38 MAPK in infected cardiomyocytes, which has been shown to induce apoptosis, impair contractility, and increase fibrosis [24] .", [["Cardiac", "ANATOMY", 0, 7], ["endothelial", "ANATOMY", 69, 80], ["cardiomyocytes", "ANATOMY", 143, 157], ["Cardiac dysfunction", "DISEASE", 0, 19], ["endothelial dysfunction", "DISEASE", 69, 92], ["fibrosis", "DISEASE", 236, 244], ["Cardiac", "ORGAN", 0, 7], ["patients", "ORGANISM", 32, 40], ["endothelial", "TISSUE", 69, 80], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 122, 130], ["cardiomyocytes", "CELL", 143, 157], ["p38 MAPK", "PROTEIN", 122, 130], ["infected cardiomyocytes", "CELL_TYPE", 134, 157], ["patients", "SPECIES", 32, 40], ["Cardiac dysfunction", "PROBLEM", 0, 19], ["COVID", "TEST", 23, 28], ["this endothelial dysfunction", "PROBLEM", 64, 92], ["overactivation of p38 MAPK", "PROBLEM", 104, 130], ["infected cardiomyocytes", "PROBLEM", 134, 157], ["apoptosis", "PROBLEM", 190, 199], ["increase fibrosis", "PROBLEM", 227, 244], ["dysfunction", "OBSERVATION", 8, 19], ["infected cardiomyocytes", "ANATOMY", 134, 157], ["apoptosis", "OBSERVATION", 190, 199], ["contractility", "OBSERVATION_MODIFIER", 208, 221], ["increase", "OBSERVATION_MODIFIER", 227, 235], ["fibrosis", "OBSERVATION", 236, 244]]], ["Additionally, elevated p38 MAPK levels are also implicated in hypoxic pulmonary vasoconstriction and vascular remodeling, which are poor predictors of outcome in acute lung injury [25, 26] .", [["pulmonary", "ANATOMY", 70, 79], ["vascular", "ANATOMY", 101, 109], ["lung", "ANATOMY", 168, 172], ["acute lung injury", "DISEASE", 162, 179], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 23, 31], ["pulmonary", "ORGAN", 70, 79], ["vascular", "MULTI-TISSUE_STRUCTURE", 101, 109], ["lung", "ORGAN", 168, 172], ["p38 MAPK", "PROTEIN", 23, 31], ["elevated p38 MAPK levels", "PROBLEM", 14, 38], ["hypoxic pulmonary vasoconstriction", "PROBLEM", 62, 96], ["vascular remodeling", "PROBLEM", 101, 120], ["acute lung injury", "PROBLEM", 162, 179], ["elevated", "OBSERVATION_MODIFIER", 14, 22], ["p38 MAPK", "OBSERVATION", 23, 31], ["hypoxic", "OBSERVATION_MODIFIER", 62, 69], ["pulmonary", "ANATOMY", 70, 79], ["vasoconstriction", "OBSERVATION", 80, 96], ["vascular", "ANATOMY", 101, 109], ["remodeling", "OBSERVATION", 110, 120], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["lung", "ANATOMY", 168, 172], ["injury", "OBSERVATION", 173, 179]]], ["These effects are not entirely unexpected as excessive Ang II signaling, which transmits through p38 MAPK, also produces similar effects.", [["Ang II", "CHEMICAL", 55, 61], ["Ang II", "GENE_OR_GENE_PRODUCT", 55, 61], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 97, 105], ["Ang II", "PROTEIN", 55, 61], ["p38 MAPK", "PROTEIN", 97, 105], ["excessive Ang II signaling", "PROBLEM", 45, 71], ["p38 MAPK", "TEST", 97, 105], ["not entirely unexpected", "UNCERTAINTY", 18, 41], ["similar", "OBSERVATION_MODIFIER", 121, 128], ["effects", "OBSERVATION_MODIFIER", 129, 136]]], ["However, in this instance, both direct viral activation of p38 MAPK and overactive Ang II p38 signaling may combine to create severe clinical complications.Implications for therapyA number of direct p38 MAPK inhibitors are in clinical trials for other indications and could be repurposed for randomized, controlled trials (RCT) in patients at risk for serious COVID-19 infection.", [["Ang", "CHEMICAL", 83, 86], ["infection", "DISEASE", 369, 378], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 59, 67], ["Ang II p38", "GENE_OR_GENE_PRODUCT", 83, 93], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 199, 207], ["patients", "ORGANISM", 331, 339], ["p38 MAPK", "PROTEIN", 59, 67], ["Ang II", "PROTEIN", 83, 89], ["p38", "PROTEIN", 90, 93], ["p38 MAPK", "PROTEIN", 199, 207], ["patients", "SPECIES", 331, 339], ["p38 MAPK", "TEST", 59, 67], ["overactive Ang II p38 signaling", "TREATMENT", 72, 103], ["severe clinical complications", "PROBLEM", 126, 155], ["therapyA", "TREATMENT", 173, 181], ["direct p38 MAPK inhibitors", "TREATMENT", 192, 218], ["randomized, controlled trials (RCT)", "TREATMENT", 292, 327], ["serious COVID-19 infection", "PROBLEM", 352, 378], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["infection", "OBSERVATION", 369, 378]]], ["Losmapimod is the most clinically studied p38 inhibitor and it has a favorable reasonable safety profile.", [["Losmapimod", "CHEMICAL", 0, 10], ["Losmapimod", "CHEMICAL", 0, 10], ["Losmapimod", "SIMPLE_CHEMICAL", 0, 10], ["p38", "GENE_OR_GENE_PRODUCT", 42, 45], ["p38 inhibitor", "TREATMENT", 42, 55]]], ["In 12 healthy volunteers, a single IV infusion of 3 mg of losmapimod and a subsequent 15 mg oral dose were safe and well-tolerated.", [["oral", "ANATOMY", 92, 96], ["losmapimod", "CHEMICAL", 58, 68], ["losmapimod", "CHEMICAL", 58, 68], ["volunteers", "ORGANISM", 14, 24], ["losmapimod", "SIMPLE_CHEMICAL", 58, 68], ["oral", "ORGANISM_SUBDIVISION", 92, 96], ["a single IV infusion", "TREATMENT", 26, 46], ["losmapimod", "TREATMENT", 58, 68]]], ["Headache was the only adverse event reported more than once.", [["Headache", "DISEASE", 0, 8], ["Headache", "PROBLEM", 0, 8]]], ["Also reported were nausea, fatigue, dry mouth, neuralgia and nasopharyngitis.", [["nausea", "DISEASE", 19, 25], ["fatigue", "DISEASE", 27, 34], ["dry mouth", "DISEASE", 36, 45], ["neuralgia", "DISEASE", 47, 56], ["nasopharyngitis", "DISEASE", 61, 76], ["nausea", "PROBLEM", 19, 25], ["fatigue", "PROBLEM", 27, 34], ["dry mouth", "PROBLEM", 36, 45], ["neuralgia", "PROBLEM", 47, 56], ["nasopharyngitis", "PROBLEM", 61, 76], ["nausea", "OBSERVATION", 19, 25], ["dry mouth", "ANATOMY", 36, 45], ["neuralgia", "OBSERVATION", 47, 56], ["nasopharyngitis", "OBSERVATION", 61, 76]]], ["Nausea was the only adverse event thought to be drug related [27] .", [["Nausea", "DISEASE", 0, 6], ["Nausea", "PROBLEM", 0, 6]]], ["In a 28-day RCT comparing 7.5 mg of losmapimod twice daily versus placebo in hypercholesterolemic patients, losmapimod was well-tolerated and safe in 27 patients, with no J o u r n a l P r e -p r o o f Journal Pre-proof serious adverse events.", [["losmapimod", "CHEMICAL", 36, 46], ["hypercholesterolemic", "DISEASE", 77, 97], ["losmapimod", "CHEMICAL", 108, 118], ["losmapimod", "CHEMICAL", 108, 118], ["losmapimod", "SIMPLE_CHEMICAL", 36, 46], ["patients", "ORGANISM", 98, 106], ["losmapimod", "SIMPLE_CHEMICAL", 108, 118], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 153, 161], ["losmapimod", "TREATMENT", 36, 46], ["placebo in hypercholesterolemic patients", "TREATMENT", 66, 106], ["losmapimod", "TREATMENT", 108, 118], ["serious adverse events", "PROBLEM", 220, 242]]], ["The most commonly reported side effect was headache and there were no differences between treatment groups in other safety data-labs, vital signs, and ECGincluding liver function tests [28] .", [["liver", "ANATOMY", 164, 169], ["headache", "DISEASE", 43, 51], ["liver", "ORGAN", 164, 169], ["headache", "PROBLEM", 43, 51], ["treatment groups", "TREATMENT", 90, 106], ["other safety data", "TEST", 110, 127], ["labs", "TEST", 128, 132], ["vital signs", "TEST", 134, 145], ["ECGincluding liver function tests", "TEST", 151, 184], ["liver", "ANATOMY", 164, 169]]], ["In a 12-week RCT of 7.5 mg of losmapimod twice daily in 3503 patients previously hospitalized with acute myocardial infarction, 16% of the 1738 patients in the on-treatment group experienced serious adverse events compared to 14.2% in the placebo group, requiring study drug discontinuation in 4.4% of on-drug patients and 3.9% of placebo patients [29] .", [["myocardial", "ANATOMY", 105, 115], ["losmapimod", "CHEMICAL", 30, 40], ["acute myocardial infarction", "DISEASE", 99, 126], ["losmapimod", "CHEMICAL", 30, 40], ["losmapimod", "SIMPLE_CHEMICAL", 30, 40], ["patients", "ORGANISM", 61, 69], ["myocardial", "MULTI-TISSUE_STRUCTURE", 105, 115], ["patients", "ORGANISM", 144, 152], ["patients", "ORGANISM", 310, 318], ["patients", "ORGANISM", 339, 347], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 144, 152], ["patients", "SPECIES", 310, 318], ["patients", "SPECIES", 339, 347], ["losmapimod", "TREATMENT", 30, 40], ["acute myocardial infarction", "PROBLEM", 99, 126], ["serious adverse events", "PROBLEM", 191, 213], ["study drug discontinuation", "TREATMENT", 264, 290], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["myocardial", "ANATOMY", 105, 115], ["infarction", "OBSERVATION", 116, 126]]], ["Dilmapimod is another p38 inhibitor previously studied in 77 patients at risk of acute lung injury following trauma in a clinical trial with no relevant safety findings [30] .Implications for therapyVarious other p38 MAPK inhibitors are currently in clinical trials for a range of indications.ConclusionsThe p38 MAPK pathway is a key mediator of inflammation implicated in lung and heart injury.", [["lung", "ANATOMY", 87, 91], ["lung", "ANATOMY", 373, 377], ["heart", "ANATOMY", 382, 387], ["Dilmapimod", "CHEMICAL", 0, 10], ["acute lung injury", "DISEASE", 81, 98], ["trauma", "DISEASE", 109, 115], ["inflammation", "DISEASE", 346, 358], ["lung and heart injury", "DISEASE", 373, 394], ["Dilmapimod", "CHEMICAL", 0, 10], ["Dilmapimod", "SIMPLE_CHEMICAL", 0, 10], ["p38", "GENE_OR_GENE_PRODUCT", 22, 25], ["patients", "ORGANISM", 61, 69], ["lung", "ORGAN", 87, 91], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 213, 221], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 308, 316], ["lung", "ORGAN", 373, 377], ["heart", "ORGAN", 382, 387], ["p38 MAPK", "PROTEIN", 213, 221], ["p38", "PROTEIN", 308, 311], ["MAPK", "PROTEIN", 312, 316], ["patients", "SPECIES", 61, 69], ["Dilmapimod", "TREATMENT", 0, 10], ["another p38 inhibitor", "TREATMENT", 14, 35], ["acute lung injury", "PROBLEM", 81, 98], ["trauma", "PROBLEM", 109, 115], ["therapy", "TREATMENT", 192, 199], ["Various other p38 MAPK inhibitors", "TREATMENT", 199, 232], ["The p38 MAPK pathway", "TEST", 304, 324], ["inflammation", "PROBLEM", 346, 358], ["lung and heart injury", "PROBLEM", 373, 394], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["lung", "ANATOMY", 87, 91], ["injury", "OBSERVATION", 92, 98], ["inflammation", "OBSERVATION", 346, 358], ["lung", "ANATOMY", 373, 377], ["heart", "ANATOMY", 382, 387], ["injury", "OBSERVATION", 388, 394]]], ["The SARS-CoV-2 virus, like SARS-CoV and other RNA respiratory viruses, may directly upregulate p38 MAPK, perhaps for replication purposes.", [["SARS-CoV-2 virus", "ORGANISM", 4, 20], ["SARS-CoV", "ORGANISM", 27, 35], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 95, 103], ["p38 MAPK", "PROTEIN", 95, 103], ["CoV-2 virus", "SPECIES", 9, 20], ["SARS-CoV-2 virus", "SPECIES", 4, 20], ["SARS-CoV", "SPECIES", 27, 35], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["2 virus", "PROBLEM", 13, 20], ["SARS", "PROBLEM", 27, 31], ["other RNA respiratory viruses", "PROBLEM", 40, 69], ["p38 MAPK", "TEST", 95, 103], ["replication purposes", "TEST", 117, 137], ["respiratory viruses", "OBSERVATION", 50, 69]]], ["However, the unique viral entry mechanism of SARS-CoV-2 may also shut off disables a key counterbalancing mechanism employed by the cell to dampen p38 signaling through ACE2 activity.", [["cell", "ANATOMY", 132, 136], ["SARS", "DISEASE", 45, 49], ["SARS-CoV-2", "ORGANISM", 45, 55], ["cell", "CELL", 132, 136], ["p38", "GENE_OR_GENE_PRODUCT", 147, 150], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["p38", "PROTEIN", 147, 150], ["ACE2", "PROTEIN", 169, 173], ["SARS-CoV", "SPECIES", 45, 53], ["SARS", "PROBLEM", 45, 49]]], ["This combination may allow a perfect storm of unrestrained p38 MAPK activity, promoting inflammation, vasoconstriction, and thrombosis, while simultaneously benefiting the viral lifecycle.", [["inflammation", "DISEASE", 88, 100], ["thrombosis", "DISEASE", 124, 134], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 59, 67], ["p38 MAPK", "PROTEIN", 59, 67], ["promoting inflammation", "PROBLEM", 78, 100], ["vasoconstriction", "PROBLEM", 102, 118], ["thrombosis", "PROBLEM", 124, 134], ["inflammation", "OBSERVATION", 88, 100], ["vasoconstriction", "OBSERVATION", 102, 118], ["thrombosis", "OBSERVATION", 124, 134], ["viral lifecycle", "OBSERVATION", 172, 187]]], ["As such, p38 MAPK inhibition may be an appropriate treatment for SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 65, 85], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 9, 17], ["SARS-CoV-2", "ORGANISM", 65, 75], ["p38 MAPK", "PROTEIN", 9, 17], ["SARS-CoV-2", "SPECIES", 65, 75], ["p38 MAPK inhibition", "TEST", 9, 28], ["an appropriate treatment", "TREATMENT", 36, 60], ["SARS", "PROBLEM", 65, 69], ["CoV", "PROBLEM", 70, 73], ["2 infection", "PROBLEM", 74, 85], ["infection", "OBSERVATION", 76, 85]]], ["This is supported by a small preclinical study of SARS-CoV infection in a mouse model.", [["SARS-CoV infection", "DISEASE", 50, 68], ["SARS-CoV", "ORGANISM", 50, 58], ["mouse", "ORGANISM", 74, 79], ["mouse", "SPECIES", 74, 79], ["SARS-CoV", "SPECIES", 50, 58], ["mouse", "SPECIES", 74, 79], ["a small preclinical study", "TEST", 21, 46], ["SARS", "PROBLEM", 50, 54], ["CoV infection", "PROBLEM", 55, 68], ["a mouse model", "TREATMENT", 72, 85], ["small", "OBSERVATION_MODIFIER", 23, 28], ["CoV", "OBSERVATION_MODIFIER", 55, 58], ["infection", "OBSERVATION", 59, 68]]], ["Further preclinical trials should be performed to implicate elucidate the role of p38 activation in animal models of SARS-CoV-2.", [["SARS", "DISEASE", 117, 121], ["p38", "GENE_OR_GENE_PRODUCT", 82, 85], ["SARS-CoV-2", "ORGANISM", 117, 127], ["p38", "PROTEIN", 82, 85], ["SARS-CoV", "SPECIES", 117, 125]]], ["More importantly, safe, and well tolerated tolerable p38 MAPK inhibitors that are already in clinical stages of development.", [["p38 MAPK", "GENE_OR_GENE_PRODUCT", 53, 61], ["p38 MAPK", "PROTEIN", 53, 61], ["p38 MAPK inhibitors", "TREATMENT", 53, 72]]], ["These drugs should be considered J o u r n a l P r e -p r o o f Journal Pre-proof for could be readily repurposed in randomized, controlled trials enrolling in patients at risk for serious COVID-19 complications.Disclosures:No conflicts of interest exist for either author.Funding:This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Funding:J o u r n a l P r e -p r o o f", [["COVID", "DISEASE", 189, 194], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["These drugs", "TREATMENT", 0, 11], ["serious COVID-19 complications", "PROBLEM", 181, 211], ["No", "UNCERTAINTY", 224, 226]]]], "a5ba1cf818602473ad4bdf9bdea334f76107f970": [["India went into a lockdown on the 24 th of March 2020 to contain the spread of SARS-CoV2 and augment healthcare infrastructure.", [["SARS", "DISEASE", 79, 83], ["SARS", "PROBLEM", 79, 83]]], ["The lockdown imposed restrictions on both human and vehicular movement and curbed the availability of out-patient based medical services in both public and private sectors.", [["human", "ORGANISM", 42, 47], ["patient", "ORGANISM", 106, 113], ["human", "SPECIES", 42, 47], ["patient", "SPECIES", 106, 113], ["human", "SPECIES", 42, 47], ["The lockdown imposed restrictions", "TREATMENT", 0, 33], ["vehicular movement", "OBSERVATION", 52, 70]]], ["The pandemic, inflicting more than 200 countries, has exposed weaknesses in our public health preparedness and structure of our healthcare systems.", [["The pandemic", "PROBLEM", 0, 12], ["pandemic", "OBSERVATION_MODIFIER", 4, 12]]]], "c6b4bc9d758eb2542292da9540b16861b6e1b023": [["\u2022 Sarcoidosis is a common yet incurable, chronic granulomatous disease of unknown etiology treated with non-specific anti-inflammatory and/or immunosuppressive drugs.", [["Sarcoidosis", "DISEASE", 2, 13], ["Sarcoidosis", "PROBLEM", 2, 13], ["chronic granulomatous disease", "PROBLEM", 41, 70], ["non-specific anti-inflammatory", "TREATMENT", 104, 134], ["immunosuppressive drugs", "TREATMENT", 142, 165], ["Sarcoidosis", "OBSERVATION", 2, 13], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["granulomatous", "OBSERVATION", 49, 62]]]], "PMC3407358": [["The order Nidovirales [1] includes positive-sense single-stranded RNA (ssRNA+) viruses of three families: Arteriviridae [2] (12.7\u201315.7-kb genomes; \u201csmall-sized nidoviruses\u201d), Coronaviridae [3] and Roniviridae [4] (26.3\u201331.7 kb; the last two families are jointly referred to as \u201clarge-sized nidoviruses\u201d) [5].", [["Roniviridae [4", "CELL", 197, 211], ["Arteriviridae", "TEST", 106, 119], ["genomes", "TEST", 138, 145], ["small-sized nidoviruses", "TREATMENT", 148, 171], ["Coronaviridae", "TREATMENT", 175, 188], ["Roniviridae", "TREATMENT", 197, 208]]], ["All other known ssRNA+ viruses have genome sizes below 20 kb.", [["All other known ssRNA+ viruses", "PROBLEM", 0, 30], ["ssRNA", "OBSERVATION", 16, 21], ["viruses", "OBSERVATION", 23, 30], ["sizes", "OBSERVATION_MODIFIER", 43, 48]]], ["Recently, two closely related viruses, Cavally virus (CAVV) and Nam Dinh virus (NDiV), were discovered by two independent groups of researchers in C\u00f4te d\u2019Ivoire in 2004 and in Vietnam in 2002, respectively [6, 7].", [["Cavally virus", "ORGANISM", 39, 52], ["CAVV", "ORGANISM", 54, 58], ["Nam Dinh virus", "ORGANISM", 64, 78], ["Dinh virus", "SPECIES", 68, 78], ["Cavally virus", "SPECIES", 39, 52], ["CAVV", "SPECIES", 54, 58], ["Nam Dinh virus", "SPECIES", 64, 78], ["NDiV", "SPECIES", 80, 84], ["two closely related viruses", "PROBLEM", 10, 37], ["Cavally virus", "PROBLEM", 39, 52], ["Nam Dinh virus", "PROBLEM", 64, 78], ["closely related", "OBSERVATION_MODIFIER", 14, 29], ["viruses", "OBSERVATION", 30, 37]]], ["CAVV was isolated from various mosquito species belonging to the genera Culex, Aedes, Anopheles and Uranotaenia [7].", [["CAVV", "CHEMICAL", 0, 4], ["CAVV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Anopheles", "ORGANISM", 86, 95], ["CAVV", "SPECIES", 0, 4], ["CAVV", "TREATMENT", 0, 4]]], ["It was most frequently found in Culex species, especially Culex nebulosus.", [["Culex species", "ORGANISM", 32, 45], ["Culex nebulosus", "ORGANISM", 58, 73], ["Culex nebulosus", "SPECIES", 58, 73], ["Culex nebulosus", "SPECIES", 58, 73], ["Culex species", "PROBLEM", 32, 45]]], ["Except for Culex quinquefasciatus, which circulates worldwide, the other mosquito species are endemic to Africa.", [["Culex quinquefasciatus", "DISEASE", 11, 33], ["Culex quinquefasciatus", "ORGANISM", 11, 33], ["Culex quinquefasciatus", "SPECIES", 11, 33], ["Culex quinquefasciatus", "SPECIES", 11, 33], ["Culex quinquefasciatus", "PROBLEM", 11, 33], ["the other mosquito species", "PROBLEM", 63, 89], ["worldwide", "OBSERVATION_MODIFIER", 52, 61]]], ["NDiV was isolated from Culex vishnui, which is endemic to Asia, and Culex tritaeniorhynchus, which circulates in Asia and Africa [6], and there are indications that it may infect more mosquito species (Nga, unpublished data).", [["NDiV", "CHEMICAL", 0, 4], ["NDiV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Culex vishnui", "ORGANISM", 23, 36], ["Culex tritaeniorhynchus", "ORGANISM", 68, 91], ["NDiV", "PROTEIN", 0, 4], ["Culex vishnui", "SPECIES", 23, 36], ["Culex tritaeniorhynchus", "SPECIES", 68, 91], ["NDiV", "SPECIES", 0, 4], ["Culex vishnui", "SPECIES", 23, 36], ["Culex tritaeniorhynchus", "SPECIES", 68, 91]]], ["Analysis of abundance patterns of 39 CAVV isolates in different habitat types along an anthropogenic disturbance gradient has indicated an increase in virus prevalence from natural to modified habitat types [8].", [["abundance patterns", "TEST", 12, 30], ["CAVV isolates", "TREATMENT", 37, 50], ["different habitat types", "PROBLEM", 54, 77], ["an anthropogenic disturbance gradient", "PROBLEM", 84, 121], ["an increase in virus prevalence", "PROBLEM", 136, 167], ["anthropogenic disturbance", "OBSERVATION", 87, 112], ["increase", "OBSERVATION_MODIFIER", 139, 147], ["virus", "OBSERVATION", 151, 156]]], ["A significantly higher prevalence was found especially in human settlements.", [["human", "ORGANISM", 58, 63], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63]]], ["Analysis of habitat-specific virus diversity and ancestral state reconstruction demonstrated an origin of CAVV in a pristine rainforest with subsequent spread into agriculture and human settlements [7].", [["CAVV", "CHEMICAL", 106, 110], ["human", "ORGANISM", 180, 185], ["human", "SPECIES", 180, 185], ["CAVV", "SPECIES", 106, 110], ["human", "SPECIES", 180, 185], ["habitat", "TEST", 12, 19], ["specific virus diversity", "PROBLEM", 20, 44], ["ancestral state reconstruction", "TREATMENT", 49, 79], ["a pristine rainforest", "TREATMENT", 114, 135], ["pristine rainforest", "OBSERVATION", 116, 135]]], ["Notably, it was shown for the first time that virus diversity decreased and prevalence increased during the process of emergence from a pristine rainforest habitat into surrounding areas of less host biodiversity due to anthropogenic modification [7].", [["virus diversity", "PROBLEM", 46, 61], ["a pristine rainforest habitat", "TREATMENT", 134, 163], ["anthropogenic modification", "TREATMENT", 220, 246], ["less", "OBSERVATION_MODIFIER", 190, 194], ["host biodiversity", "OBSERVATION", 195, 212], ["anthropogenic modification", "OBSERVATION", 220, 246]]], ["Both viruses were propagated in Aedes albopictus cells and characterized using different techniques.", [["cells", "ANATOMY", 49, 54], ["Aedes albopictus cells", "CELL", 32, 54], ["Aedes albopictus cells", "CELL_TYPE", 32, 54], ["Aedes albopictus", "SPECIES", 32, 48], ["Aedes albopictus", "SPECIES", 32, 48], ["Both viruses", "PROBLEM", 0, 12], ["viruses", "OBSERVATION", 5, 12], ["albopictus cells", "OBSERVATION", 38, 54]]], ["A number of common properties place CAVV and NDiV in the order Nidovirales.", [["CAVV", "GENE_OR_GENE_PRODUCT", 36, 40], ["NDiV", "GENE_OR_GENE_PRODUCT", 45, 49], ["NDiV", "PROTEIN", 45, 49], ["CAVV", "TREATMENT", 36, 40], ["NDiV", "TREATMENT", 45, 49]]], ["These properties include (i) the genome organization with multiple open reading frames (ORFs), (ii) the predicted proteomes (Fig. 1), (iii) the production of enveloped, spherical virions, and (iv) the synthesis of genome-length and subgenome-length viral RNAs in infected cells [6, 7].", [["virions", "ANATOMY", 179, 186], ["cells", "ANATOMY", 272, 277], ["cells", "CELL", 272, 277], ["multiple open reading frames", "DNA", 58, 86], ["ORFs", "DNA", 88, 92], ["subgenome-length viral RNAs", "RNA", 232, 259], ["infected cells", "CELL_TYPE", 263, 277], ["length", "TEST", 221, 227], ["subgenome", "TEST", 232, 241], ["length viral RNAs in infected cells", "PROBLEM", 242, 277], ["spherical virions", "OBSERVATION", 169, 186], ["infected cells", "OBSERVATION", 263, 277]]], ["Particularly, the two viruses were found to encode key molecular markers characteristic of all nidoviruses: a 3C-like main protease (3CLpro, also known as Mpro) flanked by two transmembrane (tM) domains encoded in replicase ORF1a, as well as an RNA-dependent RNA polymerase (RdRp) and a combination of a Zn-binding module (Zm) fused with a superfamily 1 helicase (HEL1) encoded in ORF1b.", [["transmembrane", "ANATOMY", 176, 189], ["3CLpro", "GENE_OR_GENE_PRODUCT", 133, 139], ["Mpro", "GENE_OR_GENE_PRODUCT", 155, 159], ["transmembrane", "CELLULAR_COMPONENT", 176, 189], ["ORF1a", "GENE_OR_GENE_PRODUCT", 224, 229], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 245, 273], ["Zn-", "GENE_OR_GENE_PRODUCT", 304, 307], ["HEL1", "GENE_OR_GENE_PRODUCT", 364, 368], ["ORF1b", "GENE_OR_GENE_PRODUCT", 381, 386], ["nidoviruses", "PROTEIN", 95, 106], ["3C-like main protease", "PROTEIN", 110, 131], ["3CLpro", "PROTEIN", 133, 139], ["Mpro", "PROTEIN", 155, 159], ["transmembrane (tM) domains", "PROTEIN", 176, 202], ["ORF1a", "PROTEIN", 224, 229], ["RNA-dependent RNA polymerase", "PROTEIN", 245, 273], ["RdRp", "PROTEIN", 275, 279], ["Zn-binding module", "PROTEIN", 304, 321], ["Zm", "PROTEIN", 323, 325], ["superfamily 1 helicase", "PROTEIN", 340, 362], ["HEL1", "PROTEIN", 364, 368], ["ORF1b", "PROTEIN", 381, 386], ["the two viruses", "PROBLEM", 14, 29], ["a 3C-like main protease (3CLpro", "TREATMENT", 108, 139], ["an RNA-dependent RNA polymerase", "PROBLEM", 242, 273], ["a Zn-binding module (Zm)", "TREATMENT", 302, 326], ["viruses", "OBSERVATION", 22, 29]]], ["As in other nidovirus genomes, ORFs 1a and 1b were found to overlap by a few nucleotides in both CAVV and NDiV.", [["nucleotides", "CHEMICAL", 77, 88], ["ORFs 1a", "GENE_OR_GENE_PRODUCT", 31, 38], ["1b", "GENE_OR_GENE_PRODUCT", 43, 45], ["nidovirus genomes", "DNA", 12, 29], ["ORFs 1a and 1b", "DNA", 31, 45], ["CAVV", "DNA", 97, 101], ["NDiV", "DNA", 106, 110], ["ORFs 1a", "TEST", 31, 38], ["a few nucleotides", "TREATMENT", 71, 88], ["NDiV", "TREATMENT", 106, 110]]], ["The ORF1a/1b overlap region includes a putative -1 ribosomal frameshift site (RFS) that is expected to direct the translation of ORF1b by a fraction of the ribosomes that start translation at the ORF1a initiation codon.", [["ribosomes", "ANATOMY", 156, 165], ["ORF1a/1b", "GENE_OR_GENE_PRODUCT", 4, 12], ["ORF1b", "GENE_OR_GENE_PRODUCT", 129, 134], ["ribosomes", "CELLULAR_COMPONENT", 156, 165], ["ORF1a", "GENE_OR_GENE_PRODUCT", 196, 201], ["ORF1a/1b overlap region", "DNA", 4, 27], ["putative -1 ribosomal frameshift site", "DNA", 39, 76], ["RFS", "DNA", 78, 81], ["ORF1b", "PROTEIN", 129, 134], ["ribosomes", "RNA", 156, 165], ["ORF1a initiation codon", "DNA", 196, 218], ["The ORF1a/1b overlap region", "PROBLEM", 0, 27], ["a putative -1 ribosomal frameshift site", "PROBLEM", 37, 76], ["ribosomal frameshift", "OBSERVATION", 51, 71]]], ["Thus, a frameshift just upstream of the ORF1a termination codon mediates the production of a C-terminally extended polyprotein jointly encoded by ORF1a and ORF1b.", [["C", "CHEMICAL", 93, 94], ["ORF1a", "GENE_OR_GENE_PRODUCT", 40, 45], ["ORF1a", "GENE_OR_GENE_PRODUCT", 146, 151], ["ORF1b", "GENE_OR_GENE_PRODUCT", 156, 161], ["ORF1a termination codon", "DNA", 40, 63], ["ORF1a", "PROTEIN", 146, 151], ["ORF1b", "PROTEIN", 156, 161], ["a frameshift", "PROBLEM", 6, 18], ["the ORF1a termination codon", "TREATMENT", 36, 63], ["a C-terminally extended polyprotein", "PROBLEM", 91, 126], ["frameshift", "OBSERVATION", 8, 18]]], ["Combined, these markers form the characteristic nidovirus constellation: tM-3CLpro-tM_RFS_RdRp_Zm-HEL1 (Fig. 1) [1, 5].", [["tM-3CLpro", "TREATMENT", 73, 82]]], ["Likewise, virion proteins are encoded in ORFs that are located downstream of ORF1b and expressed from a set of subgenomic mRNAs.", [["ORF1b", "GENE_OR_GENE_PRODUCT", 77, 82], ["virion proteins", "PROTEIN", 10, 25], ["ORFs", "DNA", 41, 45], ["ORF1b", "DNA", 77, 82], ["subgenomic mRNAs", "RNA", 111, 127], ["virion proteins", "PROBLEM", 10, 25], ["subgenomic mRNAs", "PROBLEM", 111, 127], ["virion proteins", "OBSERVATION", 10, 25], ["subgenomic mRNAs", "OBSERVATION", 111, 127]]], ["No similarities were found between the (putative) structural proteins of CAVV and NDiV and those of other nidoviruses [6, 7].", [["CAVV", "GENE_OR_GENE_PRODUCT", 73, 77], ["NDiV", "GENE_OR_GENE_PRODUCT", 82, 86], ["structural proteins", "PROTEIN", 50, 69], ["CAVV", "PROTEIN", 73, 77], ["NDiV", "PROTEIN", 82, 86], ["CAVV", "TREATMENT", 73, 77], ["NDiV", "TREATMENT", 82, 86]]], ["The most distinctive molecular characteristic of CAVV and NDiV, however, is the ~20-kb genome size, that is intermediate between the size ranges of small-sized and large-sized nidovirus genomes.", [["CAVV", "CANCER", 49, 53], ["NDiV", "GENE_OR_GENE_PRODUCT", 58, 62], ["CAVV", "DNA", 49, 53], ["NDiV", "DNA", 58, 62], ["small-sized and large-sized nidovirus genomes", "DNA", 148, 193], ["small-sized and large-sized nidovirus genomes", "PROBLEM", 148, 193], ["most distinctive", "OBSERVATION_MODIFIER", 4, 20], ["CAVV", "OBSERVATION", 49, 53], ["20-kb genome", "OBSERVATION_MODIFIER", 81, 93], ["size", "OBSERVATION_MODIFIER", 94, 98], ["intermediate", "OBSERVATION_MODIFIER", 108, 120], ["size", "OBSERVATION_MODIFIER", 133, 137], ["ranges", "OBSERVATION_MODIFIER", 138, 144], ["small", "OBSERVATION_MODIFIER", 148, 153], ["-sized", "OBSERVATION_MODIFIER", 153, 159], ["large", "OBSERVATION_MODIFIER", 164, 169], ["sized", "OBSERVATION_MODIFIER", 170, 175], ["nidovirus genomes", "OBSERVATION", 176, 193]]], ["Consequently, each of the two viruses has been proposed to prototype a new nidovirus family [6, 7].", [["viruses", "OBSERVATION", 30, 37]]]], "5ff7d74c2b3a2ea85d1ebe7023cdffc64ddb8d6d": [], "PMC5899835": [["IntroductionInfluenza is an infectious disease affecting mainly upper respiratory tract worldwide.", [["upper respiratory tract", "ANATOMY", 64, 87], ["Influenza", "DISEASE", 12, 21], ["infectious disease affecting mainly upper respiratory tract", "DISEASE", 28, 87], ["upper respiratory", "ORGANISM_SUBDIVISION", 64, 81], ["tract", "ORGANISM_SUBDIVISION", 82, 87], ["Influenza", "PROBLEM", 12, 21], ["an infectious disease", "PROBLEM", 25, 46], ["infectious", "OBSERVATION", 28, 38], ["upper", "ANATOMY_MODIFIER", 64, 69], ["respiratory tract", "ANATOMY", 70, 87]]], ["Influenza virus causes between three and five million severe cases and an estimated 250,000\u2013350,000 deaths annually.", [["Influenza virus", "DISEASE", 0, 15], ["deaths", "DISEASE", 100, 106], ["Influenza virus", "ORGANISM", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus causes", "PROBLEM", 0, 22], ["virus", "OBSERVATION", 10, 15]]], ["In the European Union, there are between 40,000 and 220,000 annual deaths attributable to influenza.", [["deaths", "DISEASE", 67, 73], ["influenza", "DISEASE", 90, 99], ["influenza", "PROBLEM", 90, 99], ["influenza", "OBSERVATION", 90, 99]]], ["However, mortality is only the tip of the iceberg in terms of the disease burden, since influenza also causes a decrease in functional status and increased dependency in the elderly [1].", [["influenza", "DISEASE", 88, 97], ["the disease burden", "PROBLEM", 62, 80], ["influenza", "PROBLEM", 88, 97], ["a decrease in functional status", "PROBLEM", 110, 141], ["increased dependency", "PROBLEM", 146, 166], ["tip", "OBSERVATION_MODIFIER", 31, 34], ["iceberg", "OBSERVATION", 42, 49], ["disease", "OBSERVATION", 66, 73], ["decrease", "OBSERVATION_MODIFIER", 112, 120], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["dependency", "OBSERVATION_MODIFIER", 156, 166]]], ["Estimating the burden of disease caused by influenza is difficult because many cases do not require medical care, or no confirmatory laboratory tests are widely performed to all influenza like illness\u2019 cases [2, 3].Methods ::: Main textEpidemiological surveillance of severe cases of influenza in Catalonia during five epidemic influenza seasons (2010\u20132015), beginning on week 40 of the season until week 20 of the following year, with the recording by twelve hospitals (covering 95,3% of the population) from the PIDIRAC sentinel network of SHCLCI reported to the epidemiological surveillance units corresponding to each hospital [5, 7].Methods ::: Main textSHCLCI cases were cases with previous influenza like illness symptoms (sudden onset of symptoms and/or fever; malaise; headache; muscle pain; and/or cough; sore throat; shortness of breath) who presented to a hospital facility and complyed with SHCLCI case definition.", [["muscle", "ANATOMY", 788, 794], ["influenza", "DISEASE", 43, 52], ["influenza", "DISEASE", 178, 187], ["illness", "DISEASE", 193, 200], ["influenza", "DISEASE", 284, 293], ["influenza", "DISEASE", 328, 337], ["influenza like illness", "DISEASE", 697, 719], ["fever", "DISEASE", 762, 767], ["headache", "DISEASE", 778, 786], ["muscle pain", "DISEASE", 788, 799], ["cough", "DISEASE", 808, 813], ["sore throat", "DISEASE", 815, 826], ["shortness of breath", "DISEASE", 828, 847], ["muscle", "ORGAN", 788, 794], ["disease", "PROBLEM", 25, 32], ["influenza", "PROBLEM", 43, 52], ["medical care", "TREATMENT", 100, 112], ["confirmatory laboratory tests", "TEST", 120, 149], ["influenza", "PROBLEM", 284, 293], ["previous influenza like illness symptoms", "PROBLEM", 688, 728], ["symptoms", "PROBLEM", 746, 754], ["fever", "PROBLEM", 762, 767], ["malaise", "PROBLEM", 769, 776], ["headache", "PROBLEM", 778, 786], ["muscle pain", "PROBLEM", 788, 799], ["cough", "PROBLEM", 808, 813], ["sore throat", "PROBLEM", 815, 826], ["shortness of breath", "PROBLEM", 828, 847], ["disease", "OBSERVATION", 25, 32], ["influenza", "OBSERVATION", 43, 52], ["severe", "OBSERVATION_MODIFIER", 268, 274], ["influenza", "OBSERVATION", 284, 293], ["muscle", "ANATOMY", 788, 794]]], ["SHLCIC was defined as a severe case of laboratory-confirmed influenza due to the influenza virus (A, A (H1N1)pdm09, B, C) that required hospitalization because of pneumonia, septic shock, multiorgan failure or any other severe condition, including ICU admission or who developed clinical signs during hospitalization for other reasons.", [["multiorgan", "ANATOMY", 188, 198], ["influenza", "DISEASE", 60, 69], ["influenza virus", "DISEASE", 81, 96], ["pneumonia", "DISEASE", 163, 172], ["septic shock", "DISEASE", 174, 186], ["multiorgan failure", "DISEASE", 188, 206], ["influenza virus", "ORGANISM", 81, 96], ["A, A (H1N1)pdm09", "ORGANISM", 98, 114], ["influenza virus", "SPECIES", 81, 96], ["influenza virus", "SPECIES", 81, 96], ["A", "SPECIES", 98, 99], ["influenza", "PROBLEM", 60, 69], ["the influenza virus", "PROBLEM", 77, 96], ["pdm09", "PROBLEM", 109, 114], ["pneumonia", "PROBLEM", 163, 172], ["septic shock", "PROBLEM", 174, 186], ["multiorgan failure", "PROBLEM", 188, 206], ["any other severe condition", "PROBLEM", 210, 236], ["clinical signs", "PROBLEM", 279, 293], ["pneumonia", "OBSERVATION", 163, 172], ["septic shock", "OBSERVATION", 174, 186], ["multiorgan failure", "OBSERVATION", 188, 206], ["severe", "OBSERVATION_MODIFIER", 220, 226]]], ["Influenza diagnosis was confirmed by polymerase chain reaction (PCR) and/or culture of nasopharyngeal swabs.", [["nasopharyngeal swabs", "ANATOMY", 87, 107], ["Influenza", "DISEASE", 0, 9], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 87, 107], ["Influenza diagnosis", "TEST", 0, 19], ["polymerase chain reaction", "PROBLEM", 37, 62], ["PCR", "TEST", 64, 67], ["culture", "TEST", 76, 83], ["nasopharyngeal swabs", "PROBLEM", 87, 107], ["nasopharyngeal", "ANATOMY", 87, 101]]], ["Respiratory tract samples were processed within 24 h of receipt at the laboratory.", [["Respiratory tract samples", "ANATOMY", 0, 25], ["Respiratory tract samples", "CANCER", 0, 25], ["Respiratory tract samples", "TEST", 0, 25]]], ["A 300 \u03bcL aliquot was taken for total nucleic acids extraction and eluted in 25 \u03bcL of RNase-free elution buffer using the automatic QIAsymphony system (Qiagen, Hilden, Germany) according to the manufacturer\u2019s instructions.", [["nucleic acids", "CHEMICAL", 37, 50], ["RNase", "GENE_OR_GENE_PRODUCT", 85, 90], ["RNase", "PROTEIN", 85, 90], ["A 300 \u03bcL aliquot", "TREATMENT", 0, 16], ["total nucleic acids extraction", "TREATMENT", 31, 61], ["RNase-free elution buffer", "TREATMENT", 85, 110], ["the automatic QIAsymphony system", "TREATMENT", 117, 149]]], ["Subsequently, two specific one-step multiplex real-time PCR was carried out using the Stratagene Mx3000P QPCR Systems (Agilent Technologies, Santa Clara, CA, USA), were used for typing A/B influenza virus and subtyping influenza A virus [8, 9].Methods ::: Main textFor each reported case, an epidemiological survey was made to collect anonymized demographic variables (age and sex); risk factors; ICU admission; day of onset of symptoms, of hospital admission and discharge; vaccination history; influenza virus type and subtype; and outcome at hospital discharge.", [["influenza A", "DISEASE", 219, 230], ["A/B influenza virus", "ORGANISM", 185, 204], ["influenza A virus", "ORGANISM", 219, 236], ["B influenza virus", "SPECIES", 187, 204], ["influenza A virus", "SPECIES", 219, 236], ["influenza virus", "SPECIES", 496, 511], ["A/B influenza virus", "SPECIES", 185, 204], ["influenza A virus", "SPECIES", 219, 236], ["time PCR", "TEST", 51, 59], ["the Stratagene Mx3000P QPCR Systems", "TREATMENT", 82, 117], ["typing", "TEST", 178, 184], ["A/B influenza virus", "PROBLEM", 185, 204], ["subtyping influenza A virus", "PROBLEM", 209, 236], ["symptoms", "PROBLEM", 428, 436], ["influenza virus type", "PROBLEM", 496, 516]]], ["Epidemiological survey was conducted by preventive medicine physician from data in medical history registry and public health epidemiologist in charge.Methods ::: Main textWe studied all data on SHCLCI from five influenza seasons in PIDIRAC sentinel network hospitals and made a comparative analysis of viral types and subtypes.", [["influenza", "DISEASE", 212, 221], ["sentinel network", "MULTI-TISSUE_STRUCTURE", 241, 257], ["a comparative analysis", "TEST", 277, 299], ["viral types", "PROBLEM", 303, 314], ["viral types", "OBSERVATION", 303, 314]]], ["The strain identified in > 50% of cases in each season was considered the predominant strain.", [["The strain", "PROBLEM", 0, 10], ["the predominant strain", "PROBLEM", 70, 92], ["predominant strain", "OBSERVATION", 74, 92]]], ["The statistical analysis was made using the Chi square test and Student\u2019s t test with 95% confidence intervals (CI) for continuous variables and the ANOVA test for categorical variables.Results ::: Main textDuring the 2010\u20132015 seasons 1400 cases of SHCLCI were recorded, 462 (33%) required ICU admission and 167 (12%) died: 778 (55.6%) were male.", [["SHCLCI", "DISEASE", 250, 256], ["SHCLCI", "CANCER", 250, 256], ["The statistical analysis", "TEST", 0, 24], ["the Chi square test", "TEST", 40, 59], ["CI", "TEST", 112, 114], ["continuous variables", "TEST", 120, 140], ["the ANOVA test", "TEST", 145, 159], ["categorical variables", "TEST", 164, 185], ["SHCLCI", "TEST", 250, 256]]], ["Of deaths, 111 (66.5%) occurred in patients aged \u2265 65 years and 55 (33.3%) in patients aged > 80 years (Table 1).", [["deaths", "DISEASE", 3, 9], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 78, 86]]]], "abeb360d9da928907bd8a03e22c2a4cf60a6a8d6": [["www.nature.com/scientificreports/ Material, Table S1 ), and 50 mL solution of Ca(NO 3 ) 2 \u00b74H 2 O (1.69 M) was added, then the pH of mixed solution in the flask was adjusted to 11.0 by adding ammonium solution.", [["Ca", "CHEMICAL", 78, 80], ["NO 3 ) 2 \u00b74H 2 O", "CHEMICAL", 81, 97], ["ammonium", "CHEMICAL", 192, 200], ["Ca(NO 3 ) 2", "CHEMICAL", 78, 89], ["4H 2 O", "CHEMICAL", 91, 97], ["ammonium", "CHEMICAL", 192, 200], ["Ca(NO 3 ) 2 \u00b74H 2 O", "SIMPLE_CHEMICAL", 78, 97], ["ammonium solution", "SIMPLE_CHEMICAL", 192, 209], ["Ca", "TEST", 78, 80], ["mixed solution in the flask", "TREATMENT", 133, 160], ["ammonium solution", "TREATMENT", 192, 209]]], ["The mixed solution was stirred for 24 h, and the precipitates were collected by centrifugation (10,000 rpm) and washed using Millipore water five times.", [["The mixed solution", "TREATMENT", 0, 18], ["Millipore water", "TREATMENT", 125, 140], ["mixed", "OBSERVATION_MODIFIER", 4, 9]]], ["The precipitates were dried at 60 \u00b0C for 24 h to obtain SeB-NPs powder.", [["SeB", "CHEMICAL", 56, 59], ["SeB", "CHEMICAL", 56, 59], ["SeB-NPs", "SIMPLE_CHEMICAL", 56, 63], ["SeB-NPs powder", "TREATMENT", 56, 70]]], ["Different SeB-NPs (SB1, SB2, and SB3) were synthesized by adjusting Ca/(P + Se) and Ca/Se mole ratios, as shown in Table 1 .", [["SeB-NPs", "CHEMICAL", 10, 17], ["SB1", "CHEMICAL", 19, 22], ["Ca", "CHEMICAL", 68, 70], ["Ca", "CHEMICAL", 84, 86], ["Se", "CHEMICAL", 87, 89], ["Ca", "CHEMICAL", 68, 70], ["P", "CHEMICAL", 72, 73], ["Se", "CHEMICAL", 76, 78], ["Ca", "CHEMICAL", 84, 86], ["Se", "CHEMICAL", 87, 89], ["SeB-NPs", "SIMPLE_CHEMICAL", 10, 17], ["SB1", "SIMPLE_CHEMICAL", 19, 22], ["SB2", "SIMPLE_CHEMICAL", 24, 27], ["SB3", "SIMPLE_CHEMICAL", 33, 36], ["P + Se", "SIMPLE_CHEMICAL", 72, 78], ["Ca/Se mole", "SIMPLE_CHEMICAL", 84, 94], ["SeB", "PROTEIN", 10, 13], ["Different SeB", "TEST", 0, 13], ["SB1", "TEST", 19, 22], ["SB2", "TEST", 24, 27], ["Ca", "TEST", 68, 70], ["Ca/Se mole ratios", "TEST", 84, 101]]], ["At the same time, biphasic calcium phosphate nanoparticles (BCP-NPs) and selenium-doped hydroxyapatite nanoparticles (SeHA-NPs) were prepared for comparison (Electronic Supplementary Material).Preparation of SeB-NPs with incorporation of silver ( Ag SeB-NPs).", [["calcium phosphate", "CHEMICAL", 27, 44], ["BCP-NPs", "CHEMICAL", 60, 67], ["selenium", "CHEMICAL", 73, 81], ["hydroxyapatite nanoparticles", "CHEMICAL", 88, 116], ["SeHA-NPs", "CHEMICAL", 118, 126], ["SeB-NPs", "CHEMICAL", 208, 215], ["silver", "CHEMICAL", 238, 244], ["Ag SeB-NPs", "CHEMICAL", 247, 257], ["calcium phosphate", "CHEMICAL", 27, 44], ["selenium", "CHEMICAL", 73, 81], ["hydroxyapatite", "CHEMICAL", 88, 102], ["SeB", "CHEMICAL", 208, 211], ["silver", "CHEMICAL", 238, 244], ["Ag", "CHEMICAL", 247, 249], ["SeB", "CHEMICAL", 250, 253], ["calcium phosphate nanoparticles", "SIMPLE_CHEMICAL", 27, 58], ["BCP-NPs", "SIMPLE_CHEMICAL", 60, 67], ["selenium-doped hydroxyapatite nanoparticles", "SIMPLE_CHEMICAL", 73, 116], ["SeHA-NPs", "SIMPLE_CHEMICAL", 118, 126], ["SeB-NPs", "SIMPLE_CHEMICAL", 208, 215], ["silver", "SIMPLE_CHEMICAL", 238, 244], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 247, 257], ["SeB", "PROTEIN", 208, 211], ["biphasic calcium phosphate nanoparticles", "TEST", 18, 58], ["BCP", "TEST", 60, 63], ["selenium-doped hydroxyapatite nanoparticles", "TREATMENT", 73, 116], ["SeHA-NPs)", "TREATMENT", 118, 127], ["SeB-NPs", "TREATMENT", 208, 215], ["incorporation of silver ( Ag SeB-NPs", "TREATMENT", 221, 257]]], ["200 mg of SB3 nanoparticleswas dispersed in 100 mL Millipore water in a three-neck flask, and 30 mg of AgNO 3 was added into flask slowly.", [["SB3", "CHEMICAL", 10, 13], ["AgNO 3", "CHEMICAL", 103, 109], ["AgNO 3", "CHEMICAL", 103, 109], ["SB3 nanoparticleswas", "TREATMENT", 10, 30], ["a three-neck flask", "TREATMENT", 70, 88], ["AgNO", "TREATMENT", 103, 107], ["neck", "ANATOMY", 78, 82]]], ["The solution was stirred for 3 h at room temperature (RT).", [["The solution", "TREATMENT", 0, 12]]], ["The precipitates were collected by using centrifugation (10,000 rpm) and washed five times using Millipore water to obtain Ag SeB-NPs.", [["Ag SeB", "CHEMICAL", 123, 129], ["Ag", "CHEMICAL", 123, 125], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 123, 133], ["Millipore water", "TREATMENT", 97, 112]]], ["Different Ag SeB-NPs samples were fabricated by regulating the amount of AgNO 3, as shown in Table 2 .Physicochemical characterization of SeB-NPs and Ag SeB-NPs.", [["Ag", "CHEMICAL", 10, 12], ["SeB-NPs", "CHEMICAL", 138, 145], ["Ag", "CHEMICAL", 150, 152], ["Ag", "CHEMICAL", 10, 12], ["AgNO 3", "CHEMICAL", 73, 79], ["SeB", "CHEMICAL", 138, 141], ["Ag", "CHEMICAL", 150, 152], ["Ag SeB", "SIMPLE_CHEMICAL", 10, 16], ["AgNO 3", "GENE_OR_GENE_PRODUCT", 73, 79], ["SeB-NPs", "SIMPLE_CHEMICAL", 138, 145], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 150, 160], ["Ag SeB", "PROTEIN", 10, 16], ["SeB", "PROTEIN", 138, 141], ["Different Ag SeB-NPs samples", "TREATMENT", 0, 28], ["Physicochemical characterization", "TEST", 102, 134], ["SeB-NPs", "TREATMENT", 138, 145]]], ["Fourier transform infrared spectros-copy (FT-IR) analysis.", [["Fourier transform infrared spectros", "TEST", 0, 35]]], ["FT-IR (ThermoFisher, Nicolelis5) was used to confirm the presence of specific chemical groups in SeB-NPs and Ag SeB-NPs.", [["SeB", "CHEMICAL", 97, 100], ["Ag SeB", "CHEMICAL", 109, 115], ["SeB", "CHEMICAL", 97, 100], ["Ag", "CHEMICAL", 109, 111], ["SeB-NPs", "SIMPLE_CHEMICAL", 97, 104], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 109, 119], ["IR (ThermoFisher, Nicolelis5)", "TREATMENT", 3, 32]]], ["The nanoparticles powders were mixed with KBr, ground, and pressed into thin sections, and the KBr was measured as blank control.", [["sections", "ANATOMY", 77, 85], ["KBr", "CHEMICAL", 95, 98], ["The nanoparticles powders", "TREATMENT", 0, 25], ["KBr", "TREATMENT", 42, 45], ["the KBr", "TEST", 91, 98]]], ["FT-IR spectra were obtained within the range between 4,000 and 500 cm \u22121 with a resolution of 1 cm \u22121 .Physicochemical characterization of SeB-NPs and Ag SeB-NPs.", [["SeB-NPs", "CHEMICAL", 139, 146], ["Ag", "CHEMICAL", 151, 153], ["SeB", "CHEMICAL", 139, 142], ["Ag", "CHEMICAL", 151, 153], ["SeB-NPs", "SIMPLE_CHEMICAL", 139, 146], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 151, 161], ["SeB", "PROTEIN", 139, 142], ["FT-IR spectra", "TEST", 0, 13], ["Physicochemical characterization", "TEST", 103, 135], ["SeB-NPs", "TREATMENT", 139, 146], ["500 cm", "OBSERVATION_MODIFIER", 63, 69], ["1 cm", "OBSERVATION_MODIFIER", 94, 98]]], ["Fourier transform infrared spectros-X-ray diffraction (XRD) analysis.", [["Fourier transform infrared spectros", "TEST", 0, 35], ["X-ray diffraction (XRD) analysis", "TEST", 36, 68]]], ["Both SeB-NPs and Ag SeB-NPs powders were analyzed by X-ray diffraction (XRD).", [["SeB-NPs", "CHEMICAL", 5, 12], ["Ag", "CHEMICAL", 17, 19], ["SeB", "CHEMICAL", 5, 8], ["Ag", "CHEMICAL", 17, 19], ["SeB-NPs", "SIMPLE_CHEMICAL", 5, 12], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 17, 27], ["SeB", "PROTEIN", 5, 8], ["Both SeB-NPs", "TREATMENT", 0, 12], ["Ag SeB-NPs powders", "TREATMENT", 17, 35]]], ["A X-ray diffractometer (Rigaku Smartlab 9 kW), operating at 45 kV and 200 mA with Cu K\u03b1 radiation (\u03bb = 1.5406 \u00c5) and a spinning sample holder, was used to collect the X-ray powder diffraction (XRD) patterns.", [["Cu", "CHEMICAL", 82, 84], ["Cu", "CHEMICAL", 82, 84], ["A X-ray diffractometer", "TEST", 0, 22], ["Cu K\u03b1 radiation", "TEST", 82, 97], ["a spinning sample holder", "TREATMENT", 117, 141], ["the X-ray powder diffraction", "TEST", 163, 191]]], ["Data were acquired in the 2\u03b8 range of 10\u00b0-90\u00b0 at a step increment of 0.05\u00b0.Ultraviolet-visible spectroscopy (UV-Vis) analysis.To investigate the diffuse reflectance spectra of samples, Ultraviolet-visible Spectroscopy (UV-Vis, PerkinElmer, Lambda 950) was used.", [["Data", "TEST", 0, 4], ["Ultraviolet", "TREATMENT", 75, 86], ["visible spectroscopy", "TEST", 87, 107], ["the diffuse reflectance spectra of samples", "PROBLEM", 141, 183], ["Ultraviolet", "TREATMENT", 185, 196], ["visible Spectroscopy", "TEST", 197, 217], ["diffuse", "OBSERVATION_MODIFIER", 145, 152]]], ["This instrument was equipped with an integrating sphere attachment.", [["an integrating sphere attachment", "TREATMENT", 34, 66], ["sphere attachment", "OBSERVATION", 49, 66]]], ["The sample was operated in the range of 200-800 nm at 298 K for the optical diffuse reflectance (DRS) spectra.Ultraviolet-visible spectroscopy (UV-Vis) analysis.Dynamic light scattering (DLS) analysis.", [["sample", "ANATOMY", 4, 10], ["The sample", "TEST", 0, 10], ["Ultraviolet", "TREATMENT", 110, 121], ["visible spectroscopy", "TEST", 122, 142], ["Dynamic light scattering (DLS) analysis", "TEST", 161, 200], ["diffuse", "OBSERVATION_MODIFIER", 76, 83]]], ["The size distribution of nanoparticles was examined by Dynamic Light Scattering (DLS, Malvern Zetasizer 3000E).", [["size", "OBSERVATION_MODIFIER", 4, 8], ["distribution", "OBSERVATION_MODIFIER", 9, 21], ["nanoparticles", "OBSERVATION", 25, 38]]], ["Zeta potential measurements were performed by Laser Doppler Anemometry with a Zetasizer Nano ZS/Masterszer 3000E.", [["Zeta potential measurements", "TEST", 0, 27], ["Laser Doppler Anemometry", "TEST", 46, 70], ["a Zetasizer Nano ZS/Masterszer", "TREATMENT", 76, 106]]], ["Electrophoretic mobility (converted into \u03b6-potential by the Smoluckowsky approximation) of nanoparticles was tested at 25 \u00b0C.Ultraviolet-visible spectroscopy (UV-Vis) analysis.Morphology analysis.", [["Electrophoretic mobility", "PROBLEM", 0, 24], ["nanoparticles", "TREATMENT", 91, 104], ["Ultraviolet", "TREATMENT", 125, 136], ["visible spectroscopy", "TEST", 137, 157], ["Morphology analysis", "TEST", 176, 195], ["mobility", "OBSERVATION", 16, 24]]], ["The morphology of SeB-NPs and Ag SeB-NPs was investigated by Transmission Electron Microscopy (TEM, Tecnai G2 F20) with an energy-dispersive detector (EDS) and Elemental Mapping accessories.", [["SeB-NPs", "CHEMICAL", 18, 25], ["Ag", "CHEMICAL", 30, 32], ["SeB", "CHEMICAL", 18, 21], ["Ag", "CHEMICAL", 30, 32], ["SeB-NPs", "SIMPLE_CHEMICAL", 18, 25], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 30, 40], ["SeB", "PROTEIN", 18, 21], ["Ag SeB", "PROTEIN", 30, 36], ["Electron Microscopy", "TEST", 74, 93], ["Elemental Mapping accessories", "TREATMENT", 160, 189]]], ["The obtained nanoparticles were dispersed in ethanol and sonicated for 2 h, and then the copper grid was dipped into a sample solution and dried under an infrared lamp.", [["sample", "ANATOMY", 119, 125], ["ethanol", "CHEMICAL", 45, 52], ["copper", "CHEMICAL", 89, 95], ["ethanol", "CHEMICAL", 45, 52], ["copper", "CHEMICAL", 89, 95], ["ethanol", "SIMPLE_CHEMICAL", 45, 52], ["copper", "SIMPLE_CHEMICAL", 89, 95], ["The obtained nanoparticles", "TREATMENT", 0, 26], ["the copper grid", "TREATMENT", 85, 100], ["a sample solution", "TREATMENT", 117, 134], ["an infrared lamp", "TREATMENT", 151, 167]]], ["Furthermore, the morphology of SeB-NPs and Ag SeB-NPs were observed with a cold field emission scanning electron microscope (SEM, Hitachi, S-4800).", [["SeB-NPs", "CHEMICAL", 31, 38], ["Ag", "CHEMICAL", 43, 45], ["S-4800", "CHEMICAL", 139, 145], ["SeB", "CHEMICAL", 31, 34], ["Ag", "CHEMICAL", 43, 45], ["SeB-NPs", "SIMPLE_CHEMICAL", 31, 38], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 43, 53], ["SeB", "PROTEIN", 31, 34], ["Ag SeB", "PROTEIN", 43, 49], ["SeB-NPs", "TREATMENT", 31, 38], ["Ag SeB-NPs", "TREATMENT", 43, 53], ["Hitachi", "TEST", 130, 137]]], ["Before SEM observation, the samples were coated with a thin Pt conductive layer, energy dispersive X-ray Spectroscopy (EDX) was used for the elemental composition analysis or chemical characterization.Ultraviolet-visible spectroscopy (UV-Vis) analysis.Raman spectroscopy analysis.", [["samples", "ANATOMY", 28, 35], ["Pt", "CHEMICAL", 60, 62], ["SEM observation", "TEST", 7, 22], ["the samples", "TEST", 24, 35], ["a thin Pt conductive layer", "TREATMENT", 53, 79], ["energy dispersive X-ray Spectroscopy (EDX", "TEST", 81, 122], ["the elemental composition analysis", "TEST", 137, 171], ["chemical characterization", "TEST", 175, 200], ["Ultraviolet", "TREATMENT", 201, 212], ["visible spectroscopy", "TEST", 213, 233], ["Raman spectroscopy analysis", "TEST", 252, 279]]], ["Raman spectra of both SeB-NPs and Ag SeB-NPs were recorded with a Spex Model spectrometer (LabRAM HR) from 200 to 1,600 cm \u22121 using the 488 nm wavelength excitation from an argon-ion laser. www.nature.com/scientificreports/ X-ray photoelectron spectrometer (XPS) analysis.", [["SeB-NPs", "CHEMICAL", 22, 29], ["Ag", "CHEMICAL", 34, 36], ["SeB", "CHEMICAL", 22, 25], ["Ag", "CHEMICAL", 34, 36], ["SeB-NPs", "SIMPLE_CHEMICAL", 22, 29], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 34, 44], ["Raman spectra", "TEST", 0, 13], ["both SeB-NPs", "TREATMENT", 17, 29], ["Ag SeB-NPs", "TREATMENT", 34, 44], ["a Spex Model spectrometer (LabRAM HR", "TREATMENT", 64, 100], ["the 488 nm wavelength excitation", "TREATMENT", 132, 164], ["an argon-ion laser", "TREATMENT", 170, 188], ["X-ray photoelectron spectrometer (XPS) analysis", "TEST", 224, 271], ["ion laser", "OBSERVATION", 179, 188]]], ["Both SeB-NPs and Ag SeB-NPs were also measured by X-ray Photoelectron Spectrometer (K-Alpha 0.05 eV, Thermo Scientific) to obtain their elements composition, the detailed sample preparation for XPS test refers to our previous paper 6 .Ultraviolet-visible spectroscopy (UV-Vis) analysis.Cell culture and cytocompatibility of SeB-NPs and Ag SeB-NPs.", [["Cell", "ANATOMY", 286, 290], ["SeB-NPs", "CHEMICAL", 5, 12], ["Ag", "CHEMICAL", 17, 19], ["K", "CHEMICAL", 84, 85], ["SeB-NPs", "CHEMICAL", 324, 331], ["Ag SeB-NPs", "CHEMICAL", 336, 346], ["SeB", "CHEMICAL", 5, 8], ["Ag", "CHEMICAL", 17, 19], ["SeB", "CHEMICAL", 324, 327], ["Ag", "CHEMICAL", 336, 338], ["SeB-NPs", "SIMPLE_CHEMICAL", 5, 12], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 17, 27], ["Cell", "CELL", 286, 290], ["SeB-NPs", "SIMPLE_CHEMICAL", 324, 331], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 336, 346], ["SeB", "PROTEIN", 5, 8], ["Ag SeB-NPs", "TREATMENT", 17, 27], ["XPS test", "TEST", 194, 202], ["Ultraviolet", "TREATMENT", 235, 246], ["visible spectroscopy", "TEST", 247, 267], ["Cell culture", "TEST", 286, 298], ["cytocompatibility", "TEST", 303, 320], ["SeB", "TEST", 324, 327], ["NPs", "TREATMENT", 328, 331]]], ["Regarding the potential bone tissue engineering application in the future, hFOB 1.19 cell (osteoblast type, ATCC\u00ae CRL-11372\u2122) was used to evaluate the cytocompatibility of SeB-NPs and Ag SeB-NPs.", [["bone tissue", "ANATOMY", 24, 35], ["hFOB 1.19 cell", "ANATOMY", 75, 89], ["osteoblast", "ANATOMY", 91, 101], ["\u00ae CRL-11372", "CHEMICAL", 112, 123], ["SeB-NPs", "CHEMICAL", 172, 179], ["Ag SeB-NPs", "CHEMICAL", 184, 194], ["SeB", "CHEMICAL", 172, 175], ["Ag", "CHEMICAL", 184, 186], ["bone tissue", "MULTI-TISSUE_STRUCTURE", 24, 35], ["hFOB 1.19 cell", "CELL", 75, 89], ["osteoblast type", "CELL", 91, 106], ["ATCC\u00ae CRL-11372\u2122", "CELL", 108, 124], ["SeB-NPs", "SIMPLE_CHEMICAL", 172, 179], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 184, 194], ["hFOB 1.19 cell", "CELL_LINE", 75, 89], ["SeB", "PROTEIN", 172, 175], ["ATCC\u00ae CRL-11372\u2122", "SPECIES", 108, 124], ["the potential bone tissue engineering application", "TREATMENT", 10, 59], ["CRL", "TEST", 114, 117], ["bone", "ANATOMY", 24, 28], ["tissue", "OBSERVATION", 29, 35]]], ["According to ATCC protocols, hFOB cells were cultured using Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich) supplemented with 10% fetal bovine serum, 100 U mL \u22121 penicillin, and 100 \u03bcg mL \u22121 streptomycin.", [["hFOB cells", "ANATOMY", 29, 39], ["fetal bovine serum", "ANATOMY", 140, 158], ["penicillin", "CHEMICAL", 172, 182], ["streptomycin", "CHEMICAL", 201, 213], ["penicillin", "CHEMICAL", 172, 182], ["streptomycin", "CHEMICAL", 201, 213], ["ATCC", "CELL", 13, 17], ["hFOB cells", "CELL", 29, 39], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 103, 116], ["bovine", "ORGANISM", 146, 152], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["penicillin", "SIMPLE_CHEMICAL", 172, 182], ["streptomycin", "SIMPLE_CHEMICAL", 201, 213], ["hFOB cells", "CELL_LINE", 29, 39], ["bovine", "SPECIES", 146, 152], ["ATCC", "SPECIES", 13, 17], ["bovine", "SPECIES", 146, 152], ["hFOB cells", "PROBLEM", 29, 39], ["Dulbecco", "TEST", 60, 68], ["Sigma-Aldrich)", "TREATMENT", 103, 117], ["10% fetal bovine serum", "TREATMENT", 136, 158], ["penicillin", "TREATMENT", 172, 182], ["streptomycin", "TREATMENT", 201, 213]]], ["Cells were grown in the tissue culture flask (50 mL) under a humidified atmosphere of 95% air and 5% CO 2 at 37 \u00b0C. The culture medium was changed every 2 days.", [["Cells", "ANATOMY", 0, 5], ["tissue", "ANATOMY", 24, 30], ["CO 2", "CHEMICAL", 101, 105], ["Cells", "CELL", 0, 5], ["tissue", "TISSUE", 24, 30], ["a humidified atmosphere", "TREATMENT", 59, 82], ["The culture medium", "TEST", 116, 134], ["tissue", "ANATOMY", 24, 30], ["medium", "OBSERVATION_MODIFIER", 128, 134]]], ["The cells were passaged by trypsinization, and cells at passage 5 were used for the next experiments.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 47, 52], ["cells", "CELL", 4, 9], ["cells", "CELL", 47, 52], ["The cells", "TREATMENT", 0, 9]]], ["First, a certain amount of obtained SeB-NPs and Ag SeB-NPs were added into the cell medium, and no agglomeration phenomenon was not observed under optical microscopy.", [["cell", "ANATOMY", 79, 83], ["SeB-NPs", "CHEMICAL", 36, 43], ["Ag", "CHEMICAL", 48, 50], ["SeB-NPs", "CHEMICAL", 51, 58], ["SeB", "CHEMICAL", 36, 39], ["Ag", "CHEMICAL", 48, 50], ["SeB-NPs", "SIMPLE_CHEMICAL", 36, 43], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 48, 58], ["cell", "CELL", 79, 83], ["SeB", "PROTEIN", 36, 39], ["SeB-NPs", "TREATMENT", 36, 43], ["Ag SeB-NPs", "TREATMENT", 48, 58], ["agglomeration phenomenon", "PROBLEM", 99, 123], ["optical microscopy", "TEST", 147, 165], ["no", "UNCERTAINTY", 96, 98], ["agglomeration phenomenon", "OBSERVATION", 99, 123]]], ["The cell viability cultured with nanoparticles was quantitatively investigated by the Cell Counting Kit-8 (CCK-8, Abcam) assay, and the CCK-8 assay was operated according to the CCK-8 Cell Proliferation Assay Kit protocol.", [["cell", "ANATOMY", 4, 8], ["Cell", "ANATOMY", 184, 188], ["cell", "CELL", 4, 8], ["Kit-8", "GENE_OR_GENE_PRODUCT", 100, 105], ["CCK-8", "GENE_OR_GENE_PRODUCT", 107, 112], ["Abcam", "GENE_OR_GENE_PRODUCT", 114, 119], ["CCK-8", "GENE_OR_GENE_PRODUCT", 136, 141], ["The cell viability", "TEST", 0, 18], ["nanoparticles", "TEST", 33, 46], ["the Cell Counting Kit", "TEST", 82, 103], ["CCK", "TEST", 107, 110], ["Abcam", "TEST", 114, 119], ["assay", "TEST", 121, 126], ["the CCK", "TEST", 132, 139], ["the CCK", "TEST", 174, 181], ["cell viability", "OBSERVATION", 4, 18]]], ["Finally, the absorbance at 450 nm was measured by using a microplate reader to indicate cell proliferation after culturing with nanoparticles (Electronic Supplementary Material).Ultraviolet-visible spectroscopy (UV-Vis) analysis.Antibacterial activity assay.", [["cell", "ANATOMY", 88, 92], ["cell", "CELL", 88, 92], ["the absorbance", "PROBLEM", 9, 23], ["a microplate reader", "TREATMENT", 56, 75], ["cell proliferation", "PROBLEM", 88, 106], ["culturing", "TEST", 113, 122], ["nanoparticles (Electronic Supplementary Material", "TREATMENT", 128, 176], ["Ultraviolet", "TREATMENT", 178, 189], ["visible spectroscopy", "TEST", 190, 210], ["Antibacterial activity assay", "TEST", 229, 257], ["absorbance", "OBSERVATION_MODIFIER", 13, 23], ["cell proliferation", "OBSERVATION", 88, 106]]], ["Gram-negative E. coli (ATCC 25922) and Gram-positive S. aureus (ATCC 6538) were used to evaluate the antibacterial activity of prepared SeB-NPs and Ag SeB-NPs.", [["ATCC 6538", "ANATOMY", 64, 73], ["Gram-", "CHEMICAL", 0, 5], ["ATCC 25922", "CHEMICAL", 23, 33], ["ATCC 6538", "CHEMICAL", 64, 73], ["SeB-NPs", "CHEMICAL", 136, 143], ["Ag SeB-NPs", "CHEMICAL", 148, 158], ["SeB", "CHEMICAL", 136, 139], ["Ag", "CHEMICAL", 148, 150], ["Gram-", "GENE_OR_GENE_PRODUCT", 0, 5], ["E. coli", "ORGANISM", 14, 21], ["ATCC 25922", "CELL", 23, 33], ["Gram-positive S. aureus", "ORGANISM", 39, 62], ["ATCC 6538", "CELL", 64, 73], ["SeB-NPs", "SIMPLE_CHEMICAL", 136, 143], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 148, 158], ["E. coli", "SPECIES", 14, 21], ["S. aureus", "SPECIES", 53, 62], ["E. coli", "SPECIES", 14, 21], ["ATCC 25922", "SPECIES", 23, 33], ["S. aureus", "SPECIES", 53, 62], ["ATCC", "SPECIES", 64, 68], ["Gram-negative E. coli", "PROBLEM", 0, 21], ["ATCC", "TEST", 23, 27], ["Gram-positive S. aureus", "PROBLEM", 39, 62], ["ATCC", "TEST", 64, 68], ["Ag SeB-NPs", "TREATMENT", 148, 158], ["E. coli", "OBSERVATION", 14, 21], ["aureus", "OBSERVATION", 56, 62]]], ["The single colony of E. coli and S. aureus on the Luria Bertani (LB) agar plate were transferred to a liquid LB culture medium by growing at 37 \u00b0C overnight to obtain seed culture.", [["colony", "ANATOMY", 11, 17], ["E. coli", "ORGANISM", 21, 28], ["S. aureus", "ORGANISM", 33, 42], ["E. coli", "SPECIES", 21, 28], ["S. aureus", "SPECIES", 33, 42], ["E. coli", "SPECIES", 21, 28], ["S. aureus", "SPECIES", 33, 42], ["Luria Bertani", "SPECIES", 50, 63], ["E. coli", "PROBLEM", 21, 28], ["S. aureus", "PROBLEM", 33, 42], ["a liquid LB culture", "TEST", 100, 119], ["seed culture", "TEST", 167, 179], ["colony", "OBSERVATION_MODIFIER", 11, 17], ["E. coli", "OBSERVATION", 21, 28], ["aureus", "OBSERVATION", 36, 42]]], ["100 \u03bcL of nanoparticles dispersed in ultrapure water (the concentrations of nanoparticles used were 500 \u03bcg/mL, 1,000 \u03bcg/mL and 2000 \u03bcg/mL, respectively) were mixed with 10 mL autoclaved LB medium, then 5 \u03bcL of seed cultures of E. coli or S. aureus was inoculated into the medium.", [["seed cultures", "ANATOMY", 210, 223], ["E. coli", "ORGANISM", 227, 234], ["S. aureus", "ORGANISM", 238, 247], ["E. coli", "SPECIES", 227, 234], ["S. aureus", "SPECIES", 238, 247], ["E. coli", "SPECIES", 227, 234], ["S. aureus", "SPECIES", 238, 247], ["nanoparticles", "TREATMENT", 10, 23], ["ultrapure water (the concentrations of nanoparticles", "TREATMENT", 37, 89], ["seed cultures", "TEST", 210, 223], ["E. coli", "PROBLEM", 227, 234], ["S. aureus", "PROBLEM", 238, 247], ["E. coli", "OBSERVATION", 227, 234], ["aureus", "OBSERVATION", 241, 247], ["medium", "OBSERVATION_MODIFIER", 272, 278]]], ["After culturing for 12 h at 37 \u00b0C, the optical density at 600 nm (OD 600 ) was tested by a UV-Vis spectrophotometer.", [["culturing", "TEST", 6, 15]]], ["E. coli and S. aureus were grown at the same conditions without adding nanoparticles as the control group.Ultraviolet-visible spectroscopy (UV-Vis) analysis.On the other hand, the seed culture medium was diluted into fresh LB medium and cultured under 37 \u00b0C. When the OD 600 of medium reached about 0.6, the broth was diluted to 105 CFU mL \u22121 with sterile 0.9% NaCl solution.", [["NaCl", "CHEMICAL", 361, 365], ["NaCl", "CHEMICAL", 361, 365], ["E. coli", "ORGANISM", 0, 7], ["S. aureus", "ORGANISM", 12, 21], ["E. coli", "SPECIES", 0, 7], ["S. aureus", "SPECIES", 12, 21], ["E. coli", "SPECIES", 0, 7], ["S. aureus", "SPECIES", 12, 21], ["E. coli", "PROBLEM", 0, 7], ["S. aureus", "PROBLEM", 12, 21], ["nanoparticles", "TREATMENT", 71, 84], ["Ultraviolet", "TREATMENT", 106, 117], ["visible spectroscopy", "TEST", 118, 138], ["the seed culture medium", "TEST", 176, 199], ["the broth", "TREATMENT", 304, 313], ["sterile 0.9% NaCl solution", "TREATMENT", 348, 374], ["coli", "OBSERVATION", 3, 7], ["aureus", "OBSERVATION", 15, 21]]], ["After then, the suspension (50 \u03bcL) was spread onto a 90 mm-diameter LB agar plate.", [["the suspension", "TREATMENT", 12, 26]]], ["The wells were created with a hole puncher with a diameter of 4 mm.", [["a hole puncher", "TREATMENT", 28, 42], ["diameter", "OBSERVATION_MODIFIER", 50, 58], ["4 mm", "OBSERVATION_MODIFIER", 62, 66]]], ["30 \u03bcL of the prepared nanoparticles solutions (500 \u03bcg/mL, 1,000 \u03bcg/ mL and 2000 \u03bcg/mL) were added into the wells.", [["the prepared nanoparticles solutions", "TREATMENT", 9, 45]]], ["Then, the plates were kept in an incubator at 37 \u00b0C for 12 h, the inhibition zones for each sample were recorded.Ultraviolet-visible spectroscopy (UV-Vis) analysis.Statistics.", [["sample", "ANATOMY", 92, 98], ["the plates", "TREATMENT", 6, 16], ["an incubator", "TREATMENT", 30, 42], ["each sample", "TEST", 87, 98], ["Ultraviolet", "TREATMENT", 113, 124], ["visible spectroscopy", "TEST", 125, 145]]], ["All data were expressed as means with standard deviation.", [["All data", "TEST", 0, 8]]], ["SPSS software (SPSS Inc, Chicago IL) was used for the analysis.", [["SPSS software", "TEST", 0, 13], ["Chicago IL)", "TREATMENT", 25, 36], ["the analysis", "TEST", 50, 62]]], ["Statistical analyses were performed by ANOVA or 2-way repeated-measures ANOVA with Tukey's test applied to investigate specific differences.", [["Statistical analyses", "TEST", 0, 20], ["Tukey's test", "TEST", 83, 95]]], ["Statistical significance was defined at a p value of < 0.05 for 95% confidence.Resultsphysicochemical characterization.", [["a p value", "TEST", 40, 49], ["Resultsphysicochemical characterization", "TEST", 79, 118]]], ["First, the chemical groups were analyzed by FT-IR spectroscopy, and the spectra of SeB-NPs and Ag SeB-NPs were presented in Fig. 2 .", [["SeB-NPs", "CHEMICAL", 83, 90], ["Ag", "CHEMICAL", 95, 97], ["SeB", "CHEMICAL", 83, 86], ["Ag", "CHEMICAL", 95, 97], ["SeB-NPs", "SIMPLE_CHEMICAL", 83, 90], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 95, 105], ["IR spectroscopy", "TEST", 47, 62], ["SeB-NPs", "TREATMENT", 83, 90], ["Ag SeB-NPs", "TREATMENT", 95, 105]]], ["The broad peak in the range of 3,000-3,800 cm \u22121 was due to H 2 O stretching vibrations in absorbed water.", [["H", "CHEMICAL", 60, 61], ["H", "CHEMICAL", 60, 61], ["O", "CHEMICAL", 64, 65], ["H 2 O", "SIMPLE_CHEMICAL", 60, 65], ["The broad peak", "TEST", 0, 14], ["stretching vibrations", "PROBLEM", 66, 87], ["broad", "OBSERVATION_MODIFIER", 4, 9], ["peak", "OBSERVATION_MODIFIER", 10, 14], ["range", "OBSERVATION_MODIFIER", 22, 27]]], ["As shown in Fig. 2a , while for SeB-NPs it decreased and disappeared.", [["SeB", "CHEMICAL", 32, 35], ["SeB", "CHEMICAL", 32, 35], ["SeB-NPs", "SIMPLE_CHEMICAL", 32, 39], ["SeB", "PROTEIN", 32, 35], ["SeB-NPs", "TREATMENT", 32, 39], ["decreased", "OBSERVATION_MODIFIER", 43, 52]]], ["At the same time, the band at 563 cm \u22121 was attributed to O-P-O vibration mode, and the band decreased as the Ca/Se ratio increased.", [["Ca", "CHEMICAL", 110, 112], ["Se", "CHEMICAL", 113, 115], ["O-P-O", "CHEMICAL", 58, 63], ["Ca", "CHEMICAL", 110, 112], ["Se", "CHEMICAL", 113, 115], ["Ca/Se", "SIMPLE_CHEMICAL", 110, 115], ["the band", "PROBLEM", 84, 92], ["the Ca/Se ratio", "TEST", 106, 121], ["increased", "OBSERVATION_MODIFIER", 122, 131]]], ["Notably, the sharpness of 563 cm \u22121 bands indicated the well-crystallized BCP-NPs, and the peak became rounded, www.nature.com/scientificreports/ indicated the decrease of crystallization for Se-NPs.", [["Se", "CHEMICAL", 192, 194], ["Se", "CHEMICAL", 192, 194], ["BCP-NPs", "SIMPLE_CHEMICAL", 74, 81], ["Se-NPs", "SIMPLE_CHEMICAL", 192, 198], ["the sharpness", "TEST", 9, 22], ["\u22121 bands", "TEST", 33, 41], ["NPs", "TREATMENT", 78, 81], ["sharpness", "OBSERVATION_MODIFIER", 13, 22], ["563 cm", "OBSERVATION_MODIFIER", 26, 32], ["rounded", "OBSERVATION_MODIFIER", 103, 110]]], ["However, due to the incorporation of selenium, a band of SeB-NPs at 871 cm \u22121 appeared, which was assigned to SeO 3 2\u2212 stretching.", [["selenium", "CHEMICAL", 37, 45], ["SeB-NPs", "CHEMICAL", 57, 64], ["SeO 3 2\u2212", "CHEMICAL", 110, 118], ["selenium", "CHEMICAL", 37, 45], ["SeB", "CHEMICAL", 57, 60], ["SeO 3", "CHEMICAL", 110, 115], ["selenium", "SIMPLE_CHEMICAL", 37, 45], ["SeB-NPs", "SIMPLE_CHEMICAL", 57, 64], ["SeB", "PROTEIN", 57, 60], ["the incorporation of selenium", "PROBLEM", 16, 45], ["a band of SeB-NPs", "TEST", 47, 64]]], ["The spectra of Ag SeB-NPs were shown in Fig. 2b .", [["Ag SeB-NPs", "CHEMICAL", 15, 25], ["Ag", "CHEMICAL", 15, 17], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 15, 25], ["Ag SeB", "PROTEIN", 15, 21], ["Ag SeB", "TEST", 15, 21]]], ["It was clearly noted that the peak at 1,035 cm \u22121 was ascribed to antisymmetric (v 3 ) P-O stretching vibration mode, which was mainly due to the combination of the silver nanoparticles with OH \u2212 or PO 4 3\u2212 groups of SeB-NPs.", [["silver", "CHEMICAL", 165, 171], ["OH", "CHEMICAL", 191, 193], ["PO 4 3\u2212", "CHEMICAL", 199, 206], ["SeB-NPs", "CHEMICAL", 217, 224], ["(v 3 ) P-O", "CHEMICAL", 80, 90], ["silver", "CHEMICAL", 165, 171], ["OH", "CHEMICAL", 191, 193], ["PO 4 3\u2212", "CHEMICAL", 199, 206], ["SeB", "CHEMICAL", 217, 220], ["silver nanoparticles", "SIMPLE_CHEMICAL", 165, 185], ["OH \u2212", "SIMPLE_CHEMICAL", 191, 195], ["PO 4 3\u2212 groups", "SIMPLE_CHEMICAL", 199, 213], ["SeB-NPs", "SIMPLE_CHEMICAL", 217, 224], ["P-O stretching vibration mode", "TEST", 87, 116], ["the silver nanoparticles", "TREATMENT", 161, 185], ["OH \u2212", "TREATMENT", 191, 195], ["PO", "TREATMENT", 199, 201], ["SeB-NPs", "TREATMENT", 217, 224], ["peak", "OBSERVATION_MODIFIER", 30, 34]]], ["The slight difference between Ag SeB1, Ag SeB2, and Ag SeB3 demonstrated that the chemical bonding between silver and SeB-NPs barely happened, and silver was mainly deposited on SeB-NPs via electrostatic attraction.", [["Ag", "CHEMICAL", 30, 32], ["Ag", "CHEMICAL", 39, 41], ["Ag", "CHEMICAL", 52, 54], ["silver", "CHEMICAL", 107, 113], ["SeB-NPs", "CHEMICAL", 118, 125], ["silver", "CHEMICAL", 147, 153], ["SeB-NPs", "CHEMICAL", 178, 185], ["Ag", "CHEMICAL", 30, 32], ["SeB1", "CHEMICAL", 33, 37], ["Ag", "CHEMICAL", 39, 41], ["SeB2", "CHEMICAL", 42, 46], ["Ag", "CHEMICAL", 52, 54], ["SeB3", "CHEMICAL", 55, 59], ["silver", "CHEMICAL", 107, 113], ["SeB", "CHEMICAL", 118, 121], ["silver", "CHEMICAL", 147, 153], ["SeB", "CHEMICAL", 178, 181], ["Ag SeB1", "SIMPLE_CHEMICAL", 30, 37], ["Ag SeB2", "SIMPLE_CHEMICAL", 39, 46], ["Ag SeB3", "SIMPLE_CHEMICAL", 52, 59], ["silver", "SIMPLE_CHEMICAL", 107, 113], ["SeB-NPs", "SIMPLE_CHEMICAL", 118, 125], ["silver", "SIMPLE_CHEMICAL", 147, 153], ["SeB-NPs", "SIMPLE_CHEMICAL", 178, 185], ["Ag SeB1", "PROTEIN", 30, 37], ["Ag SeB2", "PROTEIN", 39, 46], ["Ag SeB3", "PROTEIN", 52, 59], ["Ag SeB1", "TEST", 30, 37], ["the chemical bonding between silver and SeB-NPs", "TREATMENT", 78, 125], ["slight", "OBSERVATION_MODIFIER", 4, 10], ["difference", "OBSERVATION_MODIFIER", 11, 21], ["electrostatic attraction", "OBSERVATION", 190, 214]]], ["Complementary to the above FT-IR analysis, the Raman spectra of both SeB-NPs and Ag SeB-NPs were obtained.ResultsThe Raman spectra of SeB-NPs and Ag SeB-NPs were shown in Fig. 3 .", [["SeB-NPs", "CHEMICAL", 69, 76], ["Ag", "CHEMICAL", 81, 83], ["SeB-NPs", "CHEMICAL", 134, 141], ["Ag", "CHEMICAL", 146, 148], ["SeB", "CHEMICAL", 69, 72], ["Ag", "CHEMICAL", 81, 83], ["SeB", "CHEMICAL", 134, 137], ["Ag", "CHEMICAL", 146, 148], ["SeB-NPs", "SIMPLE_CHEMICAL", 69, 76], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 81, 91], ["SeB-NPs", "SIMPLE_CHEMICAL", 134, 141], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 146, 156], ["the above FT-IR analysis", "TEST", 17, 41], ["the Raman spectra", "TEST", 43, 60], ["Ag SeB-NPs", "TEST", 81, 91], ["SeB-NPs", "TREATMENT", 134, 141], ["Ag SeB-NPs", "TREATMENT", 146, 156]]], ["The OH \u22121 vibrational bands in the region of 630 cm \u22121 were not clearly observed, which was in good accord with the FT-IR results.", [["The OH \u22121 vibrational bands", "TEST", 0, 27], ["the FT", "TEST", 112, 118], ["vibrational bands", "OBSERVATION", 10, 27], ["region", "ANATOMY_MODIFIER", 35, 41], ["630 cm", "OBSERVATION_MODIFIER", 45, 51]]], ["In the case of SeB-NPs, an intense peak appeared at 960 cm \u22121 due to the stretching mode (v 1 ) of PO 4 3\u2212 group, and peaks at 430 cm \u22121 , 590 cm \u22121 , and 1,070 cm \u22121 were attributed to the stretching mode (v 2 ), bending mode (v 4 ), and stretching mode (v 3 ) of the PO 4 3\u2212 group, respectively.", [["SeB", "CHEMICAL", 15, 18], ["SeB", "CHEMICAL", 15, 18], ["SeB-NPs", "SIMPLE_CHEMICAL", 15, 22], ["PO 4 3\u2212", "SIMPLE_CHEMICAL", 99, 106], ["SeB", "PROTEIN", 15, 18], ["the stretching mode", "TEST", 69, 88], ["the stretching mode", "TREATMENT", 186, 205], ["stretching mode", "TEST", 239, 254], ["590 cm", "OBSERVATION_MODIFIER", 139, 145]]], ["The peak at 1,064 cm \u22121 corresponded to the symmetrical stretching vibration mode (v 1 ) of CO 3 2\u2212 group.", [["CO 3", "CHEMICAL", 92, 96], ["the symmetrical stretching vibration mode", "TEST", 40, 81], ["CO", "TEST", 92, 94], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["symmetrical", "OBSERVATION_MODIFIER", 44, 55], ["stretching vibration", "OBSERVATION", 56, 76]]], ["In addition, the band near 830 cm \u22121 was attributed to the symmetrical stretching mode (v 1 ) of the SeO 3 2\u2212 group.", [["SeO 3 2\u2212", "CHEMICAL", 101, 109], ["SeO 3", "CHEMICAL", 101, 106], ["SeO 3 2\u2212", "SIMPLE_CHEMICAL", 101, 109], ["SeO 3 2\u2212 group", "PROTEIN", 101, 115], ["symmetrical", "OBSERVATION_MODIFIER", 59, 70], ["stretching", "OBSERVATION", 71, 81]]], ["For Ag SeB-NPs, similar chemical groups from SeB-NPs appeared.", [["Ag", "CHEMICAL", 4, 6], ["SeB", "CHEMICAL", 45, 48], ["Ag", "CHEMICAL", 4, 6], ["SeB", "CHEMICAL", 45, 48], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 4, 14], ["SeB-NPs", "SIMPLE_CHEMICAL", 45, 52], ["Ag SeB-NPs", "TREATMENT", 4, 14]]], ["Compared with FTIR spectra, water vibrational modes should give rise to weak intensity stretching and no bending bands in Raman spectra were observed.", [["FTIR spectra", "TEST", 14, 26], ["water vibrational modes", "TREATMENT", 28, 51], ["weak intensity stretching", "PROBLEM", 72, 97], ["bending bands in Raman spectra", "PROBLEM", 105, 135], ["weak intensity", "OBSERVATION_MODIFIER", 72, 86]]], ["However, the intensity of the vibration peak at 589 cm \u22121 increased with increasing silver content.ResultsXRD was used to identify the crystalline phase, and the XRD patterns of all of the synthesized samples were shown in Fig. 4a .", [["samples", "ANATOMY", 201, 208], ["silver", "CHEMICAL", 84, 90], ["silver", "CHEMICAL", 84, 90], ["silver", "SIMPLE_CHEMICAL", 84, 90], ["the vibration peak", "TEST", 26, 44], ["increasing silver content", "PROBLEM", 73, 98], ["the XRD patterns", "TEST", 158, 174], ["the synthesized samples", "TEST", 185, 208], ["intensity", "OBSERVATION_MODIFIER", 13, 22], ["vibration", "OBSERVATION_MODIFIER", 30, 39], ["peak", "OBSERVATION_MODIFIER", 40, 44], ["increasing", "OBSERVATION_MODIFIER", 73, 83], ["silver content", "OBSERVATION", 84, 98]]], ["The peaks of HA and \u03b2-TCP were present in BCP, SeB-NPs, and Ag SeB-NPs, the peaks at 25.9\u00b0 Furthermore, the UV-Vis DRS spectroscopy was used to analyze the obtained Ag SeB-NPs, as shown in Fig. 4b .", [["\u03b2-TCP", "CHEMICAL", 20, 25], ["Ag", "CHEMICAL", 60, 62], ["Ag", "CHEMICAL", 165, 167], ["SeB", "CHEMICAL", 47, 50], ["Ag", "CHEMICAL", 60, 62], ["Ag", "CHEMICAL", 165, 167], ["SeB", "CHEMICAL", 168, 171], ["HA", "SIMPLE_CHEMICAL", 13, 15], ["\u03b2-TCP", "SIMPLE_CHEMICAL", 20, 25], ["BCP", "SIMPLE_CHEMICAL", 42, 45], ["SeB-NPs", "SIMPLE_CHEMICAL", 47, 54], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 60, 70], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 165, 175], ["Ag SeB", "PROTEIN", 165, 171], ["HA", "PROBLEM", 13, 15], ["\u03b2-TCP", "PROBLEM", 20, 25], ["BCP", "TEST", 42, 45], ["SeB", "TEST", 47, 50], ["DRS spectroscopy", "TEST", 115, 131], ["peaks", "OBSERVATION_MODIFIER", 4, 9], ["HA", "OBSERVATION_MODIFIER", 13, 15]]], ["The UV-Vis DRS absorption broadened in the region of 250-800 nm, and the band at 550 nm corresponds to the surface plasmon resonance of silver nanoparticles.", [["silver nanoparticles", "CHEMICAL", 136, 156], ["silver", "CHEMICAL", 136, 142], ["silver nanoparticles", "SIMPLE_CHEMICAL", 136, 156], ["The UV", "TREATMENT", 0, 6], ["silver nanoparticles", "TREATMENT", 136, 156], ["silver nanoparticles", "OBSERVATION", 136, 156]]], ["This phenomenon indicated that silver was deposited uniformly on SeB-NPs.", [["silver", "CHEMICAL", 31, 37], ["SeB-NPs", "CHEMICAL", 65, 72], ["silver", "CHEMICAL", 31, 37], ["SeB", "CHEMICAL", 65, 68], ["silver", "SIMPLE_CHEMICAL", 31, 37], ["SeB-NPs", "SIMPLE_CHEMICAL", 65, 72], ["silver", "OBSERVATION_MODIFIER", 31, 37], ["uniformly", "OBSERVATION_MODIFIER", 52, 61]]], ["To get a further detailed vision for the ionic species of SeB-NPs and Ag SeB-NPs, XPS measurements were performed, as shown in Fig. 5 .", [["SeB", "CHEMICAL", 58, 61], ["Ag", "CHEMICAL", 70, 72], ["SeB", "CHEMICAL", 58, 61], ["Ag", "CHEMICAL", 70, 72], ["SeB-NPs", "SIMPLE_CHEMICAL", 58, 65], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 70, 80], ["SeB", "PROTEIN", 58, 61], ["Ag SeB", "PROTEIN", 70, 76], ["XPS measurements", "TEST", 82, 98]]], ["The XPS spectra of SeB-NPs (Fig. 5a-c) found all the expected elements during the preparation process, including Ca, O, C, P, Se.", [["SeB-NPs", "CHEMICAL", 19, 26], ["Ca", "CHEMICAL", 113, 115], ["SeB", "CHEMICAL", 19, 22], ["Ca", "CHEMICAL", 113, 115], ["O", "CHEMICAL", 117, 118], ["C", "CHEMICAL", 120, 121], ["P", "CHEMICAL", 123, 124], ["SeB-NPs", "SIMPLE_CHEMICAL", 19, 26], ["Fig. 5a-c", "SIMPLE_CHEMICAL", 28, 37], ["C", "SIMPLE_CHEMICAL", 120, 121], ["The XPS", "TEST", 0, 7], ["SeB-NPs", "TREATMENT", 19, 26], ["Ca", "TEST", 113, 115]]], ["The peak at 58 eV corresponded to SeO 3 2\u2212 [Se (IV)] indicated that SeO 3 2\u2212 group was already incorporated in BCP-NPs lattice.", [["SeO 3 2\u2212", "CHEMICAL", 34, 42], ["Se", "CHEMICAL", 44, 46], ["SeO 3 2\u2212", "CHEMICAL", 68, 76], ["SeO 3 2\u2212", "CHEMICAL", 34, 42], ["[Se (IV)]", "CHEMICAL", 43, 52], ["SeO 3", "CHEMICAL", 68, 73], ["[Se (IV)", "SIMPLE_CHEMICAL", 43, 51], ["SeO 3 2\u2212", "SIMPLE_CHEMICAL", 68, 76], ["BCP-NPs", "SIMPLE_CHEMICAL", 111, 118], ["The peak", "TEST", 0, 8], ["Se (IV)", "TREATMENT", 44, 51]]], ["And the peak at 55 eV belonged to Se (0) was not observed, proving that the redox reaction happened during the preparation process.", [["Se", "CHEMICAL", 34, 36], ["Se (0)", "CHEMICAL", 34, 40], ["Se (0)", "SIMPLE_CHEMICAL", 34, 40], ["the redox reaction", "PROBLEM", 72, 90]]], ["The P2p spectra of all samples exhibited a peak at 132 eV, which was assigned to the phosphate group.", [["samples", "ANATOMY", 23, 30], ["phosphate", "CHEMICAL", 85, 94], ["phosphate", "CHEMICAL", 85, 94], ["phosphate", "SIMPLE_CHEMICAL", 85, 94], ["The P2p spectra", "TEST", 0, 15], ["all samples", "TEST", 19, 30]]], ["The double peaks at 347 eV and 351 eV were attributed to the Ca2p 3/2 and Ca2p 1/2 .", [["Ca2p 3/2", "GENE_OR_GENE_PRODUCT", 61, 69], ["Ca2p 1/2", "GENE_OR_GENE_PRODUCT", 74, 82], ["Ca2p 3/2", "PROTEIN", 61, 69], ["Ca2p 1/2", "PROTEIN", 74, 82], ["The double peaks", "PROBLEM", 0, 16], ["Ca2p", "TREATMENT", 74, 78]]], ["For Ag SeB-NPs, except for the peaks appeared in SeB-NPs, the new high peaks around 367 eV and 373 eV were assigned to Ag3d 5/2 and Ag3d 3/2 binding energies, respectively 32, 33 .ResultsThe morphology of the prepared SeB-NPs and Ag SeB-NPs was analyzed by TEM.", [["Ag", "CHEMICAL", 4, 6], ["SeB", "CHEMICAL", 49, 52], ["SeB-NPs", "CHEMICAL", 218, 225], ["Ag SeB", "CHEMICAL", 230, 236], ["Ag", "CHEMICAL", 4, 6], ["SeB", "CHEMICAL", 49, 52], ["Ag3d", "CHEMICAL", 119, 123], ["SeB", "CHEMICAL", 218, 221], ["Ag", "CHEMICAL", 230, 232], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 4, 14], ["SeB-NPs", "SIMPLE_CHEMICAL", 49, 56], ["Ag3d 5/2", "SIMPLE_CHEMICAL", 119, 127], ["SeB-NPs", "SIMPLE_CHEMICAL", 218, 225], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 230, 240], ["Ag SeB", "PROTEIN", 4, 10], ["SeB", "PROTEIN", 49, 52], ["SeB", "PROTEIN", 218, 221], ["Ag SeB", "PROTEIN", 230, 236], ["Ag SeB", "TEST", 4, 10], ["the peaks", "PROBLEM", 27, 36], ["the new high peaks", "PROBLEM", 58, 76], ["the prepared SeB-NPs", "TREATMENT", 205, 225], ["Ag SeB-NPs", "TREATMENT", 230, 240]]], ["TEM micrographs of SeB-NPs were given in Fig. 6 .", [["SeB-NPs", "CHEMICAL", 19, 26], ["SeB-NPs", "SIMPLE_CHEMICAL", 19, 26], ["TEM micrographs", "TEST", 0, 15], ["SeB-NPs", "TREATMENT", 19, 26]]], ["BCP-NPs exhibited an ellipsoidal morphology ( Figure S1 , Supplementary Materials).", [["BCP-NPs", "CHEMICAL", 0, 7], ["BCP-NPs", "SIMPLE_CHEMICAL", 0, 7], ["BCP", "TEST", 0, 3], ["ellipsoidal morphology", "OBSERVATION_MODIFIER", 21, 43]]], ["SeB-NPs showed clear needle granular morphology with a length of less than 100 nm.", [["SeB-NPs", "CHEMICAL", 0, 7], ["SeB", "CHEMICAL", 0, 3], ["SeB-NPs", "SIMPLE_CHEMICAL", 0, 7], ["SeB", "PROTEIN", 0, 3], ["a length", "TEST", 53, 61], ["clear", "OBSERVATION_MODIFIER", 15, 20], ["needle", "OBSERVATION", 21, 27], ["granular morphology", "OBSERVATION", 28, 47]]], ["The results revealed that the doping selenium influenced the morphology of SeB-NPs.", [["selenium", "CHEMICAL", 37, 45], ["SeB-NPs", "CHEMICAL", 75, 82], ["selenium", "CHEMICAL", 37, 45], ["SeB", "CHEMICAL", 75, 78], ["selenium", "SIMPLE_CHEMICAL", 37, 45], ["SeB-NPs", "SIMPLE_CHEMICAL", 75, 82], ["SeB", "PROTEIN", 75, 78], ["the doping selenium", "PROBLEM", 26, 45]]], ["Agglomeration was observed in all SeB-NPs samples.", [["SeB", "CHEMICAL", 34, 37], ["SeB", "CHEMICAL", 34, 37], ["SeB", "PROTEIN", 34, 37], ["Agglomeration", "PROBLEM", 0, 13]]], ["SEM was used to further confirm the morphology of SeB-NPs, and the SEM images were shown in Figure S2a -f (Supplementary Materials), and the nanoparticles of all samples were aggregated.", [["samples", "ANATOMY", 162, 169], ["SeB", "CHEMICAL", 50, 53], ["SeB-NPs", "SIMPLE_CHEMICAL", 50, 57], ["SeB", "PROTEIN", 50, 53], ["the SEM images", "TEST", 63, 77]]], ["With increased Ca/Se mole ratio, more SeB-NPs nanoparticles aggregated, which was certified via DLS analysis ( Figure S3 , Supplementary Materials).", [["Ca", "CHEMICAL", 15, 17], ["Se", "CHEMICAL", 18, 20], ["SeB", "CHEMICAL", 38, 41], ["Ca", "CHEMICAL", 15, 17], ["Se", "CHEMICAL", 18, 20], ["SeB", "CHEMICAL", 38, 41], ["Ca", "SIMPLE_CHEMICAL", 15, 17], ["Se", "SIMPLE_CHEMICAL", 18, 20], ["SeB-NPs nanoparticles", "SIMPLE_CHEMICAL", 38, 59], ["increased Ca/Se mole ratio", "PROBLEM", 5, 31], ["DLS analysis", "TEST", 96, 108], ["increased", "OBSERVATION_MODIFIER", 5, 14], ["Ca", "OBSERVATION", 15, 17]]], ["Furthermore, the high-angle annular dark-field (HAADF) mode image of sample SeB2 was present in Fig. 6d , which was inserted in the top-left corner, and the elemental mapping results were shown in Fig. 6e-g.", [["SeB2", "PROTEIN", 76, 80], ["sample SeB2", "TEST", 69, 80], ["the elemental mapping", "TEST", 153, 174], ["high", "OBSERVATION_MODIFIER", 17, 21], ["angle", "OBSERVATION_MODIFIER", 22, 27], ["annular", "OBSERVATION_MODIFIER", 28, 35], ["top", "OBSERVATION_MODIFIER", 132, 135], ["left", "ANATOMY_MODIFIER", 136, 140]]], ["The presence of calcium (yellow), phosphorus (blue), and selenium (green) indicated that selenium was evenly distributed in the SeB-NPs.ResultsThe TEM images of Ag SeB-NPs were displayed in Fig. 7 .", [["calcium", "CHEMICAL", 16, 23], ["phosphorus", "CHEMICAL", 34, 44], ["selenium", "CHEMICAL", 57, 65], ["selenium", "CHEMICAL", 89, 97], ["SeB", "CHEMICAL", 128, 131], ["Ag SeB-NPs", "CHEMICAL", 161, 171], ["calcium", "CHEMICAL", 16, 23], ["phosphorus", "CHEMICAL", 34, 44], ["selenium", "CHEMICAL", 57, 65], ["selenium", "CHEMICAL", 89, 97], ["SeB", "CHEMICAL", 128, 131], ["Ag", "CHEMICAL", 161, 163], ["calcium", "SIMPLE_CHEMICAL", 16, 23], ["phosphorus", "SIMPLE_CHEMICAL", 34, 44], ["blue", "SIMPLE_CHEMICAL", 46, 50], ["selenium", "SIMPLE_CHEMICAL", 57, 65], ["selenium", "SIMPLE_CHEMICAL", 89, 97], ["SeB-NPs", "SIMPLE_CHEMICAL", 128, 135], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 161, 171], ["SeB", "PROTEIN", 164, 167], ["calcium", "TEST", 16, 23], ["phosphorus (blue", "TEST", 34, 50], ["The TEM images", "TEST", 143, 157], ["Ag SeB", "TEST", 161, 167], ["selenium", "OBSERVATION", 89, 97]]], ["Compared with SeB-NPs, the Ag SeB-NPs displayed irregular morphology, and the aggregation was observed, indicating that the morphology of SeB-NPs was influenced by the deposition of silver nanoparticles.", [["SeB", "CHEMICAL", 14, 17], ["Ag", "CHEMICAL", 27, 29], ["SeB", "CHEMICAL", 30, 33], ["SeB-NPs", "CHEMICAL", 138, 145], ["silver nanoparticles", "CHEMICAL", 182, 202], ["SeB", "CHEMICAL", 14, 17], ["Ag", "CHEMICAL", 27, 29], ["SeB", "CHEMICAL", 138, 141], ["silver", "CHEMICAL", 182, 188], ["SeB-NPs", "SIMPLE_CHEMICAL", 14, 21], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 27, 37], ["SeB-NPs", "SIMPLE_CHEMICAL", 138, 145], ["silver nanoparticles", "SIMPLE_CHEMICAL", 182, 202], ["SeB", "PROTEIN", 14, 17], ["Ag SeB", "PROTEIN", 27, 33], ["the Ag SeB", "TEST", 23, 33], ["irregular morphology", "PROBLEM", 48, 68], ["the aggregation", "PROBLEM", 74, 89], ["the deposition of silver nanoparticles", "TREATMENT", 164, 202], ["irregular", "OBSERVATION_MODIFIER", 48, 57], ["morphology", "OBSERVATION_MODIFIER", 58, 68], ["silver nanoparticles", "OBSERVATION", 182, 202]]], ["According to the DLS test results ( Figure S3c , Supplementary www.nature.com/scientificreports/ Materials), multiple peaks appeared and confirmed that Ag SeB-NPs nanoparticles were further aggregated compared to SeB-NPs, which was also affirmed by SEM ( Figure S2g-i, Supplementary Materials) .", [["Ag", "CHEMICAL", 152, 154], ["SeB", "CHEMICAL", 213, 216], ["Ag", "CHEMICAL", 152, 154], ["SeB", "CHEMICAL", 213, 216], ["Ag SeB-NPs nanoparticles", "SIMPLE_CHEMICAL", 152, 176], ["SeB-NPs", "SIMPLE_CHEMICAL", 213, 220], ["the DLS test", "TEST", 13, 25], ["Ag SeB-NPs nanoparticles", "TREATMENT", 152, 176], ["SeB-NPs", "TREATMENT", 213, 220]]], ["With the increase of AgNO 3 used during the preparation procedure, the prepared Ag SeB-NPs tended to flock together, and the snowflake-like morphology was shown (Fig. 7d) .", [["AgNO 3", "CHEMICAL", 21, 27], ["Ag", "CHEMICAL", 80, 82], ["SeB-NPs", "CHEMICAL", 83, 90], ["AgNO 3", "CHEMICAL", 21, 27], ["Ag", "CHEMICAL", 80, 82], ["AgNO 3", "GENE_OR_GENE_PRODUCT", 21, 27], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 80, 90], ["AgNO 3", "PROTEIN", 21, 27], ["AgNO 3", "TREATMENT", 21, 27], ["the preparation procedure", "TREATMENT", 40, 65], ["the prepared Ag SeB-NPs", "TREATMENT", 67, 90], ["increase", "OBSERVATION_MODIFIER", 9, 17]]], ["The high-magnification image of Ag SeB2 revealed that the silver nanoparticles adhered to the surface of Ag SeB-NPs (Fig. 7c) .", [["surface", "ANATOMY", 94, 101], ["Ag", "CHEMICAL", 32, 34], ["silver nanoparticles", "CHEMICAL", 58, 78], ["Ag SeB-NPs", "CHEMICAL", 105, 115], ["Ag", "CHEMICAL", 32, 34], ["silver", "CHEMICAL", 58, 64], ["Ag", "CHEMICAL", 105, 107], ["Ag SeB2", "SIMPLE_CHEMICAL", 32, 39], ["silver nanoparticles", "SIMPLE_CHEMICAL", 58, 78], ["surface", "CELLULAR_COMPONENT", 94, 101], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 105, 115], ["Ag SeB2", "PROTEIN", 32, 39], ["Ag SeB", "PROTEIN", 105, 111], ["Ag SeB2", "TEST", 32, 39], ["the silver nanoparticles", "TREATMENT", 54, 78], ["Ag SeB", "TREATMENT", 105, 111], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["Interestingly, a rooster-like image (like the map of China) was obtained for Ag SeB2 sample, as shown in Fig. 7e , and the HAADF mode image was inserted in the bottom-right corner.", [["Ag", "CHEMICAL", 77, 79], ["Ag", "CHEMICAL", 77, 79], ["Ag", "PROTEIN", 77, 79], ["Ag SeB2 sample", "TEST", 77, 91], ["the HAADF mode image", "TEST", 119, 139], ["bottom", "ANATOMY_MODIFIER", 160, 166], ["right", "ANATOMY_MODIFIER", 167, 172], ["corner", "ANATOMY_MODIFIER", 173, 179]]], ["The elemental mapping analysis showed that silver (red, Fig. 7f) , calcium (yellow, Fig. 7g) , phosphorus (blue, Fig. 7h) , and selenium (green, Fig. 7i) were detected, proved that silver and selenium were evenly distributed in Ag SeB-NPs.", [["silver", "CHEMICAL", 43, 49], ["calcium", "CHEMICAL", 67, 74], ["phosphorus", "CHEMICAL", 95, 105], ["selenium", "CHEMICAL", 128, 136], ["silver", "CHEMICAL", 181, 187], ["selenium", "CHEMICAL", 192, 200], ["Ag SeB", "CHEMICAL", 228, 234], ["silver", "CHEMICAL", 43, 49], ["calcium", "CHEMICAL", 67, 74], ["phosphorus", "CHEMICAL", 95, 105], ["selenium", "CHEMICAL", 128, 136], ["silver", "CHEMICAL", 181, 187], ["selenium", "CHEMICAL", 192, 200], ["Ag", "CHEMICAL", 228, 230], ["silver", "SIMPLE_CHEMICAL", 43, 49], ["Fig. 7f", "SIMPLE_CHEMICAL", 56, 63], ["calcium", "SIMPLE_CHEMICAL", 67, 74], ["Fig. 7g", "SIMPLE_CHEMICAL", 84, 91], ["phosphorus", "SIMPLE_CHEMICAL", 95, 105], ["selenium", "SIMPLE_CHEMICAL", 128, 136], ["silver", "SIMPLE_CHEMICAL", 181, 187], ["selenium", "SIMPLE_CHEMICAL", 192, 200], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 228, 238], ["The elemental mapping analysis", "TEST", 0, 30], ["calcium", "TEST", 67, 74], ["yellow", "TEST", 76, 82], ["Fig.", "TEST", 84, 88], ["phosphorus (blue", "TEST", 95, 111], ["selenium", "TEST", 128, 136], ["silver and selenium", "TREATMENT", 181, 200]]], ["In addition, EDX analysis was used to further determine the elemental composition of SeB-NPs and Ag SeB-NPs, as shown in Figure S4 (Supplementary Materials).", [["SeB", "CHEMICAL", 85, 88], ["Ag", "CHEMICAL", 97, 99], ["SeB", "CHEMICAL", 85, 88], ["Ag", "CHEMICAL", 97, 99], ["SeB-NPs", "SIMPLE_CHEMICAL", 85, 92], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 97, 107], ["EDX analysis", "TEST", 13, 25], ["SeB-NPs", "TREATMENT", 85, 92], ["Ag SeB-NPs", "TREATMENT", 97, 107]]], ["According to the EDX analysis of SeB-NPs, the elements oxygen (O), phosphorous (P), calcium (Ca), and selenium (Se) were presented.", [["SeB-NPs", "CHEMICAL", 33, 40], ["oxygen", "CHEMICAL", 55, 61], ["phosphorous", "CHEMICAL", 67, 78], ["calcium", "CHEMICAL", 84, 91], ["Ca", "CHEMICAL", 93, 95], ["selenium", "CHEMICAL", 102, 110], ["Se", "CHEMICAL", 112, 114], ["SeB", "CHEMICAL", 33, 36], ["oxygen", "CHEMICAL", 55, 61], ["O", "CHEMICAL", 63, 64], ["phosphorous", "CHEMICAL", 67, 78], ["P", "CHEMICAL", 80, 81], ["calcium", "CHEMICAL", 84, 91], ["Ca", "CHEMICAL", 93, 95], ["selenium", "CHEMICAL", 102, 110], ["Se", "CHEMICAL", 112, 114], ["SeB-NPs", "SIMPLE_CHEMICAL", 33, 40], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["O)", "SIMPLE_CHEMICAL", 63, 65], ["phosphorous", "SIMPLE_CHEMICAL", 67, 78], ["calcium", "SIMPLE_CHEMICAL", 84, 91], ["Ca", "SIMPLE_CHEMICAL", 93, 95], ["selenium", "SIMPLE_CHEMICAL", 102, 110], ["Se", "SIMPLE_CHEMICAL", 112, 114], ["SeB", "PROTEIN", 33, 36], ["the EDX analysis", "TEST", 13, 29], ["the elements oxygen", "TEST", 42, 61], ["phosphorous", "TEST", 67, 78], ["calcium (Ca)", "TEST", 84, 96]]], ["With increasing Ca/Se mole ratio, the weight percent of selenium calculated from EDX decreased. www.nature.com/scientificreports/ The weight percentage of silver were 0.06, 0.13, and 0.33 for Ag SeB1, Ag SeB2, and Ag SeB3, respectively, which was consistent with the amount of AgNO3 added during the preparation of Ag SeB-NPs.Resultsin vitro cytocompatibility.", [["Ca", "CHEMICAL", 16, 18], ["Se", "CHEMICAL", 19, 21], ["selenium", "CHEMICAL", 56, 64], ["silver", "CHEMICAL", 155, 161], ["Ag", "CHEMICAL", 192, 194], ["Ag", "CHEMICAL", 201, 203], ["Ag", "CHEMICAL", 214, 216], ["AgNO3", "CHEMICAL", 277, 282], ["Ag SeB-NPs", "CHEMICAL", 315, 325], ["Ca", "CHEMICAL", 16, 18], ["Se", "CHEMICAL", 19, 21], ["selenium", "CHEMICAL", 56, 64], ["silver", "CHEMICAL", 155, 161], ["Ag", "CHEMICAL", 192, 194], ["SeB1", "CHEMICAL", 195, 199], ["Ag", "CHEMICAL", 201, 203], ["SeB2", "CHEMICAL", 204, 208], ["Ag", "CHEMICAL", 214, 216], ["SeB3", "CHEMICAL", 217, 221], ["AgNO3", "CHEMICAL", 277, 282], ["Ag", "CHEMICAL", 315, 317], ["selenium", "SIMPLE_CHEMICAL", 56, 64], ["EDX", "SIMPLE_CHEMICAL", 81, 84], ["silver", "SIMPLE_CHEMICAL", 155, 161], ["Ag SeB1", "SIMPLE_CHEMICAL", 192, 199], ["Ag SeB2", "SIMPLE_CHEMICAL", 201, 208], ["Ag SeB3", "SIMPLE_CHEMICAL", 214, 221], ["AgNO3", "SIMPLE_CHEMICAL", 277, 282], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 315, 325], ["Ag SeB1", "PROTEIN", 192, 199], ["Ag SeB2", "PROTEIN", 201, 208], ["increasing Ca/Se mole ratio", "PROBLEM", 5, 32], ["selenium", "TEST", 56, 64], ["EDX", "TEST", 81, 84], ["The weight percentage", "TEST", 130, 151], ["silver", "TEST", 155, 161], ["Ag SeB1", "TEST", 192, 199], ["Ag SeB2", "TEST", 201, 208], ["AgNO3", "TREATMENT", 277, 282], ["Ag SeB-NPs", "TREATMENT", 315, 325], ["increasing", "OBSERVATION_MODIFIER", 5, 15], ["Ca", "OBSERVATION", 16, 18], ["decreased", "OBSERVATION_MODIFIER", 85, 94], ["consistent with", "UNCERTAINTY", 247, 262], ["AgNO3", "OBSERVATION", 277, 282], ["cytocompatibility", "OBSERVATION_MODIFIER", 342, 359]]], ["The in vitro cytocompatibility test of the prepared SeB-NPs and Ag SeB-NPs is an essential prerequisite for future bone tissue engineering, and biological experiments were conducted by using hFOB 1.19 cell as the cell model.", [["bone tissue", "ANATOMY", 115, 126], ["hFOB 1.19 cell", "ANATOMY", 191, 205], ["cell", "ANATOMY", 213, 217], ["SeB-NPs", "CHEMICAL", 52, 59], ["Ag", "CHEMICAL", 64, 66], ["SeB-NPs", "CHEMICAL", 67, 74], ["SeB", "CHEMICAL", 52, 55], ["Ag", "CHEMICAL", 64, 66], ["SeB-NPs", "SIMPLE_CHEMICAL", 52, 59], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 64, 74], ["bone tissue", "MULTI-TISSUE_STRUCTURE", 115, 126], ["hFOB 1.19 cell", "CELL", 191, 205], ["cell", "CELL", 213, 217], ["hFOB 1.19 cell", "CELL_LINE", 191, 205], ["The in vitro cytocompatibility test", "TEST", 0, 35], ["the prepared SeB-NPs", "TREATMENT", 39, 59], ["Ag SeB-NPs", "TREATMENT", 64, 74], ["future bone tissue engineering", "TREATMENT", 108, 138]]], ["Figure 8 showed the CCK-8 assay results after the hFOB 1.19 cells cultured with SeB-NPs and Ag SeB-NPs for 1 and 3 days.", [["hFOB 1.19 cells", "ANATOMY", 50, 65], ["SeB-NPs", "CHEMICAL", 80, 87], ["Ag SeB-NPs", "CHEMICAL", 92, 102], ["SeB", "CHEMICAL", 80, 83], ["Ag", "CHEMICAL", 92, 94], ["CCK-8", "GENE_OR_GENE_PRODUCT", 20, 25], ["hFOB 1.19 cells", "CELL", 50, 65], ["SeB-NPs", "SIMPLE_CHEMICAL", 80, 87], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 92, 102], ["hFOB 1.19 cells", "CELL_LINE", 50, 65], ["Figure", "TEST", 0, 6], ["the CCK", "TEST", 16, 23], ["the hFOB", "TEST", 46, 54], ["SeB-NPs", "TREATMENT", 80, 87]]], ["The degree of hFOB 1.19 cells growth was recorded by the absorbance at 450 nm.", [["hFOB 1.19 cells", "ANATOMY", 14, 29], ["hFOB 1.19 cells", "CELL", 14, 29], ["hFOB 1.19 cells", "CELL_LINE", 14, 29], ["hFOB", "TEST", 14, 18], ["the absorbance", "TEST", 53, 67], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["1.19 cells", "OBSERVATION", 19, 29]]], ["For all prepared nanoparticles, the number of cells increased with the number of culture days indicated that the obtained nanoparticles had an excellent cytocompatibility.", [["cells", "ANATOMY", 46, 51], ["cells", "CELL", 46, 51], ["all prepared nanoparticles", "TREATMENT", 4, 30], ["culture days", "TEST", 81, 93], ["excellent cytocompatibility", "OBSERVATION", 143, 170]]], ["However, the cell number decreased with increasing the concentration of nanoparticles from 50 \u00b5g/mL to 2000 \u00b5g/mL.", [["cell", "ANATOMY", 13, 17], ["cell", "CELL", 13, 17], ["increasing the concentration of nanoparticles", "TREATMENT", 40, 85], ["cell", "OBSERVATION_MODIFIER", 13, 17], ["number", "OBSERVATION_MODIFIER", 18, 24], ["decreased", "OBSERVATION_MODIFIER", 25, 34]]], ["The cell morphology on day 3 was investigated using optical microscopy and fluorescent microscopy (FITC-Phalloidin/DAPI staining) and 2000 \u00b5g/mL of nanoparticles were used ( Figures S5 and S6 , Supplementary Materials).", [["cell", "ANATOMY", 4, 8], ["FITC", "CHEMICAL", 99, 103], ["DAPI", "CHEMICAL", 115, 119], ["cell", "CELL", 4, 8], ["FITC-Phalloidin", "SIMPLE_CHEMICAL", 99, 114], ["DAPI", "SIMPLE_CHEMICAL", 115, 119], ["S6", "PROTEIN", 189, 191], ["optical microscopy", "TEST", 52, 70], ["fluorescent microscopy", "TEST", 75, 97], ["FITC-Phalloidin/DAPI staining", "TREATMENT", 99, 128], ["nanoparticles", "TREATMENT", 148, 161], ["Supplementary Materials", "TREATMENT", 194, 217], ["cell morphology", "OBSERVATION", 4, 19]]], ["The cells incubated with the prepared nanoparticles showed a well-preserved morphology, which was polygonal and fully spread.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["the prepared nanoparticles", "TEST", 25, 51], ["polygonal", "OBSERVATION_MODIFIER", 98, 107], ["spread", "OBSERVATION_MODIFIER", 118, 124]]], ["Moreover, the cells proliferated with Ag SeB-NPs faster, than that with SeB-NPs.", [["cells", "ANATOMY", 14, 19], ["Ag SeB", "CHEMICAL", 38, 44], ["SeB-NPs", "CHEMICAL", 72, 79], ["Ag", "CHEMICAL", 38, 40], ["SeB", "CHEMICAL", 72, 75], ["cells", "CELL", 14, 19], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 38, 48], ["SeB-NPs", "SIMPLE_CHEMICAL", 72, 79], ["Ag SeB", "PROTEIN", 38, 44], ["SeB", "PROTEIN", 72, 75], ["Ag SeB", "TEST", 38, 44]]], ["There were no statistically significant differences in cell proliferation culturing with different samples.ResultsAntibacterial test.", [["cell", "ANATOMY", 55, 59], ["samples", "ANATOMY", 99, 106], ["cell", "CELL", 55, 59], ["statistically significant differences in cell proliferation culturing", "PROBLEM", 14, 83], ["different samples", "TEST", 89, 106], ["ResultsAntibacterial test", "TEST", 107, 132], ["no", "UNCERTAINTY", 11, 13], ["statistically", "OBSERVATION_MODIFIER", 14, 27], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["differences", "OBSERVATION_MODIFIER", 40, 51], ["cell proliferation", "OBSERVATION", 55, 73]]], ["The antibacterial activity of the prepared SeB-NPs and Ag SeB-NPs against Gram-positive S. aureus and Gram-negative E. coli bacteria was systematically evaluated, and the results were shown in Figs.", [["SeB-NPs", "CHEMICAL", 43, 50], ["Ag", "CHEMICAL", 55, 57], ["SeB-NPs", "CHEMICAL", 58, 65], ["Gram-", "CHEMICAL", 74, 79], ["SeB", "CHEMICAL", 43, 46], ["Ag", "CHEMICAL", 55, 57], ["SeB-NPs", "SIMPLE_CHEMICAL", 43, 50], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 55, 65], ["Gram-positive S. aureus", "ORGANISM", 74, 97], ["Gram-", "GENE_OR_GENE_PRODUCT", 102, 107], ["E. coli", "ORGANISM", 116, 123], ["S. aureus", "SPECIES", 88, 97], ["E. coli", "SPECIES", 116, 123], ["S. aureus", "SPECIES", 88, 97], ["E. coli", "SPECIES", 116, 123], ["the prepared SeB-NPs", "TREATMENT", 30, 50], ["Ag SeB-NPs", "TEST", 55, 65], ["Gram-positive S. aureus", "PROBLEM", 74, 97], ["Gram-negative E. coli bacteria", "PROBLEM", 102, 132], ["antibacterial activity", "OBSERVATION", 4, 26], ["coli bacteria", "OBSERVATION", 119, 132]]], ["S. aureus could cause the formation of biofilm on bone implants, and E. coli strains possess the reduction capability of selenite.", [["biofilm", "ANATOMY", 39, 46], ["bone", "ANATOMY", 50, 54], ["selenite", "CHEMICAL", 121, 129], ["selenite", "CHEMICAL", 121, 129], ["S. aureus", "ORGANISM", 0, 9], ["bone", "TISSUE", 50, 54], ["E. coli", "ORGANISM", 69, 76], ["strains", "ORGANISM", 77, 84], ["selenite", "SIMPLE_CHEMICAL", 121, 129], ["S. aureus", "SPECIES", 0, 9], ["E. coli", "SPECIES", 69, 76], ["S. aureus", "SPECIES", 0, 9], ["E. coli", "SPECIES", 69, 76], ["S. aureus", "PROBLEM", 0, 9], ["biofilm", "PROBLEM", 39, 46], ["bone implants", "TREATMENT", 50, 63], ["E. coli strains", "PROBLEM", 69, 84], ["aureus", "OBSERVATION", 3, 9], ["biofilm", "OBSERVATION_MODIFIER", 39, 46], ["bone", "ANATOMY", 50, 54], ["implants", "OBSERVATION", 55, 63], ["coli strains", "OBSERVATION", 72, 84], ["reduction", "OBSERVATION_MODIFIER", 97, 106], ["capability", "OBSERVATION_MODIFIER", 107, 117]]], ["Thus, both bacteria were used here.", [["both bacteria", "PROBLEM", 6, 19], ["bacteria", "OBSERVATION", 11, 19]]], ["The optical density at 600 nm (OD 600 ) values of S. aureus and E. coli by adding SeB-NPs and Ag SeB-NPs using different concentrations were presented in Fig. 9 .", [["SeB-NPs", "CHEMICAL", 82, 89], ["Ag SeB-NPs", "CHEMICAL", 94, 104], ["SeB", "CHEMICAL", 82, 85], ["Ag", "CHEMICAL", 94, 96], ["S. aureus", "ORGANISM", 50, 59], ["E. coli", "ORGANISM", 64, 71], ["SeB-NPs", "SIMPLE_CHEMICAL", 82, 89], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 94, 104], ["SeB", "PROTEIN", 82, 85], ["S. aureus", "SPECIES", 50, 59], ["E. coli", "SPECIES", 64, 71], ["S. aureus", "SPECIES", 50, 59], ["E. coli", "SPECIES", 64, 71], ["The optical density", "PROBLEM", 0, 19], ["S. aureus", "PROBLEM", 50, 59], ["E. coli", "PROBLEM", 64, 71], ["SeB-NPs", "TREATMENT", 82, 89], ["Ag SeB-NPs", "TREATMENT", 94, 104], ["different concentrations", "TREATMENT", 111, 135], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION", 12, 19], ["aureus", "OBSERVATION", 53, 59], ["E. coli", "OBSERVATION", 64, 71]]], ["Compared with the control group, the doping selenium into BCP-NPs had slight influence on the antibacterial activity, and it had a slight inhibitory effect against bacteria of SeB-NPs after 12 h of culture.", [["selenium", "CHEMICAL", 44, 52], ["BCP-NPs", "CHEMICAL", 58, 65], ["SeB", "CHEMICAL", 176, 179], ["selenium", "CHEMICAL", 44, 52], ["selenium", "SIMPLE_CHEMICAL", 44, 52], ["BCP-NPs", "SIMPLE_CHEMICAL", 58, 65], ["SeB-NPs", "SIMPLE_CHEMICAL", 176, 183], ["slight influence", "PROBLEM", 70, 86], ["the antibacterial activity", "TREATMENT", 90, 116], ["a slight inhibitory effect", "PROBLEM", 129, 155], ["culture", "TEST", 198, 205], ["slight", "OBSERVATION_MODIFIER", 70, 76], ["antibacterial activity", "OBSERVATION_MODIFIER", 94, 116], ["slight", "OBSERVATION_MODIFIER", 131, 137]]], ["However, the proliferation of both S. aureus and E. coli was completely suppressed by Ag SeB-NPs.", [["Ag SeB-NPs", "CHEMICAL", 86, 96], ["Ag", "CHEMICAL", 86, 88], ["S. aureus", "ORGANISM", 35, 44], ["E. coli", "ORGANISM", 49, 56], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 86, 96], ["S. aureus", "SPECIES", 35, 44], ["E. coli", "SPECIES", 49, 56], ["S. aureus", "SPECIES", 35, 44], ["E. coli", "SPECIES", 49, 56], ["both S. aureus", "PROBLEM", 30, 44], ["E. coli", "PROBLEM", 49, 56], ["proliferation", "OBSERVATION_MODIFIER", 13, 26], ["aureus", "OBSERVATION", 38, 44], ["E. coli", "OBSERVATION", 49, 56]]], ["The photos and inhibition ratio of E. coli and S. aureus grown in the actual culture tubes after adding SeB-NPs and Ag SeB-NPs after 12 h were shown in Figures S7 and S8 (Supplementary Materials) .", [["SeB-NPs", "CHEMICAL", 104, 111], ["Ag SeB-NPs", "CHEMICAL", 116, 126], ["SeB", "CHEMICAL", 104, 107], ["Ag", "CHEMICAL", 116, 118], ["E. coli", "ORGANISM", 35, 42], ["S. aureus", "ORGANISM", 47, 56], ["SeB-NPs", "SIMPLE_CHEMICAL", 104, 111], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 116, 126], ["E. coli", "SPECIES", 35, 42], ["S. aureus", "SPECIES", 47, 56], ["E. coli", "SPECIES", 35, 42], ["S. aureus", "SPECIES", 47, 56], ["The photos", "TEST", 0, 10], ["E. coli", "PROBLEM", 35, 42], ["S. aureus", "PROBLEM", 47, 56], ["the actual culture tubes", "TREATMENT", 66, 90], ["SeB-NPs", "TREATMENT", 104, 111], ["Ag SeB-NPs", "TREATMENT", 116, 126], ["E. coli", "OBSERVATION", 35, 42], ["aureus", "OBSERVATION_MODIFIER", 50, 56], ["grown", "OBSERVATION_MODIFIER", 57, 62]]], ["Furthermore, the OD 600 values of S. aureus after SeB-NPs were lower than that of E. coli, indicated that SeB-NPs had a better antibacterial effect against S. aureus than E. coli.", [["SeB-NPs", "CHEMICAL", 50, 57], ["SeB-NPs", "CHEMICAL", 106, 113], ["S. aureus", "ORGANISM", 34, 43], ["SeB-NPs", "SIMPLE_CHEMICAL", 50, 57], ["E. coli", "ORGANISM", 82, 89], ["SeB-NPs", "SIMPLE_CHEMICAL", 106, 113], ["S. aureus", "ORGANISM", 156, 165], ["E. coli", "ORGANISM", 171, 178], ["S. aureus", "SPECIES", 34, 43], ["E. coli", "SPECIES", 82, 89], ["S. aureus", "SPECIES", 156, 165], ["E. coli", "SPECIES", 171, 178], ["S. aureus", "SPECIES", 34, 43], ["E. coli", "SPECIES", 82, 89], ["S. aureus", "SPECIES", 156, 165], ["E. coli", "SPECIES", 171, 178], ["S. aureus", "PROBLEM", 34, 43], ["SeB-NPs", "TREATMENT", 50, 57], ["E. coli", "PROBLEM", 82, 89], ["S. aureus", "PROBLEM", 156, 165], ["E. coli", "PROBLEM", 171, 178], ["aureus", "OBSERVATION", 37, 43], ["aureus", "OBSERVATION", 159, 165], ["coli", "OBSERVATION", 174, 178]]], ["For Ag SeB-NPs, the inhibition ratio of both S. aureus and E. coli increased with the increase of the AgNO 3 dosage.", [["Ag SeB-NPs", "CHEMICAL", 4, 14], ["AgNO", "CHEMICAL", 102, 106], ["Ag", "CHEMICAL", 4, 6], ["AgNO 3", "CHEMICAL", 102, 108], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 4, 14], ["S. aureus", "ORGANISM", 45, 54], ["E. coli", "ORGANISM", 59, 66], ["AgNO 3", "GENE_OR_GENE_PRODUCT", 102, 108], ["S. aureus", "SPECIES", 45, 54], ["E. coli", "SPECIES", 59, 66], ["S. aureus", "SPECIES", 45, 54], ["E. coli", "SPECIES", 59, 66], ["Ag SeB", "TEST", 4, 10], ["the inhibition ratio", "TEST", 16, 36], ["S. aureus", "PROBLEM", 45, 54], ["E. coli", "PROBLEM", 59, 66], ["the AgNO 3 dosage", "TREATMENT", 98, 115], ["aureus", "OBSERVATION", 48, 54], ["E. coli", "OBSERVATION", 59, 66], ["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["There were no differences in Ag SeB-NPs against both bacteria.", [["Ag SeB-NPs", "CHEMICAL", 29, 39], ["Ag", "CHEMICAL", 29, 31], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 29, 39], ["Ag", "PROTEIN", 29, 31], ["Ag SeB", "TEST", 29, 35], ["both bacteria", "PROBLEM", 48, 61], ["no", "UNCERTAINTY", 11, 13]]], ["The antibacterial activity of nanoparticles was also confirmed by bacteriostatic circles investigation as shown in Fig. 10 .", [["nanoparticles", "SIMPLE_CHEMICAL", 30, 43], ["The antibacterial activity of nanoparticles", "TREATMENT", 0, 43], ["bacteriostatic circles investigation", "TEST", 66, 102], ["antibacterial activity", "OBSERVATION", 4, 26]]], ["The disk diffusion was used to confirm the antibacterial effect of prepared SeB-NPs and Ag SeB-NPs dispersed in ultrapure water against bacterial colonies.", [["colonies", "ANATOMY", 146, 154], ["SeB-NPs", "CHEMICAL", 76, 83], ["Ag SeB-NPs", "CHEMICAL", 88, 98], ["SeB", "CHEMICAL", 76, 79], ["Ag", "CHEMICAL", 88, 90], ["SeB-NPs", "SIMPLE_CHEMICAL", 76, 83], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 88, 98], ["bacterial colonies", "CELL_LINE", 136, 154], ["The disk diffusion", "TEST", 0, 18], ["prepared SeB-NPs", "TREATMENT", 67, 83], ["Ag SeB-NPs", "TREATMENT", 88, 98], ["bacterial colonies", "PROBLEM", 136, 154], ["bacterial colonies", "OBSERVATION", 136, 154]]], ["Photos of bacteriostatic circles for nanoparticles using different concentrations were recorded, as shown in Fig. 10 .", [["bacteriostatic circles", "TREATMENT", 10, 32], ["nanoparticles", "TREATMENT", 37, 50], ["different concentrations", "TREATMENT", 57, 81], ["bacteriostatic circles", "OBSERVATION", 10, 32]]], ["For SeB-NPs, the bacteriostatic circles of E. coli were not apparently observed, and such circles of S. aureus appeared, in which the concentration of nanoparticles did not have a significant influence on the diameter of circles.", [["SeB-NPs", "CHEMICAL", 4, 11], ["SeB", "CHEMICAL", 4, 7], ["SeB-NPs", "SIMPLE_CHEMICAL", 4, 11], ["E. coli", "ORGANISM", 43, 50], ["S. aureus", "ORGANISM", 101, 110], ["E. coli", "SPECIES", 43, 50], ["S. aureus", "SPECIES", 101, 110], ["E. coli", "SPECIES", 43, 50], ["S. aureus", "SPECIES", 101, 110], ["SeB-NPs", "TREATMENT", 4, 11], ["the bacteriostatic circles", "TEST", 13, 39], ["E. coli", "PROBLEM", 43, 50], ["S. aureus", "PROBLEM", 101, 110], ["bacteriostatic circles", "OBSERVATION", 17, 39], ["E. coli", "OBSERVATION", 43, 50], ["not apparently observed", "UNCERTAINTY", 56, 79], ["aureus", "OBSERVATION", 104, 110], ["significant", "OBSERVATION_MODIFIER", 180, 191], ["influence", "OBSERVATION", 192, 201], ["diameter", "OBSERVATION_MODIFIER", 209, 217]]], ["However, compared with SeB-NPs, Ag SeB-NPs have significant inhibition circles against S. aureus and E. coli.", [["SeB-NPs", "CHEMICAL", 23, 30], ["Ag", "CHEMICAL", 32, 34], ["SeB-NPs", "CHEMICAL", 35, 42], ["SeB", "CHEMICAL", 23, 26], ["Ag", "CHEMICAL", 32, 34], ["SeB-NPs", "SIMPLE_CHEMICAL", 23, 30], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 32, 42], ["S. aureus", "ORGANISM", 87, 96], ["E. coli", "ORGANISM", 101, 108], ["SeB", "PROTEIN", 23, 26], ["S. aureus", "SPECIES", 87, 96], ["E. coli", "SPECIES", 101, 108], ["S. aureus", "SPECIES", 87, 96], ["E. coli", "SPECIES", 101, 108], ["Ag SeB", "TEST", 32, 38], ["significant inhibition circles", "PROBLEM", 48, 78], ["S. aureus", "PROBLEM", 87, 96], ["E. coli", "PROBLEM", 101, 108], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["inhibition circles", "OBSERVATION", 60, 78], ["aureus", "OBSERVATION", 90, 96], ["E. coli", "OBSERVATION", 101, 108]]], ["The antibacterial activity of Ag SeB-NPs against E. coli was not influenced by the concentration.", [["Ag SeB-NPs", "CHEMICAL", 30, 40], ["Ag", "CHEMICAL", 30, 32], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 30, 40], ["E. coli", "ORGANISM", 49, 56], ["E. coli", "SPECIES", 49, 56], ["E. coli", "SPECIES", 49, 56], ["Ag SeB-NPs", "TREATMENT", 30, 40], ["E. coli", "PROBLEM", 49, 56], ["antibacterial", "OBSERVATION_MODIFIER", 4, 17]]], ["But, such activity against S. aureus increased with increasing of Ag SeB-NPsDiscussionThe stated objective of this study was to synthesis new-style biphasic calcium phosphate nanoparticles (BCP-NPs) with excellent cytocompatibility and antibacterial activity for further hard-tissue engineering applications.DiscussionRecently, silicon, silver, copper, zinc, selenium, iron, lithium, and titanium dioxide, et al., have been employed to mingle with bone scaffolds to improve their physicochemical properties [34] [35] [36] [37] [38] [39] [40] .", [["tissue", "ANATOMY", 276, 282], ["bone", "ANATOMY", 448, 452], ["Ag", "CHEMICAL", 66, 68], ["calcium phosphate", "CHEMICAL", 157, 174], ["BCP-NPs", "CHEMICAL", 190, 197], ["silicon", "CHEMICAL", 328, 335], ["silver", "CHEMICAL", 337, 343], ["copper", "CHEMICAL", 345, 351], ["zinc", "CHEMICAL", 353, 357], ["selenium", "CHEMICAL", 359, 367], ["iron", "CHEMICAL", 369, 373], ["lithium", "CHEMICAL", 375, 382], ["titanium dioxide", "CHEMICAL", 388, 404], ["Ag", "CHEMICAL", 66, 68], ["calcium phosphate", "CHEMICAL", 157, 174], ["silicon", "CHEMICAL", 328, 335], ["silver", "CHEMICAL", 337, 343], ["copper", "CHEMICAL", 345, 351], ["zinc", "CHEMICAL", 353, 357], ["selenium", "CHEMICAL", 359, 367], ["iron", "CHEMICAL", 369, 373], ["lithium", "CHEMICAL", 375, 382], ["titanium dioxide", "CHEMICAL", 388, 404], ["[34] [35] [36] [37] [38] [39] [40]", "CHEMICAL", 507, 541], ["S. aureus", "ORGANISM", 27, 36], ["calcium phosphate nanoparticles", "SIMPLE_CHEMICAL", 157, 188], ["BCP-NPs", "SIMPLE_CHEMICAL", 190, 197], ["tissue", "TISSUE", 276, 282], ["silicon", "SIMPLE_CHEMICAL", 328, 335], ["silver", "SIMPLE_CHEMICAL", 337, 343], ["copper", "SIMPLE_CHEMICAL", 345, 351], ["zinc", "SIMPLE_CHEMICAL", 353, 357], ["selenium", "SIMPLE_CHEMICAL", 359, 367], ["iron", "SIMPLE_CHEMICAL", 369, 373], ["lithium", "SIMPLE_CHEMICAL", 375, 382], ["titanium dioxide", "SIMPLE_CHEMICAL", 388, 404], ["bone", "TISSUE", 448, 452], ["[34] [35] [36] [37] [38] [39] [40]", "SIMPLE_CHEMICAL", 507, 541], ["S. aureus", "SPECIES", 27, 36], ["S. aureus", "SPECIES", 27, 36], ["S. aureus", "PROBLEM", 27, 36], ["this study", "TEST", 110, 120], ["synthesis new-style biphasic calcium phosphate nanoparticles", "TREATMENT", 128, 188], ["BCP-NPs", "TREATMENT", 190, 197], ["antibacterial activity", "TREATMENT", 236, 258], ["further hard-tissue engineering applications", "TREATMENT", 263, 307], ["zinc", "TREATMENT", 353, 357], ["selenium", "TREATMENT", 359, 367], ["iron", "TREATMENT", 369, 373], ["lithium", "TREATMENT", 375, 382], ["titanium dioxide", "TREATMENT", 388, 404], ["bone scaffolds", "TREATMENT", 448, 462], ["aureus", "OBSERVATION", 30, 36], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["antibacterial activity", "OBSERVATION", 236, 258]]], ["Such as, silicon could be doped into hydroxyapatite and composited into gelatine, and then, the three-dimensional (3D) printable composites were obtained.", [["silicon", "CHEMICAL", 9, 16], ["silicon", "CHEMICAL", 9, 16], ["hydroxyapatite", "CHEMICAL", 37, 51], ["hydroxyapatite", "SIMPLE_CHEMICAL", 37, 51], ["gelatine", "SIMPLE_CHEMICAL", 72, 80], ["silicon", "TREATMENT", 9, 16], ["hydroxyapatite", "TREATMENT", 37, 51], ["the three-dimensional (3D) printable composites", "TREATMENT", 92, 139]]], ["The porous scaffold could be fabricated by rapid prototyping at room temperature (RT) 39 .", [["The porous scaffold", "TREATMENT", 0, 19], ["porous scaffold", "OBSERVATION", 4, 19]]], ["The bone regeneration of bioactive silicate glass could be improved when the copper was doped at a controlled concentration (0-0.8 wt.% copper oxide), while displayed a promising antibacterial activity 41 .", [["bone", "ANATOMY", 4, 8], ["bioactive silicate", "CHEMICAL", 25, 43], ["copper", "CHEMICAL", 77, 83], ["copper oxide", "CHEMICAL", 136, 148], ["silicate", "CHEMICAL", 35, 43], ["copper", "CHEMICAL", 77, 83], ["copper oxide", "CHEMICAL", 136, 148], ["bone", "TISSUE", 4, 8], ["bioactive silicate glass", "SIMPLE_CHEMICAL", 25, 49], ["copper", "SIMPLE_CHEMICAL", 77, 83], ["copper oxide", "SIMPLE_CHEMICAL", 136, 148], ["The bone regeneration of bioactive silicate glass", "PROBLEM", 0, 49], ["bone", "ANATOMY", 4, 8], ["regeneration", "OBSERVATION", 9, 21], ["bioactive silicate glass", "OBSERVATION", 25, 49], ["improved", "OBSERVATION_MODIFIER", 59, 67], ["antibacterial activity", "OBSERVATION", 179, 201]]], ["Furthermore, compared with pure hydroxyapatite (HA) scaffold, lithium-doped hydroxyapatite scaffold not only showed a higher degradation rate but also benefit the proliferation of osteoblasts 42 .", [["osteoblasts", "ANATOMY", 180, 191], ["hydroxyapatite", "CHEMICAL", 32, 46], ["lithium", "CHEMICAL", 62, 69], ["hydroxyapatite", "CHEMICAL", 32, 46], ["lithium", "CHEMICAL", 62, 69], ["hydroxyapatite", "CHEMICAL", 76, 90], ["hydroxyapatite", "SIMPLE_CHEMICAL", 32, 46], ["lithium-doped hydroxyapatite scaffold", "SIMPLE_CHEMICAL", 62, 99], ["osteoblasts", "CELL", 180, 191], ["osteoblasts 42", "CELL_LINE", 180, 194], ["pure hydroxyapatite (HA) scaffold", "TREATMENT", 27, 60], ["lithium-doped hydroxyapatite scaffold", "TREATMENT", 62, 99], ["a higher degradation rate", "PROBLEM", 116, 141], ["the proliferation of osteoblasts", "PROBLEM", 159, 191]]], ["Ahmed et al. confirmed that the introduction of selenium www.nature.com/scientificreports/ into carbonated hydroxyapatite (CHAP) could increase the diffusion and infiltration of human fibroblasts on CHAP based scaffold 34 .", [["fibroblasts", "ANATOMY", 184, 195], ["selenium", "CHEMICAL", 48, 56], ["carbonated hydroxyapatite", "CHEMICAL", 96, 121], ["CHAP", "CHEMICAL", 123, 127], ["selenium", "CHEMICAL", 48, 56], ["hydroxyapatite", "CHEMICAL", 107, 121], ["CHAP", "CHEMICAL", 123, 127], ["selenium", "SIMPLE_CHEMICAL", 48, 56], ["carbonated hydroxyapatite", "SIMPLE_CHEMICAL", 96, 121], ["CHAP", "SIMPLE_CHEMICAL", 123, 127], ["human", "ORGANISM", 178, 183], ["fibroblasts", "CELL", 184, 195], ["human fibroblasts", "CELL_TYPE", 178, 195], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["scientificreports/ into carbonated hydroxyapatite", "TREATMENT", 72, 121], ["the diffusion", "PROBLEM", 144, 157], ["human fibroblasts", "PROBLEM", 178, 195], ["CHAP based scaffold", "TREATMENT", 199, 218], ["infiltration", "OBSERVATION", 162, 174], ["human fibroblasts", "OBSERVATION", 178, 195]]], ["Developing a multifunctional scaffold, which combines excellent biocompatibility, osteoinductivity, and antibacterial ability, which is considered to be the next-generation orthopedic implants for hard tissue engineering applications 43, 44 .", [["tissue", "ANATOMY", 202, 208], ["tissue", "TISSUE", 202, 208], ["a multifunctional scaffold", "PROBLEM", 11, 37], ["osteoinductivity", "PROBLEM", 82, 98], ["antibacterial ability", "PROBLEM", 104, 125], ["the next-generation orthopedic implants", "TREATMENT", 153, 192], ["multifunctional scaffold", "OBSERVATION", 13, 37], ["excellent", "OBSERVATION_MODIFIER", 54, 63], ["biocompatibility", "OBSERVATION_MODIFIER", 64, 80], ["antibacterial ability", "OBSERVATION", 104, 125]]], ["Selenium, silver, and antibacterial drugs, such as cephalexin and chlorhexidine, were commonly used to impart antibacterial function to the composite scaffolds [45] [46] [47] [48] .", [["Selenium", "CHEMICAL", 0, 8], ["silver", "CHEMICAL", 10, 16], ["cephalexin", "CHEMICAL", 51, 61], ["chlorhexidine", "CHEMICAL", 66, 79], ["Selenium", "CHEMICAL", 0, 8], ["silver", "CHEMICAL", 10, 16], ["cephalexin", "CHEMICAL", 51, 61], ["chlorhexidine", "CHEMICAL", 66, 79], ["Selenium", "SIMPLE_CHEMICAL", 0, 8], ["silver", "SIMPLE_CHEMICAL", 10, 16], ["cephalexin", "SIMPLE_CHEMICAL", 51, 61], ["chlorhexidine", "SIMPLE_CHEMICAL", 66, 79], ["Selenium", "TREATMENT", 0, 8], ["silver", "TREATMENT", 10, 16], ["antibacterial drugs", "TREATMENT", 22, 41], ["cephalexin", "TREATMENT", 51, 61], ["chlorhexidine", "TREATMENT", 66, 79]]], ["Nguyen et al. investigated that selenium nanoparticles could inhibit Staphylococcus aureus, with low toxicity to mammalian cells 49 .", [["cells", "ANATOMY", 123, 128], ["selenium", "CHEMICAL", 32, 40], ["Staphylococcus aureus", "DISEASE", 69, 90], ["toxicity", "DISEASE", 101, 109], ["selenium", "CHEMICAL", 32, 40], ["selenium nanoparticles", "SIMPLE_CHEMICAL", 32, 54], ["Staphylococcus aureus", "ORGANISM", 69, 90], ["mammalian cells", "CELL", 113, 128], ["mammalian cells", "CELL_TYPE", 113, 128], ["Staphylococcus aureus", "SPECIES", 69, 90], ["Staphylococcus aureus", "SPECIES", 69, 90], ["selenium nanoparticles", "PROBLEM", 32, 54], ["Staphylococcus aureus", "PROBLEM", 69, 90], ["low toxicity to mammalian cells", "PROBLEM", 97, 128], ["Staphylococcus aureus", "OBSERVATION", 69, 90], ["low toxicity", "OBSERVATION_MODIFIER", 97, 109]]], ["Wang et al. identified that after coating poly(ether ether ketone) (PEEK) medical devices with selenium nanoparticles, the growth of Pseudomonas aeruginosa could be significantly inhibited 29 .", [["poly(ether ether ketone", "CHEMICAL", 42, 65], ["PEEK", "CHEMICAL", 68, 72], ["selenium", "CHEMICAL", 95, 103], ["poly(ether ether ketone)", "CHEMICAL", 42, 66], ["PEEK", "CHEMICAL", 68, 72], ["selenium", "CHEMICAL", 95, 103], ["poly(ether ether ketone)", "SIMPLE_CHEMICAL", 42, 66], ["PEEK", "SIMPLE_CHEMICAL", 68, 72], ["selenium nanoparticles", "SIMPLE_CHEMICAL", 95, 117], ["Pseudomonas aeruginosa", "ORGANISM", 133, 155], ["Pseudomonas aeruginosa", "SPECIES", 133, 155], ["Pseudomonas aeruginosa", "SPECIES", 133, 155], ["coating poly(ether ether ketone) (PEEK) medical devices", "TREATMENT", 34, 89], ["selenium nanoparticles", "TREATMENT", 95, 117], ["Pseudomonas aeruginosa", "PROBLEM", 133, 155]]], ["However, the uncontrolled release of drugs, the potential systemic toxicity of medicine, and the aggregation of nanoparticles hindered the potential functions of the scaffolds.", [["toxicity", "DISEASE", 67, 75], ["drugs", "TREATMENT", 37, 42], ["medicine", "TREATMENT", 79, 87], ["the aggregation of nanoparticles", "TREATMENT", 93, 125], ["the scaffolds", "TREATMENT", 162, 175], ["uncontrolled", "OBSERVATION_MODIFIER", 13, 25]]], ["For these reasons, drugs with selenium, and silver were mainly encapsulated, or mixed, coated into the scaffold 50, 51 .", [["selenium", "CHEMICAL", 30, 38], ["silver", "CHEMICAL", 44, 50], ["selenium", "CHEMICAL", 30, 38], ["silver", "CHEMICAL", 44, 50], ["selenium", "SIMPLE_CHEMICAL", 30, 38], ["silver", "SIMPLE_CHEMICAL", 44, 50], ["drugs", "TREATMENT", 19, 24], ["selenium, and silver", "TREATMENT", 30, 50]]], ["Here, we first fabricated the selenium-doped biphasic calcium phosphate nanoparticles, which were incorporated with silver nanoparticles.", [["selenium", "CHEMICAL", 30, 38], ["calcium phosphate", "CHEMICAL", 54, 71], ["silver nanoparticles", "CHEMICAL", 116, 136], ["selenium", "CHEMICAL", 30, 38], ["calcium phosphate", "CHEMICAL", 54, 71], ["silver", "CHEMICAL", 116, 122], ["selenium", "SIMPLE_CHEMICAL", 30, 38], ["calcium phosphate nanoparticles", "SIMPLE_CHEMICAL", 54, 85], ["silver nanoparticles", "SIMPLE_CHEMICAL", 116, 136], ["doped biphasic calcium phosphate nanoparticles", "TREATMENT", 39, 85], ["silver nanoparticles", "TREATMENT", 116, 136], ["silver nanoparticles", "OBSERVATION", 116, 136]]], ["The physicochemical properties of the obtained Ag SeB-NPs were deeply characterized by FT-IR, XRD, UV-Vis, Raman, and XPS analysis.", [["Ag", "CHEMICAL", 47, 49], ["Ag", "CHEMICAL", 47, 49], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 47, 57], ["Ag SeB-NPs", "TREATMENT", 47, 57], ["FT", "TEST", 87, 89], ["XRD", "TEST", 94, 97], ["XPS analysis", "TEST", 118, 130]]], ["In this study, SeB-NPs were synthesized by co-precipitation and ion-exchange sorption, aka, post-precipitation, occurred simultaneously.", [["SeB", "CHEMICAL", 15, 18], ["SeB", "CHEMICAL", 15, 18], ["SeB-NPs", "SIMPLE_CHEMICAL", 15, 22], ["this study", "TEST", 3, 13], ["ion-exchange sorption", "TREATMENT", 64, 85], ["aka", "PROBLEM", 87, 90], ["post-precipitation", "PROBLEM", 92, 110]]], ["By substituting PO 4 3\u2212 on the surface of BCP-NPs to adsorb SeO 3 2\u2212 group, then a port of SeO 3 2\u2212 ions entered the lattice (HA or \u03b2-TCP) 52 .", [["surface", "ANATOMY", 31, 38], ["PO 4 3\u2212", "CHEMICAL", 16, 23], ["BCP-NPs", "CHEMICAL", 42, 49], ["SeO 3 2\u2212", "CHEMICAL", 60, 68], ["SeO 3 2\u2212 ions", "CHEMICAL", 91, 104], ["SeO 3", "CHEMICAL", 60, 65], ["SeO 3 2", "CHEMICAL", 91, 98], ["surface", "CELLULAR_COMPONENT", 31, 38], ["BCP-NPs", "SIMPLE_CHEMICAL", 42, 49], ["SeO 3 2\u2212", "SIMPLE_CHEMICAL", 60, 68], ["SeO 3 2\u2212 ions", "SIMPLE_CHEMICAL", 91, 104], ["a port of SeO", "TREATMENT", 81, 94]]], ["The addition of selenium dopant could influence the phase composition, and the resulting SeB-NPs could be tentatively represented as Ca 10 (PO 4 ) X (SeO 3 ) (6-X) (OH) 2 + Ca 3 (PO 4 ) X (SeO 3 ) (6-X) .", [["selenium dopant", "CHEMICAL", 16, 31], ["SeB", "CHEMICAL", 89, 92], ["Ca", "CHEMICAL", 133, 135], ["Ca", "CHEMICAL", 173, 175], ["selenium", "CHEMICAL", 16, 24], ["SeB", "CHEMICAL", 89, 92], ["Ca 10 (PO 4 ) X (SeO 3 ) (6-X) (OH) 2", "CHEMICAL", 133, 170], ["Ca 3 (PO 4 ) X", "CHEMICAL", 173, 187], ["SeO 3 )", "CHEMICAL", 189, 196], ["selenium dopant", "SIMPLE_CHEMICAL", 16, 31], ["SeB-NPs", "SIMPLE_CHEMICAL", 89, 96], ["Ca 10 (PO 4 ) X (SeO 3 ) (6-X) (OH) 2 + Ca 3 (PO 4 ) X (SeO 3 )", "SIMPLE_CHEMICAL", 133, 196], ["6-X", "SIMPLE_CHEMICAL", 198, 201], ["SeB", "PROTEIN", 89, 92], ["selenium dopant", "TREATMENT", 16, 31], ["the resulting SeB-NPs", "TREATMENT", 75, 96], ["Ca", "TEST", 133, 135], ["Ca", "TEST", 173, 175]]], ["The FT-IR spectra of SeB-NPs and BCP-NPs showed the v 1 + v 3 phosphate vibration in the region of 1,200-900 cm \u22121 and v 4 phosphate bands in the range of 650-500 cm \u22121 , as shown in Fig. 2a 53 .", [["SeB-NPs", "CHEMICAL", 21, 28], ["phosphate", "CHEMICAL", 62, 71], ["phosphate", "CHEMICAL", 123, 132], ["SeB", "CHEMICAL", 21, 24], ["phosphate", "CHEMICAL", 62, 71], ["phosphate", "CHEMICAL", 123, 132], ["SeB-NPs", "SIMPLE_CHEMICAL", 21, 28], ["BCP-NPs", "SIMPLE_CHEMICAL", 33, 40], ["The FT", "TEST", 0, 6], ["SeB-NPs", "TEST", 21, 28], ["BCP", "TEST", 33, 36], ["the v", "TEST", 48, 53], ["phosphate vibration", "TEST", 62, 81], ["phosphate bands", "TEST", 123, 138], ["region", "ANATOMY_MODIFIER", 89, 95], ["500 cm", "OBSERVATION_MODIFIER", 159, 165]]], ["The O-Se-O asymmetric bond stretching at 731 cm \u22121 was detected for SeB-NPs, and the SeO 3 2\u2212 group at 783 cm \u22121 was measured as well.", [["O-Se", "CHEMICAL", 4, 8], ["SeO 3 2\u2212", "CHEMICAL", 85, 93], ["O-Se-O", "CHEMICAL", 4, 10], ["SeB", "CHEMICAL", 68, 71], ["SeO 3", "CHEMICAL", 85, 90], ["O-Se-O", "SIMPLE_CHEMICAL", 4, 10], ["SeB-NPs", "SIMPLE_CHEMICAL", 68, 75], ["SeB", "PROTEIN", 68, 71], ["asymmetric bond stretching", "PROBLEM", 11, 37], ["asymmetric", "OBSERVATION_MODIFIER", 11, 21], ["bond stretching", "OBSERVATION", 22, 37]]], ["With decreased Ca/Se mole ratio, the peaks belonging to the SeO 3 2\u2212 group became stronger, which confirmed the presence of SeO 3 2\u2212 group in SeB-NPs 54 .", [["Ca", "CHEMICAL", 15, 17], ["Se", "CHEMICAL", 18, 20], ["SeO 3 2\u2212", "CHEMICAL", 60, 68], ["SeO 3 2\u2212", "CHEMICAL", 124, 132], ["SeB-NPs", "CHEMICAL", 142, 149], ["Ca", "CHEMICAL", 15, 17], ["Se", "CHEMICAL", 18, 20], ["SeO 3 2\u2212", "CHEMICAL", 60, 68], ["SeO 3 2\u2212", "CHEMICAL", 124, 132], ["SeB", "CHEMICAL", 142, 145], ["SeO 3 2\u2212", "SIMPLE_CHEMICAL", 60, 68], ["SeO 3 2\u2212", "SIMPLE_CHEMICAL", 124, 132], ["SeB-NPs 54", "SIMPLE_CHEMICAL", 142, 152], ["decreased Ca/Se mole ratio", "PROBLEM", 5, 31], ["decreased", "OBSERVATION_MODIFIER", 5, 14], ["Ca", "OBSERVATION", 15, 17]]], ["After XPS analysis of SeB-NPs, there was one peak at 58 eV of the Se3d scanning, which also proved that only SeO 3 2\u2212 [Se (IV)] instead of SeO 4 3\u2212 [Se (VI)] was incorporated into SeB-NPs (Fig. 5 ).", [["SeB", "CHEMICAL", 22, 25], ["SeO 3 2\u2212 [Se", "CHEMICAL", 109, 121], ["SeO 4 3\u2212 [Se", "CHEMICAL", 139, 151], ["SeB-NPs", "CHEMICAL", 180, 187], ["SeB", "CHEMICAL", 22, 25], ["SeO 3", "CHEMICAL", 109, 114], ["Se (IV)]", "CHEMICAL", 119, 127], ["SeO 4 3", "CHEMICAL", 139, 146], ["Se (VI)", "CHEMICAL", 149, 156], ["SeB", "CHEMICAL", 180, 183], ["SeB-NPs", "SIMPLE_CHEMICAL", 22, 29], ["Se3d", "SIMPLE_CHEMICAL", 66, 70], ["SeO 3 2\u2212 [Se (IV)]", "SIMPLE_CHEMICAL", 109, 127], ["SeO 4 3\u2212 [Se (VI)]", "SIMPLE_CHEMICAL", 139, 157], ["SeB-NPs", "SIMPLE_CHEMICAL", 180, 187], ["SeB", "PROTEIN", 22, 25], ["SeB", "PROTEIN", 180, 183], ["XPS analysis", "TEST", 6, 18], ["the Se3d scanning", "TEST", 62, 79]]], ["However, after the deposition of silver nanoparticles on the surface of SeB-NPs, no chemical bonds were formed between silver and SeB-NPs (Figs.", [["surface", "ANATOMY", 61, 68], ["silver nanoparticles", "CHEMICAL", 33, 53], ["SeB-NPs", "CHEMICAL", 72, 79], ["silver", "CHEMICAL", 119, 125], ["SeB-NPs", "CHEMICAL", 130, 137], ["silver", "CHEMICAL", 33, 39], ["SeB", "CHEMICAL", 72, 75], ["silver", "CHEMICAL", 119, 125], ["SeB", "CHEMICAL", 130, 133], ["silver nanoparticles", "SIMPLE_CHEMICAL", 33, 53], ["surface", "CELLULAR_COMPONENT", 61, 68], ["SeB-NPs", "SIMPLE_CHEMICAL", 72, 79], ["silver", "SIMPLE_CHEMICAL", 119, 125], ["SeB-NPs", "SIMPLE_CHEMICAL", 130, 137], ["SeB", "PROTEIN", 72, 75], ["the deposition of silver nanoparticles", "TREATMENT", 15, 53], ["SeB-NPs", "TREATMENT", 72, 79], ["chemical bonds", "PROBLEM", 84, 98], ["no", "UNCERTAINTY", 81, 83], ["chemical bonds", "OBSERVATION", 84, 98]]], ["Next, the crystallinity of SeB-NPs and Ag SeB-NPs was evaluated by XRD, as shown in Fig. 4a .", [["SeB-NPs", "CHEMICAL", 27, 34], ["Ag", "CHEMICAL", 39, 41], ["SeB", "CHEMICAL", 27, 30], ["Ag", "CHEMICAL", 39, 41], ["SeB-NPs", "SIMPLE_CHEMICAL", 27, 34], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 39, 49], ["SeB", "PROTEIN", 27, 30], ["SeB", "PROTEIN", 42, 45], ["SeB-NPs", "TREATMENT", 27, 34], ["Ag SeB-NPs", "TREATMENT", 39, 49]]], ["The appearance of HA and \u03b2-TCP in all samples was expected.", [["samples", "ANATOMY", 38, 45], ["\u03b2-TCP", "CHEMICAL", 25, 30], ["\u03b2-TCP", "SIMPLE_CHEMICAL", 25, 30], ["samples", "CANCER", 38, 45], ["HA", "PROBLEM", 18, 20], ["\u03b2-TCP in all samples", "PROBLEM", 25, 45], ["HA", "OBSERVATION_MODIFIER", 18, 20]]], ["The relative intensity of the diffraction peak at 25.9\u00b0 (0 0 2) (D (002) , Miller's plane) was chosen to calculate the crystallite size (Scherrer equation) 55, 56 .", [["the diffraction peak", "TEST", 26, 46], ["intensity", "OBSERVATION_MODIFIER", 13, 22], ["diffraction", "OBSERVATION_MODIFIER", 30, 41], ["peak", "OBSERVATION_MODIFIER", 42, 46], ["crystallite", "OBSERVATION_MODIFIER", 119, 130], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["The crystallite means size varied for BCP-NPs, SeB-NPs, and Ag SeB-NPs, were calculated by Scherrer equation (Supplementary Materials).", [["SeB-NPs", "CHEMICAL", 47, 54], ["Ag", "CHEMICAL", 60, 62], ["SeB", "CHEMICAL", 47, 50], ["Ag", "CHEMICAL", 60, 62], ["BCP-NPs", "SIMPLE_CHEMICAL", 38, 45], ["SeB-NPs", "SIMPLE_CHEMICAL", 47, 54], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 60, 70], ["BCP", "TEST", 38, 41], ["NPs", "TREATMENT", 42, 45], ["SeB-NPs", "TREATMENT", 47, 54], ["Ag SeB-NPs", "TREATMENT", 60, 70], ["crystallite", "OBSERVATION_MODIFIER", 4, 15], ["size", "OBSERVATION_MODIFIER", 22, 26]]], ["Compared with BCP-NPs, the unit cell dimensions of SeB-NPs were decreased, which proved the incorporation of SeO 3 2\u2212 group.", [["cell", "ANATOMY", 32, 36], ["SeB-NPs", "CHEMICAL", 51, 58], ["SeO 3 2\u2212", "CHEMICAL", 109, 117], ["SeB", "CHEMICAL", 51, 54], ["SeO 3", "CHEMICAL", 109, 114], ["BCP-NPs", "SIMPLE_CHEMICAL", 14, 21], ["cell", "CELL", 32, 36], ["SeB-NPs", "SIMPLE_CHEMICAL", 51, 58], ["SeO 3 2\u2212", "SIMPLE_CHEMICAL", 109, 117], ["SeB", "PROTEIN", 51, 54], ["BCP", "TEST", 14, 17], ["unit cell", "OBSERVATION_MODIFIER", 27, 36], ["dimensions", "OBSERVATION_MODIFIER", 37, 47], ["decreased", "OBSERVATION_MODIFIER", 64, 73]]], ["This inclusion was due to the different shape between SeO 3 2\u2212 group (trigonal pyramids) and PO 4 3\u2212 group (tetrahedra), and phosphate-to-selenite substitution resulted in paired Ca 2+ and OH \u2212 vacancies to rebalance the charge 57 .", [["SeO 3 2\u2212 group", "CHEMICAL", 54, 68], ["PO 4 3\u2212 group", "CHEMICAL", 93, 106], ["phosphate", "CHEMICAL", 125, 134], ["selenite", "CHEMICAL", 138, 146], ["Ca", "CHEMICAL", 179, 181], ["OH", "CHEMICAL", 189, 191], ["SeO 3 2\u2212", "CHEMICAL", 54, 62], ["PO 4 3\u2212", "CHEMICAL", 93, 100], ["tetrahedra", "CHEMICAL", 108, 118], ["phosphate", "CHEMICAL", 125, 134], ["selenite", "CHEMICAL", 138, 146], ["Ca 2+", "CHEMICAL", 179, 184], ["OH", "CHEMICAL", 189, 191], ["SeO 3 2\u2212", "SIMPLE_CHEMICAL", 54, 62], ["trigonal pyramids", "SIMPLE_CHEMICAL", 70, 87], ["PO 4 3\u2212 group", "SIMPLE_CHEMICAL", 93, 106], ["phosphate-to-selenite", "SIMPLE_CHEMICAL", 125, 146], ["Ca 2+", "SIMPLE_CHEMICAL", 179, 184], ["OH \u2212 vacancies", "SIMPLE_CHEMICAL", 189, 203], ["SeO 3 2\u2212 group (trigonal pyramids)", "TREATMENT", 54, 88], ["PO 4 3\u2212 group (tetrahedra)", "TREATMENT", 93, 119], ["phosphate", "TREATMENT", 125, 134], ["selenite substitution", "TREATMENT", 138, 159], ["paired Ca", "TEST", 172, 181], ["OH \u2212 vacancies", "TREATMENT", 189, 203]]], ["As the Ca/Se mole ratio decreased, the corresponding crystallinity increased.", [["Ca", "CHEMICAL", 7, 9], ["Se", "CHEMICAL", 10, 12], ["Ca", "CHEMICAL", 7, 9], ["Se", "CHEMICAL", 10, 12], ["the Ca/Se mole ratio", "TEST", 3, 23], ["the corresponding crystallinity", "PROBLEM", 35, 66], ["decreased", "OBSERVATION_MODIFIER", 24, 33], ["crystallinity", "OBSERVATION_MODIFIER", 53, 66], ["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["However, the crystallinity of Ag SeB-NPs with different AgNO 3 concentrations changed slightly, mainly because silver nanoparticles were only deposited on the surface of SeB-NPs without chemical reaction occurred, which was consistent with the UV-Vis DRS testing results.", [["surface", "ANATOMY", 159, 166], ["Ag SeB-NPs", "CHEMICAL", 30, 40], ["AgNO", "CHEMICAL", 56, 60], ["silver nanoparticles", "CHEMICAL", 111, 131], ["SeB-NPs", "CHEMICAL", 170, 177], ["Ag", "CHEMICAL", 30, 32], ["AgNO 3", "CHEMICAL", 56, 62], ["silver", "CHEMICAL", 111, 117], ["SeB", "CHEMICAL", 170, 173], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 30, 40], ["AgNO 3", "SIMPLE_CHEMICAL", 56, 62], ["silver nanoparticles", "SIMPLE_CHEMICAL", 111, 131], ["surface", "CELLULAR_COMPONENT", 159, 166], ["SeB-NPs", "SIMPLE_CHEMICAL", 170, 177], ["Ag SeB", "PROTEIN", 30, 36], ["the crystallinity of Ag SeB-NPs", "TREATMENT", 9, 40], ["different AgNO 3 concentrations", "TREATMENT", 46, 77], ["silver nanoparticles", "TREATMENT", 111, 131], ["chemical reaction", "PROBLEM", 186, 203], ["without", "UNCERTAINTY", 178, 185], ["chemical reaction", "OBSERVATION", 186, 203], ["consistent with", "UNCERTAINTY", 224, 239]]], ["Rameshbabu et al. identified that silver could influence the crystallinity of HA via heat treatment and further changed the nanosize of HA 55 .", [["silver", "CHEMICAL", 34, 40], ["HA", "CHEMICAL", 78, 80], ["silver", "CHEMICAL", 34, 40], ["silver", "SIMPLE_CHEMICAL", 34, 40], ["HA", "SIMPLE_CHEMICAL", 78, 80], ["HA via heat treatment", "TREATMENT", 78, 99], ["the nanosize of HA", "TREATMENT", 120, 138]]], ["Furthermore, the morphology of SeB-NPs showed a typical needle-like bundle shape, which was different from BCP-NPs ( Fig. 6 and Figure S1 , Supplementary Materials).", [["SeB-NPs", "CHEMICAL", 31, 38], ["SeB", "CHEMICAL", 31, 34], ["SeB-NPs", "SIMPLE_CHEMICAL", 31, 38], ["BCP-NPs", "SIMPLE_CHEMICAL", 107, 114], ["SeB", "PROTEIN", 31, 34], ["SeB-NPs", "TEST", 31, 38], ["a typical needle-like bundle shape", "PROBLEM", 46, 80], ["BCP", "TEST", 107, 110], ["typical", "OBSERVATION_MODIFIER", 48, 55], ["needle", "OBSERVATION", 56, 62], ["bundle shape", "OBSERVATION", 68, 80]]], ["Unfortunately, the strong tendency to agglomerate made it impossible to evaluate its size distribution.", [["agglomerate", "OBSERVATION", 38, 49], ["size", "OBSERVATION_MODIFIER", 85, 89]]], ["After the deposition of silver, the morphology of Ag SeB-NPs www.nature.com/scientificreports/ tended to be further aggregated, and Ag SeB-NPs changed to snowflake-like agglomerate with increasing AgNO 3 concentration.", [["silver", "CHEMICAL", 24, 30], ["Ag SeB", "CHEMICAL", 50, 56], ["Ag", "CHEMICAL", 132, 134], ["AgNO 3", "CHEMICAL", 197, 203], ["silver", "CHEMICAL", 24, 30], ["Ag", "CHEMICAL", 50, 52], ["Ag", "CHEMICAL", 132, 134], ["AgNO 3", "CHEMICAL", 197, 203], ["silver", "SIMPLE_CHEMICAL", 24, 30], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 50, 60], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 132, 142], ["AgNO 3", "SIMPLE_CHEMICAL", 197, 203], ["Ag SeB", "PROTEIN", 50, 56], ["AgNO 3", "PROTEIN", 197, 203], ["Ag SeB-NPs", "TREATMENT", 132, 142], ["snowflake", "TREATMENT", 154, 163], ["increasing AgNO 3 concentration", "TREATMENT", 186, 217]]], ["Element mapping analysis confirmed that selenium was uniformly distributed in SeB-NPs, and silver was spread on the surface of Ag SeB-NPs (Figs.", [["surface", "ANATOMY", 116, 123], ["selenium", "CHEMICAL", 40, 48], ["SeB-NPs", "CHEMICAL", 78, 85], ["silver", "CHEMICAL", 91, 97], ["Ag SeB-NPs", "CHEMICAL", 127, 137], ["selenium", "CHEMICAL", 40, 48], ["SeB", "CHEMICAL", 78, 81], ["silver", "CHEMICAL", 91, 97], ["Ag", "CHEMICAL", 127, 129], ["selenium", "SIMPLE_CHEMICAL", 40, 48], ["SeB-NPs", "SIMPLE_CHEMICAL", 78, 85], ["silver", "SIMPLE_CHEMICAL", 91, 97], ["surface", "CELLULAR_COMPONENT", 116, 123], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 127, 137], ["Ag SeB", "PROTEIN", 127, 133], ["Element mapping analysis", "TEST", 0, 24]]], ["Selenium has been widely applied in diverse areas such as the food and pharmaceutical industries.", [["Selenium", "CHEMICAL", 0, 8], ["Selenium", "CHEMICAL", 0, 8], ["Selenium", "SIMPLE_CHEMICAL", 0, 8], ["Selenium", "TREATMENT", 0, 8], ["widely", "OBSERVATION_MODIFIER", 18, 24], ["diverse", "OBSERVATION_MODIFIER", 36, 43], ["areas", "OBSERVATION_MODIFIER", 44, 49], ["pharmaceutical industries", "OBSERVATION", 71, 96]]], ["Many studies have confirmed that selenium doped HA not only exhibited low cytotoxicity for osteoblastic cells but also reduced the chance of tumor recurrence 24, 29 .", [["osteoblastic cells", "ANATOMY", 91, 109], ["tumor", "ANATOMY", 141, 146], ["selenium", "CHEMICAL", 33, 41], ["tumor", "DISEASE", 141, 146], ["selenium", "CHEMICAL", 33, 41], ["selenium doped HA", "SIMPLE_CHEMICAL", 33, 50], ["osteoblastic cells", "CELL", 91, 109], ["tumor", "CANCER", 141, 146], ["osteoblastic cells", "CELL_TYPE", 91, 109], ["Many studies", "TEST", 0, 12], ["selenium doped HA", "PROBLEM", 33, 50], ["low cytotoxicity", "PROBLEM", 70, 86], ["osteoblastic cells", "PROBLEM", 91, 109], ["tumor recurrence", "PROBLEM", 141, 157], ["osteoblastic cells", "OBSERVATION", 91, 109], ["tumor", "OBSERVATION", 141, 146]]], ["It was necessary to estimate the toxicity of the obtained SeB-NPs and Ag SeB-NPs for further tissue engineering applications.", [["tissue", "ANATOMY", 93, 99], ["toxicity", "DISEASE", 33, 41], ["SeB", "CHEMICAL", 58, 61], ["Ag SeB-NPs", "CHEMICAL", 70, 80], ["SeB", "CHEMICAL", 58, 61], ["Ag", "CHEMICAL", 70, 72], ["SeB-NPs", "SIMPLE_CHEMICAL", 58, 65], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 70, 80], ["tissue", "TISSUE", 93, 99], ["the toxicity", "PROBLEM", 29, 41], ["NPs", "TREATMENT", 62, 65], ["Ag SeB-NPs", "TREATMENT", 70, 80], ["further tissue engineering applications", "TREATMENT", 85, 124]]], ["Osteoblasts were commonly used to evaluate the cytocompatibility of nanoparticles and/or scaffold in tissue engineering 58, 59 .", [["Osteoblasts", "ANATOMY", 0, 11], ["tissue", "ANATOMY", 101, 107], ["Osteoblasts", "CELL", 0, 11], ["nanoparticles", "SIMPLE_CHEMICAL", 68, 81], ["tissue", "TISSUE", 101, 107], ["Osteoblasts", "CELL_TYPE", 0, 11], ["Osteoblasts", "PROBLEM", 0, 11], ["the cytocompatibility of nanoparticles", "PROBLEM", 43, 81]]], ["In this study, the cytocompatibility of SeB-NPs and Ag SeB-NPs was assessed by culturing with hFOB 1.19 cells.", [["hFOB 1.19 cells", "ANATOMY", 94, 109], ["SeB-NPs", "CHEMICAL", 40, 47], ["Ag SeB-NPs", "CHEMICAL", 52, 62], ["SeB", "CHEMICAL", 40, 43], ["Ag", "CHEMICAL", 52, 54], ["SeB-NPs", "SIMPLE_CHEMICAL", 40, 47], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 52, 62], ["hFOB 1.19 cells", "CELL", 94, 109], ["hFOB 1.19 cells", "CELL_LINE", 94, 109], ["this study", "TEST", 3, 13], ["SeB-NPs", "TREATMENT", 40, 47], ["Ag SeB-NPs", "TREATMENT", 52, 62], ["hFOB", "TEST", 94, 98]]], ["BCP-NPs possessed excellent cytocompatibility, and the incorporation of selenium into BCP-NPs did not reduce the cellular biocompatibility 60 .", [["cellular", "ANATOMY", 113, 121], ["BCP-NPs", "CHEMICAL", 0, 7], ["selenium", "CHEMICAL", 72, 80], ["BCP-NPs", "CHEMICAL", 86, 93], ["selenium", "CHEMICAL", 72, 80], ["BCP-NPs", "SIMPLE_CHEMICAL", 0, 7], ["selenium", "SIMPLE_CHEMICAL", 72, 80], ["BCP-NPs", "SIMPLE_CHEMICAL", 86, 93], ["cellular", "CELL", 113, 121], ["the incorporation of selenium into BCP", "TREATMENT", 51, 89], ["NPs", "TREATMENT", 90, 93], ["the cellular biocompatibility", "TEST", 109, 138], ["excellent cytocompatibility", "OBSERVATION", 18, 45], ["cellular biocompatibility", "OBSERVATION", 113, 138]]], ["According to CCK-8 analysis (Fig. 8) , osteoblasts proliferated with SeB-NPs over days, and the growth of cells was not influenced by the Ca/Se mole ratio.", [["osteoblasts", "ANATOMY", 39, 50], ["cells", "ANATOMY", 106, 111], ["SeB-NPs", "CHEMICAL", 69, 76], ["Ca", "CHEMICAL", 138, 140], ["Se", "CHEMICAL", 141, 143], ["SeB", "CHEMICAL", 69, 72], ["Ca", "CHEMICAL", 138, 140], ["Se", "CHEMICAL", 141, 143], ["CCK-8", "GENE_OR_GENE_PRODUCT", 13, 18], ["osteoblasts", "CELL", 39, 50], ["SeB-NPs", "SIMPLE_CHEMICAL", 69, 76], ["cells", "CELL", 106, 111], ["Se mole", "SIMPLE_CHEMICAL", 141, 148], ["osteoblasts", "CELL_TYPE", 39, 50], ["SeB", "PROTEIN", 69, 72], ["CCK", "TEST", 13, 16], ["Fig.", "TEST", 29, 33], ["osteoblasts", "PROBLEM", 39, 50], ["SeB-NPs", "TREATMENT", 69, 76], ["the growth of cells", "PROBLEM", 92, 111], ["the Ca/Se mole ratio", "TEST", 134, 154], ["osteoblasts", "ANATOMY", 39, 50]]], ["After the deposition of silver, cells cultured with all Ag SeB-NPs samples had similar proliferation profiles compared with SeB-NPs.", [["cells", "ANATOMY", 32, 37], ["silver", "CHEMICAL", 24, 30], ["Ag", "CHEMICAL", 56, 58], ["SeB-NPs", "CHEMICAL", 124, 131], ["silver", "CHEMICAL", 24, 30], ["Ag", "CHEMICAL", 56, 58], ["SeB", "CHEMICAL", 124, 127], ["silver", "SIMPLE_CHEMICAL", 24, 30], ["cells", "CELL", 32, 37], ["Ag SeB", "SIMPLE_CHEMICAL", 56, 62], ["SeB-NPs", "SIMPLE_CHEMICAL", 124, 131], ["Ag SeB", "PROTEIN", 56, 62], ["SeB", "PROTEIN", 124, 127], ["the deposition of silver, cells", "TREATMENT", 6, 37], ["all Ag SeB", "TEST", 52, 62], ["NPs samples", "TEST", 63, 74], ["proliferation profiles", "OBSERVATION", 87, 109]]], ["Not only can the addition of selenium and silver improve the growth of the cells with BCP-NPs, but the antibacterial activity was acquired, which has potential for infection-resistant replacement materials 61, 62 .DiscussionFinally, the typical Gram-positive S. aureus and Gram-negative E. coli bacteria were used to evaluate the antibacterial activity of synthesized SeB-NPs and Ag SeB-NPs.", [["cells", "ANATOMY", 75, 80], ["selenium", "CHEMICAL", 29, 37], ["silver", "CHEMICAL", 42, 48], ["BCP-NPs", "CHEMICAL", 86, 93], ["infection", "DISEASE", 164, 173], ["SeB-NPs", "CHEMICAL", 368, 375], ["Ag SeB-NPs", "CHEMICAL", 380, 390], ["selenium", "CHEMICAL", 29, 37], ["silver", "CHEMICAL", 42, 48], ["SeB", "CHEMICAL", 368, 371], ["Ag", "CHEMICAL", 380, 382], ["selenium", "SIMPLE_CHEMICAL", 29, 37], ["silver", "SIMPLE_CHEMICAL", 42, 48], ["cells", "CELL", 75, 80], ["BCP-NPs", "SIMPLE_CHEMICAL", 86, 93], ["Gram-", "GENE_OR_GENE_PRODUCT", 245, 250], ["S. aureus", "ORGANISM", 259, 268], ["E. coli", "ORGANISM", 287, 294], ["SeB-NPs", "SIMPLE_CHEMICAL", 368, 375], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 380, 390], ["S. aureus", "SPECIES", 259, 268], ["E. coli", "SPECIES", 287, 294], ["S. aureus", "SPECIES", 259, 268], ["E. coli", "SPECIES", 287, 294], ["selenium", "TREATMENT", 29, 37], ["silver", "TREATMENT", 42, 48], ["BCP-NPs", "TREATMENT", 86, 93], ["the antibacterial activity", "TEST", 99, 125], ["infection", "PROBLEM", 164, 173], ["resistant replacement materials", "TREATMENT", 174, 205], ["the typical Gram-positive S. aureus", "PROBLEM", 233, 268], ["Gram-negative E. coli bacteria", "PROBLEM", 273, 303], ["synthesized SeB", "TREATMENT", 356, 371], ["NPs", "TREATMENT", 372, 375], ["Ag SeB-NPs", "TREATMENT", 380, 390], ["infection", "OBSERVATION", 164, 173], ["aureus", "OBSERVATION", 262, 268], ["coli bacteria", "OBSERVATION", 290, 303]]], ["S. aureus, the most common virulent pathogen, and due to the biofilm formation and documented antibiotic resistance, can cause bone-implants-associated infections in hospitalized patients.", [["biofilm", "ANATOMY", 61, 68], ["bone", "ANATOMY", 127, 131], ["infections", "DISEASE", 152, 162], ["S. aureus", "ORGANISM", 0, 9], ["bone", "TISSUE", 127, 131], ["patients", "ORGANISM", 179, 187], ["S. aureus", "SPECIES", 0, 9], ["patients", "SPECIES", 179, 187], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["the most common virulent pathogen", "PROBLEM", 11, 44], ["the biofilm formation", "PROBLEM", 57, 78], ["antibiotic resistance", "TREATMENT", 94, 115], ["bone-implants", "PROBLEM", 127, 140], ["associated infections", "PROBLEM", 141, 162], ["aureus", "OBSERVATION", 3, 9], ["most common", "OBSERVATION_MODIFIER", 15, 26], ["virulent", "OBSERVATION_MODIFIER", 27, 35], ["pathogen", "OBSERVATION", 36, 44], ["antibiotic resistance", "OBSERVATION", 94, 115], ["bone", "ANATOMY", 127, 131], ["implants", "OBSERVATION", 132, 140], ["infections", "OBSERVATION", 152, 162]]], ["Here, S. aureus was used together with E. coli (due to the highly capable of reduction) 63 .", [["S. aureus", "ORGANISM", 6, 15], ["E. coli", "ORGANISM", 39, 46], ["S. aureus", "SPECIES", 6, 15], ["E. coli", "SPECIES", 39, 46], ["S. aureus", "SPECIES", 6, 15], ["E. coli", "SPECIES", 39, 46], ["S. aureus", "PROBLEM", 6, 15], ["E. coli", "PROBLEM", 39, 46], ["aureus", "OBSERVATION", 9, 15]]], ["Selenium could promote the formation of superoxide radicals and, enhance oxidative stress, which resulted in the damage of bacterial cell walls 64 Besides, selenium could inhibit the biofilm formation of the S. aureus and the growth of E. coli 65, 66 .", [["cell walls", "ANATOMY", 133, 143], ["biofilm", "ANATOMY", 183, 190], ["Selenium", "CHEMICAL", 0, 8], ["superoxide", "CHEMICAL", 40, 50], ["selenium", "CHEMICAL", 156, 164], ["Selenium", "CHEMICAL", 0, 8], ["superoxide", "CHEMICAL", 40, 50], ["selenium", "CHEMICAL", 156, 164], ["Selenium", "SIMPLE_CHEMICAL", 0, 8], ["superoxide radicals", "SIMPLE_CHEMICAL", 40, 59], ["selenium", "SIMPLE_CHEMICAL", 156, 164], ["S. aureus", "ORGANISM", 208, 217], ["E. coli", "ORGANISM", 236, 243], ["S. aureus", "SPECIES", 208, 217], ["E. coli", "SPECIES", 236, 243], ["S. aureus", "SPECIES", 208, 217], ["E. coli", "SPECIES", 236, 243], ["Selenium", "TREATMENT", 0, 8], ["superoxide radicals", "TREATMENT", 40, 59], ["enhance oxidative stress", "PROBLEM", 65, 89], ["the damage of bacterial cell walls", "PROBLEM", 109, 143], ["the biofilm formation", "PROBLEM", 179, 200], ["the S. aureus", "PROBLEM", 204, 217], ["E. coli", "TEST", 236, 243], ["superoxide radicals", "OBSERVATION", 40, 59], ["bacterial cell walls", "OBSERVATION", 123, 143], ["biofilm", "OBSERVATION", 183, 190], ["aureus", "OBSERVATION", 211, 217], ["growth", "OBSERVATION_MODIFIER", 226, 232]]], ["Figures 9 and 10 illustrated the antibacterial activity of SeB-NPs and Ag SeB-NPs against S. aureus and E. coli colonies.", [["colonies", "ANATOMY", 112, 120], ["SeB-NPs", "CHEMICAL", 59, 66], ["Ag SeB-NPs", "CHEMICAL", 71, 81], ["SeB", "CHEMICAL", 59, 62], ["Ag", "CHEMICAL", 71, 73], ["SeB-NPs", "SIMPLE_CHEMICAL", 59, 66], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 71, 81], ["S. aureus", "ORGANISM", 90, 99], ["E. coli", "ORGANISM", 104, 111], ["S. aureus", "SPECIES", 90, 99], ["E. coli", "SPECIES", 104, 111], ["S. aureus", "SPECIES", 90, 99], ["E. coli", "SPECIES", 104, 111], ["Figures", "TEST", 0, 7], ["SeB-NPs", "TREATMENT", 59, 66], ["Ag SeB", "TEST", 71, 77], ["S. aureus", "PROBLEM", 90, 99], ["E. coli colonies", "PROBLEM", 104, 120], ["aureus", "OBSERVATION", 93, 99], ["E. coli colonies", "OBSERVATION", 104, 120]]], ["It was noted that the introduction of selenium in BCP-NPs could not empower the antibacterial performance on SeB-NPs.", [["selenium", "CHEMICAL", 38, 46], ["BCP-NPs", "CHEMICAL", 50, 57], ["SeB-NPs", "CHEMICAL", 109, 116], ["selenium", "CHEMICAL", 38, 46], ["selenium", "SIMPLE_CHEMICAL", 38, 46], ["BCP-NPs", "SIMPLE_CHEMICAL", 50, 57], ["SeB-NPs", "SIMPLE_CHEMICAL", 109, 116], ["selenium in BCP", "TREATMENT", 38, 53], ["NPs", "TREATMENT", 54, 57]]], ["Besides, the antibacterial activity of the selenium-doped hydroxyapatite nanoparticles (SeHA-NPs) was investigated herein for comparison ( Figures S9 and S10 , Supplementary Materials).", [["selenium", "CHEMICAL", 43, 51], ["hydroxyapatite nanoparticles", "CHEMICAL", 58, 86], ["SeHA-NPs", "CHEMICAL", 88, 96], ["selenium", "CHEMICAL", 43, 51], ["hydroxyapatite", "CHEMICAL", 58, 72], ["selenium-doped hydroxyapatite nanoparticles", "SIMPLE_CHEMICAL", 43, 86], ["SeHA-NPs", "SIMPLE_CHEMICAL", 88, 96], ["the antibacterial activity", "TEST", 9, 35], ["the selenium-doped hydroxyapatite nanoparticles", "TREATMENT", 39, 86], ["antibacterial activity", "OBSERVATION", 13, 35]]], ["The results revealed that SeHA-NPs didn't display inhibitory activity against S. aureus and E. coli, which was slightly different from previous reports 58, 60 .", [["SeHA-NPs", "CHEMICAL", 26, 34], ["SeHA", "CHEMICAL", 26, 30], ["SeHA-NPs", "SIMPLE_CHEMICAL", 26, 34], ["S. aureus", "ORGANISM", 78, 87], ["E. coli", "ORGANISM", 92, 99], ["S. aureus", "SPECIES", 78, 87], ["E. coli", "SPECIES", 92, 99], ["S. aureus", "SPECIES", 78, 87], ["E. coli", "SPECIES", 92, 99], ["SeHA", "TEST", 26, 30], ["S. aureus", "PROBLEM", 78, 87], ["E. coli", "PROBLEM", 92, 99], ["aureus", "OBSERVATION", 81, 87], ["E. coli", "OBSERVATION", 92, 99]]], ["The different results might be due to the varying morphology of SeHA-NPs used in this work, demonstrating that the antibacterial effect of nanoparticles is greatly influenced by the shape and size.DiscussionHowever, after deposition of silver on SeB-NPs, the growth of S. aureus and E. coli were both decreased significantly.", [["SeHA-NPs", "CHEMICAL", 64, 72], ["silver", "CHEMICAL", 236, 242], ["SeB-NPs", "CHEMICAL", 246, 253], ["SeHA", "CHEMICAL", 64, 68], ["silver", "CHEMICAL", 236, 242], ["SeB", "CHEMICAL", 246, 249], ["SeHA-NPs", "SIMPLE_CHEMICAL", 64, 72], ["silver", "SIMPLE_CHEMICAL", 236, 242], ["SeB-NPs", "SIMPLE_CHEMICAL", 246, 253], ["S. aureus", "ORGANISM", 269, 278], ["E. coli", "ORGANISM", 283, 290], ["S. aureus", "SPECIES", 269, 278], ["E. coli", "SPECIES", 283, 290], ["S. aureus", "SPECIES", 269, 278], ["E. coli", "SPECIES", 283, 290], ["SeHA-NPs", "TREATMENT", 64, 72], ["the antibacterial effect of nanoparticles", "TREATMENT", 111, 152], ["SeB-NPs", "TREATMENT", 246, 253], ["S. aureus", "PROBLEM", 269, 278], ["E. coli", "PROBLEM", 283, 290], ["might be due to", "UNCERTAINTY", 22, 37], ["antibacterial effect", "OBSERVATION", 115, 135], ["shape", "OBSERVATION_MODIFIER", 182, 187], ["size", "OBSERVATION_MODIFIER", 192, 196], ["growth", "OBSERVATION_MODIFIER", 259, 265], ["aureus", "OBSERVATION", 272, 278], ["E. coli", "OBSERVATION", 283, 290], ["decreased", "OBSERVATION_MODIFIER", 301, 310]]], ["Assuming that a large number of silver nanoparticles might be released from Ag SeB-NPs, which can inhibit the initial bacterial adhesion and growth, the mechanism of prepared Ag SeB-NPs was displayed in Fig. 11 .", [["silver nanoparticles", "CHEMICAL", 32, 52], ["Ag SeB-NPs", "CHEMICAL", 76, 86], ["Ag SeB-NPs", "CHEMICAL", 175, 185], ["silver", "CHEMICAL", 32, 38], ["Ag", "CHEMICAL", 76, 78], ["Ag", "CHEMICAL", 175, 177], ["silver nanoparticles", "SIMPLE_CHEMICAL", 32, 52], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 76, 86], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 175, 185], ["Ag SeB", "PROTEIN", 175, 181], ["a large number of silver nanoparticles", "TREATMENT", 14, 52], ["Ag SeB-NPs", "TREATMENT", 76, 86], ["the initial bacterial adhesion", "PROBLEM", 106, 136], ["large", "OBSERVATION_MODIFIER", 16, 21], ["bacterial adhesion", "OBSERVATION", 118, 136]]], ["Previous papers reported that the release of silver nanoparticles could be regulated by pH, calcium, and phosphate ion concentrations in the surrounding medium 67 .", [["silver nanoparticles", "CHEMICAL", 45, 65], ["calcium", "CHEMICAL", 92, 99], ["phosphate", "CHEMICAL", 105, 114], ["silver", "CHEMICAL", 45, 51], ["calcium", "CHEMICAL", 92, 99], ["phosphate", "CHEMICAL", 105, 114], ["silver nanoparticles", "SIMPLE_CHEMICAL", 45, 65], ["calcium", "SIMPLE_CHEMICAL", 92, 99], ["phosphate ion", "SIMPLE_CHEMICAL", 105, 118], ["the release of silver nanoparticles", "TREATMENT", 30, 65], ["pH", "TEST", 88, 90], ["calcium", "TEST", 92, 99], ["phosphate ion concentrations", "TREATMENT", 105, 133]]], ["Notably, the acidic environment could generate the release of silver nanoparticles.", [["silver nanoparticles", "CHEMICAL", 62, 82], ["silver", "CHEMICAL", 62, 68], ["silver nanoparticles", "SIMPLE_CHEMICAL", 62, 82], ["silver nanoparticles", "TREATMENT", 62, 82], ["silver nanoparticles", "OBSERVATION", 62, 82]]], ["Therefore, because of the growth of oral bacteria under acidic conditions, the future use of Ag SeB-NPs could be expanded to dental applications 68 .", [["oral", "ANATOMY", 36, 40], ["Ag SeB-NPs", "CHEMICAL", 93, 103], ["Ag", "CHEMICAL", 93, 95], ["oral", "ORGANISM_SUBDIVISION", 36, 40], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 93, 103], ["oral bacteria under acidic conditions", "PROBLEM", 36, 73], ["Ag SeB-NPs", "TREATMENT", 93, 103]]], ["Besides, selenium-doped bone mineral nanoparticles performed effective bone tumor inhibition.", [["bone", "ANATOMY", 24, 28], ["bone tumor", "ANATOMY", 71, 81], ["selenium", "CHEMICAL", 9, 17], ["tumor", "DISEASE", 76, 81], ["selenium", "CHEMICAL", 9, 17], ["selenium", "SIMPLE_CHEMICAL", 9, 17], ["bone", "TISSUE", 24, 28], ["bone tumor", "CANCER", 71, 81], ["selenium-doped bone mineral nanoparticles", "TREATMENT", 9, 50], ["bone tumor inhibition", "PROBLEM", 71, 92], ["bone", "ANATOMY", 24, 28], ["bone", "ANATOMY", 71, 75], ["tumor", "OBSERVATION", 76, 81]]], ["Thus, Ag SeB-NPs has potential advantages in the fabrication of a multifunctional bone scaffold for healing related bone tumor diseases.", [["bone", "ANATOMY", 82, 86], ["bone tumor", "ANATOMY", 116, 126], ["Ag SeB-NPs", "CHEMICAL", 6, 16], ["bone tumor", "DISEASE", 116, 126], ["Ag", "CHEMICAL", 6, 8], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 6, 16], ["bone", "TISSUE", 82, 86], ["bone tumor", "CANCER", 116, 126], ["Ag SeB", "PROTEIN", 6, 12], ["the fabrication", "TREATMENT", 45, 60], ["a multifunctional bone scaffold", "TREATMENT", 64, 95], ["healing related bone tumor diseases", "PROBLEM", 100, 135], ["bone", "ANATOMY", 82, 86], ["bone", "ANATOMY", 116, 120], ["tumor", "OBSERVATION", 121, 126]]], ["The balance between biocompatibility and antibacterial properties of Ag SeB-NPs, i.e., the excellent cytocompatibility, and productive inhibition activity against bacteria, supported the significance of Ag SeB-NPs in biomedical applications.", [["Ag SeB-NPs", "CHEMICAL", 69, 79], ["Ag SeB-NPs", "CHEMICAL", 203, 213], ["Ag", "CHEMICAL", 69, 71], ["Ag", "CHEMICAL", 203, 205], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 69, 79], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 203, 213], ["Ag SeB", "PROTEIN", 203, 209], ["biocompatibility", "TREATMENT", 20, 36], ["antibacterial properties", "TREATMENT", 41, 65], ["Ag SeB-NPs", "TREATMENT", 69, 79], ["productive inhibition activity", "PROBLEM", 124, 154], ["bacteria", "PROBLEM", 163, 171], ["Ag SeB", "TREATMENT", 203, 209], ["biomedical applications", "TREATMENT", 217, 240]]], ["However, future applications require further in vitro and in vivo investigations, including the release profile of silver nanoparticles and selenium.", [["silver nanoparticles", "CHEMICAL", 115, 135], ["selenium", "CHEMICAL", 140, 148], ["silver", "CHEMICAL", 115, 121], ["selenium", "CHEMICAL", 140, 148], ["silver nanoparticles", "SIMPLE_CHEMICAL", 115, 135], ["selenium", "SIMPLE_CHEMICAL", 140, 148], ["vivo investigations", "TEST", 61, 80]]], ["Mechanism of antibacterial activity of prepared Ag SeB-NPs against bacteria.", [["Ag SeB-NPs", "CHEMICAL", 48, 58], ["Ag", "CHEMICAL", 48, 50], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 48, 58], ["antibacterial activity", "PROBLEM", 13, 35], ["prepared Ag SeB", "TREATMENT", 39, 54], ["bacteria", "PROBLEM", 67, 75], ["antibacterial activity", "OBSERVATION", 13, 35]]], ["Silver ions were released from Ag SeB-NPs to produce free radicals, which resulted in reactive oxygen species (ROS), and damaged bacteria until bacterial death.conclusionsIn summary, a well-developed nanostructured SeB-NPs and Ag SeB-NPs with excellent biocompatibility and suitable antibacterial properties were fabricated herein.", [["Silver ions", "CHEMICAL", 0, 11], ["Ag SeB-NPs", "CHEMICAL", 31, 41], ["oxygen", "CHEMICAL", 95, 101], ["ROS", "CHEMICAL", 111, 114], ["death", "DISEASE", 154, 159], ["SeB-NPs", "CHEMICAL", 215, 222], ["Ag", "CHEMICAL", 227, 229], ["Silver", "CHEMICAL", 0, 6], ["Ag", "CHEMICAL", 31, 33], ["oxygen", "CHEMICAL", 95, 101], ["SeB", "CHEMICAL", 215, 218], ["Ag", "CHEMICAL", 227, 229], ["Silver ions", "SIMPLE_CHEMICAL", 0, 11], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 31, 41], ["free radicals", "SIMPLE_CHEMICAL", 53, 66], ["reactive oxygen species", "SIMPLE_CHEMICAL", 86, 109], ["ROS", "SIMPLE_CHEMICAL", 111, 114], ["SeB-NPs", "SIMPLE_CHEMICAL", 215, 222], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 227, 237], ["Silver ions", "TREATMENT", 0, 11], ["Ag SeB-NPs", "TREATMENT", 31, 41], ["free radicals", "PROBLEM", 53, 66], ["reactive oxygen species", "PROBLEM", 86, 109], ["damaged bacteria", "PROBLEM", 121, 137], ["bacterial death", "PROBLEM", 144, 159], ["nanostructured SeB-NPs", "TREATMENT", 200, 222], ["Ag SeB-NPs", "TREATMENT", 227, 237], ["suitable antibacterial properties", "TREATMENT", 274, 307], ["ions", "OBSERVATION", 7, 11], ["reactive", "OBSERVATION_MODIFIER", 86, 94], ["oxygen species", "OBSERVATION", 95, 109], ["bacterial death", "OBSERVATION", 144, 159], ["biocompatibility", "OBSERVATION", 253, 269]]], ["FI-IR, Raman, XRD and XPS analysis certified that the SeO 3 2\u2212 was doped at PO 4 3\u2212 position.", [["SeO 3 2\u2212", "CHEMICAL", 54, 62], ["SeO 3 2", "CHEMICAL", 54, 61], ["SeO 3 2\u2212", "SIMPLE_CHEMICAL", 54, 62], ["PO 4 3\u2212 position", "DNA", 76, 92], ["XRD", "TEST", 14, 17], ["XPS analysis", "TEST", 22, 34]]], ["The needle-cluster-like morphology of SeB-NPs was obtained, and the formed Ag SeB-NPs tended to flock together, which was confirmed by TEM.", [["SeB-NPs", "CHEMICAL", 38, 45], ["Ag", "CHEMICAL", 75, 77], ["SeB-NPs", "CHEMICAL", 78, 85], ["SeB", "CHEMICAL", 38, 41], ["Ag", "CHEMICAL", 75, 77], ["SeB", "CHEMICAL", 78, 81], ["SeB-NPs", "SIMPLE_CHEMICAL", 38, 45], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 75, 85], ["SeB", "PROTEIN", 38, 41], ["Ag SeB", "PROTEIN", 75, 81], ["the formed Ag SeB-NPs", "TREATMENT", 64, 85]]], ["After culturing with hFOB 1.19 cells, both SeB-NPs and Ag SeB-NPs behaved excellent cytocompatibility.", [["hFOB 1.19 cells", "ANATOMY", 21, 36], ["SeB-NPs", "CHEMICAL", 43, 50], ["Ag", "CHEMICAL", 55, 57], ["SeB", "CHEMICAL", 43, 46], ["Ag", "CHEMICAL", 55, 57], ["hFOB 1.19 cells", "CELL", 21, 36], ["SeB-NPs", "SIMPLE_CHEMICAL", 43, 50], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 55, 65], ["hFOB 1.19 cells", "CELL_LINE", 21, 36], ["culturing", "TEST", 6, 15], ["hFOB", "TEST", 21, 25], ["Ag SeB-NPs", "TREATMENT", 55, 65], ["excellent cytocompatibility", "OBSERVATION", 74, 101]]], ["Next, the Gram-negative E. coli and Grampositive S. aureus were used to verify that Ag SeB-NPs had better antibacterial activity than SeB-NPs.", [["Ag", "CHEMICAL", 84, 86], ["SeB-NPs", "CHEMICAL", 87, 94], ["SeB-NPs", "CHEMICAL", 134, 141], ["Ag", "CHEMICAL", 84, 86], ["SeB", "CHEMICAL", 134, 137], ["Gram-", "GENE_OR_GENE_PRODUCT", 10, 15], ["E. coli", "ORGANISM", 24, 31], ["Grampositive S. aureus", "ORGANISM", 36, 58], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 84, 94], ["SeB-NPs", "SIMPLE_CHEMICAL", 134, 141], ["E. coli", "SPECIES", 24, 31], ["S. aureus", "SPECIES", 49, 58], ["E. coli", "SPECIES", 24, 31], ["S. aureus", "SPECIES", 49, 58], ["the Gram-negative E. coli", "TEST", 6, 31], ["Grampositive S. aureus", "PROBLEM", 36, 58], ["Ag SeB", "TEST", 84, 90], ["E. coli", "OBSERVATION", 24, 31]]], ["The results obtained support the significance of Ag SeB-NPs in diverse biomedical applications.Data availabilityAll data generated or analyzed during this study are included in the published article and its Supplementary Materials files and are available from the corresponding author on reasonable request.Data availabilityReceived: 5 November 2019; Accepted: 4 August 2020", [["Ag SeB-NPs", "CHEMICAL", 49, 59], ["Ag", "CHEMICAL", 49, 51], ["Ag SeB-NPs", "SIMPLE_CHEMICAL", 49, 59], ["Ag SeB", "PROTEIN", 49, 55], ["Ag SeB", "TREATMENT", 49, 55], ["diverse biomedical applications", "TREATMENT", 63, 94], ["All data", "TEST", 112, 120], ["this study", "TEST", 150, 160]]]], "PMC7457442": [["BackgroundDiabetes mellitus and psychiatric disorders share a mutual interface: the challenge of living and overcoming diabetes may result in emotional overload, and the presence of depression and anxiety symptoms may be associated with lower treatment adherence, leading to worse glycemic control [1, 2].", [["BackgroundDiabetes mellitus", "DISEASE", 0, 27], ["psychiatric disorders", "DISEASE", 32, 53], ["diabetes", "DISEASE", 119, 127], ["emotional overload", "DISEASE", 142, 160], ["depression", "DISEASE", 182, 192], ["anxiety", "DISEASE", 197, 204], ["BackgroundDiabetes mellitus", "PROBLEM", 0, 27], ["psychiatric disorders", "PROBLEM", 32, 53], ["overcoming diabetes", "PROBLEM", 108, 127], ["emotional overload", "PROBLEM", 142, 160], ["depression", "PROBLEM", 182, 192], ["anxiety symptoms", "PROBLEM", 197, 213], ["lower treatment adherence", "TREATMENT", 237, 262]]], ["In patients with diabetes, the prevalence of depression and anxiety symptoms is about two to four times greater than in the general population [3, 4].", [["diabetes", "DISEASE", 17, 25], ["depression", "DISEASE", 45, 55], ["anxiety", "DISEASE", 60, 67], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["diabetes", "PROBLEM", 17, 25], ["depression", "PROBLEM", 45, 55], ["anxiety symptoms", "PROBLEM", 60, 76], ["diabetes", "OBSERVATION", 17, 25], ["depression", "OBSERVATION", 45, 55]]], ["Although more research is needed to fully understand the link between diabetes and depression, it is clear that metabolic dysregulation influences brain function and disturbances in peripheral glucose regulation might be associated with depressed mood [5, 6].", [["brain", "ANATOMY", 147, 152], ["diabetes", "DISEASE", 70, 78], ["depression", "DISEASE", 83, 93], ["glucose", "CHEMICAL", 193, 200], ["depressed mood", "DISEASE", 237, 251], ["glucose", "CHEMICAL", 193, 200], ["brain", "ORGAN", 147, 152], ["peripheral", "ANATOMICAL_SYSTEM", 182, 192], ["glucose", "SIMPLE_CHEMICAL", 193, 200], ["diabetes", "PROBLEM", 70, 78], ["depression", "PROBLEM", 83, 93], ["metabolic dysregulation influences brain function", "PROBLEM", 112, 161], ["disturbances in peripheral glucose regulation", "PROBLEM", 166, 211], ["depressed mood", "PROBLEM", 237, 251], ["metabolic dysregulation", "OBSERVATION", 112, 135]]], ["Some cases of depression might result from low levels of insulin-like growth factor (IGF) into the brain, wich was shown to produce antidepressant behavioural responses in experimental studies [6\u20138].", [["brain", "ANATOMY", 99, 104], ["depression", "DISEASE", 14, 24], ["antidepressant", "CHEMICAL", 132, 146], ["insulin-like growth factor", "GENE_OR_GENE_PRODUCT", 57, 83], ["IGF", "GENE_OR_GENE_PRODUCT", 85, 88], ["brain", "ORGAN", 99, 104], ["insulin-like growth factor", "PROTEIN", 57, 83], ["IGF", "PROTEIN", 85, 88], ["depression", "PROBLEM", 14, 24], ["low levels of insulin", "PROBLEM", 43, 64], ["experimental studies", "TEST", 172, 192], ["depression", "OBSERVATION", 14, 24], ["low levels", "OBSERVATION_MODIFIER", 43, 53], ["brain", "ANATOMY", 99, 104]]], ["Nutrient-activated gut to brain signaling pathways also appear to play a role in the genesis of depressive symptoms.", [["gut", "ANATOMY", 19, 22], ["brain", "ANATOMY", 26, 31], ["depressive symptoms", "DISEASE", 96, 115], ["gut", "ORGANISM_SUBDIVISION", 19, 22], ["brain", "ORGAN", 26, 31], ["depressive symptoms", "PROBLEM", 96, 115]]], ["A highly significant association between leptin levels, depressed mood and sleep disturbances has been shown in normal-weight individuals [6, 9].", [["depressed mood", "DISEASE", 56, 70], ["sleep disturbances", "DISEASE", 75, 93], ["leptin", "GENE_OR_GENE_PRODUCT", 41, 47], ["leptin", "PROTEIN", 41, 47], ["A highly significant association between leptin levels", "PROBLEM", 0, 54], ["depressed mood", "PROBLEM", 56, 70], ["sleep disturbances", "PROBLEM", 75, 93], ["highly", "OBSERVATION_MODIFIER", 2, 8], ["significant", "OBSERVATION_MODIFIER", 9, 20]]], ["Also, ghrelin can exert antidepressant effects in men and carbohydrates appear to lead to ghrelin suppression [6, 10, 11].BackgroundThe association between diabetes and mental health disorders could be exacerbated in a stressful environment, and psychological distress could increase depressive symptoms and cause adverse diabetes outcomes [12, 13].", [["ghrelin", "CHEMICAL", 6, 13], ["antidepressant", "CHEMICAL", 24, 38], ["diabetes", "DISEASE", 156, 164], ["mental health disorders", "DISEASE", 169, 192], ["psychological distress", "DISEASE", 246, 268], ["depressive symptoms", "DISEASE", 284, 303], ["diabetes", "DISEASE", 322, 330], ["carbohydrates", "CHEMICAL", 58, 71], ["ghrelin", "GENE_OR_GENE_PRODUCT", 6, 13], ["men", "ORGANISM", 50, 53], ["carbohydrates", "SIMPLE_CHEMICAL", 58, 71], ["ghrelin", "GENE_OR_GENE_PRODUCT", 90, 97], ["men", "SPECIES", 50, 53], ["carbohydrates", "TREATMENT", 58, 71], ["ghrelin suppression", "PROBLEM", 90, 109], ["diabetes", "PROBLEM", 156, 164], ["mental health disorders", "PROBLEM", 169, 192], ["psychological distress", "PROBLEM", 246, 268], ["depressive symptoms", "PROBLEM", 284, 303], ["adverse diabetes outcomes", "PROBLEM", 314, 339]]], ["The emergence of a potentially fatal pandemic represents a new reason for uncertainty and anxiety in this group of patients.", [["anxiety", "DISEASE", 90, 97], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["anxiety", "PROBLEM", 90, 97]]], ["Since December 2019, when a series of cases of severe pneumonia caused by a new coronavirus was described in Wuhan-China, the COVID-19 infection, as it became known, quickly spread throughout the world [14\u201316].", [["pneumonia", "DISEASE", 54, 63], ["coronavirus", "DISEASE", 80, 91], ["infection", "DISEASE", 135, 144], ["coronavirus", "ORGANISM", 80, 91], ["COVID-19", "ORGANISM", 126, 134], ["COVID-19", "SPECIES", 126, 134], ["severe pneumonia", "PROBLEM", 47, 63], ["a new coronavirus", "PROBLEM", 74, 91], ["the COVID-19 infection", "PROBLEM", 122, 144], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["pneumonia", "OBSERVATION", 54, 63], ["new", "OBSERVATION_MODIFIER", 76, 79], ["coronavirus", "OBSERVATION", 80, 91], ["infection", "OBSERVATION", 135, 144]]], ["On Jul 07th, more than 11 million and 600 thousand confirmed cases have been identified worldwide, totaling 538 thousand deaths [17].", [["deaths", "DISEASE", 121, 127]]], ["The first case of someone suffering from COVID-19 in South America was confirmed on February 26th, 2020 in S\u00e3o Paulo, Brazil.", [["COVID", "DISEASE", 41, 46], ["someone", "ORGANISM", 18, 25]]], ["Since then, Brazil has recorded the largest number of cases in Latin America and recently has emerged as a new epicenter of the pandemic in the world [18].BackgroundA number of measures have been taken to prevent the spread of COVID-19, involving the isolation of suspected cases, tracking and monitoring of contacts, and dissemination of regional and national information, which included the recommendation of social distancing, especially for high risk groups such as patients with diabetes [19].", [["diabetes", "DISEASE", 484, 492], ["patients", "ORGANISM", 470, 478], ["patients", "SPECIES", 470, 478], ["COVID", "TEST", 227, 232], ["diabetes", "PROBLEM", 484, 492], ["largest", "OBSERVATION_MODIFIER", 36, 43], ["number", "OBSERVATION_MODIFIER", 44, 50], ["new", "OBSERVATION_MODIFIER", 107, 110]]], ["The social distancing recommendation have a psychological effect even in patients without diabetes, as shown by Talevi et al. [20].", [["diabetes", "DISEASE", 90, 98], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["diabetes", "PROBLEM", 90, 98]]], ["In this review, the authors report that up to 53.8% of people experienced psychological distress during the initial stage of the COVID-19 outbreak.", [["psychological distress", "DISEASE", 74, 96], ["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61], ["psychological distress", "PROBLEM", 74, 96], ["the COVID", "TEST", 125, 134]]], ["A range of negative psychological responses were identified, such as anxiety, depression, insomnia and worries about individuals\u2019 own health and family.", [["anxiety", "DISEASE", 69, 76], ["depression", "DISEASE", 78, 88], ["insomnia", "DISEASE", 90, 98], ["anxiety", "PROBLEM", 69, 76], ["depression", "PROBLEM", 78, 88], ["insomnia", "PROBLEM", 90, 98]]], ["The levels of stress, anxiety and depression ranged from mild to moderate-severe [20\u201324].", [["anxiety", "DISEASE", 22, 29], ["depression", "DISEASE", 34, 44], ["stress", "PROBLEM", 14, 20], ["anxiety", "PROBLEM", 22, 29], ["depression", "PROBLEM", 34, 44], ["mild to moderate-severe", "PROBLEM", 57, 80], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["moderate", "OBSERVATION_MODIFIER", 65, 73], ["severe", "OBSERVATION_MODIFIER", 74, 80]]], ["Among patients with confirmed infection, findings show that nearly 50% of people diagnosed with COVID-19 had depressive symptoms, over 55% had anxiety and almost 70% had somatic symptoms [20, 25].BackgroundThe psychological repercussion of the current scenario in patients with diabetes is still hypothetical.", [["infection", "DISEASE", 30, 39], ["COVID", "DISEASE", 96, 101], ["depressive symptoms", "DISEASE", 109, 128], ["anxiety", "DISEASE", 143, 150], ["diabetes", "DISEASE", 278, 286], ["patients", "ORGANISM", 6, 14], ["people", "ORGANISM", 74, 80], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 6, 14], ["people", "SPECIES", 74, 80], ["patients", "SPECIES", 264, 272], ["infection", "PROBLEM", 30, 39], ["COVID", "TEST", 96, 101], ["depressive symptoms", "PROBLEM", 109, 128], ["anxiety", "PROBLEM", 143, 150], ["somatic symptoms", "PROBLEM", 170, 186], ["diabetes", "PROBLEM", 278, 286], ["infection", "OBSERVATION", 30, 39]]], ["It is well known that those patients, due to the conditions of the underlying disease, already have a greater tendency to develop psychiatric disorders throughout life.", [["psychiatric disorders", "DISEASE", 130, 151], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["the underlying disease", "PROBLEM", 63, 85], ["psychiatric disorders", "PROBLEM", 130, 151], ["disease", "OBSERVATION", 78, 85]]], ["It is possible that the COVID-19 pandemic, as well as the social isolation determined by it, may interfere with parameters of mental health in patients with diabetes.", [["diabetes", "DISEASE", 157, 165], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["the COVID", "TEST", 20, 29], ["diabetes", "PROBLEM", 157, 165]]], ["The present study aimed to investigate the impact of the current pandemic on the prevalence of mental health disorders in patients with type 1 and type 2 diabetes.Study design and setting ::: MethodsThis is a cross-sectional study developed to assess the prevalence of mental health disorders in a cohort of patients living with diabetes during the social distancing period due to COVID-19 pandemic.", [["health disorders", "DISEASE", 102, 118], ["type 1 and type 2 diabetes", "DISEASE", 136, 162], ["health disorders", "DISEASE", 276, 292], ["diabetes", "DISEASE", 329, 337], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 308, 316], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 308, 316], ["The present study", "TEST", 0, 17], ["mental health disorders", "PROBLEM", 95, 118], ["type 1 and type 2 diabetes", "PROBLEM", 136, 162], ["Methods", "TREATMENT", 192, 199], ["a cross-sectional study", "TEST", 207, 230], ["mental health disorders", "PROBLEM", 269, 292], ["diabetes", "PROBLEM", 329, 337], ["COVID", "TEST", 381, 386], ["pandemic", "PROBLEM", 390, 398], ["diabetes", "OBSERVATION", 154, 162]]], ["Electronic medical records were used to select patients with diabetes in a follow-up at the Endocrinology department of a public hospital in Southern Brazil.", [["diabetes", "DISEASE", 61, 69], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["diabetes", "PROBLEM", 61, 69]]], ["Patients who met the inclusion criteria received a telephone call for an invitation and application of the informed consent form (by electronic means or audio recording).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Participants who agreed to participate in this study received a second phone call for data capture.", [["Participants", "SPECIES", 0, 12], ["this study", "TEST", 42, 52]]], ["All the study procedures started 1 month after the disclosure of the national ordinance that standardizes the social distancing recommendation for risk groups, including diabetes, in Brazil.", [["diabetes", "DISEASE", 170, 178], ["All the study procedures", "TEST", 0, 24], ["diabetes", "PROBLEM", 170, 178]]], ["At the time of the evaluation, the state of Rio Grande do Sul followed the Contingency Plan and State Action for the Prevention of the Human Infection COVID-19, which restricted the functioning of establishments that offer essential services and which regulated the indication of an exceptional teleworking regime for people with respiratory diseases, immunosuppressed or with chronic disease, upon medical recommendation.", [["respiratory", "ANATOMY", 330, 341], ["respiratory diseases", "DISEASE", 330, 350], ["chronic disease", "DISEASE", 377, 392], ["Human", "ORGANISM", 135, 140], ["people", "ORGANISM", 318, 324], ["Human", "SPECIES", 135, 140], ["people", "SPECIES", 318, 324], ["Human Infection COVID-19", "SPECIES", 135, 159], ["the evaluation", "TEST", 15, 29], ["the Human Infection COVID", "PROBLEM", 131, 156], ["an exceptional teleworking regime", "TREATMENT", 280, 313], ["respiratory diseases", "PROBLEM", 330, 350], ["chronic disease", "PROBLEM", 377, 392], ["Infection", "OBSERVATION", 141, 150]]], ["All data were collected in 8 days in order to have the same pandemic time for all participants.", [["participants", "SPECIES", 82, 94], ["All data", "TEST", 0, 8]]], ["All contacts were made by telephone by trained researchers in order to preserve participants from social exposure.", [["participants", "SPECIES", 80, 92]]], ["All data collected during the phone calls were recorded directly on an electronic database validated by the study staff.Participants ::: MethodsPatients with type 1 and type 2 diabetes in a regular follow-up at the Endocrinology outpatient clinic, who attended a medical appointment in a one-year period, for type 2 diabetes, and three-year period for type 1 diabetes (from 2016 to 2019), were identified in an electronic database.", [["type 1 and type 2 diabetes", "DISEASE", 158, 184], ["type 2 diabetes", "DISEASE", 309, 324], ["type 1 diabetes", "DISEASE", 352, 367], ["Participants", "SPECIES", 120, 132], ["All data", "TEST", 0, 8], ["type 2 diabetes", "PROBLEM", 169, 184], ["type 2 diabetes", "PROBLEM", 309, 324], ["type 1 diabetes", "PROBLEM", 352, 367], ["diabetes", "OBSERVATION", 316, 324]]], ["Inclusion criteria involved age \u2265 18 years old, an hemoglobin A1c (HbA1c) test collected between January and March 2020 at the hospital laboratory, and having a valid telephone number in the electronic medical record.", [["hemoglobin A1c", "GENE_OR_GENE_PRODUCT", 51, 65], ["hemoglobin", "PROTEIN", 51, 61], ["HbA1c", "PROTEIN", 67, 72], ["an hemoglobin A1c", "TEST", 48, 65], ["HbA1c", "TEST", 67, 72]]], ["Patients who had any physical or cognitive impairment that prevented the application of the study questionnaires (such as dementia and severe hearing impairment), as well as patients who were hospitalized at the time of the study, were excluded.Variables and data sources ::: MethodsThe primary outcome assessed was the prevalence of minor psychiatric disorders among patients with type 1 and type 2 diabetes.", [["cognitive impairment", "DISEASE", 33, 53], ["dementia", "DISEASE", 122, 130], ["hearing impairment", "DISEASE", 142, 160], ["psychiatric disorders", "DISEASE", 340, 361], ["type 1 and type 2 diabetes", "DISEASE", 382, 408], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 174, 182], ["patients", "ORGANISM", 368, 376], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 368, 376], ["any physical or cognitive impairment", "PROBLEM", 17, 53], ["the study questionnaires", "TEST", 88, 112], ["dementia", "PROBLEM", 122, 130], ["severe hearing impairment)", "PROBLEM", 135, 161], ["the study", "TEST", 220, 229], ["Methods", "TREATMENT", 276, 283], ["minor psychiatric disorders", "PROBLEM", 334, 361], ["type 2 diabetes", "PROBLEM", 393, 408], ["diabetes", "OBSERVATION", 400, 408]]], ["Secondary outcomes included the prevalence of diabetes-related emotional distress, eating disorders and sleeping disorders at the moment of the study.Variables and data sources ::: MethodsFor the assessment of psychological distress, such as anxiety and depression, the Brazilian validated version of the Self Report Questionnaire-20 (SRQ 20) was used [26, 27].", [["diabetes", "DISEASE", 46, 54], ["emotional distress", "DISEASE", 63, 81], ["eating disorders", "DISEASE", 83, 99], ["sleeping disorders", "DISEASE", 104, 122], ["psychological distress", "DISEASE", 210, 232], ["anxiety", "DISEASE", 242, 249], ["depression", "DISEASE", 254, 264], ["diabetes", "PROBLEM", 46, 54], ["emotional distress", "PROBLEM", 63, 81], ["eating disorders", "PROBLEM", 83, 99], ["sleeping disorders", "PROBLEM", 104, 122], ["the study", "TEST", 140, 149], ["Methods", "TREATMENT", 181, 188], ["the assessment", "TEST", 192, 206], ["psychological distress", "PROBLEM", 210, 232], ["anxiety", "PROBLEM", 242, 249], ["depression", "PROBLEM", 254, 264], ["diabetes", "OBSERVATION", 46, 54]]], ["This 20-item questionnaire addresses questions related to physical and psychoemotional symptoms that may have been presented in the past 30 days, asking yes or no questions.", [["physical and psychoemotional symptoms", "PROBLEM", 58, 95]]], ["A positive screening for minor psychiatric disorders was considered when the survey scored greater than or equal to 7, which was considered a sign of current mental suffering.Variables and data sources ::: MethodsDiabetes-related emotional distress was assessed by the Brazilian validated version of the Problem Areas in Diabetes Scale (B-PAID), which is a 20-item questionnaire that contemplates the patient\u2019s perspective on the impact of certain issues related to diabetes on a 4-point response scale, with responses ranging from 0 = \u201cit is not a problem\u201d to 4 = \u201cit is a serious problem\u201d.", [["psychiatric disorders", "DISEASE", 31, 52], ["MethodsDiabetes", "CHEMICAL", 206, 221], ["emotional distress", "DISEASE", 230, 248], ["Diabetes", "DISEASE", 321, 329], ["diabetes", "DISEASE", 466, 474], ["patient", "ORGANISM", 401, 408], ["patient", "SPECIES", 401, 408], ["A positive screening", "TEST", 0, 20], ["minor psychiatric disorders", "PROBLEM", 25, 52], ["the survey", "TEST", 73, 83], ["current mental suffering", "PROBLEM", 150, 174], ["MethodsDiabetes", "TREATMENT", 206, 221], ["emotional distress", "PROBLEM", 230, 248], ["Diabetes Scale", "TREATMENT", 321, 335], ["certain issues", "PROBLEM", 440, 454], ["diabetes", "PROBLEM", 466, 474]]], ["The scores for each item were summed up, and then multiplied by 1.25 to generate a total score out of 100.", [["a total score", "TEST", 81, 94]]], ["Severe diabetes emotional distress was considered present when the score was greater than or equal to 40 [28, 29].Variables and data sources ::: MethodsThe prevalence of eating disorders was assessed by the Brazilian validated version of the Eating Attitudes Test (EAT-26).", [["diabetes emotional distress", "DISEASE", 7, 34], ["eating disorders", "DISEASE", 170, 186], ["Severe diabetes emotional distress", "PROBLEM", 0, 34], ["the score", "TEST", 63, 72], ["Methods", "TREATMENT", 145, 152], ["eating disorders", "PROBLEM", 170, 186], ["diabetes", "OBSERVATION", 7, 15]]], ["This survey addresses 26 issues related to eating habits and attitudes on a 3-point response scale, with responses ranging from 0 = \u201cnever\u201d to 3 = \u201calways\u201d.", [["a 3-point response scale", "TREATMENT", 74, 98]]], ["The presence of a significant eating disorder was considered when the score was greater than or equal to 20 [30, 31].Variables and data sources ::: MethodsTo assess sleep disorders, the Brazilian version of the Mini Sleep Questionnaire (MSQ), a 10-item scale, was used on a 7-point response scale, with responses ranging from 1 = \u201cnever\u201d to 7 = \u201calways\u201d.", [["eating disorder", "DISEASE", 30, 45], ["sleep disorders", "DISEASE", 165, 180], ["a significant eating disorder", "PROBLEM", 16, 45], ["the score", "TEST", 66, 75], ["Methods", "TREATMENT", 148, 155], ["sleep disorders", "PROBLEM", 165, 180], ["a 10-item scale", "TREATMENT", 243, 258], ["responses", "TEST", 303, 312], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["eating disorder", "OBSERVATION", 30, 45]]], ["A sleep disorder (moderate or severe) was considered when a score greater than or equal to 28 was present [32, 33].Variables and data sources ::: MethodsIt should be noted that the scales used to assess mental health disorders were designed for self-application.", [["sleep disorder", "DISEASE", 2, 16], ["A sleep disorder", "PROBLEM", 0, 16], ["moderate or severe)", "PROBLEM", 18, 37], ["a score", "TEST", 58, 65], ["Methods", "TREATMENT", 146, 153], ["mental health disorders", "PROBLEM", 203, 226], ["sleep disorder", "OBSERVATION", 2, 16], ["moderate", "OBSERVATION_MODIFIER", 18, 26], ["severe", "OBSERVATION_MODIFIER", 30, 36]]], ["To minimize this effect, the researchers strictly followed the steps of the questionnaires, repeating the alternative answers to each question only when requested to be as accurate as possible.Variables and data sources ::: MethodsDemographics and clinical data, such as the presence of comorbidities, continuous use medications, weight and height\u2014obtained from the last visit for calculating the body mass index (BMI) \u2013, and HbA1c (high-performance liquid chromatography method) data from the last 3 months were collected from electronic medical records.", [["body", "ANATOMY", 397, 401], ["body", "ORGANISM_SUBDIVISION", 397, 401], ["clinical data", "TEST", 248, 261], ["comorbidities", "PROBLEM", 287, 300], ["medications", "TREATMENT", 317, 328], ["weight", "TEST", 330, 336], ["calculating the body mass index", "TEST", 381, 412], ["BMI", "TEST", 414, 417], ["HbA1c", "TEST", 426, 431]]], ["Cardiovascular disease was considered present if there was a previous history of coronary heart disease, stroke, or heart failure registered in medical records.", [["Cardiovascular", "ANATOMY", 0, 14], ["coronary", "ANATOMY", 81, 89], ["heart", "ANATOMY", 90, 95], ["heart", "ANATOMY", 116, 121], ["Cardiovascular disease", "DISEASE", 0, 22], ["coronary heart disease", "DISEASE", 81, 103], ["stroke", "DISEASE", 105, 111], ["heart failure", "DISEASE", 116, 129], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 81, 95], ["heart", "ORGAN", 116, 121], ["Cardiovascular disease", "PROBLEM", 0, 22], ["coronary heart disease", "PROBLEM", 81, 103], ["stroke", "PROBLEM", 105, 111], ["heart failure", "PROBLEM", 116, 129], ["disease", "OBSERVATION", 15, 22], ["coronary heart", "ANATOMY", 81, 95], ["disease", "OBSERVATION", 96, 103], ["stroke", "OBSERVATION", 105, 111], ["heart", "ANATOMY", 116, 121], ["failure", "OBSERVATION", 122, 129]]], ["The presence of diabetes complications was also documented according to medical records.", [["diabetes complications", "DISEASE", 16, 38], ["diabetes complications", "PROBLEM", 16, 38], ["diabetes", "OBSERVATION", 16, 24]]], ["The presence of retinopathy was considered based on the last registered fundus examination.", [["fundus", "ANATOMY", 72, 78], ["retinopathy", "DISEASE", 16, 27], ["fundus", "MULTI-TISSUE_STRUCTURE", 72, 78], ["retinopathy", "PROBLEM", 16, 27], ["the last registered fundus examination", "TEST", 52, 90], ["retinopathy", "OBSERVATION", 16, 27]]], ["For neuropathy, it was considered the presence of a documented diagnosis of previous neuropathy or a monofilament 10 g test altered in the last medical appointment.", [["neuropathy", "DISEASE", 4, 14], ["neuropathy", "DISEASE", 85, 95], ["neuropathy", "PROBLEM", 4, 14], ["previous neuropathy", "PROBLEM", 76, 95], ["a monofilament", "TREATMENT", 99, 113], ["neuropathy", "OBSERVATION", 4, 14], ["neuropathy", "OBSERVATION", 85, 95]]], ["For diabetic nephropathy, it was considered the presence of microalbuminuria or chronic kidney disease in which the etiology was attributed to diabetes in the medical records.Variables and data sources ::: MethodsSome clinical data, such as the use of antidepressant or anxiolytic drugs and previous diagnosis of psychiatric disorders, were obtained from both electronic medical records and checked directly with the patients during the phone calls.", [["kidney", "ANATOMY", 88, 94], ["diabetic nephropathy", "DISEASE", 4, 24], ["microalbuminuria", "DISEASE", 60, 76], ["chronic kidney disease", "DISEASE", 80, 102], ["diabetes", "DISEASE", 143, 151], ["antidepressant", "CHEMICAL", 252, 266], ["psychiatric disorders", "DISEASE", 313, 334], ["kidney", "ORGAN", 88, 94], ["patients", "ORGANISM", 417, 425], ["patients", "SPECIES", 417, 425], ["diabetic nephropathy", "PROBLEM", 4, 24], ["microalbuminuria", "PROBLEM", 60, 76], ["chronic kidney disease", "PROBLEM", 80, 102], ["diabetes", "PROBLEM", 143, 151], ["antidepressant", "TREATMENT", 252, 266], ["anxiolytic drugs", "TREATMENT", 270, 286], ["psychiatric disorders", "PROBLEM", 313, 334], ["diabetic", "OBSERVATION_MODIFIER", 4, 12], ["nephropathy", "OBSERVATION", 13, 24], ["microalbuminuria", "OBSERVATION", 60, 76], ["chronic", "OBSERVATION_MODIFIER", 80, 87], ["kidney", "ANATOMY", 88, 94], ["disease", "OBSERVATION", 95, 102], ["diabetes", "OBSERVATION", 143, 151]]], ["Previous diagnosis of common mental disorder was considered if there was a previous or current diagnosis of depressive episode, major depressive disorder or anxiety disorders.", [["common mental disorder", "DISEASE", 22, 44], ["depressive episode", "DISEASE", 108, 126], ["depressive disorder", "DISEASE", 134, 153], ["anxiety disorders", "DISEASE", 157, 174], ["common mental disorder", "PROBLEM", 22, 44], ["depressive episode", "PROBLEM", 108, 126], ["major depressive disorder", "PROBLEM", 128, 153], ["anxiety disorders", "PROBLEM", 157, 174], ["common", "OBSERVATION_MODIFIER", 22, 28], ["mental disorder", "OBSERVATION", 29, 44]]], ["Compliance with the recommendation of social distance was questioned directly to the participants according to the follow: (1) total social distancing was considered when the patient did not leave the house under any circumstances; (2) partial social distancing was considered when the patient left the house only for basic activities (such as going to the market and pharmacy); or (3) no social distancing, when the patient maintained regular activities.Variables and data sources ::: MethodsThe institutional ethics committee approved the study protocol (Number 4.029.368), and all authors signed the confidentiality document for data use.Sample size ::: MethodsThe sample size was calculated for a prevalence survey with finite population correction.", [["patient", "ORGANISM", 175, 182], ["patient", "ORGANISM", 286, 293], ["patient", "ORGANISM", 417, 424], ["participants", "SPECIES", 85, 97], ["patient", "SPECIES", 175, 182], ["patient", "SPECIES", 286, 293], ["patient", "SPECIES", 417, 424], ["Methods", "TREATMENT", 486, 493], ["the study protocol", "TEST", 537, 555], ["Methods", "TREATMENT", 657, 664], ["The sample size", "TEST", 664, 679], ["finite population correction", "TREATMENT", 724, 752], ["size", "OBSERVATION_MODIFIER", 648, 652], ["size", "OBSERVATION_MODIFIER", 675, 679]]], ["Considering that the prevalence of anxiety and depression disorders among patients with type 1 was 17.6% and type 2 diabetes was 16%, we considered a mean prevalence known of 17%.", [["anxiety", "DISEASE", 35, 42], ["depression disorders", "DISEASE", 47, 67], ["diabetes", "DISEASE", 116, 124], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["anxiety", "PROBLEM", 35, 42], ["depression disorders", "PROBLEM", 47, 67], ["type 2 diabetes", "PROBLEM", 109, 124], ["a mean prevalence", "TEST", 148, 165]]], ["The calculation was performed taking into account that in 2019 there were 16.8 million individuals with diabetes in Brazil.", [["diabetes", "DISEASE", 104, 112], ["The calculation", "TEST", 0, 15], ["diabetes", "PROBLEM", 104, 112]]], ["The number required for an analysis with 5% accuracy and 85% confidence level was 117 patients [4, 34, 35].", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["an analysis", "TEST", 24, 35], ["5% accuracy", "TEST", 41, 52], ["confidence level", "TEST", 61, 77]]], ["The number of patients included with type 1 diabetes and type 2 diabetes was determined randomly.", [["type 1 diabetes", "DISEASE", 37, 52], ["type 2 diabetes", "DISEASE", 57, 72], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["type 1 diabetes", "PROBLEM", 37, 52], ["type 2 diabetes", "PROBLEM", 57, 72], ["diabetes", "OBSERVATION", 44, 52], ["diabetes", "OBSERVATION", 64, 72]]], ["The limitations imposed by the current pandemic and the recommendation of social distancing to patients with diabetes added difficulty in approaching and contacting a greater number of patients, which motivated the choice of the 85% confidence level.Statistical methods ::: MethodsAnalyses were performed using SPSS Statistics 20.", [["diabetes", "DISEASE", 109, 117], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 185, 193], ["diabetes", "PROBLEM", 109, 117], ["MethodsAnalyses", "TEST", 274, 289], ["SPSS Statistics", "TEST", 311, 326]]], ["Descriptive data are presented as mean and standard deviation (SD) or percentages.", [["standard deviation (SD) or percentages", "PROBLEM", 43, 81]]], ["The data distribution was analysed and, since it had a normal distribution, parametric tests were used.", [["The data distribution", "TEST", 0, 21], ["parametric tests", "TEST", 76, 92], ["normal", "OBSERVATION", 55, 61]]], ["In order to evaluate possible differences according to diabetes type, statistical analyses included unpaired t-test for continuous variables and \u03c72 test for categorical variables.", [["diabetes", "DISEASE", 55, 63], ["diabetes type", "PROBLEM", 55, 68], ["statistical analyses", "TEST", 70, 90], ["unpaired t-test", "TEST", 100, 115], ["continuous variables", "TEST", 120, 140], ["\u03c72 test", "TEST", 145, 152], ["categorical variables", "TEST", 157, 178]]], ["The primary outcome (minor psychiatric disorders) was then evaluated as the dependent variable in a multivariable logistic regression model designed to control for possible confounders in the interaction between the primary outcome and the diabetes type.", [["psychiatric disorders", "DISEASE", 27, 48], ["diabetes", "DISEASE", 240, 248], ["minor psychiatric disorders", "PROBLEM", 21, 48], ["the diabetes type", "PROBLEM", 236, 253]]], ["An \u03b1 level of \u2264 0.05 was used to determine statistical significance.", [["An \u03b1 level", "TEST", 0, 10]]], ["This study followed the STROBE statement for the reporting.Participant characteristics ::: ResultsA total of 245 potentially eligible patients were identified, and 146 were randomly recruited to participate in the study.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["This study", "TEST", 0, 10], ["the study", "TEST", 210, 219]]], ["The recruitment stopped after inclusion of the planned sample size, when 120 individuals, 52 with type 1 and 68 with type 2 diabetes, agreed to participate and provided informed consent (see Additional file 1: Figure S1).", [["type 2 diabetes", "DISEASE", 117, 132], ["type 2 diabetes", "PROBLEM", 117, 132], ["recruitment", "OBSERVATION_MODIFIER", 4, 15]]], ["Age, sex, diabetes duration, and HbA1c levels did not differ by enrollment status (data not shown).Participant characteristics ::: ResultsOverall (n = 120), participants had a mean age of 54.8 \u00b1 14.4 years old; 55.8% were female, 85.8% white and 76.7% overweight/obese.", [["diabetes", "DISEASE", 10, 18], ["participants", "SPECIES", 157, 169], ["diabetes duration", "PROBLEM", 10, 27], ["HbA1c levels", "TEST", 33, 45], ["obese", "PROBLEM", 263, 268], ["obese", "OBSERVATION", 263, 268]]], ["The mean diabetes duration was 21.8 \u00b1 10.9 years and the HbA1c value was 9.0 \u00b1 1.6% (75 \u00b1 17.5 mmol/mol) (see Table 1).", [["diabetes", "DISEASE", 9, 17], ["The mean diabetes duration", "TEST", 0, 26], ["the HbA1c value", "TEST", 53, 68]]], ["Patients with type 2 diabetes were older (62.3 \u00b1 9.1 vs. 45.0 \u00b1 14.2 years of age; p < 0.001), had a greater racial representation (22.1% vs. 3.8% not white; p = 0.02) and a higher prevalence of overweight and obesity (95.6% vs. 51.9%; p < 0.001), when compared with patients with type 1 diabetes.", [["type 2 diabetes", "DISEASE", 14, 29], ["overweight", "DISEASE", 195, 205], ["obesity", "DISEASE", 210, 217], ["type 1 diabetes", "DISEASE", 281, 296], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 267, 275], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 267, 275], ["type 2 diabetes", "PROBLEM", 14, 29], ["a greater racial representation", "PROBLEM", 99, 130], ["white", "TEST", 151, 156], ["overweight", "PROBLEM", 195, 205], ["obesity", "PROBLEM", 210, 217], ["type 1 diabetes", "PROBLEM", 281, 296], ["greater", "OBSERVATION_MODIFIER", 101, 108], ["obesity", "OBSERVATION", 210, 217], ["diabetes", "OBSERVATION", 288, 296]]], ["Although younger, type 1 diabetes patients had a longer diabetes duration (25.2 \u00b1 11.5 vs. 19.2 \u00b1 9.7 years; p < 0.01).", [["diabetes", "DISEASE", 25, 33], ["diabetes", "DISEASE", 56, 64], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["type 1 diabetes", "PROBLEM", 18, 33], ["a longer diabetes duration", "PROBLEM", 47, 73]]], ["Both groups were comparable with respect to HbA1c levels and presence of diabetes complications.Participant characteristics ::: ResultsFrom the whole group, 9 patients (7 type 1, and 3 type 2 diabetes) had some previous serious psychiatric diagnosis, which were not considered as common mental disorders in analysis.", [["diabetes complications", "DISEASE", 73, 95], ["diabetes", "DISEASE", 192, 200], ["psychiatric", "DISEASE", 228, 239], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["HbA1c levels", "TEST", 44, 56], ["diabetes complications", "PROBLEM", 73, 95], ["3 type 2 diabetes", "PROBLEM", 183, 200], ["common mental disorders in analysis", "PROBLEM", 280, 315], ["diabetes", "OBSERVATION", 73, 81]]], ["Among patients with type 1 diabetes, 3 had a diagnosis of schizophrenia; 1 bipolar mood disorder; 1 borderline personality disorder; and 1 self-mutilation history.", [["type 1 diabetes", "DISEASE", 20, 35], ["schizophrenia", "DISEASE", 58, 71], ["bipolar mood disorder", "DISEASE", 75, 96], ["borderline personality disorder", "DISEASE", 100, 131], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["type 1 diabetes", "PROBLEM", 20, 35], ["schizophrenia", "PROBLEM", 58, 71], ["1 bipolar mood disorder", "PROBLEM", 73, 96], ["1 borderline personality disorder", "PROBLEM", 98, 131], ["diabetes", "OBSERVATION", 27, 35], ["schizophrenia", "OBSERVATION", 58, 71]]], ["Among patients with type 2 diabetes, 1 patient had a previous diagnosis of schizophrenia and 1 had a diagnosis of obsessive\u2013compulsive disorder.", [["type 2 diabetes", "DISEASE", 20, 35], ["schizophrenia", "DISEASE", 75, 88], ["obsessive\u2013compulsive disorder", "DISEASE", 114, 143], ["patients", "ORGANISM", 6, 14], ["patient", "ORGANISM", 39, 46], ["patients", "SPECIES", 6, 14], ["patient", "SPECIES", 39, 46], ["type 2 diabetes", "PROBLEM", 20, 35], ["schizophrenia", "PROBLEM", 75, 88], ["obsessive\u2013compulsive disorder", "PROBLEM", 114, 143], ["schizophrenia", "OBSERVATION", 75, 88], ["obsessive\u2013compulsive disorder", "OBSERVATION", 114, 143]]], ["There was no difference between type 1 and type 2 diabetes regarding the presence of previous common mental disorders.", [["diabetes", "DISEASE", 50, 58], ["difference between type 1", "PROBLEM", 13, 38], ["type 2 diabetes", "PROBLEM", 43, 58], ["previous common mental disorders", "PROBLEM", 85, 117], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["diabetes", "OBSERVATION", 50, 58], ["common", "OBSERVATION_MODIFIER", 94, 100], ["mental disorders", "OBSERVATION", 101, 117]]], ["Regarding social distancing, in total, 42.5% of patients were following the guidance of total isolation, 50% were on partial social distancing (leaving home only for basic activities) and only 7.5% were not on doing any type of social distancing (keeping regular daily activities).", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["total isolation", "TREATMENT", 88, 103]]], ["There was no difference between groups with regard to social distancing.Survey results ::: ResultsIn the studied participants, 93.3% (94.2% in type 1 and 92.6% in type 2 diabetes, p = 0.73) had some sign of a psychiatric disorder, which was assessed by a positive screening in at least one of all the specific scales measured in this study (minor psychiatric disorders, diabetes-related emotional distress, and eating and sleeping disorders).Survey results ::: ResultsRegarding the primary outcome, the presence of psychological distress, that measure depressive and anxiety symptoms, 44.2% of patients had a positive screening based on the SRQ 20 (see Fig. 1).", [["diabetes", "DISEASE", 170, 178], ["psychiatric disorder", "DISEASE", 209, 229], ["psychiatric disorders", "DISEASE", 347, 368], ["diabetes", "DISEASE", 370, 378], ["emotional distress", "DISEASE", 387, 405], ["eating and sleeping disorders", "DISEASE", 411, 440], ["psychological distress", "DISEASE", 515, 537], ["depressive and anxiety", "DISEASE", 552, 574], ["patients", "ORGANISM", 594, 602], ["SRQ 20", "DNA", 641, 647], ["participants", "SPECIES", 113, 125], ["patients", "SPECIES", 594, 602], ["type", "TEST", 143, 147], ["type 2 diabetes", "PROBLEM", 163, 178], ["p", "TEST", 180, 181], ["a psychiatric disorder", "PROBLEM", 207, 229], ["a positive screening", "TEST", 253, 273], ["this study", "TEST", 329, 339], ["minor psychiatric disorders", "PROBLEM", 341, 368], ["diabetes", "PROBLEM", 370, 378], ["emotional distress", "PROBLEM", 387, 405], ["sleeping disorders", "PROBLEM", 422, 440], ["psychological distress", "PROBLEM", 515, 537], ["depressive and anxiety symptoms", "PROBLEM", 552, 583], ["a positive screening", "TEST", 607, 627], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["psychiatric disorder", "OBSERVATION", 209, 229]]], ["In the type 1 diabetes group, this prevalence was 32.7%, while in the group with type 2 diabetes, the prevalence of psychological distress was higher, 52.9% (p = 0.03).", [["type 1 diabetes", "DISEASE", 7, 22], ["type 2 diabetes", "DISEASE", 81, 96], ["psychological distress", "DISEASE", 116, 138], ["type 2 diabetes", "PROBLEM", 81, 96], ["psychological distress", "PROBLEM", 116, 138], ["diabetes", "OBSERVATION", 14, 22], ["diabetes", "OBSERVATION", 88, 96]]], ["The question number 17 of the SRQ 20 (\u201chas the thought of ending your life been on your mind\u201c) addresses suicidal ideation, and, overall, 6.7% of patients had a positive response to this item.", [["suicidal ideation", "DISEASE", 105, 122], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["suicidal ideation", "PROBLEM", 105, 122]]], ["Also, considering all the demographic and clinical differences between type 1 and type 2 diabetes patients showed in Table 1, we performed a multivariable logistic regression to evaluate the impact of variables of clinical interest on the interaction between the primary outcome (minor psychiatric disorders) and the type of diabetes (see Table 2).", [["diabetes", "DISEASE", 89, 97], ["psychiatric disorders", "DISEASE", 286, 307], ["diabetes", "DISEASE", 325, 333], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["type 2 diabetes", "PROBLEM", 82, 97], ["a multivariable logistic regression", "PROBLEM", 139, 174], ["minor psychiatric disorders", "PROBLEM", 280, 307], ["diabetes", "PROBLEM", 325, 333]]], ["We included into the model; age, sex, race/ethnicity, age of diabetes diagnosis, HbA1c, BMI, previous common mental disorders, and social distancing.", [["diabetes", "DISEASE", 61, 69], ["common mental disorders", "DISEASE", 102, 125], ["diabetes diagnosis", "PROBLEM", 61, 79], ["HbA1c", "TEST", 81, 86], ["BMI", "PROBLEM", 88, 91], ["previous common mental disorders", "PROBLEM", 93, 125]]], ["The adjusted Odds Ratio and its 95% confidence interval for the interaction between minor psychiatric disorders and type 2 diabetes was 7.60 (1.97\u201329.34).Survey results ::: ResultsSecondary outcomes included the prevalence of diabetes-related emotional distress, eating disorders and sleeping disorders.", [["psychiatric disorders", "DISEASE", 90, 111], ["type 2 diabetes", "DISEASE", 116, 131], ["diabetes", "DISEASE", 226, 234], ["emotional distress", "DISEASE", 243, 261], ["eating disorders", "DISEASE", 263, 279], ["sleeping disorders", "DISEASE", 284, 302], ["Ratio", "TEST", 18, 23], ["minor psychiatric disorders", "PROBLEM", 84, 111], ["type 2 diabetes", "PROBLEM", 116, 131], ["diabetes", "PROBLEM", 226, 234], ["emotional distress", "PROBLEM", 243, 261], ["eating disorders", "PROBLEM", 263, 279], ["sleeping disorders", "PROBLEM", 284, 302], ["diabetes", "OBSERVATION", 226, 234]]], ["The presence of diabetes-related emotional distress was found in 29.2% of patients; eating disorders in 75.8%; and moderate/severe sleeping disorders in 77.5% of patients (Fig. 1).", [["diabetes", "DISEASE", 16, 24], ["emotional distress", "DISEASE", 33, 51], ["eating disorders", "DISEASE", 84, 100], ["sleeping disorders", "DISEASE", 131, 149], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 162, 170], ["diabetes", "PROBLEM", 16, 24], ["emotional distress", "PROBLEM", 33, 51], ["eating disorders", "PROBLEM", 84, 100], ["moderate/severe sleeping disorders", "PROBLEM", 115, 149], ["diabetes", "OBSERVATION", 16, 24], ["moderate", "OBSERVATION_MODIFIER", 115, 123], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["sleeping disorders", "OBSERVATION", 131, 149]]], ["There was no significant difference in these outcomes between patients with type 1 and type 2 diabetes.", [["type 1 and type 2 diabetes", "DISEASE", 76, 102], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["type 1 and type 2 diabetes", "PROBLEM", 76, 102], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["diabetes", "OBSERVATION", 94, 102]]], ["In the type 1 diabetes group, the prevalence of diabetes-related emotional distress was 28.8% vs. 29.4% in the type 2 diabetes group (p = 0.95).", [["type 1 diabetes", "DISEASE", 7, 22], ["diabetes", "DISEASE", 48, 56], ["emotional distress", "DISEASE", 65, 83], ["diabetes", "DISEASE", 118, 126], ["diabetes", "PROBLEM", 48, 56], ["emotional distress", "PROBLEM", 65, 83], ["diabetes", "OBSERVATION", 14, 22], ["diabetes", "OBSERVATION", 48, 56]]], ["For the eating disorders evaluation, 78.8% of patients with type 1 diabetes showed a positive screening for eating disorders vs. 73.5% of those living with type 2 diabetes (p = 0.50).", [["eating disorders", "DISEASE", 8, 24], ["type 1 diabetes", "DISEASE", 60, 75], ["eating disorders", "DISEASE", 108, 124], ["type 2 diabetes", "DISEASE", 156, 171], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["the eating disorders", "PROBLEM", 4, 24], ["evaluation", "TEST", 25, 35], ["type 1 diabetes", "PROBLEM", 60, 75], ["eating disorders", "PROBLEM", 108, 124], ["type 2 diabetes", "PROBLEM", 156, 171]]], ["In the analysis of sleep pattern, 76.9% of patients with type 1 diabetes showed signs of moderate/severe sleep disorder vs. 77.9% of those living with type 2 diabetes (p = 0.89).", [["type 1 diabetes", "DISEASE", 57, 72], ["sleep disorder", "DISEASE", 105, 119], ["type 2 diabetes", "DISEASE", 151, 166], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["sleep pattern", "TEST", 19, 32], ["type 1 diabetes", "PROBLEM", 57, 72], ["moderate/severe sleep disorder", "PROBLEM", 89, 119], ["type 2 diabetes", "PROBLEM", 151, 166], ["moderate", "OBSERVATION_MODIFIER", 89, 97], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["sleep disorder", "OBSERVATION", 105, 119]]], ["We also performed a multivariable logistic regression to evaluate the impact of BMI on the interaction between the positive screening for eating and sleeping disorders and the type of diabetes, and no significant interaction was identified (data not shown).Discussion and conclusionsIn this study, we sought to investigate psychological characteristics of people living with diabetes after 1 month of social distancing recommendations in Brazil.", [["sleeping disorders", "DISEASE", 149, 167], ["diabetes", "DISEASE", 184, 192], ["diabetes", "DISEASE", 375, 383], ["people", "ORGANISM", 356, 362], ["people", "SPECIES", 356, 362], ["a multivariable logistic regression", "PROBLEM", 18, 53], ["BMI", "PROBLEM", 80, 83], ["the positive screening", "TEST", 111, 133], ["sleeping disorders", "PROBLEM", 149, 167], ["diabetes", "PROBLEM", 184, 192], ["significant interaction", "PROBLEM", 201, 224], ["this study", "TEST", 286, 296], ["diabetes", "PROBLEM", 375, 383], ["diabetes", "OBSERVATION", 184, 192]]], ["We found a high prevalence of significant psychological distress among patients with type 1 and type 2 diabetes, with approximately 93% of the studied patients showing signs of current mental suffering in some psychological specific area.", [["psychological distress", "DISEASE", 42, 64], ["type 1 and type 2 diabetes", "DISEASE", 85, 111], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 151, 159], ["significant psychological distress", "PROBLEM", 30, 64], ["type 1", "PROBLEM", 85, 91], ["type 2 diabetes", "PROBLEM", 96, 111], ["current mental suffering", "PROBLEM", 177, 201], ["high prevalence", "OBSERVATION_MODIFIER", 11, 26], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["psychological distress", "OBSERVATION", 42, 64], ["diabetes", "OBSERVATION", 103, 111]]], ["Almost half of the patients had a positive screening for psychological distress, such as anxiety and depression, with a significant greater tendency in patients with type 2 diabetes.", [["psychological distress", "DISEASE", 57, 79], ["anxiety", "DISEASE", 89, 96], ["depression", "DISEASE", 101, 111], ["type 2 diabetes", "DISEASE", 166, 181], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 152, 160], ["psychological distress", "PROBLEM", 57, 79], ["anxiety", "PROBLEM", 89, 96], ["depression", "PROBLEM", 101, 111], ["a significant greater tendency", "PROBLEM", 118, 148], ["type 2 diabetes", "PROBLEM", 166, 181], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["greater", "OBSERVATION_MODIFIER", 132, 139], ["tendency", "OBSERVATION_MODIFIER", 140, 148], ["diabetes", "OBSERVATION", 173, 181]]], ["The presence of diabetes-related emotional distress was present in only 29.2% of the interviewees, which does not appear to directly justify the high prevalence of psychiatric disorders found in this study.", [["diabetes", "DISEASE", 16, 24], ["emotional distress", "DISEASE", 33, 51], ["psychiatric disorders", "DISEASE", 164, 185], ["diabetes", "PROBLEM", 16, 24], ["emotional distress", "PROBLEM", 33, 51], ["psychiatric disorders", "PROBLEM", 164, 185], ["this study", "TEST", 195, 205], ["diabetes", "OBSERVATION", 16, 24]]], ["Approximately three out of four patients had a positive screening for eating and sleeping disorders, which may reflect the systemic repercussion of a latent anxiety condition.Discussion and conclusionsIt is well documented that depression and anxiety are more prevalent among patients with diabetes when compared to general population [36\u201338].", [["eating and sleeping disorders", "DISEASE", 70, 99], ["anxiety", "DISEASE", 157, 164], ["depression", "DISEASE", 228, 238], ["anxiety", "DISEASE", 243, 250], ["diabetes", "DISEASE", 290, 298], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 276, 284], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 276, 284], ["sleeping disorders", "PROBLEM", 81, 99], ["a latent anxiety condition", "PROBLEM", 148, 174], ["depression", "PROBLEM", 228, 238], ["anxiety", "PROBLEM", 243, 250], ["diabetes", "PROBLEM", 290, 298], ["depression", "OBSERVATION", 228, 238]]], ["An epidemiological study by Meurs et al. evaluating more than 90,000 patients found an 80% increased risk of depression and anxiety in patients with diabetes [36].", [["depression", "DISEASE", 109, 119], ["anxiety", "DISEASE", 124, 131], ["diabetes", "DISEASE", 149, 157], ["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 135, 143], ["An epidemiological study", "TEST", 0, 24], ["depression", "PROBLEM", 109, 119], ["anxiety", "PROBLEM", 124, 131], ["diabetes", "PROBLEM", 149, 157], ["depression", "OBSERVATION", 109, 119]]], ["The data described in the literature shows a co-prevalence of diabetes and depression ranging from 17.6 to 21% [39, 40].", [["diabetes", "DISEASE", 62, 70], ["depression", "DISEASE", 75, 85], ["The data", "TEST", 0, 8], ["diabetes", "PROBLEM", 62, 70], ["depression", "PROBLEM", 75, 85], ["diabetes", "OBSERVATION", 62, 70]]], ["In Brazil, the prevalence of depression in patients with diabetes, in usual situations, appears to be similar to that found in other countries, reaching 22% in the most recently published study [41].", [["depression", "DISEASE", 29, 39], ["diabetes", "DISEASE", 57, 65], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["depression", "PROBLEM", 29, 39], ["diabetes", "PROBLEM", 57, 65], ["depression", "OBSERVATION", 29, 39], ["diabetes", "OBSERVATION", 57, 65]]], ["Considering the current scenario, a study by Huang et al. in China showed a prevalence of anxiety and depression in the general population of 35% and 20%, respectively [42].", [["anxiety", "DISEASE", 90, 97], ["depression", "DISEASE", 102, 112], ["a study", "TEST", 34, 41], ["anxiety", "PROBLEM", 90, 97], ["depression", "PROBLEM", 102, 112]]], ["This makes us reflect about the possible impact that 1 month of social distancing, associated with all the stressors related to the current pandemic, has on this group of patients.", [["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179]]], ["Health appointments not fully available, difficulties in obtaining diabetes medications and supplies, besides the lack of scientific information regarding the real relationship between COVID-19 and diabetes, may have contributed to the high prevalence of psychological distress found in this study.", [["diabetes", "DISEASE", 67, 75], ["diabetes", "DISEASE", 198, 206], ["psychological distress", "DISEASE", 255, 277], ["diabetes medications", "TREATMENT", 67, 87], ["COVID", "TEST", 185, 190], ["diabetes", "PROBLEM", 198, 206], ["psychological distress", "PROBLEM", 255, 277], ["this study", "TEST", 287, 297]]], ["The possible vulnerability intrinsic to diabetes seems to be exacerbated in the current scenario.Discussion and conclusionsIt is important to notice that the COVID-19 pandemic may impact patients with type 1 and type 2 diabetes differently.", [["diabetes", "DISEASE", 40, 48], ["type 1 and type 2 diabetes", "DISEASE", 201, 227], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["diabetes", "PROBLEM", 40, 48], ["type 2 diabetes differently", "PROBLEM", 212, 239], ["possible", "UNCERTAINTY", 4, 12], ["diabetes", "OBSERVATION", 40, 48], ["seems to be", "UNCERTAINTY", 49, 60], ["exacerbated", "OBSERVATION_MODIFIER", 61, 72]]], ["There is a tendency for a higher prevalence of depression in patients with type 2 diabetes when compared to those with type 1 diabetes in normal situations.", [["depression", "DISEASE", 47, 57], ["type 2 diabetes", "DISEASE", 75, 90], ["type 1 diabetes", "DISEASE", 119, 134], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["a tendency", "PROBLEM", 9, 19], ["depression", "PROBLEM", 47, 57], ["type 2 diabetes", "PROBLEM", 75, 90], ["type 1 diabetes", "PROBLEM", 119, 134], ["tendency", "OBSERVATION_MODIFIER", 11, 19], ["depression", "OBSERVATION", 47, 57], ["diabetes", "OBSERVATION", 82, 90], ["diabetes", "OBSERVATION", 126, 134], ["normal situations", "OBSERVATION", 138, 155]]], ["A study performed by Bak et al. showed that patients with type 2 diabetes had almost twice the prevalence of depression symptoms when compared to those with type 1 diabetes [43].", [["type 2 diabetes", "DISEASE", 58, 73], ["depression", "DISEASE", 109, 119], ["type 1 diabetes", "DISEASE", 157, 172], ["Bak", "GENE_OR_GENE_PRODUCT", 21, 24], ["patients", "ORGANISM", 44, 52], ["Bak", "PROTEIN", 21, 24], ["patients", "SPECIES", 44, 52], ["A study", "TEST", 0, 7], ["type 2 diabetes", "PROBLEM", 58, 73], ["depression symptoms", "PROBLEM", 109, 128], ["type 1 diabetes", "PROBLEM", 157, 172]]], ["In addition, intrinsic differences in types of diabetes can be affected in different ways during the period of social distancing.", [["diabetes", "DISEASE", 47, 55], ["diabetes", "PROBLEM", 47, 55], ["intrinsic", "OBSERVATION_MODIFIER", 13, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34], ["diabetes", "OBSERVATION", 47, 55]]], ["In type 1 diabetes, which requires precision in terms of the amount and timing of insulin administration, having more time at home could result in improved adherence and disease control.", [["type 1 diabetes", "DISEASE", 3, 18], ["insulin", "GENE_OR_GENE_PRODUCT", 82, 89], ["type 1 diabetes", "PROBLEM", 3, 18], ["insulin administration", "TREATMENT", 82, 104], ["disease control", "TREATMENT", 170, 185], ["type 1", "OBSERVATION_MODIFIER", 3, 9], ["diabetes", "OBSERVATION", 10, 18]]], ["On the other hand, in type 2 diabetes, the maintenance of healthy habits, including physical exercise and balanced diet, can be greatly impaired during quarantine.", [["type 2 diabetes", "DISEASE", 22, 37], ["type 2 diabetes", "PROBLEM", 22, 37], ["diabetes", "OBSERVATION", 29, 37]]], ["These possible differences can have a positive or negative impact in terms of glycemic control, contributing differently to the appearance of psychological distress during the COVID-19 pandemic.", [["psychological distress", "DISEASE", 142, 164], ["glycemic control", "TREATMENT", 78, 94], ["psychological distress", "PROBLEM", 142, 164], ["the COVID", "TEST", 172, 181], ["pandemic", "PROBLEM", 185, 193]]], ["It should be noted that these differences are still hypothetical, requiring specific studies for a better understanding.Discussion and conclusionsBesides the high prevalence of psychological distress, our findings highlight the observation that the risk of suicide may be increased during the period of social distancing by COVID-19 in patients with diabetes.", [["psychological distress", "DISEASE", 177, 199], ["COVID-19", "CHEMICAL", 324, 332], ["diabetes", "DISEASE", 350, 358], ["patients", "ORGANISM", 336, 344], ["patients", "SPECIES", 336, 344], ["specific studies", "TEST", 76, 92], ["psychological distress", "PROBLEM", 177, 199], ["suicide", "PROBLEM", 257, 264], ["diabetes", "PROBLEM", 350, 358], ["high prevalence", "OBSERVATION_MODIFIER", 158, 173], ["increased", "OBSERVATION_MODIFIER", 272, 281]]], ["In the studied cohort, almost 7% of patients expressed positive responses to the question \u201chas the thought of ending your life been on your mind?\u201d in the SRQ 20.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44]]], ["It is important to notice that the questionnaires were applied in a single phone call interview generated by researchers who had no bond or previous connection with participants.", [["participants", "SPECIES", 165, 177]]], ["Our findings are compatible with what was exposed by Gunnel et al., which stated that the pandemic would cause distress and leave many people vulnerable to mental health problems and suicidal behavior.", [["suicidal behavior", "DISEASE", 183, 200], ["people", "ORGANISM", 135, 141], ["people", "SPECIES", 135, 141], ["distress", "PROBLEM", 111, 119], ["mental health problems", "PROBLEM", 156, 178], ["suicidal behavior", "PROBLEM", 183, 200], ["compatible with", "UNCERTAINTY", 17, 32]]], ["This reinforces the importance of the active and ongoing participation of mental health professionals in policy task forces during this critical period [45].Discussion and conclusionsOur study also showed a high prevalence of eating disorders among patients with diabetes after 1 month of social distancing.", [["eating disorders", "DISEASE", 226, 242], ["diabetes", "DISEASE", 263, 271], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["Our study", "TEST", 183, 192], ["eating disorders", "PROBLEM", 226, 242], ["diabetes", "PROBLEM", 263, 271], ["high prevalence", "OBSERVATION_MODIFIER", 207, 222]]], ["Literature data show that approximately 14% to 35% of patients with diabetes have a positive screening for eating disorders when assessed by EAT-26, a percentage much lower than the one found in our cohort [46, 47].", [["diabetes", "DISEASE", 68, 76], ["eating disorders", "DISEASE", 107, 123], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["Literature data", "TEST", 0, 15], ["diabetes", "PROBLEM", 68, 76], ["eating disorders", "PROBLEM", 107, 123]]], ["A pilot study by Fernandez-Aranda et al. demonstrated that, after just 2 weeks of confinement, almost 38% of patients reported symptoms related to eating disorders.", [["eating disorders", "DISEASE", 147, 163], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["A pilot study", "TEST", 0, 13], ["patients reported symptoms", "PROBLEM", 109, 135], ["eating disorders", "PROBLEM", 147, 163]]], ["The authors reflect that concerns about health and fitness during confinement might serve as a precipitating factor for the development of an eating disorder in vulnerable individuals [48].", [["eating disorder", "DISEASE", 142, 157], ["a precipitating factor", "PROBLEM", 93, 115], ["an eating disorder", "PROBLEM", 139, 157]]], ["It is important to note that our study was carried out after a longer period of social distancing, but in milder confinement conditions, different from the lockdown measures evaluated in the study by Fernandez-Aranda et al. Nevertheless, although not evaluated in our study, the high prevalence of eating disorders in this population could interfere in diet and, consequently, in glycemic control.Discussion and conclusionsAnother relevant aspect of our study was the high prevalence of sleep disorders in patients with diabetes during this period.", [["eating disorders", "DISEASE", 298, 314], ["sleep disorders", "DISEASE", 487, 502], ["diabetes", "DISEASE", 520, 528], ["patients", "ORGANISM", 506, 514], ["patients", "SPECIES", 506, 514], ["our study", "TEST", 29, 38], ["the study", "TEST", 187, 196], ["our study", "TEST", 264, 273], ["eating disorders", "PROBLEM", 298, 314], ["our study", "TEST", 450, 459], ["sleep disorders", "PROBLEM", 487, 502], ["diabetes", "PROBLEM", 520, 528]]], ["Only one study was carried out to assess sleep quality during the COVID-19 pandemic, which showed 18% prevalence of sleeping disorders [43].", [["sleeping disorders", "DISEASE", 116, 134], ["one study", "TEST", 5, 14], ["the COVID", "TEST", 62, 71], ["sleeping disorders", "PROBLEM", 116, 134]]], ["We believe that the presence of a positive screening for moderate and severe sleep disorder in our cohort is possibly multifactorial: the presence of obstructive sleep apnea in the groups with highest BMI, eventual nocturnal hypoglycemia episodes, staying longer time at home, practicing less physical activity, and having irregular sleep times may play an important role in this variable.", [["sleep disorder", "DISEASE", 77, 91], ["obstructive sleep apnea", "DISEASE", 150, 173], ["nocturnal hypoglycemia", "DISEASE", 215, 237], ["a positive screening", "TEST", 32, 52], ["moderate and severe sleep disorder", "PROBLEM", 57, 91], ["obstructive sleep apnea", "PROBLEM", 150, 173], ["highest BMI", "PROBLEM", 193, 204], ["eventual nocturnal hypoglycemia episodes", "PROBLEM", 206, 246], ["irregular sleep times", "PROBLEM", 323, 344], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["sleep disorder", "OBSERVATION", 77, 91], ["possibly", "UNCERTAINTY", 109, 117], ["obstructive", "OBSERVATION_MODIFIER", 150, 161], ["sleep apnea", "OBSERVATION", 162, 173]]], ["In addition, it is possible that the presence of insomnia in this period reflects an anxiety sign related to a heightened concern about the risk of having COVID-19 while having diabetes.", [["insomnia", "DISEASE", 49, 57], ["anxiety", "DISEASE", 85, 92], ["diabetes", "DISEASE", 177, 185], ["insomnia", "PROBLEM", 49, 57], ["an anxiety sign", "PROBLEM", 82, 97], ["COVID", "TEST", 155, 160], ["diabetes", "PROBLEM", 177, 185], ["insomnia", "OBSERVATION", 49, 57], ["diabetes", "OBSERVATION", 177, 185]]], ["These hypotheses are merely speculation, requiring specific studies for better understanding.Discussion and conclusionsIt is important to highlight some limitations of the present study.", [["specific studies", "TEST", 51, 67], ["the present study", "TEST", 168, 185]]], ["This study involved a cross-sectional research design and data regarding mental health that was not assessed before the period of social distancing for comparison in this same population.", [["This study", "TEST", 0, 10]]], ["The absence of a control group without diabetes is also a limitation of the study.", [["diabetes", "DISEASE", 39, 47], ["diabetes", "PROBLEM", 39, 47], ["the study", "TEST", 72, 81]]], ["It must be taken into account that a relatively small sample was included in this study, although in accordance to the sample size calculation.", [["a relatively small sample", "PROBLEM", 35, 60], ["this study", "TEST", 77, 87], ["the sample size calculation", "TEST", 115, 142], ["small", "OBSERVATION_MODIFIER", 48, 53], ["size", "OBSERVATION_MODIFIER", 126, 130]]], ["In addition, patients were selected from a single tertiary center, which can limit external validity.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["Some parameters, such as labor activities and patients\u2019 current purchasing power, and specific information on the use of antipsychotics and mood stabilizers were not available in the electronic medical records and were not assessed directly with the participants, not allowing us to interpret the medication use and economic impact of this period in mental health.Discussion and conclusionsSome limitations should be considered in relation to the scales used.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["participants", "SPECIES", 250, 262], ["antipsychotics", "TREATMENT", 121, 135], ["mood stabilizers", "TREATMENT", 140, 156]]], ["The scales used to assess psychiatric disorders work as screening tools and have no diagnostic value.", [["psychiatric disorders", "DISEASE", 26, 47], ["psychiatric disorders", "PROBLEM", 26, 47], ["screening tools", "TEST", 56, 71], ["diagnostic value", "TEST", 84, 100]]], ["The scales used were originally validated for self-application and, in our study, they were applied by researchers through phone calls due to the limitations imposed by the current scenario.", [["our study", "TEST", 71, 80]]], ["The self-report-questionnaire (SRQ-20), which was used to assess the primary outcome, has validation for minor psychiatric disorders screening in primary health care in Brazil [48].", [["psychiatric disorders", "DISEASE", 111, 132], ["minor psychiatric disorders", "PROBLEM", 105, 132]]], ["Despite not presenting validation for screening in patients in tertiary care, patients with diabetes mellitus are included in primary care samples.", [["diabetes mellitus", "DISEASE", 92, 109], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 78, 86], ["screening", "TEST", 38, 47], ["diabetes mellitus", "PROBLEM", 92, 109]]], ["For the assessment of eating disorders, the eating attitudes test (EAT-26) was used.", [["eating disorders", "DISEASE", 22, 38], ["the assessment", "TEST", 4, 18], ["eating disorders", "PROBLEM", 22, 38], ["the eating attitudes test", "TEST", 40, 65]]], ["Although there are no validation studies in the population with diabetes, their results are widely generalizable and used for screening, indicating food preoccupation and restriction [30, 31].", [["diabetes", "DISEASE", 64, 72], ["validation studies", "TEST", 22, 40], ["diabetes", "PROBLEM", 64, 72], ["screening", "TEST", 126, 135], ["no", "UNCERTAINTY", 19, 21]]], ["The EAT-26 is often indicated as one of the methods of choice for the initial assessment of eating disorders in patients with diabetes, according to Young-Hyman et al. [49].", [["eating disorders", "DISEASE", 92, 108], ["diabetes", "DISEASE", 126, 134], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["the initial assessment", "TEST", 66, 88], ["eating disorders", "PROBLEM", 92, 108], ["diabetes", "PROBLEM", 126, 134]]], ["The mini sleep questionaire (MSQ) used to assess sleep disorders has validation only for the general population and there are no specific studies on its use in patients with diabetes [32, 33].Discussion and conclusionsDespite not having a diagnostic purpose, this study found a high number of patients showing evidence of significant psychological distress among patients with type 1 and type 2 diabetes during the COVID-19 pandemic.", [["sleep disorders", "DISEASE", 49, 64], ["diabetes", "DISEASE", 174, 182], ["psychological distress", "DISEASE", 334, 356], ["type 1 and type 2 diabetes", "DISEASE", 377, 403], ["patients", "ORGANISM", 160, 168], ["patients", "ORGANISM", 293, 301], ["patients", "ORGANISM", 363, 371], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 293, 301], ["patients", "SPECIES", 363, 371], ["The mini sleep questionaire (MSQ)", "TREATMENT", 0, 33], ["sleep disorders", "PROBLEM", 49, 64], ["the general population", "PROBLEM", 89, 111], ["diabetes", "PROBLEM", 174, 182], ["this study", "TEST", 259, 269], ["significant psychological distress", "PROBLEM", 322, 356], ["type 1", "PROBLEM", 377, 383], ["type 2 diabetes", "PROBLEM", 388, 403], ["the COVID", "TEST", 411, 420], ["pandemic", "PROBLEM", 424, 432], ["evidence of", "UNCERTAINTY", 310, 321], ["significant", "OBSERVATION_MODIFIER", 322, 333], ["psychological", "OBSERVATION_MODIFIER", 334, 347], ["distress", "OBSERVATION", 348, 356], ["diabetes", "OBSERVATION", 395, 403]]], ["Our results serve as an alarm for the impact that the current scenario may have on the mental health of patients with diabetes.", [["diabetes", "DISEASE", 118, 126], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["diabetes", "PROBLEM", 118, 126]]], ["The data from this study highlight the need for mental health access and support for patients with type 1 and type 2 diabetes during and after this pandemic.", [["type 1 and type 2 diabetes", "DISEASE", 99, 125], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["this study", "TEST", 14, 24], ["mental health access", "TREATMENT", 48, 68], ["support", "TREATMENT", 73, 80], ["type 1", "PROBLEM", 99, 105], ["type 2 diabetes", "PROBLEM", 110, 125], ["this pandemic", "PROBLEM", 143, 156], ["diabetes", "OBSERVATION", 117, 125]]], ["Future studies and actions should address the impact of strategies to care for mental health in diabetes and to prevent glycemic control deterioration during a quarantine period.", [["diabetes", "DISEASE", 96, 104], ["Future studies", "TEST", 0, 14], ["diabetes", "PROBLEM", 96, 104], ["glycemic control deterioration", "PROBLEM", 120, 150]]]], "PMC7358157": [["Case presentation ::: IntroductionA 61-year-old Taiwanese man presented to the emergency department on March 15th, 2020, with a 2-day history of dry cough and general malaise.", [["dry cough", "DISEASE", 145, 154], ["Taiwanese", "ORGANISM", 48, 57], ["man", "ORGANISM", 58, 61], ["man", "SPECIES", 58, 61], ["dry cough", "PROBLEM", 145, 154], ["general malaise", "PROBLEM", 159, 174], ["cough", "OBSERVATION", 149, 154], ["malaise", "OBSERVATION", 167, 174]]], ["The patient had a past history of hypertension, hepatitis B, and hearing impairment.", [["hypertension", "DISEASE", 34, 46], ["hepatitis B", "DISEASE", 48, 59], ["hearing impairment", "DISEASE", 65, 83], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["hypertension", "PROBLEM", 34, 46], ["hepatitis B", "PROBLEM", 48, 59], ["hearing impairment", "PROBLEM", 65, 83], ["hypertension", "OBSERVATION", 34, 46], ["hepatitis", "OBSERVATION", 48, 57]]], ["He was afebrile at triage, and his vital signs were within normal limits.", [["He", "ORGANISM", 0, 2], ["afebrile", "PROBLEM", 7, 15], ["his vital signs", "TEST", 31, 46], ["normal limits", "OBSERVATION", 59, 72]]], ["The physical examination was unremarkable.", [["The physical examination", "TEST", 0, 24], ["unremarkable", "OBSERVATION", 29, 41]]], ["Another person who went on the trip had tested positive for COVID-19.Case presentation ::: IntroductionChest radiography at presentation indicated mildly increased infiltrations in both lungs (Figure 1A).", [["lungs", "ANATOMY", 186, 191], ["lungs", "ORGAN", 186, 191], ["person", "SPECIES", 8, 14], ["COVID", "TEST", 60, 65], ["IntroductionChest radiography", "TEST", 91, 120], ["mildly increased infiltrations in both lungs", "PROBLEM", 147, 191], ["mildly", "OBSERVATION_MODIFIER", 147, 153], ["increased", "OBSERVATION_MODIFIER", 154, 163], ["infiltrations", "OBSERVATION", 164, 177], ["both", "ANATOMY_MODIFIER", 181, 185], ["lungs", "ANATOMY", 186, 191]]], ["Routine laboratory and serology tests were performed, including influenza polymerase chain reaction (PCR), mycoplasma IgG, IgM, PCR and SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) tests.", [["mycoplasma IgG", "PROTEIN", 107, 121], ["IgM", "PROTEIN", 123, 126], ["SARS-CoV", "SPECIES", 136, 144], ["Routine laboratory and serology tests", "TEST", 0, 37], ["influenza polymerase chain reaction", "PROBLEM", 64, 99], ["PCR", "TEST", 101, 104], ["mycoplasma IgG", "TEST", 107, 121], ["IgM", "TEST", 123, 126], ["PCR", "TEST", 128, 131], ["SARS", "TEST", 136, 140], ["CoV", "TEST", 141, 144], ["chain reaction", "TEST", 168, 182], ["RT-PCR) tests", "TEST", 184, 197]]], ["Laboratory results showed only slightly elevated liver transaminases (AST: 80 U/L, ALT: 58 U/L).", [["liver", "ANATOMY", 49, 54], ["liver", "ORGAN", 49, 54], ["AST", "SIMPLE_CHEMICAL", 70, 73], ["liver transaminases", "PROTEIN", 49, 68], ["AST", "PROTEIN", 70, 73], ["slightly elevated liver transaminases", "PROBLEM", 31, 68], ["AST", "TEST", 70, 73], ["U", "TEST", 78, 79], ["L", "TEST", 80, 81], ["ALT", "TEST", 83, 86], ["U/L", "TEST", 91, 94], ["slightly", "OBSERVATION_MODIFIER", 31, 39], ["elevated", "OBSERVATION", 40, 48], ["liver", "ANATOMY", 49, 54]]], ["The RT-PCR results from his nasopharyngeal swab confirmed the presence of SARS-CoV-2.", [["nasopharyngeal swab", "ANATOMY", 28, 47], ["SARS", "DISEASE", 74, 78], ["nasopharyngeal swab", "CANCER", 28, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 74, 84], ["SARS-CoV", "SPECIES", 74, 82], ["The RT-PCR", "TEST", 0, 10], ["his nasopharyngeal swab", "TEST", 24, 47], ["SARS", "PROBLEM", 74, 78], ["CoV", "TEST", 79, 82], ["nasopharyngeal", "ANATOMY", 28, 42]]], ["Moreover the mycoplasma IgM result was also positive (1054.4 U/mL) with an equivocal level of IgG (242.5 U/mL) and the mycoplasma PCR result was negative.Case presentation ::: IntroductionDuring hospitalization, the patient received standard therapy.", [["mycoplasma", "ORGANISM", 13, 23], ["IgM", "GENE_OR_GENE_PRODUCT", 24, 27], ["IgG", "GENE_OR_GENE_PRODUCT", 94, 97], ["patient", "ORGANISM", 216, 223], ["mycoplasma IgM", "PROTEIN", 13, 27], ["IgG", "PROTEIN", 94, 97], ["patient", "SPECIES", 216, 223], ["the mycoplasma IgM", "TEST", 9, 27], ["IgG", "TEST", 94, 97], ["U/mL", "TEST", 105, 109], ["the mycoplasma PCR", "TEST", 115, 133], ["standard therapy", "TREATMENT", 233, 249]]], ["A fever of up to 38.2oC developed on day 3 after the onset of symptoms and subsided one day later.", [["fever", "DISEASE", 2, 7], ["A fever", "PROBLEM", 0, 7], ["symptoms", "PROBLEM", 62, 70], ["fever", "OBSERVATION", 2, 7]]], ["At the same time, the patient also experienced diarrhea and respiratory distress, which required the use of an oxygen cannula.", [["respiratory", "ANATOMY", 60, 71], ["diarrhea", "DISEASE", 47, 55], ["respiratory distress", "DISEASE", 60, 80], ["oxygen", "CHEMICAL", 111, 117], ["oxygen", "CHEMICAL", 111, 117], ["patient", "ORGANISM", 22, 29], ["oxygen", "SIMPLE_CHEMICAL", 111, 117], ["patient", "SPECIES", 22, 29], ["diarrhea", "PROBLEM", 47, 55], ["respiratory distress", "PROBLEM", 60, 80], ["an oxygen cannula", "TREATMENT", 108, 125], ["diarrhea", "OBSERVATION", 47, 55], ["respiratory distress", "OBSERVATION", 60, 80], ["oxygen cannula", "OBSERVATION", 111, 125]]], ["Chest radiography showed the progression of bilateral ground-glass patches (Figure1B).", [["Chest radiography", "TEST", 0, 17], ["bilateral ground-glass patches (Figure1B)", "PROBLEM", 44, 85], ["progression", "OBSERVATION_MODIFIER", 29, 40], ["bilateral", "ANATOMY_MODIFIER", 44, 53], ["ground", "OBSERVATION_MODIFIER", 54, 60], ["glass patches", "OBSERVATION", 61, 74]]], ["High-resolution computed tomography (HRCT) was ordered on day 5, which revealed multiple patches of ground-glass opacity, crazy-paving pattern, and peribronchial consolidation on the right upper lobe, middle lobe, and bilateral lower lobes (Figure 2).Case presentation ::: IntroductionAzithromycin at 500 mg QD was prescribed for three days along with hydroxychloroquine at 200 mg Q8H for a total of eight days.", [["peribronchial", "ANATOMY", 148, 161], ["right upper lobe", "ANATOMY", 183, 199], ["middle lobe", "ANATOMY", 201, 212], ["lower lobes", "ANATOMY", 228, 239], ["Azithromycin", "CHEMICAL", 285, 297], ["QD", "CHEMICAL", 308, 310], ["hydroxychloroquine", "CHEMICAL", 352, 370], ["Q8H", "CHEMICAL", 381, 384], ["Azithromycin", "CHEMICAL", 285, 297], ["hydroxychloroquine", "CHEMICAL", 352, 370], ["Q8H", "CHEMICAL", 381, 384], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 189, 199], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 201, 212], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 228, 239], ["Azithromycin", "SIMPLE_CHEMICAL", 285, 297], ["QD", "SIMPLE_CHEMICAL", 308, 310], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 352, 370], ["ground-glass opacity", "PROBLEM", 100, 120], ["peribronchial consolidation on the right upper lobe, middle lobe, and bilateral lower lobes", "PROBLEM", 148, 239], ["Introduction", "TREATMENT", 273, 285], ["Azithromycin", "TREATMENT", 285, 297], ["hydroxychloroquine", "TREATMENT", 352, 370], ["multiple", "OBSERVATION_MODIFIER", 80, 88], ["patches", "OBSERVATION_MODIFIER", 89, 96], ["ground-glass opacity", "OBSERVATION", 100, 120], ["crazy", "OBSERVATION_MODIFIER", 122, 127], ["paving pattern", "OBSERVATION", 128, 142], ["peribronchial", "ANATOMY_MODIFIER", 148, 161], ["consolidation", "OBSERVATION", 162, 175], ["right upper lobe", "ANATOMY", 183, 199], ["middle lobe", "ANATOMY", 201, 212], ["bilateral", "ANATOMY_MODIFIER", 218, 227], ["lower lobes", "ANATOMY", 228, 239]]], ["No adverse event was observed after the therapy.", [["adverse event", "PROBLEM", 3, 16], ["the therapy", "TREATMENT", 36, 47], ["adverse", "OBSERVATION_MODIFIER", 3, 10]]], ["The patient\u2019s clinical condition and chest plain film both improved (Figure 1C).", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["chest plain film", "TEST", 37, 53], ["chest", "ANATOMY", 37, 42]]], ["In follow-up examinations, mycoplasma IgM and IgG levels returned to the normal range (471.3 and 154.1 U/mL, respectively) on March 30th, and the RT-PCR result of a nasopharyngeal swab was negative for SARS-CoV-2 on April 8th.DiscussionCOVID-19 has become a global pandemic in 2020, with confirmed cases and mortalities increasing each day around the world [1, 7].", [["nasopharyngeal swab", "ANATOMY", 165, 184], ["IgM", "GENE_OR_GENE_PRODUCT", 38, 41], ["IgG", "GENE_OR_GENE_PRODUCT", 46, 49], ["nasopharyngeal swab", "CANCER", 165, 184], ["mycoplasma IgM", "PROTEIN", 27, 41], ["IgG", "PROTEIN", 46, 49], ["SARS-CoV", "SPECIES", 202, 210], ["follow-up examinations", "TEST", 3, 25], ["mycoplasma IgM", "TEST", 27, 41], ["IgG levels", "TEST", 46, 56], ["the RT-PCR", "TEST", 142, 152], ["a nasopharyngeal swab", "TEST", 163, 184], ["SARS", "PROBLEM", 202, 206], ["CoV", "TEST", 207, 210], ["nasopharyngeal", "ANATOMY", 165, 179]]], ["Mysycoplasma pneumoniae accounts for 10-40% of CAP, which predominantly affects children more than 4 years old and adolescents.", [["Mysycoplasma pneumoniae", "DISEASE", 0, 23], ["CAP", "DISEASE", 47, 50], ["Mysycoplasma pneumoniae", "ORGANISM", 0, 23], ["children", "ORGANISM", 80, 88], ["Mysycoplasma pneumoniae", "SPECIES", 0, 23], ["children", "SPECIES", 80, 88], ["adolescents", "SPECIES", 115, 126], ["Mysycoplasma pneumoniae", "SPECIES", 0, 23], ["Mysycoplasma pneumoniae", "PROBLEM", 0, 23]]], ["However, the prevalence may be underestimated in adults and the elderly [8].", [["may be", "UNCERTAINTY", 24, 30]]], ["The exact number of cases of concomitant infection of COVID-19 and M. pneumoniae is not yet known.", [["infection", "DISEASE", 41, 50], ["COVID-19", "CHEMICAL", 54, 62], ["COVID-19", "ORGANISM", 54, 62], ["M. pneumoniae", "ORGANISM", 67, 80], ["M. pneumoniae", "SPECIES", 67, 80], ["COVID-19", "SPECIES", 54, 62], ["M. pneumoniae", "SPECIES", 67, 80], ["concomitant infection", "PROBLEM", 29, 50], ["COVID", "TEST", 54, 59], ["M. pneumoniae", "PROBLEM", 67, 80], ["concomitant", "OBSERVATION_MODIFIER", 29, 40], ["infection", "OBSERVATION", 41, 50], ["pneumoniae", "OBSERVATION", 70, 80]]], ["The positive RT-PCR results confirmed the diagnosis of COVID-19, and the rise and fall of mycoplasma IgM titers in our patient suggested an acute phase with M. pnumoniae infection.", [["M. pnumoniae infection", "DISEASE", 157, 179], ["COVID-19", "CELL", 55, 63], ["IgM", "GENE_OR_GENE_PRODUCT", 101, 104], ["patient", "ORGANISM", 119, 126], ["M. pnumoniae", "ORGANISM", 157, 169], ["IgM", "PROTEIN", 101, 104], ["patient", "SPECIES", 119, 126], ["M. pnumoniae", "SPECIES", 157, 169], ["M. pnumoniae", "SPECIES", 157, 169], ["The positive RT-PCR", "TEST", 0, 19], ["COVID", "TEST", 55, 60], ["mycoplasma IgM titers", "TEST", 90, 111], ["an acute phase", "PROBLEM", 137, 151], ["M. pnumoniae infection", "PROBLEM", 157, 179], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["infection", "OBSERVATION", 170, 179]]], ["Patients with COVID-19 can present a wide variety of non-specific symptoms that are common for viral infections.", [["COVID-19", "CHEMICAL", 14, 22], ["viral infections", "DISEASE", 95, 111], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 14, 19], ["non-specific symptoms", "PROBLEM", 53, 74], ["viral infections", "PROBLEM", 95, 111], ["infections", "OBSERVATION", 101, 111]]], ["Life-threatening complications may develop, including septic shock and ARDS, especially in individuals with comorbidities and the elderly[3].", [["septic shock", "DISEASE", 54, 66], ["ARDS", "DISEASE", 71, 75], ["Life-threatening complications", "PROBLEM", 0, 30], ["septic shock", "PROBLEM", 54, 66], ["ARDS", "PROBLEM", 71, 75], ["comorbidities", "PROBLEM", 108, 121], ["septic", "OBSERVATION_MODIFIER", 54, 60], ["ARDS", "OBSERVATION", 71, 75]]], ["Because of the ongoing nature of the COVID-19 outbreak, the number of mortalities varies from country to country.", [["the COVID", "TEST", 33, 42]]], ["Although mycoplasma pneumonia is presumably benign in nature, its presentation may also range from mild viral-infection-like symptoms to life-threatening conditions, including ARDS and multiple organ failure.", [["organ", "ANATOMY", 194, 199], ["mycoplasma pneumonia", "DISEASE", 9, 29], ["viral-infection", "DISEASE", 104, 119], ["ARDS", "DISEASE", 176, 180], ["multiple organ failure", "DISEASE", 185, 207], ["organ", "ORGAN", 194, 199], ["mycoplasma pneumonia", "PROBLEM", 9, 29], ["mild viral-infection", "PROBLEM", 99, 119], ["symptoms", "PROBLEM", 125, 133], ["threatening conditions", "PROBLEM", 142, 164], ["ARDS", "PROBLEM", 176, 180], ["multiple organ failure", "PROBLEM", 185, 207], ["mycoplasma", "OBSERVATION_MODIFIER", 9, 19], ["pneumonia", "OBSERVATION", 20, 29], ["presumably", "UNCERTAINTY", 33, 43], ["benign", "OBSERVATION_MODIFIER", 44, 50], ["mild", "OBSERVATION_MODIFIER", 99, 103], ["viral", "OBSERVATION_MODIFIER", 104, 109], ["infection", "OBSERVATION", 110, 119], ["ARDS", "OBSERVATION", 176, 180], ["multiple", "OBSERVATION_MODIFIER", 185, 193], ["organ", "ANATOMY", 194, 199], ["failure", "OBSERVATION", 200, 207]]], ["A study on patients with mycoplasma infections identified 416 patients, of which 68 (16.3%) required admission to the intensive care unit (ICU), and the ICU mortality rate was 29.4% [8].DiscussionIn terms of image findings, the most common features in chest radiographs of COVID-19 pneumonia include ground-glass opacities, bilateral or local patchy shadowing, and interstitial abnormalities [3, 9].", [["chest", "ANATOMY", 252, 257], ["interstitial", "ANATOMY", 365, 377], ["mycoplasma infections", "DISEASE", 25, 46], ["pneumonia", "DISEASE", 282, 291], ["interstitial abnormalities", "DISEASE", 365, 391], ["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 62, 70], ["chest", "ORGANISM_SUBDIVISION", 252, 257], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 62, 70], ["A study", "TEST", 0, 7], ["mycoplasma infections", "PROBLEM", 25, 46], ["the ICU mortality rate", "TEST", 149, 171], ["image findings", "TEST", 208, 222], ["chest radiographs", "TEST", 252, 269], ["COVID", "TEST", 273, 278], ["pneumonia", "PROBLEM", 282, 291], ["ground-glass opacities", "PROBLEM", 300, 322], ["bilateral or local patchy shadowing", "PROBLEM", 324, 359], ["interstitial abnormalities", "PROBLEM", 365, 391], ["chest", "ANATOMY", 252, 257], ["pneumonia", "OBSERVATION", 282, 291], ["ground-glass opacities", "OBSERVATION", 300, 322], ["bilateral", "ANATOMY_MODIFIER", 324, 333], ["local", "OBSERVATION_MODIFIER", 337, 342], ["patchy", "OBSERVATION_MODIFIER", 343, 349], ["shadowing", "OBSERVATION_MODIFIER", 350, 359], ["interstitial", "ANATOMY_MODIFIER", 365, 377], ["abnormalities", "OBSERVATION", 378, 391]]], ["In chest radiographs of mycoplasma pneumonia, the most common patterns are peribronchial and perivascular interstitial infiltrates, airspace consolidation, and nodular opacification[10, 11].", [["chest", "ANATOMY", 3, 8], ["peribronchial", "ANATOMY", 75, 88], ["perivascular interstitial infiltrates", "ANATOMY", 93, 130], ["airspace", "ANATOMY", 132, 140], ["nodular", "ANATOMY", 160, 167], ["mycoplasma pneumonia", "DISEASE", 24, 44], ["peribronchial", "MULTI-TISSUE_STRUCTURE", 75, 88], ["perivascular interstitial infiltrates", "PATHOLOGICAL_FORMATION", 93, 130], ["airspace", "MULTI-TISSUE_STRUCTURE", 132, 140], ["chest radiographs", "TEST", 3, 20], ["mycoplasma pneumonia", "PROBLEM", 24, 44], ["peribronchial and perivascular interstitial infiltrates", "PROBLEM", 75, 130], ["airspace consolidation", "PROBLEM", 132, 154], ["nodular opacification", "PROBLEM", 160, 181], ["chest", "ANATOMY", 3, 8], ["mycoplasma pneumonia", "OBSERVATION", 24, 44], ["most common", "OBSERVATION_MODIFIER", 50, 61], ["peribronchial", "OBSERVATION", 75, 88], ["perivascular", "ANATOMY_MODIFIER", 93, 105], ["interstitial", "ANATOMY_MODIFIER", 106, 118], ["infiltrates", "OBSERVATION", 119, 130], ["airspace", "ANATOMY_MODIFIER", 132, 140], ["consolidation", "OBSERVATION", 141, 154], ["nodular", "OBSERVATION_MODIFIER", 160, 167], ["opacification", "OBSERVATION", 168, 181]]], ["In HRCT, the most common features reported for COVID-19 pneumonia are bilateral and subpleural areas of ground-glass opacification, consolidation affecting the lower lobes, or both[4, 12, 13, 14].DiscussionOne study analyzed the HRCT patterns in 28 patients with mycoplasma pneumonia, and the most common patterns were ground glass attenuation (86%) and airspace consolidation (79%) [10].Thus, based on the current findings and previous reports, it may be difficult to distinguish between the two diseases using chest radiographs and HRCT.", [["subpleural areas", "ANATOMY", 84, 100], ["lower lobes", "ANATOMY", 160, 171], ["airspace", "ANATOMY", 354, 362], ["chest", "ANATOMY", 512, 517], ["pneumonia", "DISEASE", 56, 65], ["mycoplasma pneumonia", "DISEASE", 263, 283], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 160, 171], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["HRCT", "TEST", 3, 7], ["COVID", "TEST", 47, 52], ["pneumonia", "PROBLEM", 56, 65], ["bilateral and subpleural areas of ground-glass opacification", "PROBLEM", 70, 130], ["consolidation affecting the lower lobes", "PROBLEM", 132, 171], ["One study", "TEST", 206, 215], ["the HRCT patterns", "TEST", 225, 242], ["mycoplasma pneumonia", "PROBLEM", 263, 283], ["ground glass attenuation", "PROBLEM", 319, 343], ["airspace consolidation", "PROBLEM", 354, 376], ["the two diseases", "PROBLEM", 489, 505], ["chest radiographs", "TEST", 512, 529], ["HRCT", "TEST", 534, 538], ["pneumonia", "OBSERVATION", 56, 65], ["bilateral", "ANATOMY_MODIFIER", 70, 79], ["subpleural", "ANATOMY_MODIFIER", 84, 94], ["ground-glass opacification", "OBSERVATION", 104, 130], ["consolidation", "OBSERVATION", 132, 145], ["lower lobes", "ANATOMY", 160, 171], ["both", "OBSERVATION_MODIFIER", 176, 180], ["mycoplasma", "OBSERVATION_MODIFIER", 263, 273], ["pneumonia", "OBSERVATION", 274, 283], ["ground glass attenuation", "OBSERVATION", 319, 343], ["airspace", "ANATOMY_MODIFIER", 354, 362], ["consolidation", "OBSERVATION", 363, 376], ["chest", "ANATOMY", 512, 517]]], ["Indeed, the HRCT of our patient exhibited features resembling both COVID-19 and mycoplasma pneumonia.DiscussionCurrently, there is no standard therapy for COVID-19 infected patients and supportive care remains the mainstay of treatment.", [["mycoplasma pneumonia", "DISEASE", 80, 100], ["COVID-19 infected", "DISEASE", 155, 172], ["patient", "ORGANISM", 24, 31], ["COVID-19", "ORGANISM", 155, 163], ["patients", "ORGANISM", 173, 181], ["patient", "SPECIES", 24, 31], ["patients", "SPECIES", 173, 181], ["the HRCT", "TEST", 8, 16], ["COVID", "TEST", 67, 72], ["mycoplasma pneumonia", "PROBLEM", 80, 100], ["standard therapy", "TREATMENT", 134, 150], ["COVID", "TEST", 155, 160], ["supportive care", "TREATMENT", 186, 201], ["treatment", "TREATMENT", 226, 235], ["mycoplasma", "OBSERVATION_MODIFIER", 80, 90], ["pneumonia", "OBSERVATION", 91, 100], ["no", "UNCERTAINTY", 131, 133]]], ["Meanwhile, macrolides such as azithromycin are considered the drugs of choice for non-macrolide-resistant M. pneumoniae due to their efficacy, and they are generally well tolerated[15].", [["macrolides", "CHEMICAL", 11, 21], ["azithromycin", "CHEMICAL", 30, 42], ["non-macrolide", "CHEMICAL", 82, 95], ["M. pneumoniae", "DISEASE", 106, 119], ["macrolides", "CHEMICAL", 11, 21], ["azithromycin", "CHEMICAL", 30, 42], ["non-macrolide", "CHEMICAL", 82, 95], ["macrolides", "SIMPLE_CHEMICAL", 11, 21], ["azithromycin", "SIMPLE_CHEMICAL", 30, 42], ["non-macrolide", "SIMPLE_CHEMICAL", 82, 95], ["M. pneumoniae", "ORGANISM", 106, 119], ["M. pneumoniae", "SPECIES", 106, 119], ["M. pneumoniae", "SPECIES", 106, 119], ["macrolides", "TREATMENT", 11, 21], ["azithromycin", "TREATMENT", 30, 42], ["non-macrolide-resistant M. pneumoniae", "PROBLEM", 82, 119], ["pneumoniae", "OBSERVATION", 109, 119]]], ["The importance of early administration of effective antibiotics for patients with mycoplasma pneumonia has been demonstrated in a study which reported that patients required admission to ICUs for acute respiratory failure did not receive appropriate antibiotics until approximately 10 days after diagnosis[16].", [["respiratory", "ANATOMY", 202, 213], ["mycoplasma pneumonia", "DISEASE", 82, 102], ["acute respiratory failure", "DISEASE", 196, 221], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 156, 164], ["effective antibiotics", "TREATMENT", 42, 63], ["mycoplasma pneumonia", "PROBLEM", 82, 102], ["a study", "TEST", 128, 135], ["acute respiratory failure", "PROBLEM", 196, 221], ["appropriate antibiotics", "TREATMENT", 238, 261], ["pneumonia", "OBSERVATION", 93, 102], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["respiratory failure", "OBSERVATION", 202, 221]]], ["Our patient received Azithromycin therapy when mycoplasma pneumonia was diagnosed with good response.ConclusionPatients with mycoplasma pneumonia and COVID-19 pneumonia may have similar presentations in clinical and radiographic features.", [["Azithromycin", "CHEMICAL", 21, 33], ["mycoplasma pneumonia", "DISEASE", 47, 67], ["mycoplasma pneumonia", "DISEASE", 125, 145], ["pneumonia", "DISEASE", 159, 168], ["Azithromycin", "CHEMICAL", 21, 33], ["patient", "ORGANISM", 4, 11], ["Azithromycin", "SIMPLE_CHEMICAL", 21, 33], ["patient", "SPECIES", 4, 11], ["COVID-19", "SPECIES", 150, 158], ["Azithromycin therapy", "TREATMENT", 21, 41], ["mycoplasma pneumonia", "PROBLEM", 47, 67], ["mycoplasma pneumonia", "PROBLEM", 125, 145], ["COVID-19 pneumonia", "PROBLEM", 150, 168], ["pneumonia", "OBSERVATION", 58, 67], ["good response", "OBSERVATION", 87, 100], ["mycoplasma", "OBSERVATION_MODIFIER", 125, 135], ["pneumonia", "OBSERVATION", 136, 145], ["pneumonia", "OBSERVATION", 159, 168]]], ["With the continuing increase in the number of COVID cases, the presence of mycoplasma coinfection could be easily overlooked.", [["COVID", "DISEASE", 46, 51], ["mycoplasma coinfection", "DISEASE", 75, 97], ["mycoplasma coinfection", "PROBLEM", 75, 97], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["mycoplasma coinfection", "OBSERVATION", 75, 97]]], ["We have reported a patient who presented with non-specific symptoms, including general malaise and dry cough, and there was no lymphopenia.", [["dry cough", "DISEASE", 99, 108], ["lymphopenia", "DISEASE", 127, 138], ["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["non-specific symptoms", "PROBLEM", 46, 67], ["general malaise", "PROBLEM", 79, 94], ["dry cough", "PROBLEM", 99, 108], ["lymphopenia", "PROBLEM", 127, 138], ["malaise", "OBSERVATION", 87, 94], ["cough", "OBSERVATION", 103, 108], ["no", "UNCERTAINTY", 124, 126], ["lymphopenia", "OBSERVATION", 127, 138]]], ["Further testing confirmed the co-infection with SARS-CoV-2 and M. pneumoniae, and there was good recovery after combination therapy.", [["SARS", "DISEASE", 48, 52], ["SARS-CoV-2", "ORGANISM", 48, 58], ["M. pneumoniae", "ORGANISM", 63, 76], ["CoV-2", "SPECIES", 53, 58], ["M. pneumoniae", "SPECIES", 63, 76], ["SARS-CoV-2", "SPECIES", 48, 58], ["M. pneumoniae", "SPECIES", 63, 76], ["Further testing", "TEST", 0, 15], ["the co-infection", "PROBLEM", 26, 42], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56], ["M. pneumoniae", "PROBLEM", 63, 76], ["combination therapy", "TREATMENT", 112, 131], ["co-infection", "OBSERVATION", 30, 42], ["pneumoniae", "OBSERVATION", 66, 76], ["good", "OBSERVATION_MODIFIER", 92, 96], ["recovery", "OBSERVATION_MODIFIER", 97, 105]]], ["Therefore, every COVID-19 patient should undergo a meticulous screening routine to ensure that adequate treatment is provided.Ethics approval and consent to participateThe Institutional Review Board of Chang Gung Medical Foundation approved this study (202000631B0).Declaration of Competing InterestThe authors declare that they have no competing interests.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["a meticulous screening routine", "TEST", 49, 79], ["adequate treatment", "TREATMENT", 95, 113], ["this study", "TEST", 241, 251]]]]}